<SEC-DOCUMENT>0001144204-16-091600.txt : 20160330
<SEC-HEADER>0001144204-16-091600.hdr.sgml : 20160330
<ACCEPTANCE-DATETIME>20160330171633
ACCESSION NUMBER:		0001144204-16-091600
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160330
DATE AS OF CHANGE:		20160330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		161540734

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v435519_10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 10%; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">(Mark One)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 90%; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF&nbsp;THE SECURITIES EXCHANGE ACT OF&nbsp;1934</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">For the fiscal year ended December&nbsp;31, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">Or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF&nbsp;THE SECURITIES EXCHANGE ACT OF&nbsp;1934</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commission file number&nbsp;0-9314</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ABEONA THERAPEUTICS&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.05in; padding-left: 0.05in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt"><U>Delaware</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt">(State or other
        jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt">incorporation or
        organization)</P></TD>
    <TD STYLE="width: 50%; padding-right: 0.05in; padding-left: 0.05in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>83-0221517</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification No.)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.05in; padding-left: 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt"><U>3333 Lee Parkway,
        Suite 600, Dallas, TX</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt">(Address of principal
        executive offices)</P></TD>
    <TD STYLE="padding-right: 0.05in; padding-left: 0.05in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>75219</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Registrant&rsquo;s
telephone number, including area code: (214)&nbsp;665-9495</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section&nbsp;12(b) of the Act:
None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section&nbsp;12(g) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, $0.01 par value</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Title of each Class&nbsp;</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; padding-right: 0.05in; padding-left: 0.05in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">NASDAQ
Capital Markets&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.05in; padding-left: 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate by check
mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act.&nbsp;Yes&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT>
No&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is
not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;Yes&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT>
No&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90&nbsp;days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Yes&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>
No&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT>
No <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if disclosure of delinquent
filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K (&sect;229.405 of this chapter) is not contained herein, and will not be
contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part&nbsp;III of this Form&nbsp;10-K or any amendment to this Form&nbsp;10-K.&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the Registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of
&ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule&nbsp;12b-2
of the Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt">Large accelerated
        filer&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></P></TD>
    <TD STYLE="width: 25%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Accelerated filer&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></FONT></TD>
    <TD STYLE="width: 25%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Non-accelerated filer&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Do not check if a smaller reporting company)</P></TD>
    <TD STYLE="width: 25%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Smaller reporting company&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule&nbsp;12b-2 of the Exchange Act).&nbsp;Yes&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT> No&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The aggregate market value of the voting and non-voting common equity
held by non-affiliates computed by reference to the average bid and asked price of such common equity, as of&nbsp;June 30, 2015,
was approximately $74,700,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The number of shares outstanding of the registrant&rsquo;s
common stock as of March 30, 2016 was 32,743,013 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DOCUMENTS INCORPORATED BY REFERENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Portions of the registrant&rsquo;s definitive
Proxy Statement relating to our 2016 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual
Report on Form 10-K where indicated.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; border-bottom: Black 3px double">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-underline-style: double">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%"></TD>
    <TD STYLE="width: 77%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Page</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001"><U>Part I</U></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Item 1.</TD>
    <TD><A HREF="#a_002">Business</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Item 1A.</TD>
    <TD><A HREF="#a_003">Risk Factors</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">15</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Item 2.</TD>
    <TD><A HREF="#a_004">Properties</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Item 3.</TD>
    <TD><A HREF="#a_005">Legal Proceedings</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Item 4.</TD>
    <TD><A HREF="#a_006">Mine Safety Disclosures</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_007">Executive Officers of the Registrant</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_008"><U>Part II</U></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Item 5.</TD>
    <TD><A HREF="#a_010">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Item 6.</TD>
    <TD><A HREF="#a_011">Selected Financial Data</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Item 7.</TD>
    <TD><A HREF="#a_012">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Item 7A.</TD>
    <TD><A HREF="#a_013">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Item 8.</TD>
    <TD><A HREF="#a_014">Financial Statements and Supplementary Data</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Item 9.</TD>
    <TD><A HREF="#a_015">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Item 9A.</TD>
    <TD><A HREF="#a_016">Controls and Procedures</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Item 9B.</TD>
    <TD><A HREF="#a_017">Other Information</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_018"><U>Part III</U></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Item 10.</TD>
    <TD><A HREF="#a_019">Directors, Executive Officers and Corporate Governance</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Item 11.</TD>
    <TD><A HREF="#a_020">Executive Compensation</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Item 12.</TD>
    <TD><A HREF="#a_021">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Item 13.</TD>
    <TD><A HREF="#a_022">Certain Relationships and Related Transactions and Director Independence</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Item 14.</TD>
    <TD><A HREF="#a_023">Principal Accounting Fees and Services</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Item 15.</TD>
    <TD><A HREF="#a_024">Exhibits, Financial Statement Schedules</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_025"><U>Signatures</U></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">41</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This Form 10-K (including the information
incorporated by reference) contains &lsquo;&lsquo;forward-looking statements&rsquo;&rsquo; within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks
and uncertainties. These statements and other risks described below as well as those discussed elsewhere in this Form 10-K, documents
incorporated by reference and other documents and reports that we file periodically with the Securities and Exchange Commission
(&ldquo;SEC&rdquo;) include, without limitation, statements relating to uncertainties associated with research and development
activities, clinical trials, our ability to raise capital, the timing of and our ability to achieve regulatory approvals, dependence
on others to market our licensed products, collaborations and our ability to attract licensing partners, future cash flow, the
timing and receipt of licensing and milestone revenues, the future success of our marketed products and products in development,
our belief that advances in biotechnology will provide significant opportunities to develop new treatments for rare diseases, our
sales projections, and the sales projections of our licensing partners, our ability to achieve licensing milestones, the size of
the prospective markets in which we may offer products, anticipated product launches and our commercialization strategies, anticipated
product approvals and timing thereof, product opportunities, clinical trials and U.S. Food and Drug Administration (&lsquo;&lsquo;FDA&rsquo;&rsquo;)
applications, as well as our drug development strategy, our clinical development organization expectations regarding our rate of
technological developments and competition, our plan not to establish an internal marketing organization, our expectations regarding
minimizing development risk and developing and introducing technology, the terms of future licensing arrangements, our ability
to secure additional financing for our operations, our ability to establish new relationships and maintain current relationships,
our ability to attract and retain key personnel, our belief that we will not pay any cash dividends in the foreseeable future,
our belief that a failure to obtain necessary additional capital in the future will result in our operations being jeopardized,
our expectation that we will continue to incur losses, our belief that we will expend substantial funds to conduct research and
development programs, preclinical studies and clinical trials of potential products, our belief that we have a rich pipeline of
products and product candidates, our belief that recently licensed technology will enable us to provide new therapeutic applications
and expand market opportunities while enhancing margins, our belief that we will continue to evaluate the most cost-effective methods
to advance our programs, our ability to achieve profitability on a sustained basis or at all, and our expected cash burn rate.
These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements
by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo;
&ldquo;could,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo;
or &ldquo;continue&rdquo; or the negative of such terms or other comparable terminology. We intend the forward-looking statements
to be covered by the safe harbor for forward-looking statements in these sections. The forward-looking information is based on
various factors and was derived using numerous assumptions.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Forward-looking statements necessarily involve
risks and uncertainties, and our actual results could differ materially from those anticipated in the forward-looking statements
due to a number of factors, including those set forth below in Item 1A. Risk Factors and elsewhere in this Form 10-K. The factors
set forth under &ldquo;Risk Factors&rdquo; and other cautionary statements made in this Form 10-K should be read and understood
as being applicable to all related forward-looking statements wherever they appear in this Form 10-K. The forward-looking statements
contained in this Form 10-K represent our judgment only as of the date of this Annual Report on Form 10-K. We caution readers not
to place undue reliance on such statements. Except as required by law, we undertake no obligation to update publicly any forward-looking
statements for any reason, even if new information becomes available or other events occur in the future.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_001"></A>PART I </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_002"></A><B>ITEM 1. BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Abeona Therapeutics Inc. (together with our
subsidiaries, &ldquo;we&rdquo;, &ldquo;our&rdquo;, &ldquo;Abeona&rdquo; or the &ldquo;Company&rdquo;) is a Delaware corporation.
We are focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases.
Abeona's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo
syndrome (MPS IIIB and IIIA, respectively). We are also developing ABO-201 (AAV CLN3) gene therapy for Juvenile Neuronal Ceroid
Lipofuscinoses (JNCL) also known as juvenile Batten disease; and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel
CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare
plasma protein therapies including PTB-101 SDF Alpha&trade; (alpha-1 protease inhibitor) for inherited COPD using our proprietary
SDF&trade; (Salt Diafiltration) ethanol-free process. Our principal executive office is located at 3333 Lee Parkway, Suite 600,
Dallas, Texas 75219. Our website address is <FONT STYLE="color: Black"><I><U>www.abeonatherapeutics.com</U></I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Product Development Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Abeona is focused on developing and delivering
gene therapy and plasma-based products for severe and life-threatening rare diseases. A rare disease is one that affects fewer
than 200,000 people in the United States. There are nearly 7,000 rare diseases, which may involve chronic illness, disability,
and often, premature death. More than 25 million Americans and 30 million Europeans have one. While rare diseases can affect any
age group, about 50% of people affected are children (15 million); and rare diseases account for 35% of deaths in the first year
of life. These rare diseases are often poorly diagnosed, very complex, and have no treatment or not very effective treatment&mdash;over
95% of rare diseases do not have a single FDA or EMA approved drug treatment. However, most rare diseases are often caused by changes
in genes&mdash;80% are genetic in origin and can present at any stage of life. We believe emerging insights in genetics and advances
in biotechnology, as well as new approaches and collaboration between researchers, industry, regulators and patient groups, provide
significant opportunities to develop breakthrough treatments for rare diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Developing Next Generation Gene Therapy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Gene therapy is the use of DNA as a potential
therapy to treat a disease. In many disorders, particularly genetic diseases caused by a single genetic defect, gene therapy aims
to treat a disease by delivering the correct copy of DNA into a patient's cells. The healthy, functional copy of the therapeutic
gene then helps the cell function correctly. In gene therapy, DNA that encodes a therapeutic protein is packaged within a &quot;vector&quot;,
often a &ldquo;naked&rdquo; virus, which is used to transfer the DNA to the inside of cells within the body. Gene therapy can be
delivered by a direct injection, either intravenously (IV) or directly into a specific tissue in the body, where it is taken up
by individual cells. Once inside cells, the correct DNA is expressed by the cell machinery, resulting in the production of missing
or defective protein, which in turn is proposed to treat the patient's underlying disease and can provide long-term benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Abeona is developing next generation adeno-associated
virus (AAV) gene therapies. Viruses such as AAV are utilized because they have evolved a way of encapsulating and delivering one
or more genes of the size needed for clinical application, and can be purified in large quantities at high concentration. Unlike
AAV vectors found in nature, the AAV vectors used by Abeona have been genetically-modified such that they do not replicate. Although
the preclinical studies in animal models of disease demonstrate the promising impact of AAV-mediated gene expression to affected
tissues such as the heart, liver and muscle, our programs use a specific virus that is capable of delivering therapeutic DNA across
the blood brain barrier and into the central nervous system (CNS) and the somatic system (body), making them attractive for addressing
lysosomal storage diseases which have severe CNS manifestations of the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lysosomal storage diseases (LSD) are a group
of rare inborn errors of metabolism resulting from deficiency in normal lysosomal function. These diseases are characterized by
progressive accumulation of storage material within the lysosomes of affected cells, ultimately leading to cellular dysfunction.
Multiple tissues ranging from musculoskeletal and visceral to tissues of the central nervous system are typically involved in disease
pathology. Since the advent of enzyme replacement therapy (ERT) to manage some LSDs, general clinical outcomes have significantly
improved; however, treatment with infused protein is lifelong and continued disease progression is still evident in patients. Thus,
AAV-based gene therapy may provide a viable alternative or adjunctive therapy to current management strategies for LSDs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our initial programs are focused on LSDs such
as Mucopolysaccharidosis (MPS) IIIA and IIIB. Also known as Sanfilippo syndromes type A and type B, MPS III is a progressive neuromuscular
disease with profound CNS involvement. Our lead product candidates, ABO-101 and ABO-102, have been developed to replace the damaged,
malfunctioning enzymes within target cells with the normal, functioning version. ABO-201 is a similar product, using an AAV to
deliver the correct lysosomal gene that is defective in juvenile neuronal ceroid lipofuscinosis. Delivered via a single injection,
these drugs are only given once.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>ABO-101 for MPS III B and ABO-102 for
MPS III A (Sanfilippo syndrome)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mucopolysaccharidosis (MPS) type III (Sanfilippo
syndrome) is a group of four inherited genetic diseases, described as type A, B, C or D, which cause enzyme deficiencies that result
in the abnormal accumulation of glycosaminoglycans (sugars) in body tissues. MPS III is a lysosomal storage disease, a group of
rare inborn errors of metabolism resulting from deficiency in normal lysosomal function. The incidence of MPS III (all four types
combined) is estimated to be 1 in 70,000 births.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mucopolysaccharides are long chains of sugar
molecules used in the building of connective tissues in the body. There is a continuous process in the body of replacing used materials
and breaking them down for disposal. Children with MPS III are missing an enzyme called heparan sulfate which is essential in breaking
down the used mucopolysaccharides. The partially broken down mucopolysaccharides remain stored in cells in the body causing progressive
damage. Babies may show little sign of the disease, but as more and more cells become damaged, symptoms start to appear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In MPS III, the predominant symptoms occur
due to accumulation within the central nervous system (CNS), including the brain and spinal cord, resulting in cognitive decline,
motor dysfunction, and eventual death. To date, there is no cure for MPS III and treatments are largely supportive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Abeona is developing next generation AAV-based
gene therapies for MPS III (Sanfilippo syndrome), which involves a one-time delivery of a normal copy of the defective gene to
cells of the central nervous system with the aim of reversing the effects of the genetic errors that cause the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After a single dose in Sanfilippo preclinical
models, ABO-101 and ABO-102 induced cells in the CNS and peripheral organs to produce the missing enzymes which helped repair the
damage caused to the cells. Preclinical <I>in vivo</I> efficacy studies in Sanfilippo syndrome have demonstrated functional benefits
that remain for months after treatment. A single dose of ABO-101 or ABO-102 significantly restored normal cell and organ function,
corrected cognitive defects that remained months after drug administration, increased neuromuscular control and increased the lifespan
of animals with MPS III over 100% one year after treatment compared to untreated control animals. These results are consistent
with studies from several laboratories suggesting AAV treatment could potentially benefit patients with Sanfilippo Syndrome Type
A and B. In addition, safety studies conducted in animal models of Sanfilippo syndromes have demonstrated that delivery of AB0-101
or AB0-102 are well tolerated with minimal side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>ABO-201 for Juvenile Neuronal Ceroid
Lipofuscinoses (JNCL) (or Juvenile Batten Disease (JBD))</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ABO-201 (AAV CLN3) is an AAV-based gene therapy
which has shown promising preclinical efficacy in delivery of a normal copy of the defective CLN3 gene to cells of the central
nervous system with the aim of reversing the effects of the genetic errors that cause JNCL. JNCL is a rare, fatal, autosomal recessive
(inherited) disorder of the nervous system that typically begins in children between 4 and 8 years of age. Often the first noticeable
sign of JNCL is vision impairment, which tends to progress rapidly and eventually result in blindness. As the disease progresses,
children experience the loss of previously acquired skills (developmental regression). This progression usually begins with the
loss of the ability to speak in complete sentences. Children then lose motor skills, such as the ability to walk or sit. They also
develop movement abnormalities that include rigidity or stiffness, slow or diminished movements (hypokinesia), and stooped posture.
Beginning in mid- to late childhood, affected children may have recurrent seizures (epilepsy), heart problems, behavioral problems,
and difficulty sleeping. Life expectancy is greatly reduced. Most people with juvenile Batten disease live into their twenties
or thirties. As yet, no specific treatment is known that can halt or reverse the symptoms of JNCL disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">JNCL disease is the most common form of a group
of disorders known as neuronal ceroid lipofuscinoses (NCLs). Collectively, all forms of NCL affect an estimated 2 to 4 in 100,000
live births in the United States. NCLs are more common in Finland, where approximately 1 in 12,500 individuals are affected; as
well as Sweden, other parts of northern Europe, and Newfoundland, Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Most cases of JNCL disease are caused by mutations
in the CLN3 gene, which is the focus of our AAV-based gene therapy approach. These mutations disrupt the function of cellular structures
called lysosomes. Lysosomes are compartments in the cell that normally digest and recycle different types of molecules. Lysosome
malfunction leads to a buildup of fatty substances called lipopigments and proteins within these cell structures. These accumulations
occur in cells throughout the body, but neurons in the brain seem to be particularly vulnerable to damage. The progressive death
of cells, especially in the brain, leads to vision loss, seizures, and intellectual decline in children with JNCL disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>ABO-301 for Fanconi Anemia (FA)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ABO-301 (AAV FANCC) is an AAV-based gene therapy
which has shown promising preclinical efficacy in delivery of a normal copy of the defective gene to cells of the hematopoietic
or blood system with the aim of reversing the effects of the genetic errors that cause Fanconi anemia (FA). FA is a rare (1 in
160,000) pediatric, autosomal recessive (inherited) disease characterized by multiple physical abnormalities, organ defects, bone
marrow failure, and a higher than normal risk of cancer. The average lifespan for people with FA is 20 to 30 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The major function of bone marrow is to produce
new blood cells. In FA, a DNA mutation renders the FANCC gene nonfunctional. Loss of FANCC causes patient skeletal abnormalities
and leads to bone marrow failure. FA patients also have much higher rates of hematological diseases, such as acute myeloid leukemia
(AML) or tumors of the head, neck, skin, gastrointestinal system, or genital tract. The likelihood of developing one of these cancers
in people with FA is between 10 and 30 percent. Aside from bone marrow transplantation (BMT) there are no specific treatments known
that can halt or reverse the symptoms of FA. Reparing fibroblast cells in FA patients with a functional FANCC gene is the focus
of our AAV-based gene therapy approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Using a novel CRISPR (clustered, regularly
interspaced short palindromic repeats)-Cas9 (CRISPR associated protein 9) system, researchers used a protein-RNA complex composed
of an enzyme known as Cas9 bound to a guide RNA molecule that has been designed to recognize a particular DNA sequence. The RNA
molecules guide the Cas9 complex to the location in the genome that requires repair. CRISPR-Cas9 uniquely enables surgically efficient
knock-out, knock-down or selective editing of defective genes in the context of their natural promoters, unlocking the potential
to treat both recessive and dominant forms of genetic diseases. Most importantly, this approach has the potential to allow more
precise gene modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Plasma-based Therapeutics using the SDF&trade;
technology platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Abeona&rsquo;s proprietary Salt Diafiltration
Process&trade; (SDF) focuses on ethanol-free extraction of therapeutic biologics from human plasma. Plasma biologics are biopharmaceutical
proteins extracted, purified, and formulated from human blood plasma by the use of biotechnological processing techniques including
precipitation, diafiltration, affinity chromatography, and ion-exchange chromatography. These products are rendered virus-safe
by means of chemical treatment, nanofiltration, and pasteurization. Plasma biologics primarily address indications arising from
genetic deficiencies, which are increasingly being identified by means of newly available rapid and low-cost diagnostic genetic
tests. Examples of plasma biologics include Alpha-1 Antitrypsin (also known as alpha-1 proteinase inhibitor, A1PI), Intravenous
Immune Globulin (IVIG), Anti-Hemophilic Factor VIII (AHF) and Albumin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Plasma biologics are currently obtained from
human plasma by a fractionation process known as the Cohn Cold Ethanol Fractionation Process (Cohn Process), which was developed
prior to World War II to provide a stable solution of human albumin for the rapid treatment of hemorrhagic shock on the battlefield.
This process employs various concentrations of ethanol combined with adjustments of pH, ionic strength, and temperature to bring
about the necessary separations by precipitation. Ethanol can inactivate many of the plasma proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In contrast to the highly denaturing Cohn Process,
Abeona&rsquo;s patented SDF&trade; method involves a short two-step, ethanol-free salt precipitation process optimized to extract
a wide range of therapeutically useful biologic proteins from human blood plasma. SDF&trade; enables the production of higher yields
of these proteins compared with the Cohn Process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>PTB-101 SDF Alpha&trade; (alpha-1 protease
inhibitor) for emphysema or chronic obstructive pulmonary disease (COPD)</I></B> <B><I>due to severe congenital deficiency of A1PI
(alpha-1-antitrypsin deficiency)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Alpha-1 antitrypsin deficiency is a rare (1
in 1,500 to 3,500) genetic (inherited) autosomal disorder that may cause lung disease from an inability to neutralize the enzyme
neutrophil elastase and liver disease from retained misfolded protein. Alpha-1 antitrypsin deficiency occurs worldwide, but its
prevalence varies by population. Alpha-1 antitrypsin is also known as alpha-1 proteinase inhibitor (A1PI).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">About 10 percent of infants with alpha-1 antitrypsin
deficiency develop liver disease, which often causes yellowing of the skin and whites of the eyes (jaundice). Approximately 15
percent of adults with alpha-1 antitrypsin deficiency develop liver damage (cirrhosis) due to the formation of scar tissue in the
liver. Signs of cirrhosis include a swollen abdomen, swollen feet or legs, and jaundice. Individuals with alpha-1 antitrypsin deficiency
are also at risk of developing a type of liver cancer called hepatocellular carcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Alpha-1 antitrypsin deficiency is inherited
with an autosomal codominant pattern, which means that two different versions of the gene may be active (expressed), and both versions
contribute to the genetic trait. The most common version (allele) of the SERPINA1 gene, called M, produces normal levels of alpha-1
antitrypsin. Most people in the general population have two copies of the M allele (MM) in each cell. Other versions of the SERPINA1
gene lead to reduced levels of alpha-1 antitrypsin. For example, the S allele produces moderately low levels of this protein, and
the Z allele produces very little alpha-1 antitrypsin. Individuals with two copies of the Z allele (ZZ) in each cell are likely
to have alpha-1 antitrypsin deficiency. Those with the SZ combination have an increased risk of developing liver and lung diseases
such as chronic obstructive pulmonary disease (COPD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It is estimated that about 200,000 individuals
in the United States and Europe have severe alpha-1 antitrypsin deficiency. However, only about 5% of this number have been diagnosed
as symptoms caused by this deficiency are very similar to asthma and chronic obstructive pulmonary disease (COPD) from non-genetic
causes. Only about 1&ndash;2% of COPD patients have severe alpha-1 antitrypsin deficiency. The Global Initiative for Chronic Obstructive
Lung Disease (GOLD) defines COPD as group of airflow-limited diseases including emphysema and chronic bronchitis. While severe
alpha-1 antitrypsin deficiency can lead to or exacerbate all forms of COPD, it is considered to be the dominant cause of Panacinar
Emphysema, a form of emphysema which causes gradual destruction of all lung aveolii.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>PTB-101 SDF Alpha&trade; (alpha1-proteinase
inhibitor) for Alpha-1 Antitrypsin Deficiency (Alpha-1)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Abeona is developing PTB-101 SDF Alpha&trade;
(alpha-1-proteinase inhibitor) for chronic augmentation and maintenance therapy in adults with clinically evident panacinar emphysema
and other forms of COPD due to severe deficiency of alpha-1-proteinase inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Polymer Hydrogel Technology (PHT&trade;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>MuGard<SUP>&reg;</SUP> (mucoadhesive
oral wound rinse) approved for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">MuGard<SUP>&reg;</SUP> is our marketed product
for the management of oral mucositis, a frequent side-effect of cancer therapy for which there is no other established treatment.
MuGard, a proprietary nanopolymer formulation, has received marketing clearance from the FDA in the US as well as Europe, China,
Australia, New Zealand and Korea. We launched MuGard in the U.S. in 2010 and licensed MuGard for commercialization in the U.S.
to AMAG Pharmaceuticals, Inc. (AMAG) in 2013. We licensed MuGard to RHEI Pharmaceuticals, N.V. (RHEI) for China and other Southeast
Asian countries in 2010; Hanmi Pharmaceutical Co. Ltd. (Hanmi) for South Korea in 2014; and Norgine B.V. (Norgine) for the European
Union, Switzerland, Norway, Iceland, Lichtenstein, Australia and New Zealand in 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>ProctiGard&trade; (mucoadhesive oral
wound rinse) approved for rectal mucositis and radiation proctitis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ProctiGard&trade; received 510(K) marketing
clearance from the FDA on July 22, 2014 for the treatment of symptomatic management of rectal mucositis. ProctiGard is our product
for the treatment of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region. Radiation proctitis,
or RP, is the inflammation and damage to the lower portion of the colon after exposure to x-rays or ionizing radiation as part
of radiation therapy. RP is most common after treatments for cancer, such as cervical, colon and prostate cancer. RP can be acute,
occurring within weeks of initiation of therapy, or can occur months or years after treatment. We intend to commercialize ProctiGard
in a manner similar to the commercialization of MuGard, which may include confirmatory clinical trials, with the objective of commercialization
in collaboration with marketing partners globally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">We believe
that the value of technology both to us and to our potential corporate partners is established and enhanced by our broad intellectual
property positions. Consequently, we have already been issued and seek to obtain additional U.S. and foreign patent protection
for our products, including those under development and for new discoveries. Patent applications are filed with the U.S. Patent
and Trademark Office and, when appropriate, with the Paris Convention&rsquo;s Patent Cooperation Treaty (PCT) Countries (most major
countries in Western Europe and the Far East) for our inventions and prospective products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">We have a
strategy of maintaining an ongoing line of patent continuation applications for each major category of patentable carrier and delivery
technology. By this approach, we are extending the intellectual property protection of our basic targeting technology and initial
agents to cover additional specific carriers and agents, some of which are anticipated to carry the priority dates of the original
applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Gene licensed
patents</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have secured an exclusive license through
Nationwide Children&rsquo;s Hospital to the ABO-101 and ABO-102 patent portfolios for developing treatments for patients with Sanfilippo
Syndrome Type A and Type B. This portfolio comprises one patent family: &ldquo;Products and methods for delivery of polynuleotides
by adeno-associated virus for lysosomal storage disorders&rdquo;. Additionally, we have secured FDA Orphan drug designation for
both Sanfilippo A and B, which will provide 7 years of post-launch market exclusivity for both ABO-101 and ABO-102 in the U.S.
ABO-101 and ABO-102 are also eligible for 12 years of Biologics exclusivity upon approval in the US and 10 years of exclusivity
in the EU upon marketing authorization. We will be seeking Orphan Drug Status within the EMA, which will grant 10 years of post-market
exclusivity in the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We licensed the rights to two patents (62/092,501
and 62/146,793) with an exclusive, worldwide, licensing agreement with the UNeMed Corporation. The patents are &ldquo;Compositions
and Methods for the Treatment of Juvenile Neuronal Ceroid Lipofuscinosis&rdquo; and &ldquo;Gene Therapy for Juvenile Batten Disease&rdquo;
for an AAV gene therapy for the treatment of juvenile Batten disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We licensed one patent (62/000,590), &ldquo;Method
for Editing a Genetic Sequence&rdquo; with an exclusive, worldwide, licensing agreement with the University of Minnesota for an
AAV gene therapy for the treatment of patients with Fanconi anemia (FA) disorder and other rare blood diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We licensed two patents (13/594,773 and EPO
12756603.2) with a nonexclusive license agreement with Stanford University for an AAV delivery vector for the treatment of FA
and rare blood disease platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Plasma
based patents</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">We licensed
our SDF patents from Licensor issued U.S. Patents #7,879,331, #7,879,332, and #8,293,242, the last of which expires in September
2025. We have also licensed issued patents in Europe, China and Australia and pending applications in Canada and India. SDF patents
from Licensor the last of which expires in September 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>MuGard
patents</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">For our mucoadhesive
liquid technology, used in MuGard, two U.S. patents have been issued and two European patents have been granted. One European patent
has been issued in 19 European countries the other patent is in nationalization process. Patents have also been granted, or are
under review, in several other major territories worldwide. Our mucoadhesive liquid technology patents and applications cover a
range of products for a variety of diseases and conditions affecting the oral cavity, including the management of the various phases
of mucositis. MuGard mucoadhesive technology patents expire in 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">In addition
to issued patents, we have a number of pending patent applications. If issued, the patents underlying these applications could
extend the patent life of our technologies beyond the dates listed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">We are subject
to extensive regulation by the federal government, principally by the FDA, and, to a lesser extent, by other federal and state
agencies as well as comparable agencies in foreign countries where registration of products will be pursued. Although a number
of our formulations incorporate extensively tested drug substances, because the resulting formulations make claims of enhanced
efficacy and/or improved side effect profiles, they are expected to be classified as new drugs by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">The Federal
Food, Drug and Cosmetic Act and other federal, state and foreign statutes and regulations govern the testing, manufacturing, safety,
labeling, storage, shipping and record keeping of our products. The FDA has the authority to approve or not approve new drug applications
and inspect research, clinical and manufacturing records and facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">Among the
requirements for drug approval and testing is that the prospective manufacturer&rsquo;s facilities and methods conform to the FDA&rsquo;s
Code of Good Manufacturing Practices regulations, which establishes the minimum requirements for methods to be used in, and the
facilities or controls to be used during, the production process. Such facilities are subject to ongoing FDA inspection to insure
compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">The steps
required before a pharmaceutical product may be produced and marketed in the U.S. include preclinical tests, the filing of an Investigational
New Drug (&lsquo;&lsquo;IND&rsquo;&rsquo;) application with the FDA, which must become effective pursuant to FDA regulations before
human clinical trials may commence, numerous phases of clinical testing and the FDA approval of a New Drug Application (NDA) prior
to commercial sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">Preclinical
tests are conducted in the laboratory, usually involving animals, to evaluate the safety and efficacy of the potential product.
The results of preclinical tests are submitted as part of the IND application and are fully reviewed by the FDA prior to granting
the sponsor permission to commence clinical trials in humans. All trials are conducted under International Conference on Harmonization,
good clinical practice guidelines. All investigator sites and sponsor facilities are subject to FDA inspection to insure compliance.
Clinical trials typically involve a three-phase process. Phase 1 the initial clinical evaluations, consists of administering the
drug and testing for safety and tolerated dosages and in some indications such as cancer and HIV, as preliminary evidence of efficacy
in humans. Phase 2 involves a study to evaluate the effectiveness of the drug for a particular indication and to determine optimal
dosage and dose interval and to identify possible adverse side effects and risks in a larger patient group. When a product is found
safe, and initial efficacy is established in Phase 2, it is then evaluated in Phase 3 clinical trials. Phase 3 trials consist of
expanded multi-location testing for efficacy and safety to evaluate the overall benefit-to-risk index of the investigational drug
in relationship to the disease treated. The results of preclinical and human clinical testing are submitted to the FDA in the form
of an NDA for approval to commence commercial sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">The process
of forming the requisite testing, data collection, analysis and compilation of an IND and an NDA is labor intensive and costly
and may take a protracted time period. In some cases, tests may have to be redone or new tests instituted to comply with FDA requests.
Review by the FDA may also take considerable time and there is no guarantee that an NDA will be approved. Therefore, we cannot
estimate with any certainty the length of the approval cycle.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">We are also
governed by other federal, state and local laws of general applicability, such as laws regulating working conditions, employment
practices, as well as environmental protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>License Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Gene therapy
license agreements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On May 15,
2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children&rsquo;s Hospital to the
AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. This portfolio
comprises 1 patent family: &ldquo;Products and methods for delivery of polynuleotides by adeno-associated virus for lysosomal storage
disorders&rdquo;. Additionally, Abeona has secured FDA Orphan drug designation for both Sanfilippo A and B, which will provide
7 years of post-launch market exclusivity for both ABX-A and ABX-B in the U.S. Abeona will be seeking Orphan Drug Status within
the EMA, which will grant 10 years of post-market exclusivity in the European Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On June 5,
2015, we entered into an exclusive, worldwide, licensing agreement with the UNeMed Corporation, the technology transfer and commercialization
office for the University of Nebraska Medical Center (UNMC) in Omaha, Nebraska, for an AAV gene therapy for the treatment of juvenile
Batten disease. We licensed the rights to two patents (62/092,501 and 62/146,793). Under the terms of the licensing agreement,
we paid a license fee of $75,000 and will pay milestone payments on certain milestone events. Commencing with the first commercial
sale of licensed products a royalty will be paid. Terms of the agreement require we execute a sponsored research agreement with
UNMC focused on additional efficacy studies within 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On October
14, 2015 we entered into a sponsored research agreement with UNMC to support ongoing AAV/CLN3 projects in the amount of $215,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On June 5,
2015, we entered into an exclusive, worldwide, licensing agreement with the University of Minnesota for an AAV gene therapy for
the treatment of patients with Fanconi anemia (FA) disorder and other rare blood diseases. We licensed one patent (62/000,590),
Method for Editing a Genetic Sequence. Under terms of the licensing agreement, we paid a license fee of $80,000, will pay an additional
license fee of $50,000, will pay annual maintenance fees and a royalty fee with the first commercial sale of licensed products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On September
17, 2015, we entered into a nonexclusive license agreement with Stanford University for an AAV delivery vector for the treatment
of FA and rare blood disease platform. This license augments the University of Minnesota agreement. We licensed two patents (13/594,773
and EPO 12756603.2). Under terms of the licensing agreement, we paid a license fee of $25,000, will pay annual maintenance fees
and a royalty fee with the first commercial sale of licensed products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Plasma-based
therapeutics license agreements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On September
22, 2014, we entered into an exclusive, worldwide, licensing agreement with Licensor to obtain rights to utilize and to sub-license
to other pharmaceuticals firms, its patented methods for the extraction of therapeutic biologics from human plasma. Under the terms
of the licensing agreement, as amended on January 23, 2015, we paid a license fee of $1 million in cash, will pay $4,000,000 in
cash or 1,096,151 shares of our common stock in 2017, a regulatory approval milestone payment of 513,375 shares of our common stock
upon the first FDA regulatory approval of a drug derived from the Licensor&rsquo;s proprietary SDF process, and a tiered royalty
on annual net sales of plasma fractions produced with Licensor&rsquo;s proprietary SDF process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">We believe
that Licensor&rsquo;s proprietary fractionation process is expected to significantly enhance yields of key value blood proteins,
including A1PI, expanding market opportunities, while greatly enhancing margins. The Company obtained rights to utilize and sub-license
to other pharmaceutical firms the recently patented improved methods for the extraction of therapeutic biologics from human plasma.
We believe that Licensor&rsquo;s lead product, A1PI, offers a low-risk, high revenue, short time to market respiratory product
for treatment of inherited COPD (pulmonary emphysema), among other genetic A1PI deficiencies. Additionally, the ability to extract
several additional therapeutically useful and important proteins, due to the process being less destructive than historical fractionation
processes, may enable us to seek new therapeutic applications and address high-value-added orphan indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>MuGard license agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On June 6,
2013 we entered into an exclusive license agreement with AMAG related to the commercialization of MuGard in the U.S. and its territories.
Under the terms of the licensing agreement, we received an upfront licensing fee of $3.3 million and will receive a tiered, double-digit
royalty on net sales of MuGard in the licensed territories. AMAG also purchased our existing MuGard inventory. The $3.3 million
license fee is accounted for as deferred revenue and is recognized over ten years, which is the life of the license agreement.
The license term expires June 6, 2023. The license can also terminate in the event of breach by either us or AMAG or by AMAG at
anytime with 180 days prior notice of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On March
11, 2014, we announced we had entered into an exclusive license agreement with Hanmi related to MuGard commercialization in South
Korea. Under the terms of the agreement, we received an upfront licensing fee and double digit royalties on sales of MuGard in
the licensed territory. The license term expires February 26, 2024. The license can also terminate in the event of breach or by
Hanmi at anytime with 180 days prior notice of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On August
7, 2014, we entered into an exclusive license agreement with Norgine, a leading independent European specialty pharmaceutical company,
for the commercialization of MuGard in Europe. Under the terms of the license agreement, we could receive up to $10 million in
milestone payments and an escalating double digit royalty on the net sales of the oral mucositis product, MuGard, in the licensed
territories. Norgine will develop, manufacture, and commercialize MuGard in the European Union, Switzerland, Norway, Iceland and
Lichtenstein. Norgine anticipates launching MuGard in 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">The pharmaceutical
and biotechnology industry is characterized by intense competition, rapid product development and technological change. Competition
is intense among manufacturers of prescription pharmaceuticals and other product areas where we may develop and market products
in the future. Most of our potential competitors are large, well established pharmaceutical, chemical or healthcare companies with
considerably greater financial, marketing, sales and technical resources than are available to us. Additionally, many of our potential
competitors have research and development capabilities that may allow such competitors to develop new or improved products that
may compete with our product lines. Our potential products could be rendered obsolete or made uneconomical by the development of
new products to treat the conditions to be addressed by our developments, technological advances affecting the cost of production,
or marketing or pricing actions by one or more of our potential competitors. Our business, financial condition and results of operation
could be materially adversely affected by any one or more of such developments. We cannot assure you that we will be able to compete
successfully against current or future competitors or that competition will not have a material adverse effect on our business,
financial condition and results of operations. Academic institutions, governmental agencies and other public and private research
organizations are also conducting research activities and seeking patent protection and may commercialize products on their own
or with the assistance of major health care companies in areas where we are developing product candidates. We are aware of certain
development projects for products to treat or prevent certain diseases targeted by us, and the existence of these potential products
or other products or treatments of which we are not aware, or products or treatments that may be developed in the future, may adversely
affect the marketability of products developed by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Gene therapy
competition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">The gene
therapy industry is highly competitive and driven by several large competitors including Bluebird, Voyager, Regenx, Spark, Dimension,
Avalanche, Uniqure, and Lysogene. We face competition from both US based and international based producers of plasma products who
may have greater access to capital, production facilities and resources for both research and development as well as commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Plasma-based
therapeutics competition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">The plasma
therapeutics industry is highly competitive and driven by several large competitors including Baxter International, Inc. (&ldquo;Baxter&rdquo;),
CSL Behring (&ldquo;CSL&rdquo;) and Grifols SA (&ldquo;Grifols&rdquo;). Each of these groups produce A1PI under the name of the
following, Baxter (Aralast, license of Glassia from Kamada), CSL (Zemairia) and Grifols (Prolastin) Other regional competitors
include, but are not limited to, BPL, Kedrion, LFB Group SA, and Octapharma AG. We face competition from both US based and international
based producers of plasma products who may have greater access to capital, production facilities and resources for both research
and development as well as supplies of plasma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">Furthermore,
plasma derived products also face competition from products that are not derived from plasma, and other courses of treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>MuGard
competition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">ActoGeniX
N.V., Alder Biopharmaceuticals, Inc., Applied Protein Sciences, LLC, Avaxia Biologics, Inc., BioAlliance Pharma S.A., BMG Pharma
s.r.l., Camurus AB, DARA BioSciences, Inc. EUSA Pharma, Galera Therapeutics, Inc. Maya Biotech Ltd., NephRx, Piramal Healthcare
Ltd., Soligenix, Inc. and Synedgen are developing products to treat mucositis that may compete with our mucoadhesive liquid technology.
Products which are marketed to treat mucositis include Caphosol by EUSA Pharma, Gelclair by DARA BioSciences, Inc., Episil by Camurus
AB, and Kepivance by Biovitrum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">Many of these
competitors have greater financial and other resources, including larger research and development, marketing and manufacturing
organizations. As a result, our competitors may successfully develop technologies and drugs that are more effective or less costly
than any that we are developing or which would render our technology and future products obsolete and noncompetitive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">In addition,
some of our competitors have greater experience than we do in conducting preclinical and clinical trials and obtaining FDA and
other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals for drug candidates
more rapidly than we do. Companies that complete clinical trials, obtain required regulatory agency approvals and commence commercial
sale of their drugs before their competitors may achieve a significant competitive advantage. Drugs resulting from our research
and development efforts or from our joint efforts with collaborative partners therefore may not be commercially competitive with
our competitors&rsquo; existing products or products under development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">In the area
of advanced drug delivery, which is the focus of our early stage research and development activities, a number of companies are
developing or evaluating enhanced drug delivery systems. We expect that technological developments will occur at a rapid rate and
that competition is likely to intensify as various alternative delivery system technologies achieve similar if not identical advantages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">Even if our
products are fully developed and receive required regulatory approval, of which there can be no assurance, we believe that our
products can only compete successfully if marketed by a company having expertise and a strong presence in the therapeutic area.
Consequently, we do not currently plan to establish an internal marketing organization. By forming strategic alliances with major
and regional pharmaceutical companies, management believes that our development risks should be minimized and that the technology
potentially could be more rapidly developed and successfully introduced into the marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Other Key Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>2015 Financings</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 23, 2015 we closed a $7 million private
placement of common stock consisting of 2,333,333 shares of our common stock, at a price of $3.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 11, 2015, we closed a $10 million private
placement of common stock consisting of 1,250,000 shares of our common stock, at a price of $8.00 per share and warrants to purchase
625,000 shares of common stock. The warrants have an exercise price of $8.00 per share and are exercisable for 30 months from the
closing date. A total net of $9.2 million was received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also in connection with the financing, the
placement agent received warrants to purchase 50,000 shares of common stock at $11.00 per share and which are exercisable for five
years from the closing date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the second quarter we received additional
financing of $4.6 million through warrant exercises of our $5.00 warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 31, 2015 we closed an upsized $15.5
million direct placement of registered common stock with institutional investors, including Soros Fund Management and Perceptive
Life Science Fund, and two members of our Board of Directors. The financing was comprised of 2.83 million shares of our common
stock at a price of $5.50 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>$14 Million Financing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 24, 2014, we announced the closing
of an underwritten public offering of 3,500,000 shares of our common stock, and warrants to purchase up to an aggregate 3,500,000
shares of common stock, at an offering price of $4.00 per share and $.01 per warrant. The warrants have a per share exercise price
of $5.00, are exercisable immediately, and expire 5 years from the date of issuance. The gross proceeds to the Company from this
offering were $14,035,000, before deducting underwriting discounts and commissions and other estimated offering expenses. All of
the shares and warrants in the offering were sold by the Company. The shares and warrants began trading on The NASDAQ Capital Market
on December 19, 2014 under the symbols &ldquo;PTBI&rdquo; and &ldquo;PTBIW,&rdquo; respectively. In connection with the closing
of the public offering, on December 24, 2014, all of our outstanding Series A and Series B preferred stock was converted into common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Acquisition
of Abeona Therapeutics LLC</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 5, 2015, the Company, Plasmatech
Merger Sub Inc. (&ldquo;Merger Sub&rdquo;), a wholly owned subsidiary of the Company and a Delaware corporation, Abeona Therapeutics
LLC, an Ohio limited liability company (&ldquo;Abeona Ohio&rdquo;) and Paul A. Hawkins, an individual, solely in his capacity
as Member Representative (&ldquo;Member Representative&rdquo;) entered into an Agreement and Plan of Merger (the &ldquo;Merger
Agreement&rdquo;). Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with
and into Abeona Ohio, with Abeona Ohio continuing as the surviving corporation and became a wholly owned subsidiary of the Company
(the &ldquo;Merger&rdquo;). Our Board of Directors and the Managers of Abeona Ohio have unanimously approved the transaction.
The merger closed on May 15, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Merger, the Company
issued to Abeona Ohio members a total of 3,979,761 common shares upon closing of the transaction, and may issue up to an additional
$9 million in performance milestones, in common stock or cash, at the Company&rsquo;s option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Plasma Technologies LLC License (&ldquo;Licensor&rdquo;)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On September
22, 2014, we entered into an exclusive, worldwide licensing agreement with Licensor to obtain rights to utilize and to sub-license
its patented methods for the extraction of therapeutic biologics from human plasma. Plasma biologics are bio-pharmaceutical proteins
extracted, purified, and formulated from human blood plasma by the use of biotechnological processing techniques including precipitation,
diafiltration, affinity chromatography, and ion-exchange chromatography. Because plasma biologics are biosimilar, they are less
likely than recombinant or transgenic proteins to cause toxic or other adverse reactions, or cause adverse immunological responses
such as the stimulation of inhibitors in recipients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">Under the
terms of the licensing agreement, as amended on January 23, 2015, we paid a license fee of $1 million in cash, will pay $4,000,000
in cash or 1,096,151 shares of our common stock in 2017, a regulatory approval milestone payment of 513,375 shares of our common
stock upon the first FDA regulatory approval of a drug derived from the Licensor&rsquo;s proprietary SDF process, and a tiered
royalty on annual net sales of plasma fractions produced with Licensor&rsquo;s proprietary SDF process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Miscellaneous</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 5, 2015 we announced that enrollment
has begun in a clinical trial at UCLA&rsquo;s Jonsson Comprehensive Cancer Center that is evaluating MuGard in the prevention and
treatment of stomatitis in breast cancer patients using Everolimus (marketed by Novartis Oncology under the tradename Afinitor&reg;).
The title of the trial is &ldquo;Phase II Randomized Trial of MuGard Compared With Best Supportive Care for Prevention and Treatment
of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy&rdquo;
and details on the trial design and enrollment can be found on its website, clinicaltrials.gov, under the identifier NCT02015559.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2015 we announced that Hanmi has
received marketing approval in Korea from the country&rsquo;s Ministry of Food and Drug Safety (&ldquo;MFDS&rdquo;) and the Korea
Testing &amp; Research Institute (KTR) for MuGard. Under the terms of the previously announced marketing agreement, Hanmi will
import MuGard from the United States and marketing will commence. Hanmi intends to market MuGard in Korea under the trade name
Mucogard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 7, 2015 we announced we had appointed
Charlie Strange, M.D. to our Scientific Advisory Board (SAB). Dr. Strange is a highly regarded thought leader in the Alpha-1 community,
and has extensive clinical experience in designing and managing Alpha-1 clinical studies. We believe his advice and counsel will
help accelerate development and approval of our proprietary SDF Alpha&trade; biologic drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 12, 2015 we announced that Todd Wider,
MD joined our board of directors. Dr. Wider has a strong medical background and significant experience in small and mid-cap biotechnology
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 15, 2015 Timothy J. Miller, PhD became
our President and CEO and joined our board of directors. <FONT STYLE="background-color: white">Dr. Miller was President &amp; CEO
of Abeona Therapeutics LLC from 2013 to 2015. He has 16 years of scientific research, product development, regulatory and clinical
operations expertise, with a focus on transitioning novel biotherapeutics through pre-clinical phases and into Phase 1 and 2 human
clinical trials. Dr. Miller earned his PhD in Pharmacology with a focus on Gene therapy/Cystic Fibrosis from Case Western University.
He also holds a B.S. in Biology and M.S. in Molecular Biology from John Carroll University (Cleveland, OH).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 8, 2015 we licensed exclusive worldwide
rights to an AAV gene therapy and intellectual property for the treatment of JNCL also known as juvenile Batten disease from UNeMed
Corporation, the technology transfer and commercialization office for the University of Nebraska Medical Center in Omaha, Nebraska
for undisclosed terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 15, 2015 we licensed exclusive worldwide
rights to an AAV gene therapy and intellectual property from the University of Minnesota to treat patients with Fanconi anemia
(FA) disorder and other rare blood diseases using the CRISPR/cas9 technology platform for undisclosed terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2015 we announced we changed our
name to Abeona Therapeutics Inc. from PlasmaTech Biopharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 7, 2015 we announced preliminary results
of our SDF plasma protein programs, confirming that multiple batches of our two-step salt precipitation process yields resultant
fractions with significantly enhanced levels of alpha-1 protease inhibitor and immunoglobulins (IVIG) relative to the industry-standard
Cohn process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 6, 2015 we announced a license with
Stanford University for AAV LK19, a therapeutic gene delivery vector for the treatment of Fanconi anemia (FA) and rare blood disease
platform. The license augments a previously announced license agreement with the University of Minnesota for ABO-301 (AAV-FANCC)
to treat patients with FA disorder and other rare blood diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 11, 2016 we announced initial regulatory
approval for Phase 1/2 gene therapy clinical studies for patients with Sanfilippo syndrome types A and B. The Interministerial
Council of Genetically Modified Organisms has approved the Genetically Modified Organism (GMO) Voluntary Release regulatory filings
for both Phase 1/2 Gene Therapy Clinical Studies to treat patients with ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH) for patients
with Sanfilippo syndrome type A (MPS IIIA) or type B (MPS IIIB). Additionally, the Comite Etico De Investigacion Clinica de Euskadi
(CEIC-E) has approved the ethical committee regulatory filings for both ABO-101 and ABO-102. Abeona plans to file CTAs for both
programs shortly for the upcoming clinical studies to be conducted at Cruces University Hospital (Bilbao, Spain).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 29, 2016 we announced the FDA cleared
our Investigational New Drug Application for ABO-102 (AAV-SGSH), a single treatment strategy for Mucopolysaccharidosis Type IIIA
(MPS IIIA). The ABO-102 IND application is now active and enables Nationwide Children&rsquo;s Hospital (Columbus, OH) to initiate
a Phase 1/2 clinical study designed to assess the safety, tolerability and potential efficacy of ABO-102 in children with MPS III
A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our principal executive office is located at
3333 Lee Parkway, Suite 600, Dallas, Texas 75219. Our telephone number is (214) 665-9495. We also have offices in New York at 1325
Avenue of the Americas, 27<SUP>th</SUP> Floor, New York, NY 10019. Our telephone number is (212) 786-6208. We also have offices
and laboratory in Ohio at 6555 Carnegie Ave., 4<SUP>th</SUP> Floor, Cleveland, OH 44103.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We were incorporated in Wyoming in 1974 as
Chemex Corporation, and in 1983 we changed our name to Chemex Pharmaceuticals, Inc. We changed our state of incorporation from
Wyoming to Delaware on June 30, 1989. In 1996 we merged with Access Pharmaceuticals, Inc., a private Texas corporation, and changed
our name to Access Pharmaceuticals, Inc. On October 24, 2014 we changed our name to PlasmaTech Biopharmaceuticals, Inc. On June
19, 2015 we changed our name to Abeona Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Suppliers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Some materials used by us are specialized.
We obtain materials from several suppliers based in different countries around the world. If materials are unavailable from one
supplier we generally have alternate suppliers available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 30, 2016, we had 15 full-time employees,
six of whom have advanced scientific degrees. We have never experienced employment-related work stoppages and consider that we
maintain good relations with our personnel. In addition, to complement our internal expertise, we have contracts with scientific
consultants, contract research organizations and university research laboratories that specialize in various aspects of drug development
including clinical development, regulatory affairs, toxicology, process scale-up and preclinical testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Web Availability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We make available free of charge through our
website, <U>www.abeonatherapeutics.com</U>, our annual reports on Form 10-K and other reports that we file with the Securities
and Exchange Commission as well as certain of our corporate governance policies, including the charters for the audit, compensation
and nominating and corporate governance committees of the Board of Directors (the &ldquo;Board&rdquo;) and our code of ethics,
corporate governance guidelines and whistleblower policy. We will also provide to any person without charge, upon request, a copy
of any of the foregoing materials. Any such request must be made in writing to us at: Abeona Therapeutics Inc. c/o Investor Relations,
3333 Lee Parkway, Suite 600, Dallas, TX 75219.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_003"></A>ITEM 1A. RISK FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Relating to our Business and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We have experienced a history of losses,
we expect to incur future losses and we may be unable to obtain necessary additional capital to fund operations in the future.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have recorded minimal revenue to date and
have incurred an accumulated deficit of approximately $310.6 million through December 31, 2015 and $296.1 million through December
31, 2014. Net loss allocable to common stockholders for the year ended December 31, 2015 was $14.5 million and the net loss for
the year ended December 31, 2014 was $29.7 million. Our losses have resulted principally from costs incurred in research and development
activities related to our efforts to develop clinical drug candidates, from losses due to derivatives and from the associated administrative
costs. We expect to incur additional operating losses over the next several years. We also expect cumulative losses to increase
if we expand research and development efforts and preclinical and clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We require substantial capital for our
development programs and operating expenses, to pursue regulatory clearances and to prosecute and defend our intellectual property
rights. We will need to raise substantial additional capital to support our ongoing and planned operations.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we raise additional funds by issuing equity
securities, further dilution to existing stockholders will result and future investors may be granted rights superior to those
of existing stockholders. If adequate funds are not available to us through additional equity offerings, we may be required to
delay, reduce the scope of or eliminate one or more of our research and development programs or to obtain funds by entering into
arrangements with collaborative partners or others that require us to issue additional equity securities or to relinquish rights
to certain technologies or drug candidates that we would not otherwise issue or relinquish in order to continue independent operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We do not have significant operating revenue
and may never attain profitability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have funded our operations primarily
through private sales of common stock, preferred stock and convertible notes. Contract research payments and licensing fees from
corporate alliances and mergers have also provided funding for our operations. Our ability to achieve significant revenue or profitability
depends upon our licensees ability to successfully market MuGard in North America, Europe, Australia, New Zealand, Korea and China
or to complete the development of our drug candidates, to develop and obtain patent protection and regulatory approvals for our
drug candidates and to manufacture and commercialize the resulting drugs. We are not expecting any significant revenues in the
short-term from our products or product candidates. Furthermore, we may not be able to ever successfully identify, develop, commercialize,
patent, manufacture, obtain required regulatory approvals and market any additional products. Moreover, even if we do identify,
develop, commercialize, patent, manufacture, and obtain required regulatory approvals to market additional products, we may not
generate revenues or royalties from commercial sales of these products for a significant number of years, if at all. Therefore,
our proposed operations are subject to all the risks inherent in the establishment of a new business enterprise. In the next few
years, our revenues may be limited to minimal product sales and royalties, and any amounts that we receive under strategic partnerships
and research or drug development collaborations that we may establish and, as a result, we may be unable to achieve or maintain
profitability in the future or to achieve significant revenues in order to fund our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We may not successfully commercialize our
drug candidates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our drug candidates are subject to the risks
of failure inherent in the development of pharmaceutical products based on new technologies, and our failure to develop safe commercially
viable drugs would severely limit our ability to become profitable or to achieve significant revenues. We may be unable to successfully
commercialize our drug candidates because:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">some or all of our drug candidates may be found to be unsafe or ineffective or otherwise fail to
meet applicable regulatory standards or receive necessary regulatory clearances;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">our drug candidates, if safe and effective, may be too difficult to develop into commercially viable
drugs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">it may be difficult to manufacture or market our drug candidates on a large scale;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">proprietary rights of third parties may preclude us from marketing our drug candidates; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">third parties may market superior or equivalent drugs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The success of our research and development
activities, upon which we primarily focus, is uncertain.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our primary focus is on our research and development
activities and the commercialization of compounds covered by proprietary biopharmaceutical patents and patent applications. Research
and development activities, by their nature, preclude definitive statements as to the time required and costs involved in reaching
certain objectives. Actual research and development costs, therefore, could significantly exceed budgeted amounts and estimated
time frames may require significant extension. Cost overruns, unanticipated regulatory delays or demands, unexpected adverse side
effects or insufficient therapeutic efficacy will prevent or substantially slow our research and development effort and our business
could ultimately suffer. We anticipate that we will remain principally engaged in research and development activities for an indeterminate,
but substantial, period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We may be unable to successfully develop,
market, or commercialize our products or our product candidates without establishing new relationships and maintaining current
relationships and our ability to successfully commercialize, and market our product candidates could be limited if a number of
these existing relationships are terminated.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our strategy for the research, development
and commercialization of our potential pharmaceutical products may require us to enter into various arrangements with corporate
and academic collaborators, licensors, licensees and others, in addition to our existing relationships with other parties. Specifically,
we may seek to joint venture, sublicense or enter other marketing arrangements with parties that have an established marketing
capability or we may choose to pursue the commercialization of such products on our own. We may, however, be unable to establish
such additional collaborative arrangements, license agreements, or marketing agreements as we may deem necessary to develop, commercialize
and market our potential pharmaceutical products on acceptable terms. Furthermore, if we maintain and establish arrangements or
relationships with third parties, our business may depend upon the successful performance by these third parties of their responsibilities
under those arrangements and relationships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We may be unable to successfully manufacture
our products and our product candidates in clinical quantities or for commercial purposes without the assistance of contract manufacturers,
which may be difficult for us to obtain and maintain.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have limited experience in the manufacture
of pharmaceutical products in clinical quantities or for commercial purposes and we may not be able to manufacture any new pharmaceutical
products that we may develop. As a result, we have established, and in the future intend to establish arrangements with contract
manufacturers to supply sufficient quantities of products to conduct clinical trials and for the manufacture, packaging, labeling
and distribution of finished pharmaceutical products if any of our potential products are approved for commercialization. If we
are unable to contract for a sufficient supply of our potential pharmaceutical or biopharmaceutical products on acceptable terms,
our preclinical and human clinical testing schedule may be delayed, resulting in the delay of our clinical programs and submission
of product candidates for regulatory approval. This may cause our business to suffer if there are delays or difficulties in establishing
relationships with manufacturers to produce, package, label and distribute our finished pharmaceutical or biopharmaceutical or
other medical products, if any. Moreover, US contract manufacturers that we may use must adhere to current Good Manufacturing Practices,
as required by the FDA. In this regard, the FDA will not issue a pre-market approval or product and establishment licenses, where
applicable, to a manufacturing facility for the products until the manufacturing facility passes a pre-approval plant inspection.
If we are unable to obtain or retain third party manufacturing on commercially acceptable terms, we may not be able to commercialize
our products as planned. Our potential dependence upon third parties for the manufacture of our products may adversely affect our
ability to generate profits or acceptable profit margins and our ability to develop and deliver such products on a timely and competitive
basis.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We are subject to extensive governmental
regulation which increases our cost of doing business and may affect our ability to commercialize any new products that we may
develop.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA and comparable agencies in foreign
countries impose substantial requirements upon the introduction of pharmaceutical products through lengthy and detailed laboratory,
preclinical and clinical testing procedures and other costly and time-consuming procedures to establish safety and efficacy. All
of our drugs and drug candidates require receipt and maintenance of governmental approvals for commercialization. Preclinical and
clinical trials and manufacturing of our drug candidates will be subject to the rigorous testing and approval processes of the
FDA and corresponding foreign regulatory authorities. Satisfaction of these requirements typically takes a significant number of
years and can vary substantially based upon the type, complexity and novelty of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to the time-consuming and uncertain nature
of the drug candidate development process and the governmental approval process described above, we cannot assure you when we,
independently or with our collaborative partners, might submit a New Drug Application, or NDA, for FDA or other regulatory review.
Further, our ability to commence and/or complete development projects will be subject to our ability to raise enough funds to pay
for the development costs of these projects. Government regulation also affects the manufacturing and marketing of pharmaceutical
products. Government regulations may delay marketing of our potential drugs for a considerable or indefinite period of time, impose
costly procedural requirements upon our activities and furnish a competitive advantage to larger companies or companies more experienced
in regulatory affairs. Delays in obtaining governmental regulatory approval could adversely affect our marketing as well as our
ability to generate significant revenues from commercial sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our drug candidates may not receive FDA or
other regulatory approvals on a timely basis or at all. Moreover, if regulatory approval of a drug candidate is granted, such approval
may impose limitations on the indicated use for which such drug may be marketed. Even if we obtain initial regulatory approvals
for our drug candidates, our drugs and our manufacturing facilities would be subject to continual review and periodic inspection,
and later discovery of previously unknown problems with a drug, manufacturer or facility may result in restrictions on the marketing
or manufacture of such drug, including withdrawal of the drug from the market. The FDA and other regulatory authorities stringently
apply regulatory standards and failure to comply with regulatory standards can, among other things, result in fines, denial or
withdrawal of regulatory approvals, product recalls or seizures, operating restrictions and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The uncertainty associated with preclinical
and clinical testing may affect our ability to successfully commercialize new products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before we can obtain regulatory
approvals for the commercial sale of any of our potential drugs, the drug candidates will be subject to extensive preclinical
and clinical trials to demonstrate their safety and efficacy in humans. Preclinical or clinical trials of future drug
candidates may not demonstrate the safety and efficacy to the extent necessary to obtain regulatory approvals and our drug
candidates could result in injury or death to patients in our clinical trials. In this regard, for example, adverse side
effects can occur during the clinical testing of a new drug on humans which may delay ultimate FDA approval or even lead it
to terminate our efforts to develop the drug for commercial use. Companies in the biotechnology industry have suffered
significant setbacks in advanced clinical trials, even after demonstrating promising results in earlier trials, including
injury or death. The failure to adequately demonstrate the safety and efficacy of a drug candidate under development could delay
or prevent regulatory approval of the drug candidate. A delay or failure to receive regulatory approval for any of our drug
candidates could prevent us from successfully commercializing such candidates and we could incur substantial additional
expenses in our attempt to further develop such candidates and obtain future regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We may incur substantial product liability
expenses due to the use or misuse of our products for which we may be unable to obtain insurance coverage.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our business exposes us to potential
liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical products. These risks will
expand with respect to our drug candidates, if any, that receive regulatory approval for commercial sale and we may face
substantial liability for damages in the event of adverse side effects, including injury or death, or product
defects identified with any of our products that are used in clinical tests or marketed to the public. Product liability
insurance for the biotechnology industry is generally expensive, if available at all, and as a result, we may be unable
to obtain insurance coverage at acceptable costs or in a sufficient amount in the future, if at all. We may be unable to
satisfy any claims for which we may be held liable as a result of the use or misuse of products which we developed,
manufactured or sold and any such product liability claim could adversely affect our business, operating results or financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Intense competition may limit our ability
to successfully develop and market commercial products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The biotechnology and pharmaceutical industries
are intensely competitive and subject to rapid and significant technological change. Our competitors in the U.S. and elsewhere
are numerous and include, among others, major multinational pharmaceutical and chemical companies, specialized biotechnology firms
and universities and other research institutions. Many of our competitors have and employ greater financial and other resources,
including larger research and development, marketing and manufacturing organizations. As a result, our competitors may successfully
develop technologies and drugs that are more effective or less costly than any that we are developing or which would render our
technology and future products obsolete and noncompetitive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, some of our competitors have greater
experience than we do in conducting preclinical and clinical trials and obtaining FDA and other regulatory approvals. Accordingly,
our competitors may succeed in obtaining FDA or other regulatory approvals for drug candidates more rapidly than we can. Companies
that complete clinical trials, obtain required regulatory agency approvals and commence commercial sale of their drugs before their
competitors may achieve a significant competitive advantage. Drugs resulting from our research and development efforts or from
our joint efforts with collaborative partners therefore may not be commercially competitive with our competitors&rsquo; existing
products or products under development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our ability to successfully develop and
commercialize our drug candidates will substantially depend upon the availability of reimbursement funds for the costs of the resulting
drugs and related treatments.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Market acceptance and sales of our product
candidates may depend on coverage and reimbursement policies and health care reform measures. Decisions about formulary coverage
as well as levels at which government authorities and third-party payers, such as private health insurers and health maintenance
organizations, reimburse patients for the price they pay for our products as well as levels at which these payors pay directly
for our products, where applicable, could affect whether we are able to commercialize these products. We cannot be sure that reimbursement
will be available for any of these products. Also, we cannot be sure that coverage or reimbursement amounts will not reduce the
demand for, or the price of, our products. We have not commenced efforts to have our product candidates reimbursed by government
or third party payors. If coverage and reimbursement are not available or are available only at limited levels, we may not be able
to commercialize our products. In recent years, officials have made numerous proposals to change the health care system in the
U.S. These proposals include measures that would limit or prohibit payments for certain medical treatments or subject the pricing
of drugs to government control. In addition, in many foreign countries, particularly the countries of the European Union, the pricing
of prescription drugs is subject to government control. If our products are or become subject to government regulation that limits
or prohibits payment for our products, or that subjects the price of our products to governmental control, we may not be able to
generate revenue, attain profitability or commercialize our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of legislative proposals and the
trend towards managed health care in the U.S., third-party payors are increasingly attempting to contain health care costs by limiting
both coverage and the level of reimbursement of new drugs. They may also impose strict prior authorization requirements and/or
refuse to provide any coverage of uses of approved products for medical indications other than those for which the FDA has granted
market approvals. As a result, significant uncertainty exists as to whether and how much third-party payors will reimburse patients
for their use of newly-approved drugs, which in turn will put pressure on the pricing of drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The market may not accept any pharmaceutical
products that we develop.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The drugs that we are attempting to develop
may compete with a number of well-established drugs manufactured and marketed by major pharmaceutical companies. The degree of
market acceptance of any drugs developed by us will depend on a number of factors, including the establishment and demonstration
of the clinical efficacy and safety of our drug candidates, the potential advantage of our drug candidates over existing therapies
and the reimbursement policies of government and third-party payers. Physicians, patients or the medical community in general may
not accept or use any drugs that we may develop independently or with our collaborative partners and if they do not, our business
could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Healthcare reform measures could hinder
or prevent our product candidates&rsquo; commercial success.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The U.S. government and other governments have
shown significant interest in pursuing healthcare reform. Any government-adopted reform measures could adversely impact the pricing
of healthcare products and services in the U.S. or internationally and the amount of reimbursement available from governmental
agencies or other third party payors. The continuing efforts of the U.S. and foreign governments, insurance companies, managed
care organizations and other payors of health care services to contain or reduce health care costs may adversely affect our ability
to set prices for our products which we believe are fair, and our ability to generate revenues and achieve and maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">New laws, regulations and judicial decisions,
or new interpretations of existing laws, regulations and decisions, that relate to healthcare availability, methods of delivery
or payment for products and services, or sales, marketing or pricing, may limit our potential revenue, and we may need to revise
our research and development programs. The pricing and reimbursement environment may change in the future and become more challenging
due to several reasons, including policies advanced by the current executive administration in the U.S., new healthcare legislation
or fiscal challenges faced by government health administration authorities. Specifically, in both the U.S. and some foreign jurisdictions,
there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our
ability to sell our products profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For example, in March 2010, President Obama
signed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA.
This law will substantially change the way healthcare is financed by both government health plans and private insurers, and significantly
impact the pharmaceutical industry. The PPACA contains a number of provisions that are expected to impact our business and operations
in ways that may negatively affect our potential revenues in the future. For example, the PPACA imposes a non-deductible excise
tax on pharmaceutical manufacturers or importers that sell branded prescription drugs to U.S. government programs which we believe
will increase the cost of our products. In addition, as part of the PPACA&rsquo;s provisions closing a funding gap that currently
exists in the Medicare Part D prescription drug program (commonly known as the &lsquo;&lsquo;donut hole&rsquo;&rsquo;), we will
be required to provide a discount on branded prescription drugs equal to 50% of the government-negotiated price, for drugs provided
to certain beneficiaries who fall within the donut hole. Similarly, PPACA increases the level of Medicaid rebates payable by manufacturers
of brand-name drugs from 15.1% to 23.1% and requires collection of rebates for drugs paid by Medicaid managed care organizations.
The PPACA also includes significant changes to the 340B drug discount program including expansion of the list of eligible covered
entities that may purchase drugs under the program. At the same time, the expansion in eligibility for health insurance benefits
created under PPACA is expected to increase the number of patients with insurance coverage who may receive our products. While
it is too early to predict all the specific effects the PPACA or any future healthcare reform legislation will have on our business,
they could have a material adverse effect on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Congress periodically adopts legislation like
the PPACA and the Medicare Prescription Drug, Improvement and Modernization Act of 2003, that modifies Medicare reimbursement and
coverage policies pertaining to prescription drugs. Implementation of these laws is subject to ongoing revision through regulatory
and sub regulatory policies. Congress also may consider additional changes to Medicare policies, potentially including Medicare
prescription drug policies, as part of ongoing budget negotiations. While the scope of any such legislation is uncertain at this
time, there can be no assurances that future legislation or regulations will not decrease the coverage and price that we may receive
for our proposed products. Other third-party payors are increasingly challenging the prices charged for medical products and services.
It will be time consuming and expensive for us to go through the process of seeking coverage and reimbursement from Medicare and
private payors. Our proposed products may not be considered cost-effective, and coverage and reimbursement may not be available
or sufficient to allow us to sell our proposed products on a profitable basis. Further federal and state proposals and health care
reforms are likely which could limit the prices that can be charged for the product candidates that we develop and may further
limit our commercial opportunities. Our results of operations could be materially adversely affected by proposed healthcare reforms,
by the Medicare prescription drug coverage legislation, by the possible effect of such current or future legislation on amounts
that private insurers will pay and by other health care reforms that may be enacted or adopted in the future. In September 2007,
the Food and Drug Administration Amendments Act of 2007 was enacted, giving the FDA enhanced post-marketing authority, including
the authority to require post-marketing studies and clinical trials, labeling changes based on new safety information, and compliance
with risk evaluations and mitigation strategies approved by the FDA. The FDA&rsquo;s exercise of this authority could result in
delays or increased costs during product development, clinical trials and regulatory review, increased costs to assure compliance
with post-approval regulatory requirements, and potential restrictions on the sale and/or distribution of approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our business could suffer if we lose the
services of, or fail to attract, key personnel.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are highly dependent upon the efforts of
our senior management, including our Executive Chairman, Principal Executive Officer, and board member, Steven H. Rouhandeh; our
President and Chief Executive Officer, and board member, Timothy J. Miller; our Chief Operating Officer and board member, Jeffrey
B. Davis; our Chief Financial Officer, Harrison G. Wehner, III; and our Chief Accounting Officer, Stephen B. Thompson. The loss
of the services of these individuals could delay or prevent the achievement of our research, development, marketing, or product
commercialization objectives. We do not have employment contracts with our other key personnel. We do not maintain any &lsquo;key-man&rsquo;
insurance policies on any of our key employees and we do not intend to obtain such insurance. In addition, due to the specialized
scientific nature of our business, we are highly dependent upon our ability to attract and retain qualified scientific and technical
personnel and consultants. In view of the stage of our development and our research and development programs, we have restricted
our hiring to research scientists, consultants and a small administrative staff and we have made only limited investments in manufacturing,
production, sales or regulatory compliance resources. There is intense competition among major pharmaceutical and chemical companies,
specialized biotechnology firms and universities and other research institutions for qualified personnel in the areas of our activities,
however, and we may be unsuccessful in attracting and retaining these personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Trends toward managed health care and downward
price pressures on medical products and services may limit our ability to profitably sell any drugs that we may develop.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lower prices for pharmaceutical products may
result from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">third-party-payers&rsquo; increasing challenges to the prices charged for medical products and
services;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">the trend toward managed health care in the U.S. and the concurrent growth of HMOs and similar
organizations that can control or significantly influence the purchase of healthcare services and products; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">legislative proposals to reform healthcare or reduce government insurance programs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The cost containment measures that healthcare
providers are instituting, including practice protocols and guidelines and clinical pathways, and the effect of any healthcare
reform, could limit our ability to profitably sell any drugs that we may successfully develop. Moreover, any future legislation
or regulation, if any, relating to the healthcare industry or third-party coverage and reimbursement, may cause our business to
suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Security breaches and other disruptions
could compromise our information and expose us to liability, which would cause our business and reputation to suffer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the ordinary course of our business, we
collect and store sensitive data, including intellectual property, our proprietary business information and that of our suppliers
and business partners, as well as personally identifiable information of clinical trial participants and employees. Similarly,
our business partners and third party providers possess certain of our sensitive data. The secure maintenance of this information
is critical to our operations and business strategy. Despite our security measures, our information technology and infrastructure
may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could
compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access,
disclosure or other loss of information, including our data being breached at our business partners or third-party providers, could
result in legal claims or proceedings, liability under laws that protect the privacy of personal information, disrupt our operations,
and damage our reputation which could adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>It is difficult and costly to protect our
proprietary rights, and we may not be able to ensure protection of such rights.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our commercial success will depend in part
on obtaining and maintaining patent protection and trade secret protection of our product candidates, and the methods used to manufacture
them, as well as successfully defending these patents against third-party challenges. We will only be able to protect our product
candidates from unauthorized making, using, selling and offering to sell or importation by third parties to the extent that we
have rights under valid and enforceable patents or trade secrets that cover these activities. The patent positions of pharmaceutical
and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles
remain unresolved. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date in
the U.S. The biotechnology patent situation outside the U.S. is even more uncertain. Changes in either the patent laws or in interpretations
of patent laws in the U.S. and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict
the breadth of claims that may be allowed or enforced in our issued patents or in third-party patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The degree of future protection for our proprietary
rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to
gain or keep our competitive advantage. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">others may be able to produce compounds or molecules that are competitive with our product candidates
but that are not covered by the claims of our patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we may not have been the first to make the inventions covered by our pending patent applications;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we may not have been the first to file patent applications for these inventions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">others may independently develop similar or alternative technologies or duplicate any of our technologies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">it is possible that our pending patent applications will not result in issued patents and it is
possible that our issued patents could be narrowed in scope, invalidated, held to be unenforceable, or circumvented;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we may not develop additional proprietary technologies that are patentable; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the patents of others may have an adverse effect on our business; or others may be able to misappropriate
our trade secrets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also may rely on trade secrets to protect
our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult
to protect. While we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific
collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that
a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable.
In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may
independently develop equivalent knowledge, methods and know-how.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We may incur substantial costs as a result
of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our
rights to, or use, our technology.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we choose to go to court to stop someone
else from using the inventions claimed in our patents, that individual or company has the right to ask the court to rule that these
patents are invalid and/or should not be enforced against that third party. These lawsuits are expensive and would consume time
and other resources even if we were successful in stopping the infringement of these patents. In addition, there is a risk that
the court will decide that these patents are not valid and that we do not have the right to stop the other party from using the
inventions. There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the other
party on the ground that such other party&rsquo;s activities do not infringe our rights to these patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Furthermore, a third party may claim that we
are using inventions covered by the third party&rsquo;s patent rights and may go to court to stop us from engaging in our normal
operations and activities, including making or selling our product candidates. These lawsuits are costly and could affect our results
of operations and divert the attention of managerial and technical personnel. There is a risk that a court would decide that we
are infringing the third party&rsquo;s patents and would order us to stop the activities covered by the patents. In addition, there
is a risk that a court will order us to pay the other party damages for having violated the other party&rsquo;s patents. The biotechnology
industry has produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents
cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the
interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our products or
methods of use either do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid, and we
may not be able to do this. Proving invalidity, in particular, is difficult since it requires a showing of clear and convincing
evidence to overcome the presumption of validity enjoyed by issued patents. Because some patent applications in the U.S. may be
maintained in secrecy until the patents are issued, patent applications in the U.S. and many foreign jurisdictions are typically
not published until eighteen months after filing, and publications in the scientific literature often lag behind actual discoveries,
we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending
applications or that we were the first to invent the technology. Our competitors have filed, and may in the future file, patent
applications covering technology similar to ours. Any such patent application may have priority over our patent applications and
could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent
application on inventions similar to ours, we may have to participate in an interference proceeding declared by the PTO, to determine
priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that such efforts would
be unsuccessful, resulting in a loss of our United States patent position with respect to such inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Some of our competitors may be able to sustain
the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition,
any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our
ability to raise the funds necessary to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Future litigation, including
product liability claims, private securities litigation, stockholder derivative suits and contract litigation, may adversely affect
our financial condition and results of operations or liquidity.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The development, manufacture and marketing
of pharmaceutical products of the types that we produce entail an inherent risk of product liability claims. A number of factors
could result in an unsafe condition or injury to a patient with respect to these or other products that we manufacture or sell,
including inadequate disclosure of product-related risks or product-related information. In addition, we may be the subject of
litigation involving contract disputes, stockholder derivative suites or private securities litigation. The outcome of litigation,
particularly class action lawsuits, is difficult to assess or quantify. Plaintiffs in these types of lawsuits often seek recovery
of very large or indeterminate amounts, including not only actual damages, but also punitive damages. The magnitude of the potential
losses relating to these lawsuits may remain unknown for substantial periods of time. In addition, the cost to defend against any
future litigation may be significant. Product liability claims, securities and commercial litigation and other litigation in the
future, regardless of the outcome, could have a material adverse effect on our financial condition, results of operations or liquidity. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We may not be successful in protecting our
intellectual property and proprietary rights.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends, in part, on our ability
to obtain U.S. and foreign patent protection for our drug candidates and processes, preserve our trade secrets and operate our
business without infringing the proprietary rights of third parties. Legal standards relating to the validity of patents covering
pharmaceutical and biotechnological inventions and the scope of claims made under such patents are still developing and there is
no consistent policy regarding the breadth of claims allowed in biotechnology patents. The patent position of a biotechnology firm
is highly uncertain and involves complex legal and factual questions. We cannot assure you that any existing or future patents
issued to, or licensed by, us will not subsequently be challenged, infringed upon, invalidated or circumvented by others. We cannot
assure you that any patents will be issued from any of the patent applications owned by, or licensed to, us. Furthermore, any rights
that we may have under issued patents may not provide us with significant protection against competitive products or otherwise
be commercially viable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents may have been granted to third parties
or may be granted covering products or processes that are necessary or useful to the development of our drug candidates. If our
drug candidates or processes are found to infringe upon the patents or otherwise impermissibly utilize the intellectual property
of others, our development, manufacture and sale of such drug candidates could be severely restricted or prohibited. In such event,
we may be required to obtain licenses from third parties to utilize the patents or proprietary rights of others. We cannot assure
you that we will be able to obtain such licenses on acceptable terms, if at all. If we become involved in litigation regarding
our intellectual property rights or the intellectual property rights of others, the potential cost of such litigation, regardless
of the strength of our legal position, and the potential damages that we could be required to pay could be substantial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our products could infringe on the intellectual
property rights of others, and we may be required to license technology from third parties in the future in order to market our
products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Companies in the biotechnology and pharmaceutical
industries steadfastly pursue and protect intellectual property rights. This can result in considerable and costly litigation to
determine the validity of patents and claims by third parties of infringement of patents or other intellectual property. Our gene
therapy products could be found to infringe on the intellectual property rights of others. Other companies may hold or obtain patents
or inventions or other proprietary rights in technology necessary for our business. We have or may be required to obtain licenses
from other companies to use such proprietary rights.&nbsp; We may be unable to obtain licenses to use such proprietary rights.&nbsp;
Furthermore, should we violate the terms of a license, that license could be cancelled. Our ability to achieve profitability and
positive cash flow may be negatively affected by our inability to procure such a license, the cancellation of any such license,
any new license fees arising out of any new license, or any increases in license fees we currently pay.&nbsp; Periodically companies
inquire about our products and technology in their attempts to assess whether we violate their intellectual property rights. If
we are forced to defend against infringement claims, we may face costly litigation and diversion of technical and management personnel,
even if the allegations of infringement are unwarranted. In addition, as a result of potential infringement claims, we may be required
to obtain one or more licenses from other companies to use the infringed technology, and the license fees we pay may negatively
affect our ability to achieve profitability and positive cash flow. If there is a successful claim of infringement against us and
we are unable to develop non-infringing technology or license the infringed or similar technology on a timely basis, our business,
and our ability to grow revenue and achieve profitability and positive cash flow, could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The market price of our common stock may
be volatile and adversely affected by several factors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market price of our common stock could
fluctuate significantly in response to various factors and events, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">our ability to integrate operations, technology, products and services;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">our ability to execute our business plan;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">operating results below expectations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">announcements concerning product development results, including clinical trial results, or intellectual
property rights of others;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">litigation or public concern about the safety of our potential products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">our issuance of additional securities, including debt or equity or a combination thereof, which
will be necessary to fund our operating expenses;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">announcements of technological innovations or new products by us or our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">loss of any strategic relationship;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">industry developments, including, without limitation, changes in healthcare policies or practices
or third-party reimbursement policies; economic and other external factors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">period-to-period fluctuations in our financial results; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">whether an active trading market in our common stock develops and is maintained.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the securities markets have from
time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular
companies. These market fluctuations may also materially and adversely affect the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We have not paid cash dividends in the past
and do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of our
common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never paid cash dividends on our common
stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. The payment of dividends on our
capital stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time
as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return
on your investment will only occur if the common stock price appreciates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our quarterly operating results may fluctuate
significantly.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect our operating results to be subject
to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">variations in the level of expenses related to our development programs;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">addition or termination of clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">any intellectual property infringement lawsuit in which we may become involved;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">regulatory developments affecting our product candidates; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt">&bull;</TD><TD STYLE="text-align: justify">our execution of any collaborative, licensing or similar arrangements, and the timing of payments
we may make or receive under these arrangements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If our quarterly operating results fall below
the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any
quarterly fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Provisions of our charter documents could
discourage an acquisition of our company that would benefit our stockholders and may have the effect of entrenching, and making
it difficult to remove, management.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Provisions of our Certificate of Incorporation
and By-laws may make it more difficult for a third party to acquire control of us, even if a change in control would benefit our
stockholders. In particular, shares of our preferred stock may be issued in the future without further stockholder approval and
upon such terms and conditions, and having such rights, privileges and preferences, as our Board of Directors may determine, including,
for example, rights to convert into our common stock. The rights of the holders of our common stock will be subject to, and may
be adversely affected by, the rights of the holders of any of our preferred stock that may be issued in the future. The issuance
of our preferred stock, while providing desirable flexibility in connection with possible acquisitions and other corporate purposes,
could have the effect of making it more difficult for a third party to acquire control of us. This could limit the price that certain
investors might be willing to pay in the future for shares of our common stock and discourage these investors from acquiring a
majority of our common stock. Further, the existence of these corporate governance provisions could have the effect of entrenching
management and making it more difficult to change our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Failure to achieve and maintain effective
internal controls could have a material adverse effect on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective internal controls are necessary for
us to provide reliable financial reports. If we cannot provide reliable financial reports, our operating results could be harmed.
All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined
to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on our evaluation, our management concluded
that there is no material weakness in our internal control over financial reporting for the year ended December 31, 2015 based
on the criteria established in Internal Control &mdash;Integrated Framework, 2013, issued by the Committee of Sponsoring Organizations
of the Treadway Commission (&ldquo;COSO&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we continue to evaluate and improve our
internal controls, we cannot be certain that these measures will ensure adequate controls over our financial processes and reporting
in the future. Any failure to implement required new or improved controls, or difficulties encountered in their implementation,
could harm our operating results or cause us to fail to meet our reporting obligations. Failure to achieve and maintain an effective
internal control environment could cause investors to lose confidence in our reported financial information, which could have a
material adverse effect on our stock price. Failure to comply with Section 404 could also potentially subject us to sanctions or
investigations by the Securities and Exchange Commission (&ldquo;SEC&rdquo;) or other regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>There can be no assurance that we will be
able to comply with continued listing standards of the NASDAQ Capital Market.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">We cannot
assure you that we will be able to continue to comply with the minimum bid price and the other standards that we are required to
meet in order to maintain a listing of our common stock on the NASDAQ Capital Market. Our failure to continue to meet these requirements
may result in our common stock being delisted from the NASDAQ Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our ability to use our net operating loss
carry forwards may be subject to limitation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Generally, a change of more than 50% in the
ownership of a company&rsquo;s stock, by value, over a three-year period constitutes an ownership change for U.S. federal income
tax purposes. An ownership change may limit our ability to use our net operating loss carryforwards attributable to the period
prior to the change. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards
to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax
liability for us. At December 31, 2015, we had net operating loss carryforwards aggregating approximately $209.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ownership of our shares is concentrated
in the hands of a few investors which could limit the ability of our other stockholders to influence the direction of the company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As calculated by SEC rules of beneficial ownership,
SCO Capital Partners LLC and affiliates; Perceptive Advisors LLC (and affiliates Joseph Edelman); Quantum Partners (and affiliates
Soros Fund Management LLC); and Europa International Inc. (and affiliates Knoll Capital Management) each beneficially owned approximately
42.2%, 5.2%, 5.2% and 5.1%, respectively, of our common stock  as of December 31, 2015. Accordingly, they
collectively have the ability to significantly influence or determine the election of all of our directors or the outcome of most
corporate actions requiring stockholder approval. They may exercise this ability in a manner that advances their best interests
and not necessarily those of our other stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_004"></A><B>ITEM 2. PROPERTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain approximately 2,000 square feet
of business office suites for administrative offices in New York, New York. We have a lease agreement for the facility, which terminates
in December 2016. We also have administrative offices in Dallas, Texas. We have a lease agreement for the facility, which terminates
in August 2016. We also have a laboratory and administrative offices of approximately 11,600 square feet in Cleveland, Ohio with
an additional 4,377 square feet available this year. We have a lease agreement for the facility, which terminates in December 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that our existing properties are
suitable for the conduct of our business and adequate to meet our present needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_005"></A>ITEM 3. LEGAL PROCEEDINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not currently subject to any material
pending legal proceedings.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_006"></A><B>ITEM 4. MINE SAFETY DISCLOSURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_007"></A>EXECUTIVE OFFICERS OF THE REGISTRANT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Mr. Steven
H. Rouhandeh,&nbsp;became our Executive Chairman, Principal Executive Officer, on January 1, 2015. Mr. Rouhandeh has been a director
and Chairman of the Board since March 4, 2008. He has been Chief Investment Officer of SCO Capital Partners, a group of New York
based life sciences funds since 1997.&nbsp;Mr. Rouhandeh possesses a diverse background in financial services that includes experience
in asset management, corporate finance, investment banking and law.&nbsp;He has been active throughout recent years as an executive
in venture capital and as a founder of several companies in the biotech field.&nbsp;His experience also includes positions as Managing
Director of a private equity group at Metzler Bank, a private European investment firm and Vice President, Investment Banking at
Deutsche Bank.&nbsp; Mr. Rouhandeh was also a corporate attorney at New York City-based Cravath, Swaine &amp; Moore. Mr. Rouhandeh
holds a J.D., from Harvard Law School, Harvard University and B.A. Political Science, from Southern Illinois University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Timothy
J. Miller, Ph.D.,&nbsp;became our President and Chief Executive Officer and Director on May 15, 2015. Dr. Miller was President
&amp; CEO of Abeona Therapeutics LLC from 2013 to 2015. He has 16 years of scientific research, product development, regulatory
and clinical operations expertise, with a focus on transitioning novel biotherapeutics through pre-clinical phases and into Phase
1 and 2 human clinical trials. Dr. Miller was President &amp; CEO of Red5 Pharmaceuticals from 2013 until 2015 and was Vice President,
Business Development of BioEnterprise Inc. in 2015. He was Senior Director of Product Development at SironRX Therapeutics from
2010 to 2013. Between 1996 and 2010 Dr. Miller held various positions at several companies focusing on gene therapy and regenerative
medicine. Dr. Miller earned his PhD in Pharmacology with a focus on Gene therapy/Cystic Fibrosis from Case Western University.
He also holds a B.S. in Biology and M.S. in Molecular Biology from John Carroll University (Cleveland, OH).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Mr. Jeffrey
B. Davis&nbsp;became our Chief Operating Officer on January 19, 2015. Mr. Davis is also a director since March 2006. Mr. Davis
was our Chief Executive Officer from December 26, 2007 until September 19, 2014. Mr. Davis became Acting Chief Financial Officer,
Treasurer and Secretary on November 1, 2013 through September 19, 2014. Previously, Mr. Davis served in a variety of senior investment
banking and management positions, and in senior management at a publicly traded healthcare technology company. Prior to that, Mr.
Davis was an investment banker with various Deutsche Bank banking organizations, both in the U.S. and Europe. Mr. Davis also served
in senior marketing and product management positions at AT&amp;T Bell Laboratories, where he was also a member of the technical
staff, and at Philips Medical Systems North America. &nbsp;Mr. Davis is currently on the board of Uluru, Inc., a public biotechnology
company. &nbsp;Mr. Davis holds a B.S. in biomedical engineering from Boston University and an M.B.A. degree from the Wharton School,
University of Pennsylvania<FONT STYLE="color: #555555">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #555555"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #555555"><FONT STYLE="background-color: white"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #555555"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Mr. Harrison
G. Wehner&nbsp;became our Chief Financial Officer on September 19, 2014. Mr. Wehner previously was a Managing Director with Plasma
Technologies LLC since June 1, 2014. He has over 20 years&rsquo; experience in investment banking advising on equity and debt finance
and mergers and acquisitions advisory assignments. Previously, Mr. Wehner held various senior banking roles at Canaccord Genuity
from 2012 to 2013, with CitiGroup from 2005 to 2011, and UBS from 1994 to 2005 where he worked on a variety of banking transactions
in the healthcare sector, including advisory and transactional experience in the blood fractionation industry. Mr. Wehner holds
a BA from The College of William and Mary, and an MBA from the Ross School of Business at the University of Michigan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #555555"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Stephen
B. Thompson, Vice President Finance, became the Chief Accounting Officer, Secretary and Treasurer on January 1, 2015. Mr. Thompson
consulted with the Company from December 1, 2013 through December 31, 2014. Prior to December 1, 2013 Mr. Thompson was our Vice
President from 2000 and our Chief Financial Officer from 1996. From 1990 to 1996, he was Controller and Administration Manager
of Access Pharmaceuticals, Inc., a private Texas corporation. Previously, from 1989 to 1990, Mr. Thompson was Controller of Robert
E. Woolley, Inc., a hotel real estate company where he was responsible for accounting, finances and investor relations. From 1985
to 1989, he was Controller of OKC Limited Partnership, an oil and gas company, where he was responsible for accounting, finances
and SEC reporting. Between 1975 and 1985 he held various accounting and finance positions with Santa Fe International Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_008"></A>PART II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.6in; text-align: left">ITEM&nbsp;5.</TD><TD STYLE="text-align: justify"><A NAME="a_010"></A>MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Price Range of Common Stock and Dividend
Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock has traded on The NASDAQ Capital
Market (&ldquo;NASDAQ&rdquo;) under the symbol ABEO since June 22, 2015. We also changed our corporate name to Abeona Therapeutics
Inc. on June 19, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our stock traded under the following symbols
and markets during these time periods</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">PTBI &ndash; NASDAQ - from December 19, 2014 until June 19, 2015</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">PTBI - OTC Bulletin Board, or OTCQB - from November 21, 2014 until December 17, 2014</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">ACCPD - OTCQB - from October 24, 2014 until November 21, 2014</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">ACCP - OTCQB &ndash; from June 5, 2006 until October 24, 2014</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 24, 2014 we changed our corporate
name to PlasmaTech Biopharmaceuticals, Inc. from Access Pharmaceuticals, Inc. and effected a 1 for 50 reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth, for the periods
indicated, the high and low closing prices as reported by NASDAQ and OTCQB for our common stock for fiscal years 2014 and 2013.
The OTCQB quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All per share information reflect a 1-for-50
reverse stock split effected on October 24, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Fiscal Year Ended December 31, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; text-decoration: underline; text-align: left"><U STYLE="text-decoration: none">First quarter</U></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">3.55</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">2.91</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none; text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.77</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none; text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.98</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Fiscal Year Ended December 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">29.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never declared or paid any cash dividends
on our common stock and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. The payment
of dividends, if any, in the future is within the discretion of our Board of Directors and will depend on our earnings, capital
requirements and financial condition and other relevant facts. We currently intend to retain all future earnings, if any, to finance
the development and growth of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, during 2014 we were required to pay
dividends on our Series A preferred stock at the rate of 6% per year. We were also required to pay dividends on our Series B preferred
stock at the rate of 12% per year. Both Series A and Series B preferred stock were converted into common stock on December 24,
2014. We currently have no outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of record holders of our common
stock at March 29, 2016 was approximately 7,300. On March 29, 2016, the closing price for the common stock as quoted on NASDAQ
was $2.86. There were 32,743,013 shares of common stock outstanding at March 30, 2016.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth, as of December
31, 2015, information about shares of common stock outstanding and available for issuance under our existing equity compensation
plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of securities</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">remaining available</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">for future issuance</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of securities to</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted-average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">under equity</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">be issued upon exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise price of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">compensation plans</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of outstanding options</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">outstanding options</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(excluding securities</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Plan Category</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">warrants and rights</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">warrants and rights</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">reflected in column (a))</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(a)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(b)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(c)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Equity compensation plans approved by security holders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 42%; text-align: left; padding-left: 9pt">2015 Equity Incentive Plan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">1,994,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">6.90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,601,323</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">2015 Equity Incentive Plan</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">330,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.49</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Equity compensation plans not approved by security holders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,324,084</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,601,323</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Issuer Purchases of Equity Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_011"></A><B>ITEM 6. SELECTED FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.6in; text-align: left"><B>ITEM&nbsp;7.</B></TD><TD STYLE="text-align: justify"><B><A NAME="a_012"></A>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND</B> <B>RESULTS OF OPERATIONS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following discussion should be read in conjunction with our
consolidated financial statements and related notes included in this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Abeona Therapeutics Inc. (together with our subsidiaries, &ldquo;we&rdquo;,
&ldquo;our&rdquo;, &ldquo;Abeona&rdquo; or the &ldquo;Company&rdquo;) is a Delaware corporation. We are focused on developing and
delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101
(AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA,
respectively). We are also developing ABO-201 (AAV CLN3) gene therapy for Juvenile Neuronal Ceroid Lipofuscinoses (JNCL) also known
as juvenile Batten disease; and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing
approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including
PTB-101 SDF Alpha&trade; (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF&trade; (Salt Diafiltration)
ethanol-free process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Comparison of Years Ended December 31, 2015 and December 31,
2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our licensing revenue for the year ended December
31, 2015 was $602,000 as compared to $598,000 for the same period of 2014, an increase of $4,000. We recognize licensing revenue
over the period of the performance obligation under our licensing agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recorded royalty revenue for MuGard of $438,000
for year ended December 31, 2015 as compared to $327,000 for the same period of 2014, an increase of $111,000. We licensed MuGard
to AMAG and currently receive quarterly royalties from AMAG under our agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total research and development spending for
the year ended December 31, 2015 was $4,715,000, as compared to $333,000 for the same period of 2014, an increase of $4,382,000.
The increase in research and development expenses was primarily due to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased development work on our products ($2,092,000);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased salary and related costs ($868,000) from increased scientific staff;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased stock based compensation expense for granted restricted stock ($345,000) and granted
stock options ($617,000);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">scientific consulting ($157,000); and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">other net increases in research spending ($303,000).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total general and administrative expenses were
$14,320,000 for the year ended December 31, 2015, as compared to $3,712,000 for the same period of 2014, an increase of $10,608,000.
The increase in expenses was due primarily to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased stock based compensation expense for granted restricted stock ($4,504,000) and granted
options ($1,841,000);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased investor relations expenses ($1,243,000);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased legal and audit fees ($1,238,000);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased salary and related costs ($992,000) from hiring additional general and administrative
staff;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased director fees ($482,000); and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">net increase other general and administrative expenses ($308,000).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 66pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation and amortization was $551,000
for the year ended December 31, 2015 as compared to $11,000 for the same period in 2014, an increase of $540,000. The increase
is due to amortization of licensed technology $529,000 and depreciation $11,000. We acquired new licenses and fixed assets in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating expenses for the year ended
December 31, 2015 were $19,586,000 as compared to total operating expenses of $4,056,000 for the same period of 2014, an increase
of $15,530,000 for the reasons listed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest and miscellaneous income was $4,026,000
for the year ended December 31, 2015 as compared to $45,000 for the same period of 2014, an increase of $3,981,000. Miscellaneous
income is higher in 2015 than for the same period in 2014 due to change in fair value of our contingent consideration liability
($3,898,000) related to the acquisition of Abeona Ohio and write-offs of certain accounts payables ($38,000) and interest income
($45,000).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest and other expense was $6,000 for
the year ended December 31, 2015 as compared to $582,000 in the same period of 2014, a decrease of $576,000. The interest in 2014
represents interest accrued on unpaid dividends. All dividends and accrued interest on dividends due were paid in December 2014.
There are no more dividends accruing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recorded a loss for the derivative liability
related to preferred stock of $23,110,000 for the year ended December 31, 2014. The preferred stock related to the dividends was
converted into common stock in December 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preferred stock dividends of $2,875,000 were
accrued for the year ended December 31, 2014. The preferred stock related to the dividends was converted into common stock in December
2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss allocable to common stockholders for
the year ended December 31, 2015 was $14,526,000, or a $0.53 basic and diluted loss per common share as compared to a net loss
of $29,653,000, or a $15.26 basic and diluted loss per common share, for the same period in 2014, a decreased loss of $15,127,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have historically funded our operations
primarily through public and private sales of common stock, preferred stock, convertible notes and through licensing agreements.
Our principal source of liquidity is cash and cash equivalents. Licensing payments and royalty revenues provided limited funding
for operations during the period ended December 31, 2015. As of December 31, 2015, our cash and cash equivalents were $40,138,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2015, our working capital
was $39,091,000. Our working capital at December 31, 2015 represented an increase of $30,434,000 as compared to our working capital
as of December 31, 2014 of $8,657,000. The net increase in the working capital at December 31, 2015 reflects financings, warrant
exercises and the acquisition of Abeona Therapeutics LLC (Abeona Ohio) less twelve months of net operating costs and changes in
current assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 31, 2015 we closed an upsized $15.5
million direct placement of registered common stock with institutional investors, including Soros Fund Management and Perceptive
Life Science Fund, and two members of our Board of Directors. The financing was comprised of 2.83 million shares of our common
stock at a price of $5.50 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 11, 2015, we closed a $10 million private
placement of common stock consisting of 1,250,000 shares of our common stock, at a price of $8.00 per share and warrants to purchase
625,000 shares of common stock. The warrants have an exercise price of $8.00 per share and are exercisable for 30 months from the
closing date. A total net of $9.2 million was received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also in connection with the financing, the
placement agent received warrants to purchase 50,000 shares of common stock at $11.00 per share and which are exercisable for five
years from the closing date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 23, 2015 we closed a $7 million private
placement of common stock consisting of 2,333,333 shares of our common stock, at a price of $3.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the second quarter we received additional
financing of $4.6 million through warrant exercises of our $5.00 warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we raise additional funds by selling equity
securities, the relative equity ownership of our existing investors will be diluted and the new investors could obtain terms more
favorable than previous investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On September
10, 2014, we entered into an Unsecured Grid Note, for up to $250,000 with SCO (&ldquo;Grid Note I&rdquo;). As of December 31, 2014
we had drawn a total of $250,000. The interest rate is 8% per annum and the maturity date is August 31, 2015 unless a financing
of at least $5,000,000 occurs. The financing occurred December 24, 2014 and the Grid Note I was paid in full on January 5, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On December
1, 2014, we entered into a second Unsecured Grid Note (&ldquo;Grid Note II&rdquo;), for up to $250,000 with SCO. As of December
31, 2014 we had drawn a total of $150,000. The interest rate is 8% per annum and the maturity date is November 30, 2015 unless
a financing of at least $5,000,000 occurs. The financing occurred December 24, 2014 and the Grid Note II was paid in full on January
5, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have incurred negative cash flows from operations
since inception, and have expended, and expect to continue to expend in the future, substantial funds to complete our planned product
development efforts. Since inception, our expenses have significantly exceeded revenues, resulting in an accumulated deficit as
of December 31, 2015 of $310,600,000. We cannot provide assurance that we will ever be able to generate sufficient product sales
or royalty revenue to achieve profitability on a sustained basis, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since our inception, we have devoted our resources
primarily to fund our research and development programs. We have been unprofitable since inception and to date have received limited
revenues from the sale of products. We expect to incur losses for the next several years as we continue to invest in product research
and development, preclinical studies, clinical trials and regulatory compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">We plan to
expend substantial funds to conduct research and development programs, preclinical studies and clinical trials of potential products,
including research and development with respect to our acquired and developed technology. Our future capital requirements and adequacy
of available funds will depend on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">the successful development and commercialization of our other
product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">the successful development and commercialization of products
derived from our recent license of Licensor technologies;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">the ability to establish and maintain collaborative arrangements
with corporate partners for the research, development and commercialization of products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">continued scientific progress in our research and development
programs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">the magnitude, scope and results of preclinical testing and clinical
trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">the costs involved in filing, prosecuting and enforcing patent
claims;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">the costs involved in conducting clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">competing technological developments;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">the cost of manufacturing and scale-up;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">the ability to establish and maintain effective commercialization
arrangements and activities; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">successful regulatory filings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">We have devoted
substantially all of our efforts and resources to research and development conducted on our own behalf. The following table summarizes
research and development spending by project category, which spending includes, but is not limited to, payroll and personnel expense,
lab supplies, preclinical expense, development cost, clinical trial expense, outside manufacturing expense and consulting expense:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top; padding-bottom: 1pt">(in thousands)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Twelve Months ended</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U STYLE="text-decoration: none">December 31,</U></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Inception To</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U STYLE="text-decoration: none">Date (1)</U></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">Project</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: justify">Gene therapy</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,332</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,332</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Plasma therapy</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,332</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">MuGard</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">301</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,367</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Others (2)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,020</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,715</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">333</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,051</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 15pt">(1)</TD><TD STYLE="text-align: justify">Cumulative spending from inception of the Company or project through December 31, 2015.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 15pt">(2)</TD><TD STYLE="text-align: justify">Includes other projects which the Company is no longer focused.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 15pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to uncertainties and certain of the risk
factors described above, including those relating to our ability to successfully commercialize our drug candidates, our ability
to obtain necessary additional capital to fund operations in the future, our ability to successfully manufacture our products and
our product candidates in clinical quantities or for commercial purposes, government regulation to which we are subject, the uncertainty
associated with preclinical and clinical testing, intense competition that we face, market acceptance of our products and protection
of our intellectual property, it is not possible to reliably predict future spending or time to completion by project or product
category or the period in which material net cash inflows from significant projects are expected to commence. If we are unable
to timely complete a particular project, our research and development efforts could be delayed or reduced, our business could suffer
depending on the significance of the project and we might need to raise additional capital to fund operations, as discussed in
the risk factors above, including without limitation those relating to the uncertainty of the success of our research and development
activities and our ability to obtain necessary additional capital to fund operations in the future. As discussed in such risk factors,
delays in our research and development efforts and any inability to raise additional funds could cause us to eliminate one or more
of our research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We plan to continue our policy of investing
any available funds in certificates of deposit, money market funds, government securities and investment-grade interest-bearing
securities. We do not invest in derivative financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not believe inflation or changing prices
have had a material impact on our revenue or operating costs in the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Climate Change</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not believe there is anything unique
to our business which would result in climate change regulations having a disproportional effect on us as compared to U.S. industry
overall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Critical Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">The preparation
of our consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires us to
make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period.
In applying our accounting principles, we must often make individual estimates and assumptions regarding expected outcomes or uncertainties.
As you might expect, the actual results or outcomes are often different than the estimated or assumed amounts. These differences
are usually minor and are included in our consolidated financial statements as soon as they are known. Our estimates, judgments
and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent
in the financial reporting process, actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Receivables</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">Receivables
are reported in the balance sheets at the outstanding amount net of an allowance for doubtful accounts. We continually evaluate
the creditworthiness of our customers and their financial condition and generally do not require collateral. The allowance for
doubtful accounts is based upon reviews of specific customer balances, historic losses, and general economic conditions. As of
December 31, 2015 and 2014, no allowance was recorded as all accounts were considered collectible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Licensed
Technology</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain licensed technology on our
consolidated balance sheet until either the licensed technology agreement underlying it is completed or the asset becomes impaired.
When we determine that an asset has become impaired or we abandon a project, we write down the carrying value of the related intangible
asset to its fair value and take an impairment charge in the period in which the impairment occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally licensed technology is amortized
over the life of the patent or the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We test our intangible assets for impairment
on an annual basis, or more frequently if indicators are present or changes in circumstance suggest that impairment may exist.
Events that could result in an impairment, or trigger an interim impairment assessment, include the receipt of additional clinical
or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development
program for a drug candidate or new information regarding potential sales for the drug. In connection with each annual impairment
assessment and any interim impairment assessment, we compare the fair value of the asset as of the date of the assessment with
the carrying value of the asset on our consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2015, we did not impair any licensed
technology.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I><U>Gene
therapy license agreements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On May 15,
2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children&rsquo;s Hospital to the
AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. This portfolio
comprises 1 patent family: &ldquo;Products and methods for delivery of polynuleotides by adeno-associated virus for lysosomal storage
disorders&rdquo;. Additionally, Abeona has secured FDA Orphan drug designation for both Sanfilippo A and B, which will provide
7 years of post-launch market exclusivity for both ABX-A and ABX-B in the U.S. Abeona will be seeking Orphan Drug Status within
the EMA, which will grant 10 years of post-market exclusivity in the European Union. The license is amortized over the life of
the license of 20 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On June 5,
2015, we entered into an exclusive, worldwide, licensing agreement with the UNeMed Corporation, the technology transfer and commercialization
office for the University of Nebraska Medical Center (UNMC) in Omaha, Nebraska, for an AAV gene therapy for the treatment of juvenile
Batten disease. We licensed the rights to two patents (62/092,501 and 62/146,793). Under the terms of the licensing agreement,
we paid a license fee of $75,000 and will pay milestone payments on certain milestone events. Commencing with the first commercial
sale of licensed products a royalty will be paid. Terms of the agreement require we execute a sponsored research agreement with
UNMC focused on additional efficacy studies within 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On October
14, 2015 we entered into a sponsored research agreement with UNMC to support ongoing AAV9/CLN3 projects in the amount of $215,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On June 5,
2015, we entered into an exclusive, worldwide, licensing agreement with the University of Minnesota for an AAV gene therapy for
the treatment of patients with Fanconi anemia (FA) disorder and other rare blood diseases. We licensed one patent (62/000,590),
Method for Editing a Genetic Sequence. Under terms of the licensing agreement, we paid a license fee of $80,000, will pay an additional
license fee of $50,000, will pay annual maintenance fees and a royalty fee with the first commercial sale of licensed products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On September
17, 2015, we entered into a nonexclusive license agreement with Stanford University for an AAV delivery vector for the treatment
of FA and rare blood disease platform. This license augments the University of Minnesota agreement. We licensed two patents (13/594,773
and EPO 12756603.2). Under terms of the licensing agreement, we paid a license fee of $25,000, will pay annual maintenance fees
and a royalty fee with the first commercial sale of licensed products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I><U>Plasma-based
therapeutics license agreements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">On September
22, 2014, we entered into an exclusive, worldwide licensing agreement with Licensor to obtain rights to utilize and to sub-license
to other pharmaceuticals firms, its patented methods for the extraction of therapeutic biologics from human plasma. Under the terms
of the licensing agreement, as amended on January 23, 2015, we paid a license fee of $1 million in cash, will pay $4,000,000 in
cash or 1,096,151 shares of our common stock in 2017, a regulatory approval milestone payment of 513,375 shares of our common stock
upon the first FDA regulatory approval of a drug derived from the Licensor&rsquo;s proprietary SDF process, and a tiered royalty
on annual net sales of plasma fractions produced with Licensor&rsquo;s proprietary SDF process. The license is amortized over the
life of the patent of 11 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Goodwill</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">As of
December 31, 2015, goodwill of $32.5 million was recorded on the Company's balance sheet. The implied fair value of goodwill represented
the excess of the Abeona Ohio&rsquo;s value over and above the fair value of its tangible assets and identifiable intangible assets.
In accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) No. 350 &mdash; <I>Intangibles &mdash; Goodwill and Other,
</I>goodwill is not amortized, but is rather tested annually for impairment and whenever changes in circumstances occur that would
indicate impairment.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Contingent
consideration liability</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">There is
a contingent valuation on three milestones. Per the merger agreement with Abeona Ohio each milestone would consist of either cash,
our stock or a combination of both, at the Company&rsquo;s election, equivalent to a stated dollar amount. The fair value of the
probability of achieving all three milestones was estimated at $6,489,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first milestone of receiving IND allowance
from the FDA to initiate a Phase 1 clinical study from MPS IIIA or MPSIIIB by November 15, 2015 was not met. The Company recognized
$3,898,000 in Miscellaneous Income for change in fair value of our contingent consideration liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>License Revenues and Royalties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">Our revenues
are generated from licensing, research and development agreements, royalties and product sales. We recognize revenue in accordance
with SEC Staff Accounting Bulletin No. 104 (SAB 104), Revenue Recognition. License revenue is recognized over the remaining life
of the underlying patent or period of performance obligation. Research and development revenues are recognized as services are
performed. Royalties and product revenues are recognized in the period of sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Stock Based Compensation Expense</I></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">We account
for stock based compensation expense in accordance with FASB ASC 718, Stock Based Compensation. We have two stock-based compensation
plans under which incentive and qualified stock options and restricted shares may be granted to employees, directors and consultants.
We measure the cost of the employee/director/consultant services received in exchange for an award of equity instruments based
on the grant date fair value for employees and directors and vesting date fair value of the award for consultants. We use the Black-Scholes
option pricing model to value our options which includes expected volatility, risk-free interest rate, dividend yield and estimated
expected term.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">Stock-based
compensation expense recognized for the years ended December 31, 2015 and 2014 was approximately $4,368,000 and $1,305,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off-Balance Sheet Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_013"></A><B>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_014"></A><B>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial statements required by this Item
are incorporated in this Annual Report Form 10-K on pages F-1 through F-20 hereto. Reference is made to Item 15 of this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.6in; text-align: left"><B>ITEM&nbsp;9.</B></TD><TD STYLE="text-align: justify"><B><A NAME="a_015"></A>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_016"></A><B>ITEM 9A. CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the supervision and with the participation
of our management and consultants, including the Executive Chairman (our principal executive officer) and Vice President Finance
(our principal accounting officer), we have evaluated the effectiveness of the design and operation of our disclosure controls
and procedures, as such term is defined in&nbsp;Exchange Act Rules 13a-15(e) and&nbsp;15d-15(e), as of the end of the period covered
by this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted an evaluation of the effectiveness
of the design and operation of our &ldquo;disclosure controls and procedures&rdquo; (&ldquo;Disclosure Controls&rdquo;) as of the
end of the period covered by this Form 10-K. The Disclosure Controls evaluation was conducted under the supervision and with the
participation of management and consultants, including our Executive Chairman and Chief Accounting Officer. Disclosure Controls
are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under
the Exchange Act, such as this Form 10-K, is recorded, processed, summarized and reported within the time periods specified in
the SEC&rsquo;s rules and forms. Disclosure Controls are also designed to provide reasonable assurance that such information is
accumulated and communicated to our management, including our Executive Chairman and Chief Accounting Officer, as appropriate to
allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The evaluation of our Disclosure Controls included
a review of the controls&rsquo; objectives and design, our implementation of the controls and the effect of the controls on the
information generated for use in this Form 10-K. During the course of our evaluation of our internal control over financial reporting,
we advised the Audit Committee of our Board of Directors that we identified no material weakness as defined under standards established
by the Public Company Accounting Oversight Board (United States). A material weakness is a deficiency, or combination of deficiencies,
in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&rsquo;s
annual or interim financial statements will not be prevented or detected on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Annual Report on Form 10-K does not include
an attestation report of the Company&rsquo;s registered public accounting firm regarding internal control over financial reporting.
Management&rsquo;s report was not subject to attestation by the Company&rsquo;s registered public accounting firm pursuant to rules
of the SEC that permit smaller reporting companies like us to provide only management&rsquo;s report in this Annual Report on Form
10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This report shall not be deemed to be filed
for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section,
and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of
any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_017"></A>ITEM 9B. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>


<!-- Field: Page; Sequence: 8; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_018"></A>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_019"></A>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND
CORPORATE GOVERNANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Directors and Reports of Beneficial Ownership</B>.
The information required by this Item is incorporated herein by reference from the information to be contained in our 2016 Proxy
Statement to be filed with the U.S. Securities and Exchange Commission in connection with the solicitation of proxies for our 2016
Annual Meeting of Stockholders (the Proxy Statement). The information under the heading &ldquo;Executive Officers of the Registrant&rdquo;
in Part I of this Form 10-K is also incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Code of Ethics</B>. We have adopted a Code
of Business Conduct and Ethics (the Code) that applies to all of our employees (including executive officers) and directors. The
Code is available on our website at <U>www.abeonatherapeutics.com</U> under the heading &ldquo;Investor Information.&rdquo; We
intend to satisfy the disclosure requirement regarding any waiver of a provision of the Code applicable to any executive officer
or director, by posting such information on such website. We shall provide to any person without charge, upon request, a copy
of the Code. Any such request must be made in writing to Abeona Therapeutics Inc., c/o Investor Relations, 3333 Lee Parkway, Suite
600, Dallas, TX 75219.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our corporate governance guidelines and the
charters of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee of the Board of Directors
are available on our website at <U>www.abeonatherapeutics.com</U> under the heading &ldquo;Investor Information&rdquo;. We shall
provide to any person without charge, upon request, a copy of any of the foregoing materials. Any such request must be made in
writing to Abeona Therapeutics Inc., c/o Investor Relations, 3333 Lee Parkway, Suite 600, Dallas, TX 75219.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_020"></A>ITEM 11. EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required by this Item is contained
in the Proxy Statement and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.6in; text-align: left"><B>ITEM&nbsp;12.</B></TD><TD STYLE="text-align: justify"><B><A NAME="a_021"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required by this Item is contained
in the Proxy Statement and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_022"></A>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS AND DIRECTOR INDEPENDENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required by this Item is contained
in the Proxy Statement and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_023"></A>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The information required by this Item is contained in the Proxy
Statement and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_024"></A><B>ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 86%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">a.</TD>
    <TD STYLE="text-decoration: none; text-align: justify"><U>Financial Statements</U>. The following financial statements are submitted as part of this report:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt"><A HREF="#f_001">Report of Independent Registered Public Accounting Firm</A></TD>
    <TD STYLE="text-align: center">F-1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt"><A HREF="#f_002">Consolidated Balance Sheets at December 31, 2015 and 2014</A></TD>
    <TD STYLE="text-align: center">F-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in"><A HREF="#f_003">Consolidated Statements of Operations for 2015 and 2014</A></TD>
    <TD STYLE="text-align: center">F-3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in"><A HREF="#f_004">Consolidated Statements of Stockholders&rsquo; Equity for 2015 and 2014</A></TD>
    <TD STYLE="text-align: center">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt"><A HREF="#f_005">Consolidated Statements of Cash Flows for 2015 and 2014</A></TD>
    <TD STYLE="text-align: center">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt">&nbsp;</TD>
    <TD STYLE="padding-left: 14.55pt; text-indent: -14.55pt"><A HREF="#f_006">Notes to Consolidated Financial Statements</A></TD>
    <TD STYLE="text-align: center">F-6</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify"><U>Exhibits</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">Exhibit</TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 88%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Number</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Description of Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">2.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Amended and Restated Agreement of Merger and Plan of Reorganization between the Registrant and Chemex Pharmaceuticals, Inc., dated as of October 31, 1995 (Incorporated by reference to Exhibit A of our Registration Statement on Form S-4 dated December 20, 1995, Commission File No. 33-64031)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">2.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Agreement and Plan of Merger, by and among the Registrant, Somanta Acquisition Corporation, Somanta Pharmaceuticals, Inc., Somanta Incorporated and Somanta Limited, dated April 19, 2007 (Incorporated by reference to Exhibit 2.1 to our Form 8-K dated April 18, 2007)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">2.3</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Agreement and Plan of Merger, by and among the Registrant, MACM Acquisition Corporation and MacroChem Corporation, dated July 9, 2008 (Incorporated by reference to Exhibit 2.3 of our Form 10-Q for the quarter ended June 30, 2008)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Incorporation (Incorporated by reference to Exhibit 3(a) of our Form 8-K dated July 12, 1989, Commission File Number 9-9134)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment of Certificate of Incorporation filed August 13, 1992 (Incorporated by reference to Exhibit 3.3 of our Form 10-K for year ended December 31, 1995)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.3</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Merger filed January 25, 1996 (Incorporated by reference to Exhibit E of our Registration Statement on Form S-4 dated December 20, 1995, Commission File No. 33-64031)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.4</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment of Certificate of Incorporation filed January 25, 1996 (Incorporated by reference to Exhibit E of our Registration Statement on Form S-4 dated December 20, 1995, Commission File No. 33-64031)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.5</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment of Certificate of Incorporation filed July 18, 1996 (Incorporated by reference to Exhibit 3.7 of our Form 10-K for the year ended December 31, 1996)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.6</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment of Certificate of Incorporation filed June 18, 1998. (Incorporated by reference to Exhibit 3.8 of our Form 10-Q for the quarter ended June 30, 1998)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.7</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment of Certificate of Incorporation filed July 31, 2000 (Incorporated by reference to Exhibit 3.8 of our Form 10-Q for the quarter ended March 31, 2001)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.8</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Designations of Series A Junior Participating Preferred Stock filed November 7, 2001 (Incorporated by reference to Exhibit 4.1.H of our Registration Statement on Form S-8 dated December 14, 2001, Commission File No. 333-75136)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.9</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Amended and Restated Bylaws (Incorporated by reference to Exhibit 2.1 of our Form 10-Q for the quarter ended June 30, 1996)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.10</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Designation, Rights and Preferences of Series A Cumulative Convertible Preferred Stock filed November 9, 2007 (Incorporated by reference to Exhibit 3.10 to our Form SB-2 filed on December 10, 2007.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 10%">3.11</TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 88%">Certificate of Amendment to Certificate of Designations, Rights and Preferences of Series A Cumulative Convertible Preferred Stock filed June 11, 2008 (Incorporated by reference to Exhibit 3.11 of our Form 10-Q for the quarter ended June 30, 2008)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.12</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Designations, Rights and Preferences of Series B Cumulative Convertible Preferred Stock filed October 26, 2012 (Incorporated by reference to Exhibit 10.3 of our Form 8-K filed October 26, 2012)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.13</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment of Certificate of Incorporation filed July 1, 2013 increasing the aggregate number of shares of Common Stock which we have authority to issue to Two Hundred Million (200,000,000) shares with a par value of one cent ($0.01) per share.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.14</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment of Certificate of Incorporation filed October 23, 2014 (Incorporated by reference to Exhibit 3.14 of our Form 8-K filed October 23, 2014)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.15</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment to Certificate of Designations, Rights and Preferences of Series A Cumulative Convertible Preferred Stock (Incorporated by reference to Exhibit 3.15 of our Form 8-K filed on October 23, 2014)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.16</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Amendment to Bylaws (Incorporated by reference to Exhibit 3.1 of our Form 8-K filed January 5, 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.17</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Amendment to Bylaws (Incorporated by reference to Exhibit 3.1 of our Form 8-K filed March 5, 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">3.18</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment of Certificate of Incorporation filed June 19, 2015 (Incorporated by reference
to Exhibit 3.1 of our June 22, 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">4.1*</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">2015 Equity Incentive Plan (Incorporated by reference to Exhibit 4.1 to our Form S-8 filed May
11, 2015)</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 10%">10.1*</TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 88%">1995 Stock Option Plan (Incorporated by reference to Exhibit F of our Registration Statement on Form S-4 dated December 20, 1995, Commission File No. 33-64031)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.2*</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Amendment to 1995 Stock Option Plan (Incorporated by reference to Exhibit 10.25 of our Form 10-K for the year ended December 31, 2001)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.3*</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">401(k) Plan (Incorporated by reference to Exhibit 10.20 of our Form 10-K for the year ended December 31, 1999)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.4*</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">2005 Equity Incentive Plan (Incorporated by reference to Exhibit 1 of our Proxy Statement filed on April 18, 2005)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.5</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Asset Sale Agreement dated as of October 12, 2005, between the Registrant and Uluru, Inc. (Incorporated by reference to Exhibit 10.25 of our 10-K for the year ended December 31, 2005)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.6</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Amendment to Asset Sale Agreement dated as of December 8, 2006, between the Registrant and Uluru, Inc. (Incorporated by reference to Exhibit 10.16 of our Form 10-KSB filed on April 2, 2007)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.7</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">License Agreement dated as of October 12, 2005, between the Registrant and Uluru, Inc. (Incorporated by reference to Exhibit 10.26 of our 10-K for the year ended December 31, 2005)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.8</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Board Designation Agreement dated November 15, 2007, between the Registrant and SCO Capital Partners LLC (Incorporated by reference to Exhibit 10.26 of our Form S-1 filed on March 11, 2008)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.9</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Form of Securities Purchase Agreement dated as of November 1, 2011 by and among us and the Purchasers named therein (Incorporated by reference to Exhibit 10.1 of our Form 8-K filed on November 10, 2011)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.10</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Form of Common Stock Warrant (Five Year Warrant) issued by us (Incorporated by reference to Exhibit 10.3 of our Form 8-K filed on November 10, 2011)</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 10%">10.11</TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 88%">Form of Common Stock Warrant issued by us (Incorporated by reference to Exhibit 10.3 of our Form 8-K filed on October 26, 2012)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.12+</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">License Agreement, dated June 6, 2013, by and between us and AMAG Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 10.6 to our Form 10-Q for the quarter ended June 30, 2013)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.13+</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">License Agreement, dated September 19, 2014, by and between us and Plasma Technologies, LLC. (Incorporated by reference to Exhibit 10.30 of our Form 8-K filed September 24, 2014)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.14*</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Employment Letter Agreement dated September 19, 2014, by and between us and Harrison Wehner. (Incorporated by reference to Exhibit 10.32 of our Form 8-K filed September 24, 2014)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.15</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">Amendment No. 1 to License Agreement, dated September
19, 2014, by and between us and Plasma Technologies, LLC, dated January 23, 2015 (Incorporated by reference to Exhibit 10.29 to
our Form 10-K for the year ended December 31, 2014)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.16</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Agreement and Plan of Merger, dated May 5, 2015, by and among the Company, Plasmatech Merger Sub
Inc., Abeona Therapeutics LLC and Paul A. Hawkins, in his capacity as Member Representative (Incorporated by reference to Exhibit
10.1 to our Form 10-Q for the quarter ended June 30, 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.17</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Letter Agreement, dated July 31, 2015, by and among the Company, Sabby Healthcare Master Fund Ltd.
and Sabby Volatility Warrant Master Fund, Ltd. (Incorporated by reference to Exhibit 10.1 to our Form 8-K filed July 31, 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.18</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Form of Purchase Agreement, dated July 27, 2015 (Incorporated by reference to Exhibit 10.1 to our
Form 8-K filed August 3, 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.19</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Form of Common Stock Purchase Agreement, dated April 1, 2015 (Incorporated by reference to Exhibit
10.4 to our Form 10-Q for the quarter ended June 30, 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.20</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Form of Securities Purchase Agreement dated May 6, 2015 (Incorporated by reference to Exhibit 10.5
to our Form 10-Q for the quarter ended June 30, 2015)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.21*</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Employment Agreement dated May 6, 2015 between Registrant and Timothy J. Miller (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the quarter ended September 30, 2015)</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 10%">21</TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 88%">Subsidiaries of the Registrant</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">23.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Consent of Whitley Penn LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">31.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Principal Executive Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">31.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Principal Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">32**</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Principal Executive Officer Certification and Principal Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">101</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">The following materials from the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2015 and for the fiscal year ended December 31, 2014, formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Stockholders&rsquo; Deficit, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements, tagged as blocks of text.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%">* Management contract or compensatory plan required to be filed as an Exhibit to this Form pursuant to Item 15c of the report.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>** This exhibit shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of
    1934     or otherwise subject to the liabilities of the Section, nor shall it be deemed incorporated by reference in any
    filings under the Security Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof
    and irrespective of any general incorporation language in any filing.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>+ Portions of this exhibit were omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to a request for confidential treatment.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U><A NAME="a_025"></A>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of Section 13
or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 46%">ABEONA THERAPEUTICS INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date March 30, 2016</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Steven H. Rouhandeh</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steven H. Rouhandeh</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Executive Chairman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date March 30, 2016</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Stephen B. Thompson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Stephen B. Thompson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President Finance</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial Officer and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Accounting Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">Date March 30, 2016</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid">/s/ Steven H. Rouhandeh</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steven H. Rouhandeh</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Executive Chairman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman of the Board</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date March 30, 2016</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Stephen B. Thompson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Stephen B. Thompson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President Finance</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial Officer and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Accounting Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date March 30, 2016</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Mark J. Ahn</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Mark J. Ahn, Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date March 30, 2016</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Mark J. Alvino</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Mark J. Alvino, Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date March 30, 2016</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">By:/s/ Jeffrey B. Davis</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Jeffrey B. Davis, Chief Operating Officer and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date March 30, 2016</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Stephen B. Howell</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Stephen B. Howell, Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date March 30, 2016</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Timothy J. Miller</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Timothy J. Miller, President &amp; CEO and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date March 30, 2016</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Todd Wider</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Todd Wider, Director</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="f_001"></A>Report
of Independent Registered Public Accounting Firm</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Board of Directors and Stockholders
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Abeona Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">We have audited
the accompanying consolidated balance sheets of Abeona Therapeutics Inc. and subsidiaries (the &ldquo;Company&rdquo;), as of December
31, 2015 and 2014, and the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows for the years
then ended. The Company&rsquo;s management is responsible for these consolidated financial statements. Our responsibility is to
express an opinion on these consolidated financial statements based on our audits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits
included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate
in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over
financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made
by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable
basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">In our opinion,
the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position
of Abeona Therapeutics Inc. and subsidiaries as of December 31, 2015 and 2014, and the consolidated results of their operations
and their cash flows for the years then ended in conformity with accounting principles generally accepted in the United States
of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ WHITLEY PENN LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dallas, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">March 30, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="f_002"></A>Abeona Therapeutics Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">December 31, 2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">December 31, 2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">40,138,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">11,520,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">315,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,568,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,555,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Licensed technology, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,609,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,991,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,466,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">62,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">80,055,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,582,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0.25in">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">875,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,896,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Short-term notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Current portion of deferred revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">602,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">602,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,477,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,898,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 27pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Contingent consideration liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,591,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Payable due Licensor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Long-term deferred revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,266,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,868,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,334,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,766,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.7pt">Common stock - $.01 par value; authorized 200,000,000 shares; issued 32,743,013 at December 31, 2015; issued 19,960,801 at December 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">328,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">377,993,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,690,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(310,600,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(296,074,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total stockholders' equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">67,721,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,816,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities and stockholders' equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">80,055,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,582,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part
of these consolidated statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="f_003"></A>Abeona Therapeutics Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">For the year ended <BR>December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">License revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">602,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">598,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Royalties</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">438,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">327,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,040,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">925,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,715,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,320,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,712,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">551,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,586,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,056,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,546,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,131,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest and miscellaneous income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,026,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest and other expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(582,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss on change in fair value of derivative- preferred stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(23,110,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,020,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(23,647,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,526,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(26,778,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less preferred stock dividends</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,875,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss allocable to common stockholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(14,526,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(29,653,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.53</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(15.26</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average number of common &nbsp;shares outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,597,434</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,942,905</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part
of these consolidated statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="f_004"></A>Abeona Therapeutics Inc. and Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Common
    Stock</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt; font-weight: normal">&nbsp;<U STYLE="text-decoration: none">Preferred
    Stock - A</U></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Preferred Stock -
    B</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Additional <BR>paid-in</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Treasury</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Accumulated</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Total <BR>stockholders&rsquo;
    <BR>equity</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">capital</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">stock</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(<U STYLE="text-decoration: none">deficit)</U></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(deficit)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Balance, December 31, &nbsp;2013</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">514,589</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">6,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">2,903.3617</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">1,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">251,640,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">(4,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">(266,421,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 8pt">(14,779,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    for &nbsp;services</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">22,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">349,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">349,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Preferred stock converted
    &nbsp;into common stock</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(10.0000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Additional adjustments
    for &nbsp;reverse stock split</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6,609</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Cancel treasury stock</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(4,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    for &nbsp;$4.00 share net of costs</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,500,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">35,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">12,272,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">12,307,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    for &nbsp;Series A preferred stock</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7,233,404</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">72,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(2,893.3617</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(72,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    for &nbsp;Series A preferred stock &nbsp;unpaid dividends and &nbsp;interest</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,728,365</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">17,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7,066,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7,083,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Elimination of derivative
    &nbsp;liability &ndash; preferred stock</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">24,300,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">24,300,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Series B preferred stock
    &nbsp;issued for unpaid Series B &nbsp;dividends and interest</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">304</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,047,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,047,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Series B preferred stock
    &nbsp;issued for unpaid &nbsp;liquidated damages</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">86</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">857,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">857,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    for &nbsp;Series B preferred stock, &nbsp;unpaid dividends and &nbsp;interest and liquidated &nbsp;damages</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6,951,837</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">70,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1,390</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(70,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Stock option &nbsp;compensation
    expense</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,305,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,305,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Preferred dividends</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(2,875,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(2,875,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(26,778,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(26,778,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Balance, December 31, &nbsp;2014</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">19,960,801</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">200,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">300,690,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(296,074,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,816,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    for &nbsp;services</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">105,177</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">400,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">401,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    to &nbsp;employees</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">32,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">32,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Restricted common stock
    &nbsp;issued to employees</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,350,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">13,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,807,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,820,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Exercise of $5.00 warrants</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">927,119</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,626,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,635,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    for &nbsp;$3.00 share net of costs</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,333,334</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">24,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6,977,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7,001,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    for &nbsp;$8.00 share net of costs</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,250,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">13,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8,992,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9,005,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    for &nbsp;$5.50 share net of costs</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,829,091</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">28,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">15,383,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">15,411,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Common stock issued
    to &nbsp;Abeona Ohio holders</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,979,761</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">40,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">31,718,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">31,758,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Transfer agent correction
    &nbsp;2014 reverse stock split</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(2,270</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Stock option &nbsp;compensation
    expense</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,368,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,368,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(14,526,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(14,526,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Balance, December
    31, &nbsp;2015</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">32,743,013</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">328,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">377,993,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(310,600,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">67,721,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part
of these consolidated statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="f_005"></A>Abeona Therapeutics Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSOLIDATED STATEMENTS OF CASH FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(14,526,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(26,778,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Adjustments to reconcile net loss to cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Loss on change in fair value of derivative-preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,110,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">551,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Stock option compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,368,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,305,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Stock issued to directors, employees and consultants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,852,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Stock issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">401,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">349,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Change in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.375in">Receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(79,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(287,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,174,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Interest on dividends payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">592,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">Contingent consideration milestone</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,898,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Deferred revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(602,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(349,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.5in">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,423,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,611,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Capital expenditures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(308,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Cash from Abeona Ohio acquisition</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,697,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.5in">Net cash provided by investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,389,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from $3.00 common stock issuances net of costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,001,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from $8.00 common stock issuances net of costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,005,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from $5.50 common stock issuances net of costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,411,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Proceeds from exercise of $5.00 warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,635,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from $4.00 common stock net of costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,307,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Proceeds/payment of short-term debt</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(400,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">400,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,652,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,707,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,618,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,096,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,520,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">424,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">40,138,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,520,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left">Supplemental cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt">Cash paid for interest</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">$</TD><TD STYLE="font-style: italic; text-align: right">7,000</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">$</TD><TD STYLE="font-style: italic; text-align: right">7,000</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Supplemental disclosure of noncash transactions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Shares issued to holders of Abeona Ohio for acquisition</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">31,758,000</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">-</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Contingent milestones to Abeona Ohio members</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">2,591,000</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">-</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Licensed technology from Abeona Ohio</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">2,156,000</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">-</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Conversion of Series A preferred stock unpaid dividends and interest into shares of common stock</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">-</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">7,081,000</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Conversion of Series B preferred stock unpaid dividends and interest and liquidated damages into shares of common stock</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">-</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">3,094,000</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Cancel treasury stock</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">-</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">4,000</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Payable in cash or future issuance of common shares for licensed technology</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">-</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">5,000,000</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Preferred stock dividends in dividends payable</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">-</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; text-align: right">2,875,000</TD><TD STYLE="font-style: italic; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part
of these consolidated statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="f_006"></A>Abeona Therapeutics Inc. and Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Two years ended December 31, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -63pt">NOTE 1 -
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Nature
of Operations</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify"><FONT STYLE="font-weight: normal">Abeona
Therapeutics Inc. (together with our subsidiaries, &ldquo;we&rdquo;, &ldquo;our&rdquo;, &ldquo;Abeona&rdquo; or the &ldquo;Company&rdquo;)
is a Delaware corporation. We are focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening
rare diseases. Abeona's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies
for Sanfilippo syndrome (MPS IIIB and IIIA, respectively). We are also developing ABO-201 (AAV CLN3) gene therapy for Juvenile
Neuronal Ceroid Lipofuscinoses (JNCL) also known as juvenile Batten disease; and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder
using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also
developing rare plasma protein therapies including PTB-101 SDF Alpha&trade; (alpha-1 protease inhibitor) for inherited COPD using
our proprietary SDF&trade; (Salt Diafiltration) ethanol-free process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Certain
amounts have been reclassified to conform with current period classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">A
summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements
follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Principles
of Consolidation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify"><FONT STYLE="font-weight: normal">The
consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and our wholly-owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Use
of Estimates</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">The preparation of consolidated
financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires
management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and
liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported
period. Actual results could differ from these estimates and assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Segments</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">The
Company operates in a single segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Cash
and Cash Equivalents</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify"><FONT STYLE="font-weight: normal">We
consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.&nbsp;At December
31, 2015 and 2014, we had no such investments.&nbsp;We maintain deposits primarily in two financial institutions, which may at
times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (FDIC).&nbsp; We have not
experienced any losses related to amounts in excess of FDIC limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><U>Receivables</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">Receivables are reported in the
balance sheets at the outstanding amount net of an allowance for doubtful accounts.&nbsp;We continually evaluate the creditworthiness
of our customers and their financial condition and generally do not require collateral.&nbsp;The allowance for doubtful accounts
is based upon reviews of specific customer balances, historic losses, and general economic conditions.&nbsp;As of December 31,
2015 and 2014, no allowance was recorded as all accounts are considered collectible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Property
and Equipment</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Property
and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging
from three to five years. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures
for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned and the related accumulated depreciation
are eliminated from the accounts and any gains or losses are recognized in the accompanying consolidated statements of operations
of the respective period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Licensed
Technology</U></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">We maintain licensed technology
on our consolidated balance sheet until either the licensed technology agreement underlying it is completed or the asset becomes
impaired. When we determine that an asset has become impaired or we abandon a project, we write down the carrying value of the
related intangible asset to its fair value and take an impairment charge in the period in which the impairment occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">Generally licensed technology
is amortized over the life of the patent or the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">We test our intangible assets
for impairment on an annual basis, or more frequently if indicators are present or changes in circumstance suggest that impairment
may exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the receipt of additional
clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical
development program for a drug candidate or new information regarding potential sales for the drug. In connection with each annual
impairment assessment and any interim impairment assessment, we compare the fair value of the asset as of the date of the assessment
with the carrying value of the asset on our consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">In 2015, we did not impair any
licensed technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><I><U>Gene
therapy license agreements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">On
May 15, 2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children&rsquo;s Hospital
to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. This
portfolio comprises 1 patent family: &ldquo;Products and methods for delivery of polynuleotides by adeno-associated virus for lysosomal
storage disorders&rdquo;. Additionally, Abeona has secured FDA Orphan drug designation for both Sanfilippo A and B, which will
provide 7 years of post-launch market exclusivity for both ABX-A and ABX-B in the U.S. Abeona will be seeking Orphan Drug Status
within the EMA, which will grant 10 years of post-market exclusivity in the European Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">The
license is amortized over the life of the license of 20 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><I><U>Plasma-based
therapeutics license agreements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">On
September 22, 2014, we entered into an exclusive, worldwide licensing agreement with Plasma Technologies LLC (&ldquo;Licensor&rdquo;)
to obtain rights to utilize and to sub-license to other pharmaceuticals firms, its patented methods for the extraction of therapeutic
biologics from human plasma. Under the terms of the licensing agreement, as amended on January 23, 2015, we paid a license fee
of $1 million in cash, will pay $4,000,000 in cash or 1,096,151 shares of our common stock in 2017, a regulatory approval milestone
payment of 513,375 shares of our common stock upon the first FDA regulatory approval of a drug derived from the Licensor&rsquo;s
proprietary SDF process, and a tiered royalty on annual net sales of plasma fractions produced with Licensor&rsquo;s proprietary
SDF process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">The
license is amortized over the life of the patent of 11 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><U>License Revenues and Royalties</U></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">Our revenues are generated
from licensing, research and development agreements, royalties and product sales. We recognize revenue in accordance with SEC Staff
Accounting Bulletin No. 104 (SAB 104), <I>Revenue Recognition</I>. License revenue is recognized over the remaining life of the
underlying patent. Research and development revenues are recognized as services are performed. Royalties and product sales are
recognized in the period of sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt"><U>Goodwill</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">As
of December 31, 2015, goodwill of $32.5 million was recorded on the Company's consolidated balance sheet. The implied fair value
of goodwill represented the excess of the Abeona Ohio&rsquo;s value over and above the fair value of its tangible assets and identifiable
intangible assets. In accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) No. 350 &mdash; <I>Intangibles &mdash;
Goodwill and Other, </I>goodwill is not amortized, but is rather tested annually for impairment and whenever changes in circumstances
occur that would indicate impairment.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Research
and Development Expenses</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Research
and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and
personnel expense, lab supplies, preclinical, development cost, clinical trial expense, outside manufacturing and consulting. The
cost of materials and equipment or facilities that are acquired for research and development activities and that have alternative
future uses are capitalized when acquired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><U>General and administrative expense</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">General and administrative expenses
primarily consist of personnel, contract personnel, personnel expenses to support our administrative and operating activities,
facility costs and professional expenses (i.e., legal expenses), and investor relations fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><U>Other Income</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">In 2015 and 2014, we recognized
miscellaneous income of $4,026,000 and $45,000, respectively, due to the termination of the milestone recorded on the contingent
consideration liability in 2015 and sales of platinum and monomers in 2014 and write-offs and settlements of other accounts payable
for both years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">In some of our license agreements
we are responsible as agent for arranging the manufacture of MuGard (mucoadhesive oral wound rinse) and have entered into supply
agreements with our license partners. Terms vary with each agreement but generally we arrange for the manufacture of MuGard with
a third-party and receive a fee to cover our administration, handling and overhead costs. The income is recorded in other income.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Income
Taxes</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future
tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the
period that includes the enactment date. A valuation allowance is provided for deferred tax assets to the extent their realization
is in doubt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">We
account for uncertain income tax positions in accordance with FASB ASC 740, <I>Income Taxes</I>.</FONT> <FONT STYLE="font-size: 10pt; font-weight: normal">Interest
costs and penalties related to income taxes are classified as interest expense and general and administrative costs, respectively,
in our consolidated financial statements. For the years ended December 31, 2015 and 2014, we did not recognize any uncertain tax
positions or interest or penalty expense related to income taxes. It is determined not to be reasonably likely for the amounts
of unrecognized tax benefits to significantly increase or decrease within the next 12 months. We are currently subject to a three
year statute of limitations by major tax jurisdictions for the years ended 2012, 2013 and 2014. We and our subsidiaries file income
tax returns in the U.S. federal jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Income
(Loss) Per Share</U></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.7pt; text-align: justify"><FONT STYLE="font-weight: normal">We
have presented basic income (loss) per share, computed on the basis of the weighted average number of common shares outstanding
during the year, and diluted income (loss) per share, computed on the basis of the weighted average number of common shares and
all dilutive potential common shares outstanding during the year. Potential common shares result from stock options, preferred
stock and warrants. Common equivalent shares have not been included in the net loss per share calculations for years ended December
31, 2015 and 2014 because the effect of including them would have been anti-dilutive.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify">Basic and diluted net loss per
share were determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify">(in thousands, except share and
per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">For the year ended December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify; padding-bottom: 2.5pt">Net loss allocable to common stockholders</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 15%; border-bottom: Black 2.5pt double; text-align: right">(14,526</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 15%; border-bottom: Black 2.5pt double; text-align: right">(29,653</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Weighted average shares outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,597,434</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,942,905</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Basic and diluted net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.53</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(15.26</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Net loss allocable to common stockholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(14,526</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(29,653</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">We did not include the following
securities in the table below in the computation of diluted net loss per common share because the securities were anti-dilutive
during the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">For the year ended December<BR>
 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Warrants</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">3,799,024</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">4,164,756</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Stock options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,324,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">210,134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,123,108</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,374,890</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: left"><FONT STYLE="font-weight: normal"><U>Stock-Based
Compensation</U></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">We account for stock based
compensation expense in accordance with FASB ASC 718, <I>Stock Based Compensation</I>. We have two stock-based compensation plans
under which incentive and qualified stock options and restricted shares could be granted to employees, directors and consultants.
Our 2015 Equity Incentive Plan was approved by shareholders in May 7, 2015. As of January 20, 2015, no further grants can be made
under our old plan, the 2005 Equity Incentive Plan. We measure the cost of the employee/director/consultant services received
in exchange for an award of equity instruments based on the grant date fair value for the employees and directors and vesting
date fair value for consultants of the award. We use the Black-Scholes option pricing model to value our options.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.7pt; text-align: justify"><FONT STYLE="font-weight: normal">The
following table summarizes stock-based compensation for the years ended December 31, 2015 and 2014 which was allocated as follows
(in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal">Year ended</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal"><U STYLE="text-decoration: none">December 31, 2015</U></FONT></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal">Year ended</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal"><U STYLE="text-decoration: none">December 31, 2014</U></FONT></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: normal; text-align: left">Research and development</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: normal; text-align: right">773</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: normal; text-align: right">104</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">3,595</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,201</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt; text-indent: -17.1pt; padding-left: 0.375in">Stock-based compensation expense included in operating expense</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">4,368</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,305</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left">Total stock-based compensation expense</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4,368</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1,305</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">Tax benefit</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">Stock-based compensation expense, net of tax</TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right">4,368</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right">1,305</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Recent
Accounting Pronouncements</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">In May 2014, as part of its ongoing
efforts to assist in the convergence of U.S. GAAP and International Financial Reporting Standards (&ldquo;IFRS&rdquo;), the FASB
issued ASU 2014-09 related to revenue recognition. The new guidance sets forth a new five-step revenue recognition model which
replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces
of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that
a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an
amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures
and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU
provides alternative methods of initial adoption and is effective for annual periods beginning after December 15, 2016 and interim
periods within those annual periods. In August 2015, the FASB issued ASU 2015-14 which defers the effective date of ASU 2014-09
one year making it effective for annual reporting periods beginning on or after December 15, 2017 while also providing for early
adoption as of the original effective date. We are currently continuing to evaluate the impact that this standard will have on
our consolidated financial statements as well as the appropriate method of adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 2 - RELATED PARTY TRANSACTIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">On
September 10, 2014, we entered into an Unsecured Grid Note, for up to $250,000 with SCO Capital Partners LLC (SCO). As of December
31, 2014 we had drawn a total of $250,000. The interest rate was 8% per annum and the maturity date was August 31, 2015 unless
a financing of at least $5,000,000 occurred. The financing occurred December 24, 2014 and the Grid Note was paid in full on January
5, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">On
September 10, 2014 we entered into a Share Exchange Agreement for Series B Preferred Stock between us and SCO and Beach Capital
LLC whereby we agreed in connection with the consummation of the an offering for the Series B Preferred Stock to be converted into
Common Stock. All Series B Preferred Stock dividends payable, interest on Series B Preferred Stock dividends payable and liquidated
damages will be converted into Series B Preferred Stock just prior to an offering of at least $10 million. The Series B Preferred
Stock, including the shares of Series B Preferred Stock issued upon conversion of all accrued dividends payable, interest on dividends
payable and liquidated damages thereon, subject to a liquidation preference, will be exchanged for shares of Common Stock upon
consummation of an offering at the offering price pursuant to a Share Exchange Agreement dated September 10, 2014. The conversion
into Common Stock occurred on December 24, 2014.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">On
December 1, 2014, we entered into a second Unsecured Grid Note, for up to $250,000 with SCO. As of December 31, 2014 we had drawn
a total of $150,000. The interest rate was 8% per annum and the maturity date was November 30, 2015 unless a financing of at least
$5,000,000 occurred. The financing occurred December 24, 2014 and the Grid Note was paid in full on January 5, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 3 - PROPERTY AND EQUIPMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">Property and equipment consists of the following:</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Equipment laboratory</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">139,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Furniture and office equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">209,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Leasehold improvement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">381,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">350,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Depreciation
and amortization on property and equipment was $13,000 and $2,000 for the years ended December 31, 2015 and 2014, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 4 &ndash; LICENSED TECHNOLOGY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">On
September 22, 2014, we entered into an exclusive, worldwide, licensing agreement with Licensor to obtain rights to utilize and
to sub-license to other pharmaceuticals firms, its patented methods for the extraction of therapeutic biologics from human plasma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">On
May 15, 2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children&rsquo;s Hospital
to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Licensed
technology consists of the following:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Licensed technology</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">7,156,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">5,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">547,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Licensed technology, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,609,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,991,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Amortization
on licensed technology was $538,000 and $9,000 for the years ended December 31, 2015 and 2014, respectively. The aggregate estimated
amortization expense for intangible assets remaining as of December 31, 2015 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 51%; font-weight: normal; text-align: right">2016</TD><TD STYLE="width: 7%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 40%; font-weight: normal; text-align: right">582</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: right">2017</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">582</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: right">2018</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">582</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: right">2019</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">582</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: right">2020</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">582</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: right; padding-bottom: 1pt">Thereafter</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">3,699</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: right; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right">6,609</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 5 &ndash; 401(k) PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">We
have a tax-qualified employee savings and retirement plan (the 401(k) Plan) covering all our employees. Pursuant to the 401(k)
Plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit ($18,000 in 2015
and $17,500 in 2014) and to have the amount of such reduction contributed to the 401(k) Plan. The 401(k) Plan is intended to qualify
under Section 401 of the Internal Revenue Code so that contributions by employees or by us to the 401(k) Plan, and income earned
on 401(k) Plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that contributions by us,
if any, will be deductible by us when made. At the direction of each participant, we invest the assets of the 401(k) Plan in any
of 60 investment options. Company contributions under the 401(k) Plan were $0 in 2015 and 2014.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 6 &ndash; COMMITMENTS AND CONTINGENCIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Operating
Leases</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">At
December 31, 2015, we had a commitment under a non-cancelable operating lease for our New York office until December 31, 2016 totaling
$187,000. We also had a non-cancelable operating lease for our Dallas office and lab until August 31, 2016 totaling $7,000. We
had an operating lease for our Cleveland office and lab until December 31, 2025 totaling $2,520,000. We have the option to extend
the lease for an additional five years. We can also terminate the lease early at December 31, 2020, at the end of year five, and
pay for unamortized tenant improvements. Our total lease costs and unamortized tenant improvements would total $1,744,000 with
the termination provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">The
five year lease payment schedule is (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 51%; font: normal 10pt Times New Roman, Times, Serif; text-align: right">2016</TD><TD STYLE="width: 7%; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 40%; font: normal 10pt Times New Roman, Times, Serif; text-align: right">365</TD><TD STYLE="width: 1%; font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right">2017</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right">241</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right">2018</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right">246</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right">2019</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right">250</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">2020</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right">256</TD><TD STYLE="padding-bottom: 1pt; font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">Thereafter</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: right">1,356</TD><TD STYLE="padding-bottom: 1pt; font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">Total</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: normal 10pt Times New Roman, Times, Serif; text-align: right">2,714</TD><TD STYLE="padding-bottom: 2.5pt; font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Rent
expense for the years ended December 31, 2015 and 2014 was $219,000 and $178,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Legal</U></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">We are not currently subject
to any material pending legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 7 - FAIR VALUE MEASUREMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">We calculate the fair value
of our assets and liabilities which qualify as financial instruments and include additional information in the notes to the consolidated
financial statements when the fair value is different than the carrying value of these financial instruments. The estimated fair
value of receivables, accounts payable, short-term notes payable and payable to licensor approximate their carrying amounts due
to the relatively short maturity of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">U.S. GAAP define&rsquo;s fair
value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement
date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels
of inputs used to measure fair value are as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 1 &ndash; Quoted prices in active markets for identical assets or liabilities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 2 &ndash; Observable inputs other than quoted prices included in Level 1, such as quoted
prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets
that are not active; or other inputs that are observable or can be corroborated by observable market data.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 3 &ndash; Unobservable inputs that are supported by little or no market activity and that
are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies
and similar valuation techniques that use significant unobservable inputs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">The guidance requires an entity
to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">We have segregated all financial
assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level
within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">Financial assets and liabilities
measured at fair value on a recurring basis as of December 31, 2015 and December 31, 2014 are summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt"><U>(in thousands)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">Description</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">As of <BR>December 31,<BR> 2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total Gains<BR> (Losses)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: justify; text-indent: -0.125in; padding-left: 0.25in">Contingent consideration</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,591</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,591</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,898</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt"><U>(in thousands)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">Description</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">As of <BR>December 31, <BR>
2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total Gains <BR>(Losses)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Derivative liability- preferred stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(23,110</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">In order to calculate the Level
3 Derivative liability - preferred stock, we used the Monte Carlo simulation to estimate future stock prices. The use of valuation
techniques requires the Company to make various key assumptions for inputs into the model, including assumptions about the expected
future volatility of the price of the Company&rsquo;s stock. The preferred stock liability was converted into common stock on December
24, 2014.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 8 &ndash; PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><U>Series A Cumulative Convertible
Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">All Series A Preferred Stock, Series
A dividends payable and interest on Series A Preferred Stock dividends payable were converted into 8,961,769 shares of common stock
just prior to the closing of the financing on December 24, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><U>Derivative Liability</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">Effective January 1, 2009, we adopted
the provisions of FASB ASC 815, <I>&ldquo;Derivatives and Hedging&rdquo;</I> (FASB ASC 815) (previously EITF 07-5, <I>&ldquo;Determining
Whether an Instrument (or an Embeded Feature) is Indexed to an Entity&rsquo;s Own Stock&rdquo;</I>). As a result of adopting FASB
ASC 815, warrants to purchase 77,091 of our common stock previously treated as equity pursuant to the derivative treatment exemption
were no longer afforded equity treatment. These warrants had an exercise price of $175.00 and expired on November 10, 2013 and
February 4, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">We determined that the anti-dilution
provision built into the Series A Preferred Stock and warrants issued should be considered for derivative accounting.&nbsp;FASB
ASC 815 requires freestanding contracts that are settled in a company&rsquo;s own stock to be designated as an equity instrument,
assets or liability. Under the provisions of FASB ASC 815, a contract designated as an asset or liability must be initially recorded
and carried at fair value until the contract meets the requirements for classification as equity, until the contract is exercised
or until the contract expires. We determined that the anti-dilution provision associated with the November 2007 and February 2008
preferred shares and warrants no longer met the criteria for equity accounting through the revised criteria in FASB ASC 815.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">Accordingly, at January 1, 2009, we
determined that the warrants and the Series A Preferred Stock conversion feature should be accounted for as derivative liabilities.
The preferred stock conversion feature was determined to have no fair market value at both issuance dates as well as each reporting
period until the third quarter of 2010 since management asserted that the likelihood of issuing any new equity at a price that
would trigger the anti-dilution effect to be nil. During the third quarter of 2010 we were actively raising capital. With our stock
price below $150.00 a share it was possible that we would sell shares below $150.00 per share. Since this would require an adjustment
to our convertible preferred stock we recorded a derivative liability and expense at September 30, 2010. The derivative liability
and expense was revalued at December 31, 2013 was $1,190,000; and at December 24, 2014 was $24,300,000. The change in the fair
value of the derivative was a loss of $23,110,000 in 2014. The Series A Preferred Stock was converted into common stock at December
24, 2014 and the amount of the derivative liability was reclassified to stockholders equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">The warrants were valued at issuance
and each reporting period since using the Black-Scholes model. On January 1, 2009 we reclassified the fair value of the warrants
from equity to liability as if these warrants were treated as a derivative liability since their issue date. We recorded derivative
gain of $271,000 for the year ended December 31, 2013. Warrants to purchase 72,998 shares of our common stock expired November
10, 2013. The remaining 9,992 warrants expired February 4, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><U>Series B Cumulative Convertible
Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">All Series B Preferred Stock, Series
B dividends payable, interest on Series B Preferred Stock dividends payable and liquidated damages were converted into 6,951,837
shares of common stock just prior to the closing of the financing on December 24, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><U>Liquidated Damages</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">Pursuant to the terms of an Investor
Rights Agreement with the Purchasers of Series A Preferred Stock, we were required to maintain an effective registration statement.
The Securities and Exchange Commission declared the registration statement effective November 13, 2008 relating to a portion of
such securities, and as a result, we accrued $857,000 in potential liquidated damages as of December 31, 2013 and December 31,
2012. Potential liquidated damages were capped at 10% of each holder&rsquo;s investment.&nbsp;The accrued liquidated damages of
$857,000 were converted into common stock at December 24, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><U>Preferred Stock Dividends &ndash;
Series A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">Unpaid preferred stock dividends and
interest of $6,913,416 accrued at December 24, 2014 was converted into common stock at December 24, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><U>Preferred Stock Dividends &ndash;
Series B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">Unpaid preferred stock dividends and
interest of $3,046,553 accrued at December 31, 2014 was converted into common stock at December 24, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 9 &ndash; STOCKHOLDERS&rsquo; EQUITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>2015
Financing</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">On July 31, 2015 we closed an upsized
$15.5 million direct placement of registered common stock with institutional investors, including Soros Fund Management and Perceptive
Life Science Fund, and two members of our Board of Directors. The financing was comprised of 2.83 million shares of our common
stock at a price of $5.50 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">During the second quarter we received
additional financing of $4.6 million through Warrant exercises of our $5.00 warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">On May 11, 2015 we closed a $10
million private placement of common stock consisting of 1,250,000 shares of our common stock, at a price of $8.00 per share, and
warrants to purchase 625,000 shares of our common stock with an exercise price of $10 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.2pt; text-align: justify">Also in connection with the financing,
the placement agent received warrants to purchase 50,000 shares of common stock at $11.00 per share and which are exercisable for
five years from the closing date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">On April 23, 2015 we closed an upsized
$7 million private placement of common stock consisting of 2,333,333 shares of our common stock, at a price of $3.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">On December 24, 2014, we closed
an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares
of common stock, at an offering price of $4.00 per share and $.01 per warrant.&nbsp;The warrants have a per share exercise price
of $5.00, are exercisable immediately, and expire 5 years from the date of issuance. The gross proceeds to the Company from this
offering were $14,035,000, before deducting underwriting discounts and commissions and other estimated offering expenses.&nbsp;All
of the shares and warrants in the offering were sold by the Company. In addition the underwriter received warrants to purchase
87,500 shares of common stock at $5.00 per share. The warrants are exercisable on December 18, 2015 and expire on December 18,
2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">Just before the financing closed
on December 24, 2014, the Series A and Series B preferred stock and unpaid dividends and interest and liquidated damages were converted
into common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Warrants</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">There
were warrants to purchase a total of 3,799,024 shares of common stock outstanding at December 31, 2015. All warrants were exercisable
at December 31, 2015. The warrants had various exercise prices and terms as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 1pt">Warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 1pt">Exercise</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">Expiration</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Summary of Warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Outstanding</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Date</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 49%">2015 Financing 7/31/15 (a)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">20,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">6.05</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: center">07/31/20</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>2015 Financing 5/11/15 (b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">625,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/11/17</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2015 Financing 5/11/15 agent warrants (b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5/11/20</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>2014 Financing 12/24/14 (c)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,572,881</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/24/19</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2014 Financing 12/24/14 agent warrants (c)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/18/19</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2012 Series B private placement (d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/24/18</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>2011 November private placement (e)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,898</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/10&amp;30/16</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">2011 November placement agent warrants (e)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">744</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">83.50&amp;100.00</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">11/10&amp;30/16</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none; padding-bottom: 2.5pt; text-align: center">Total<FONT STYLE="text-underline-style: double"><U STYLE="text-decoration: none">&nbsp;</U></FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,799,024</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">In connection with the offering on July 31, 2015, the placement
agent received warrants to purchase 20,000 share of common stock at $6.05 per share. The warrants are exercisable and expire on
July 31. 2020.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">In connection with the offering on May 11, 2015, warrants to
purchase 625,000 shares of common stock at $10.00 per share were issued. All of the warrants exercisable and expire November 11,
2017.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><FONT STYLE="font-weight: normal">Also
in connection with the offering on May 11, 2015, the placement agent received warrants to purchase 50,000 share of common stock
at $11.00 per share. The warrants are exercisable and expire on May 11. 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">In connection with an offering on December 24, 2014, warrants
to purchase 3,500,000 shares of common stock at $5.00 per share were purchased and issued for $0.01 per warrant. All of the warrants
are exercisable immediately and expire on December 24, 2019. At December 31, 2015, 2,572,881 warrants are outstanding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><FONT STYLE="font-weight: normal">Also
in connection with the offering on December 24, 2014, the underwriter received warrants to purchase 87,500 shares of common stock
at $5.00 per share. The warrants were exercisable on December 18, 2015 and expire on December 18, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">In connection with a private placement offering on October 25,
2012, warrants to purchase 400,001 shares of common stock at $25.00 per share were issued. All of the warrants are exercisable
immediately and expire on October 24, 2018.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">In connection with a private placement offering on November 10
and 30, 2011, warrants to purchase 42,898 shares of common stock at $100.00 per share were issued. All of the warrants are exercisable
immediately and 37,148 warrants expire November 10, 2016 and 5,750 warrants expire November 30, 2016.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><FONT STYLE="font-weight: normal">Also
in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 372 shares of
common stock at $83.50 per share were issued. Also in connection with a private placement offering on November 10 and 30, 2011,
placement agent warrants to purchase 372 shares of common stock at $100.00 per share were issued. All the placement agent warrants
are exercisable immediately and 372 warrants expire November 10, 2016 and 372 warrants expire November 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 10 - STOCK OPTION PLANS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Our
stock-based employee compensation plans described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>2015
Equity Incentive Plan</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">We
have a stock awards plan, (the 2015 Equity Incentive Plan), under which 5,000,000 shares of our authorized but unissued common
stock were reserved for issuance to employees, consultants, or to non-employee members of the Board or to any board of directors
(or similar governing authority) of any affiliate of the Company. The 2015 Equity Incentive Plan, approved by our shareholders
on May 7, 2015, replaced the previously approved stock option plan (the 2005 Equity Incentive Plan).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">For
the 2015 Equity Incentive Plan, the fair value of options was estimated at the date of grant using the Black-Scholes option pricing
model with the following weighted average assumptions used for grants in fiscal 2015: dividend yield of 0%; volatility of 102%;
risk-free interest rate of 0.86%; and expected lives of 5.0 years. The weighted average fair value of options granted was $6.90
per share during 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Summarized
information for the 2015 Equity Incentive Plan is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted-</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">average</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">exercise</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding options at January 1, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; padding-bottom: 1pt">Granted, fair value of $5.18 per share</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">1,994,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; padding-bottom: 1pt; text-align: right">6.90</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding options at December 31, 2015</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,994,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">6.90</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: justify">Exercisable at December 31, 2015</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">35,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">7.34</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">There
was no intrinsic value related to the outstanding or exercisable options under this plan at December 31, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Further
information regarding options outstanding under the 2015 Equity Incentive Plan at December 31, 2015 is summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; padding-bottom: 1pt">Number of</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">Weighted average</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; padding-bottom: 1pt">Number of</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">Weighted-average</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">options</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">options</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Range of exercise prices</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">outstanding</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">life in years</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">life in years</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 22%; font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: justify; padding-bottom: 1pt">$4.38 - 7.34</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,994,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: right">9.0</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: right">6.90</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">35,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: right">9.0</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: right">7.34</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>2005
Equity Incentive Plan</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Under
the 2005 Equity Incentive Plan, as amended, shares of our authorized but unissued common stock were reserved for issuance to employees,
consultants, or to non-employee members of the Board or to any board of directors (or similar governing authority) of any affiliate
of the Company. As of January 20, 2015 no additional shares were available for grant under the 2005 Equity Incentive Plan. A total
of 330,084 options were outstanding and exercisable under this plan at December 31, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">For
the 2005 Equity Incentive Plan, the fair value of options was estimated at the date of grant using the Black-Scholes option pricing
model with the following weighted average assumptions used for grants in fiscal 2015: dividend yield of 0%; volatility of 102%;
risk-free interest rate of 1.41%; and expected lives of 4.6 years. The weighted average fair value of the options grants was $4.52
per share in 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">The
assumptions for fiscal 2014 are: dividend yield of 0%; volatility of 102%; risk-free interest rate of 0.79%; and expected lives
of 5.5 years. The weighted average fair value of the options granted was $14.50 per share in 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Summarized
information for the 2005 Equity Incentive Plan is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted-</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">average</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">exercise</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="width: 74%; text-align: left">Outstanding options at January 1, 2014</TD><TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; text-align: right">28,784</TD><TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">$</TD><TD NOWRAP STYLE="width: 10%; text-align: right">59.00</TD><TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted, fair value of $14.50 per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">212,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Expired/forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">37.61</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Outstanding options at December 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210,084</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Granted, fair value of $4.52</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">120,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.25</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding options at December 31, 2015</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">330,084</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">13.49</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left">Exercisable at December 31, 2015</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">319,884</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">15.02</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">The
intrinsic value related to the outstanding or exercisable options under this plan at December 31, 2015 was $13,000 and $12,000,
respectively. At December 31, 2014, the intrinsic value related to the outstanding or exercisable options was none.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Further
information regarding options outstanding under the 2005 Equity Incentive Plan at December 31, 2015 is summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; padding-bottom: 1pt">Number of</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">Weighted average</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; padding-bottom: 1pt">Number of</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">Weighted-average</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">options</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">options</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Range of exercise prices</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">outstanding</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">life in years</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">life in years</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 22%; font-weight: normal; text-align: left">$3.25</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">120,000</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">4.0</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">3.25</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">110,000</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">4.0</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">3.25</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left">$11.50 - 18.50</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">200,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">7.7</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">18.33</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">199,800</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">7.7</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">18.32</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left">$30.50 - 42.50</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4.1</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">32.19</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4.1</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">32.19</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left">$69.00</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1,400</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4.0</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">69.00</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1,400</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4.0</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">69.00</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">$113.50 &ndash; 157.50</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">4,684</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: right">5.0</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">119.99</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: right">4,684</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: right">5.0</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: right">119.99</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">330,084</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">319,884</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Note
11 - Abeona Therapeutics LLC Acquisition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">On May 15, 2015, we agreed to issue
an aggregate of 3,979,761 unregistered shares of our common stock to the members of Abeona Therapeutics LLC (Abeona Ohio). Abeona
Ohio&rsquo;s principal activities were focused on developing and delivering gene therapy products for severe and life-threatening
rare diseases. Abeona Ohio's lead program is ABO-101 (AA NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene
therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively) in collaboration with patient advocate groups, researchers
and clinicians, anticipated to commence clinical trials in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">The initial consideration of $31,758,000
was calculated using the Company&rsquo;s stock price on date of the closing, May 15, 2015 of $7.98 times the number of the Company
shares (3,979,761) issued to Abeona Ohio members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">There is a contingent valuation
on three milestones. Per the merger agreement with Abeona Ohio each milestone would consist of either cash, our stock or a combination
of both, at the Company&rsquo;s election, equivalent to a stated dollar amount. The fair value of the probability of achieving
all three milestones was estimated at $6,489,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">The following
purchase price allocation is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total purchase price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 77%; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Initial consideration</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">31,758,000</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Contingent consideration</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,489,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total purchase price</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">38,247,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Allocation of the purchase price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,697,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(153,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total tangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,625,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Licensing agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,156,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,466,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total net asset value</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">38,247,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">In connection with the acquisition
$375,000 in merger costs were expensed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first milestone of receiving IND allowance
from the FDA to initiate a Phase 1 clinical study from MPS IIIA or MPSIIIB by November 15, 2015 was not met after the measurement period
ended. The Company recognized $3,898,000 in Miscellaneous Income for change in fair value of our contingent consideration liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill is not expected to be deductible
for tax purposes.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 12 - INCOME TAXES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Income
tax expense differs from the statutory amounts as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: normal; text-align: left">Income taxes at U.S. statutory rate</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: normal; text-align: right">(4,939,000</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: normal; text-align: right">(9,105,000</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left">Current year reserve</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">6,257,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1,254,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">Other</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(1,318,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">7,851,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">Total tax expense</TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">Deferred
taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities.
The temporary differences that give rise to deferred tax assets were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left">Deferred tax assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; font-weight: normal; text-align: left; padding-left: 9pt">Net operating loss carryforwards</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: normal; text-align: right">68,636,000</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: normal; text-align: right">68,263,000</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-left: 9pt">General business credit carryforwards</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">2,497,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">2,486,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-left: 9pt">State credits</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">2,055,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">2,061,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-left: 9pt">Property, equipment and goodwill</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">(25,000</TD><TD STYLE="font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-left: 9pt">Stock options</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">3,678,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">542,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-left: 9pt">Derivatives</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">(92,000</TD><TD STYLE="font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">(92,000</TD><TD STYLE="font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-left: 9pt">Deferred revenue</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1,669,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">92,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-left: 9pt">Intangible assets</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">595,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">464,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-left: 9pt">Accrued interest</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">253,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">253,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">231,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">231,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left">Gross deferred tax assets</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">79,497,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">74,300,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(79,497,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(74,300,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Net deferred taxes</TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">At
December 31, 2015, we had approximately $209,666,000 of net operating loss carryforwards and approximately $2,497,000 of general
business credit carryforwards. These carryforwards expire as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 2in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">Net operating</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center">General business</TD><TD NOWRAP STYLE="font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal">l<U STYLE="text-decoration: none">oss carryforwards</U></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD><TD NOWRAP STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">credit carryforwards</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left">2016</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left">2017</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-weight: normal; text-align: left">2018</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 25%; font-weight: normal; text-align: right">3,324,000</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 25%; font-weight: normal; text-align: right">112,000</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">Thereafter</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">206,342,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">2,385,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-decoration: none; text-align: left; padding-bottom: 2.5pt; font-style: normal">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right">209,666,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right">2,497,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">As
a result of a merger on January 25, 1996, a change in control occurred for federal income tax purposes, which limits the utilization
of pre-merger net operating loss carryforwards of approximately $3,100,000 to approximately $530,000 per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">Additionally, we acquired MacroChem
Corporation on February 25, 2009 and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both corporations were loss companies at
the time of the acquisition. Therefore, the net operating losses related to those acquisitions may be subject to annual limitations
as provided by IRC Sec. 382.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>v435519_ex21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>EXHIBIT 21 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subsidiaries of the Registrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics LLC, an Ohio company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MacroChem Corporation, a Delaware company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Virium Pharmaceuticals, Inc., a Delaware company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Somanta Pharmaceuticals, Inc., a Delaware company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tacora Corporation, a Delaware company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Virologix Corporation, a Delaware company</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>v435519_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>EXHIBIT 23.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have issued our report dated March 30,
2016, accompanying the consolidated financial statements included in the Annual Report of Abeona Therapeutics Inc. and subsidiaries
on Form 10-K for the years ended December 31, 2015 and 2014.&nbsp;We hereby consent to the incorporation by reference of said report
in the Registration Statements of Abeona Therapeutics Inc. on Form S-1 (File Nos. 333-197220, 333-179603 and 333-178415,), Form
S-3 (File No. 333-205128 and 333-204179), and Form S-8 (File Nos. 333-204055, 333-189985, 333-169067, 333-161642 and 333-125796).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Whitley Penn LLP </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dallas, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 30, 2016</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>v435519_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT 31.1</P>

<HR SIZE="4" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>PRINCIPAL EXECUTIVE OFFICER CERTIFICATION
PURSUANT TO 18 U.S.C.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 302</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OF THE SARBANES-OXLEY ACT OF 2002</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Steven H. Rouhandeh, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">1.</TD>
    <TD STYLE="font-size: 10pt">I have reviewed this Annual Report on Form 10-K of Abeona
Therapeutics Inc.</TD></TR>
<tr style="vertical-align: top">
    <td style="width: 8%; font-size: 10pt"><font style="font-size: 10pt">2.</font></td>
    <td style="width: 92%; font-size: 10pt"><font style="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><font style="font-size: 10pt">3.</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><font style="font-size: 10pt">4.</font></td>
    <td colspan="2" style="font-size: 10pt"><font style="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 8%; font-size: 10pt"><font style="font-size: 10pt">a)</font></td>
    <td style="width: 84%; font-size: 10pt"><font style="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 8%; font-size: 10pt"><font style="font-size: 10pt">b)</font></td>
    <td style="width: 84%; font-size: 10pt"><font style="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">c)</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 8%; font-size: 10pt"><font style="font-size: 10pt">d)</font></td>
    <td style="width: 84%; font-size: 10pt"><font style="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><font style="font-size: 10pt">5.</font></td>
    <td colspan="2" style="font-size: 10pt"><font style="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 8%; font-size: 10pt"><font style="font-size: 10pt">a)</font></td>
    <td style="width: 84%; font-size: 10pt"><font style="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">b)</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 60%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: March 30, 2016</P></td>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Steven H. Rouhandeh</P></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven H. Rouhandeh&#9;Executive Chairman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal Executive Officer</P>
</TD></TR>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>v435519_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT 31.2</P>

<HR SIZE="4" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>PRINCIPAL FINANCIAL OFFICER CERTIFICATION
PURSUANT TO 18 U.S.C.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 302</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OF THE SARBANES-OXLEY ACT OF 2002</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Stephen B. Thompson, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">1.</TD>
    <TD STYLE="font-size: 10pt">I have reviewed this Annual Report on Form 10-K of Abeona
Therapeutics Inc.</TD></TR>
<tr style="vertical-align: top">
    <td style="width: 8%; font-size: 10pt"><font style="font-size: 10pt">2.</font></td>
    <td style="width: 92%; font-size: 10pt"><font style="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><font style="font-size: 10pt">3.</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><font style="font-size: 10pt">4.</font></td>
    <td colspan="2" style="font-size: 10pt"><font style="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 8%; font-size: 10pt"><font style="font-size: 10pt">a)</font></td>
    <td style="width: 84%; font-size: 10pt"><font style="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 8%; font-size: 10pt"><font style="font-size: 10pt">b)</font></td>
    <td style="width: 84%; font-size: 10pt"><font style="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">c)</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 8%; font-size: 10pt"><font style="font-size: 10pt">d)</font></td>
    <td style="width: 84%; font-size: 10pt"><font style="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><font style="font-size: 10pt">5.</font></td>
    <td colspan="2" style="font-size: 10pt"><font style="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 8%; font-size: 10pt"><font style="font-size: 10pt">a)</font></td>
    <td style="width: 84%; font-size: 10pt"><font style="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">b)</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 60%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: March 30, 2016</P></td>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Stephen B. Thompson</P></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephen B. Thompson&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal Financial and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounting Officer</P>
</TD></TR>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>v435519_ex32.htm
<DESCRIPTION>EXHIBIT 32
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32</B></P>

<HR SIZE="4" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION PURSUANT TO 18 U.S.C.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SECTION 1350 AS ADOPTED PURSUANT TO SECTION
906</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OF THE SARBANES-OXLEY ACT OF 2002</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This certification set forth below is hereby made solely for
the purposes of satisfying the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 and may not be relied upon or used
for any other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A signed original of this written statement required by Section
906 has been provided to Abeona Therapeutics Inc. and will be retained by Abeona Therapeutics Inc. and furnished to the SEC or
its staff upon its request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to Section 906 of the Public Company Accounting Reform
and Investor Act of 2002 (18 U.S.C. 1350, as adopted, the &ldquo;Sarbanes-Oxley Act&rdquo;), Steven H. Rouhandeh, Executive Chairman
of Abeona Therapeutics Inc. (the &ldquo;Company&rdquo;), and Stephen B. Thompson, Vice President Finance of the Company hereby certify
that to their knowledge the Annual Report on Form 10-K for the period ended December 31, 2015 of the Company filed with the Securities
and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;) fully complies with the requirements of section 13(a) or 15(d)
of the Securities Exchange Act of 1934 and the information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company for the period specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signed at the City of Dallas, in the State of Texas, this 30th
day of March, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-right: 0; padding-left: 0; text-decoration: none; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;/s/
    Steven H. Rouhandeh</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%; padding-right: 0; padding-left: 0; text-decoration: none; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stephen
    B. Thompson</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Steven H. Rouhandeh</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Stephen B. Thompson</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Executive Chairman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Vice President Finance</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Principal Executive Officer </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Principal Financial and Accounting Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>accp-20151231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.0.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:accp="http://accesspharma.com/20151231" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="accp-20151231.xsd" />
  <xbrli:context id="c20150101to20151231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160330">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ConversionOfStockByUniqueDescriptionAxis_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">accp:ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_ConversionOfStockByUniqueDescriptionAxis_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">accp:ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ConversionOfStockByUniqueDescriptionAxis_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">accp:ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_ConversionOfStockByUniqueDescriptionAxis_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">accp:ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTermsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTerms1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">accp:LicenseAgreementTerms1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTerms1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">accp:LicenseAgreementTerms1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeStatementLocationAxis_OperatingExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_IncomeStatementLocationAxis_OperatingExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140910to20140910_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember_StatementClassOfStockAxis_SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">accp:ScoCapitalPartnersLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-09-10</xbrli:startDate>
      <xbrli:endDate>2014-09-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140910_LongtermDebtTypeAxis_UnsecuredDebtMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">accp:ScoCapitalPartnersLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141201_LongtermDebtTypeAxis_SecondUnsecuredGridNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">accp:ScoCapitalPartnersLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">accp:SecondUnsecuredGridNoteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_LongtermDebtTypeAxis_SecondUnsecuredGridNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">accp:SecondUnsecuredGridNoteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">accp:ScoCapitalPartnersLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_LongtermDebtTypeAxis_UnsecuredDebtMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">accp:ScoCapitalPartnersLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_LongtermDebtTypeAxis_SecondUnsecuredGridNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">accp:SecondUnsecuredGridNoteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">accp:ScoCapitalPartnersLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_LongtermDebtTypeAxis_UnsecuredDebtMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">accp:ScoCapitalPartnersLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PropertyPlantAndEquipmentByTypeAxis_Building2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">accp:Building2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_StatementClassOfStockAxis_PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_StatementClassOfStockAxis_PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_StatementClassOfStockAxis_PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_StatementClassOfStockAxis_PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_StatementClassOfStockAxis_PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141224">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131109to20131110_FinancialInstrumentAxis_WarrantMember_StatementClassOfStockAxis_PreferredStockOffering2008Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">accp:PreferredStockOffering2008Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-11-09</xbrli:startDate>
      <xbrli:endDate>2013-11-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140204to20140204_FinancialInstrumentAxis_WarrantMember_StatementClassOfStockAxis_PreferredStockOffering2008Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">accp:PreferredStockOffering2008Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-04</xbrli:startDate>
      <xbrli:endDate>2014-02-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementClassOfStockAxis_SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141224_StatementClassOfStockAxis_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141224_StatementClassOfStockAxis_SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150511to20150511_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-11</xbrli:startDate>
      <xbrli:endDate>2015-05-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150423to20150423_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-23</xbrli:startDate>
      <xbrli:endDate>2015-04-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150731to20150731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-31</xbrli:startDate>
      <xbrli:endDate>2015-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150511_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-05-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150423_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-04-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141224to20141224">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-12-24</xbrli:startDate>
      <xbrli:endDate>2014-12-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150511_SubsidiarySaleOfStockAxis_PlacementAgentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">accp:PlacementAgentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-05-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150511to20150511_SubsidiarySaleOfStockAxis_PlacementAgentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">accp:PlacementAgentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-11</xbrli:startDate>
      <xbrli:endDate>2015-05-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PrivatePlacement1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_SeriesBPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:SeriesBPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_PlacementAgentWarrants1Member_FinancialInstrumentAxis_Warrant2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PlacementAgentWarrants1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">accp:Warrant2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_PlacementAgentWarrants1Member_FinancialInstrumentAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PlacementAgentWarrants1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_MayFinancingAgentWarrants2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:MayFinancingAgentWarrants2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_PlacementAgentWarrants1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PlacementAgentWarrants1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member_FinancialInstrumentAxis_Warrant2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PrivatePlacement1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">accp:Warrant2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member_FinancialInstrumentAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PrivatePlacement1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_PublicOfferingAgentWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PublicOfferingAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_MayFinancing2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:MayFinancing2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ClassOfWarrantOrRightAxis_JulyFinancing2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:JulyFinancing2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ClassOfWarrantOrRightAxis_PlacementAgentWarrants1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PlacementAgentWarrants1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PrivatePlacement1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ClassOfWarrantOrRightAxis_PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ClassOfWarrantOrRightAxis_MayFinancing2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:MayFinancing2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ClassOfWarrantOrRightAxis_MayFinancingAgentWarrants2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:MayFinancingAgentWarrants2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member_FinancialInstrumentAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PrivatePlacement1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member_FinancialInstrumentAxis_Warrant2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PrivatePlacement1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">accp:Warrant2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ClassOfWarrantOrRightAxis_JulyFinancing2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:JulyFinancing2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ClassOfWarrantOrRightAxis_PublicOfferingAgentWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:PublicOfferingAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ClassOfWarrantOrRightAxis_SeriesBPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">accp:SeriesBPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PlanNameAxis_EquityIncentivePlan2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2005Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_PlanNameAxis_EquityIncentivePlan2005Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PlanNameAxis_EquityIncentivePlan2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PlanNameAxis_EquityIncentivePlan2005Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PlanNameAxis_EquityIncentivePlan2005Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeFiveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeSixMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeSixMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PlanNameAxis_EquityIncentivePlan2015Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeSixMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeSixMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">accp:RangeFiveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">accp:EquityIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150515to20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">accp:BusinessAcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-15</xbrli:startDate>
      <xbrli:endDate>2015-05-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">accp:BusinessAcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-05-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_BusinessAcquisitionAxis_BusinessAcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">accp:BusinessAcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_TaxPeriodAxis_LatestTaxYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_TaxPeriodAxis_TaxYear2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">accp:TaxYear2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementScenarioAxis_PreMergerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">accp:PreMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementScenarioAxis_PostMergerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">accp:PostMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_TaxPeriodAxis_TaxYearThereafterMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">accp:TaxYearThereafterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_TaxPeriodAxis_TaxYear2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">accp:TaxYear2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_TaxCreditCarryforwardAxis_GeneralBusinessMember_TaxPeriodAxis_TaxYear2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">accp:TaxYear2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_TaxCreditCarryforwardAxis_GeneralBusinessMember_TaxPeriodAxis_TaxYearThereafterMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">accp:TaxYearThereafterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_TaxCreditCarryforwardAxis_GeneralBusinessMember_TaxPeriodAxis_LatestTaxYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_TaxCreditCarryforwardAxis_GeneralBusinessMember_TaxPeriodAxis_TaxYear2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">accp:TaxYear2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_TaxCreditCarryforwardAxis_GeneralBusinessMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U004">
    <xbrli:measure>accp:Institution</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U005">
    <xbrli:measure>accp:License</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U006">
    <xbrli:measure>accp:Plan</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U007">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U008">
    <xbrli:measure>accp:InvestmentOptions</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U009">
    <xbrli:measure>accp:Director</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U010">
    <xbrli:measure>accp:Milestone</xbrli:measure>
  </xbrli:unit>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c20150101to20151231">false</dei:AmendmentFlag>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c20150101to20151231">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c20150101to20151231">2015-12-31</dei:DocumentPeriodEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c20150101to20151231">No</dei:EntityWellKnownSeasonedIssuer>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c20150101to20151231">No</dei:EntityVoluntaryFilers>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c20150101to20151231">Yes</dei:EntityCurrentReportingStatus>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c20150101to20151231">Smaller Reporting Company</dei:EntityFilerCategory>
  <!--Entity Public Float-->
  <dei:EntityPublicFloat contextRef="c20150630" unitRef="U001" decimals="0">74700000</dei:EntityPublicFloat>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c20150101to20151231">ABEONA THERAPEUTICS INC.</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c20150101to20151231">0000318306</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c20160330" unitRef="U002" decimals="INF">32743013</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c20150101to20151231">2015</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c20150101to20151231">FY</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType contextRef="c20150101to20151231">10-K</dei:DocumentType>
  <!--Accounts payable-->
  <us-gaap:AccountsPayableCurrent contextRef="c20141231" unitRef="U001" decimals="0">1896000</us-gaap:AccountsPayableCurrent>
  <!--Accounts payable-->
  <us-gaap:AccountsPayableCurrent contextRef="c20151231" unitRef="U001" decimals="0">875000</us-gaap:AccountsPayableCurrent>
  <!--Less accumulated depreciation and amortization-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20141231" unitRef="U001" decimals="0">10000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Less accumulated depreciation and amortization-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20151231" unitRef="U001" decimals="0">31000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20151231" unitRef="U001" decimals="0">377993000</us-gaap:AdditionalPaidInCapital>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20141231" unitRef="U001" decimals="0">300690000</us-gaap:AdditionalPaidInCapital>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Series A Preferred Stock [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Series B Preferred Stock [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20140101to20141231" unitRef="U001" decimals="0">1305000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Common Stock [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Common Stock [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Additional Paid-in Capital [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">1305000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Retained Earnings [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Treasury Stock [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20150101to20151231" unitRef="U001" decimals="0">4368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Treasury Stock [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Retained Earnings [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Additional Paid-in Capital [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">4368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Series B Preferred Stock [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition-Series A Preferred Stock [Member]-->
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <!--Stock-based compensation expense, net of tax-->
  <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c20150101to20151231" unitRef="U001" decimals="-3">4368000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
  <!--Stock-based compensation expense, net of tax-->
  <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c20140101to20141231" unitRef="U001" decimals="-3">1305000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
  <!--Allocated Share-based Compensation Expense-Operating Expense [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U001" decimals="-3">1305000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Operating Expense [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U001" decimals="-3">4368000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Research and Development [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3">773000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3">4368000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Research and Development [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3">104000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-General and Administrative [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3">3595000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-General and Administrative [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3">1201000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3">1305000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allowance for doubtful accounts receivable-->
  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c20151231" unitRef="U001" decimals="0">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <!--Allowance for doubtful accounts receivable-->
  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c20141231" unitRef="U001" decimals="0">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <!--Amortization of Intangible Assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231" unitRef="U001" decimals="0">9000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20150101to20151231" unitRef="U001" decimals="0">538000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20150101to20151231" unitRef="U002" decimals="0">6123108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount-Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20141231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0">210134</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount-Warrants [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="0">3799024</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount-Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0">2324084</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount-Warrants [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20141231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="0">4164756</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20141231" unitRef="U002" decimals="0">4374890</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20141231" unitRef="U001" decimals="0">16582000</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20151231" unitRef="U001" decimals="0">80055000</us-gaap:Assets>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20151231" unitRef="U001" decimals="0">40568000</us-gaap:AssetsCurrent>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20141231" unitRef="U001" decimals="0">11555000</us-gaap:AssetsCurrent>
  <!--Acquisition transaction cost-Business Acquisitions [Member]-->
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">375000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <!--Business Combination, Consideration Transferred-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c20150515to20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">38247000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">153000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
  <!--Business Acquisition, Equity Interest Issued or Issuable, Number of Shares-Business Acquisitions [Member]-->
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c20150515to20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U002" decimals="0">3979761</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <!--Prepaid expenses-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">28000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
  <!--Accounts receivable-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">1000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
  <!--Cash-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">3697000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <!--Business Combination, Consideration Transferred, Liabilities Incurred-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c20150515to20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">6489000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
  <!--Initial consideration-->
  <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
  <!--Initial consideration-->
  <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c20150101to20151231" unitRef="U001" decimals="0">31758000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
  <!--Initial consideration-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c20150515to20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">31758000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
  <!--Licensing agreement-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">2156000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">1000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
  <!--Contingent consideration liability-->
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c20141231" unitRef="U001" decimals="0">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <!--Contingent consideration liability-->
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c20151231" unitRef="U001" decimals="0">2591000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <!--Contingent consideration liability-Level 1 [Member]-Recurring [Member]-->
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c20151231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <!--Contingent consideration liability-Recurring [Member]-Level 2 [Member]-->
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c20151231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <!--Contingent consideration liability-Recurring [Member]-Level 3 [Member]-->
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c20151231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">2591000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <!--Contingent consideration liability-Recurring [Member]-->
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c20151231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">2591000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <!--Contingent consideration liability-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c20151231_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">3898000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <!--Business acquisition, share price (in dollars per shares)-Business Acquisitions [Member]-->
  <us-gaap:BusinessAcquisitionSharePrice contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U003" decimals="INF">7.98</us-gaap:BusinessAcquisitionSharePrice>
  <!--ABEONA THERAPEUTICS LLC ACQUISITION-->
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-transform: uppercase; text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;Note 11 - Abeona Therapeutics LLC Acquisition&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On May 15, 2015, we agreed to issue an aggregate of 3,979,761 unregistered shares of our common stock to the members of Abeona Therapeutics LLC (Abeona Ohio). Abeona Ohio&amp;#8217;s principal activities were focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Abeona Ohio's lead program is ABO-101 (AA NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively) in collaboration with patient advocate groups, researchers and clinicians, anticipated to commence clinical trials in 2016.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The initial consideration of $31,758,000 was calculated using the Company&amp;#8217;s stock price on date of the closing, May 15, 2015 of $7.98 times the number of the Company shares (3,979,761) issued to Abeona Ohio members.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;There is a contingent valuation on three milestones. Per the merger agreement with Abeona Ohio each milestone would consist of either cash, our stock or a combination of both, at the Company&amp;#8217;s election, equivalent to a stated dollar amount. The fair value of the probability of achieving all three milestones was estimated at $6,489,000.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The following purchase price allocation is as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 70%;"&gt;&lt;tr style="height: 12px; vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 47%;"&gt;Total purchase price&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 20px; vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;"&gt;Initial consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;31,758,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;"&gt;Contingent consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;6,489,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;"&gt;Total purchase price&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 20%;"&gt;38,247,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 47%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 47%;"&gt;Allocation of the purchase price&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 47%;"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;3,697,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;28,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Property and equipment&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;51,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Other assets&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 20%;"&gt;(153,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Total tangible assets&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;3,625,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 47%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Licensing agreement&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;2,156,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; width: 47%;"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 20%;"&gt;32,466,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 47%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 47%;"&gt;Total net asset value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 20%;"&gt;38,247,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;In connection with the acquisition $375,000 in merger costs were expensed.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px;"&gt;The first milestone of receiving IND allowance from the FDA to initiate a Phase 1 clinical study from MPS IIIA or MPSIIIB by November 15, 2015 was not met after the&amp;#160;measurement period ended. The Company recognized $3,898,000 in Miscellaneous Income for change in fair value of our contingent consideration liability.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px;"&gt;Goodwill is not expected to be deductible for tax purposes.&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <!--Property and equipment-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">51000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
  <!--Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net-Business Acquisitions [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">38247000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
  <!--Cash and Cash Equivalents-->
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;&lt;u&gt;Cash and Cash Equivalents&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.&amp;#160;At December 31, 2015 and 2014, we had no such investments.&amp;#160;We maintain deposits primarily in two financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (FDIC).&amp;#160; We have not experienced any losses related to amounts in excess of FDIC limits.&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20151231" unitRef="U001" decimals="0">40138000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20141231" unitRef="U001" decimals="0">11520000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20131231" unitRef="U001" decimals="0">424000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20150101to20151231" unitRef="U001" decimals="0">28618000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20140101to20141231" unitRef="U001" decimals="0">11096000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash Equivalents, at Carrying Value-->
  <us-gaap:CashEquivalentsAtCarryingValue contextRef="c20141231" unitRef="U001" decimals="0">0</us-gaap:CashEquivalentsAtCarryingValue>
  <!--Cash Equivalents, at Carrying Value-->
  <us-gaap:CashEquivalentsAtCarryingValue contextRef="c20151231" unitRef="U001" decimals="0">0</us-gaap:CashEquivalentsAtCarryingValue>
  <!--Exercise Price (in dollars per share)-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231" unitRef="U003" decimals="INF">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-Series A Preferred Stock [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U003" decimals="2">175.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-2012 Series B private placement [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231_ClassOfWarrantOrRightAxis_SeriesBPrivatePlacementMember" unitRef="U003" decimals="2" id="Item-1">25.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-May Financing 2015 [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231_ClassOfWarrantOrRightAxis_MayFinancing2015Member" unitRef="U003" decimals="2" id="Item-2">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-Warrant2 [Member]-Placement Agent Warrants 1 [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231_ClassOfWarrantOrRightAxis_PlacementAgentWarrants1Member_FinancialInstrumentAxis_Warrant2Member" unitRef="U003" decimals="2" id="Item-3">100.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-Public Offering [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231_ClassOfWarrantOrRightAxis_PublicOfferingMember" unitRef="U003" decimals="2" id="Item-4">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-Private Placement 1 [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member" unitRef="U003" decimals="2" id="Item-5">100.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-Placement Agent [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20150511_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="U003" decimals="2">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-Private Placement [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20150511_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="U003" decimals="0">10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-July Financing 2015 [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231_ClassOfWarrantOrRightAxis_JulyFinancing2015Member" unitRef="U003" decimals="2" id="Item-6">6.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-Public Offering Agent Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231_ClassOfWarrantOrRightAxis_PublicOfferingAgentWarrantsMember" unitRef="U003" decimals="2" id="Item-7">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20150630" unitRef="U003" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-May Financing Agent Warrants 2015 [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231_ClassOfWarrantOrRightAxis_MayFinancingAgentWarrants2015Member" unitRef="U003" decimals="2" id="Item-8">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Exercise Price (in dollars per share)-Warrants [Member]-Placement Agent Warrants 1 [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20151231_ClassOfWarrantOrRightAxis_PlacementAgentWarrants1Member_FinancialInstrumentAxis_WarrantMember" unitRef="U003" decimals="2" id="Item-9">83.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Class of Warrant or Right, Date from which Warrants or Rights Exercisable-->
  <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="c20150101to20151231">2015-12-18</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
  <!--Warrants granted to acquire shares of common stock (in shares)-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20151231" unitRef="U002" decimals="INF">77091</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants granted to acquire shares of common stock (in shares)-Placement Agent [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20150511_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="U002" decimals="INF">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants granted to acquire shares of common stock (in shares)-Private Placement [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20150511_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="U002" decimals="INF">625000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants Outstanding (in shares)-Private Placement 1 [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member" unitRef="U002" decimals="INF" id="Item-10">42898</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-2012 Series B private placement [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_SeriesBPrivatePlacementMember" unitRef="U002" decimals="INF" id="Item-11">400001</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-Placement Agent Warrants 1 [Member]-Warrant2 [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_PlacementAgentWarrants1Member_FinancialInstrumentAxis_Warrant2Member" unitRef="U002" decimals="0">372</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-Public Offering [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_PublicOfferingMember" unitRef="U002" decimals="INF" id="Item-12">2572881</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-Placement Agent Warrants 1 [Member]-Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_PlacementAgentWarrants1Member_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0">372</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-May Financing Agent Warrants 2015 [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_MayFinancingAgentWarrants2015Member" unitRef="U002" decimals="INF" id="Item-13">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-Placement Agent Warrants 1 [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_PlacementAgentWarrants1Member" unitRef="U002" decimals="INF" id="Item-14">744</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-Private Placement 1 [Member]-Warrant2 [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member_FinancialInstrumentAxis_Warrant2Member" unitRef="U002" decimals="0">5750</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-Private Placement 1 [Member]-Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="0">37148</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-Public Offering Agent Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_PublicOfferingAgentWarrantsMember" unitRef="U002" decimals="INF" id="Item-15">87500</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-May Financing 2015 [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_MayFinancing2015Member" unitRef="U002" decimals="INF" id="Item-16">625000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231" unitRef="U002" decimals="INF">3799024</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants Outstanding (in shares)-July Financing 2015 [Member]-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20151231_ClassOfWarrantOrRightAxis_JulyFinancing2015Member" unitRef="U002" decimals="INF" id="Item-17">20000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Commitments and Contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20141231" unitRef="U001" xsi:nil="true" />
  <!--Commitments and Contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20151231" unitRef="U001" xsi:nil="true" />
  <!--Commitments and Contingencies Disclosure [Text Block]-->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;NOTE 6 &amp;#8211; COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Operating Leases&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;At December 31, 2015, we had a commitment under a non-cancelable operating lease for our New York office until December 31, 2016 totaling $171,000. We also had a non-cancelable operating lease for our Dallas office and lab until August 31, 2016 totaling $7,000. We had an operating lease for our Cleveland office and lab until December 31, 2025 totaling $2,520,000. We have the option to extend the lease for an additional five years. We can also terminate the lease early at December 31, 2020, at the end of year five, and pay for unamortized tenant improvements. Our total lease costs and unamortized tenant improvements would total $1,744,000 with the termination provision.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;The five year lease payment schedule is (in thousands):&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; width: 40%;"&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;2016&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;349&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 16px; vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;2017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;241&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;2018&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;246&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;2019&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;250&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 1pt; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;836&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;1,922&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; clear: both; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Rent expense for the years ended December 31, 2015 and 2014 was $219,000 and $178,000, respectively.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Legal&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;We are not currently subject to any material pending legal proceedings.&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!--Common stock - $.01 par value; authorized 200,000,000 shares; issued 32,743,013 at December 31, 2015; issued 19,960,801 at December 31, 2014-->
  <us-gaap:CommonStockValue contextRef="c20151231" unitRef="U001" decimals="0">328000</us-gaap:CommonStockValue>
  <!--Common stock - $.01 par value; authorized 200,000,000 shares; issued 32,743,013 at December 31, 2015; issued 19,960,801 at December 31, 2014-->
  <us-gaap:CommonStockValue contextRef="c20141231" unitRef="U001" decimals="0">200000</us-gaap:CommonStockValue>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20151231" unitRef="U002" decimals="INF">32743013</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20141231" unitRef="U002" decimals="INF">19960801</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20151231" unitRef="U002" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20141231" unitRef="U002" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20151231" unitRef="U003" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20141231" unitRef="U003" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Principles of Consolidation-->
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;The consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <!--Preferred stock dividends-Conversion Of Series A Preferred Stock Unpaid Dividends And Interest And Liquidation Damages Into Shares Of Common Stock [Member]-->
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="c20150101to20151231_ConversionOfStockByUniqueDescriptionAxis_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" unitRef="U001" decimals="0">0</us-gaap:ConversionOfStockAmountConverted1>
  <!--Preferred stock dividends-Conversion Of Series A Preferred Stock Unpaid Dividends And Interest And Liquidation Damages Into Shares Of Common Stock [Member]-->
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="c20140101to20141231_ConversionOfStockByUniqueDescriptionAxis_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" unitRef="U001" decimals="0">7081000</us-gaap:ConversionOfStockAmountConverted1>
  <!--Preferred stock dividends-Conversion of Series B Preferred stock unpaid dividends and interest and liquidation damages into shares of common stock [Member]-->
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="c20150101to20151231_ConversionOfStockByUniqueDescriptionAxis_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" unitRef="U001" decimals="0">0</us-gaap:ConversionOfStockAmountConverted1>
  <!--Preferred stock dividends-Conversion of Series B Preferred stock unpaid dividends and interest and liquidation damages into shares of common stock [Member]-->
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="c20140101to20141231_ConversionOfStockByUniqueDescriptionAxis_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" unitRef="U001" decimals="0">3094000</us-gaap:ConversionOfStockAmountConverted1>
  <!--Preferred stock dividends-SCO Capital Partners LLC [Member]-Series B Preferred Stock [Member]-->
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="c20140910to20140910_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="-6">10000000</us-gaap:ConversionOfStockAmountConverted1>
  <!--Costs and Expenses-->
  <us-gaap:CostsAndExpenses contextRef="c20150101to20151231" unitRef="U001" decimals="0">19586000</us-gaap:CostsAndExpenses>
  <!--Costs and Expenses-->
  <us-gaap:CostsAndExpenses contextRef="c20140101to20141231" unitRef="U001" decimals="0">4056000</us-gaap:CostsAndExpenses>
  <!--Deferred Tax Assets, Goodwill and Intangible Assets-->
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c20151231" unitRef="U001" decimals="0">595000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <!--Deferred Tax Assets, Goodwill and Intangible Assets-->
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c20141231" unitRef="U001" decimals="0">464000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <!--State credits-->
  <us-gaap:DeferredTaxAssetsStateTaxes contextRef="c20141231" unitRef="U001" decimals="0">2061000</us-gaap:DeferredTaxAssetsStateTaxes>
  <!--State credits-->
  <us-gaap:DeferredTaxAssetsStateTaxes contextRef="c20151231" unitRef="U001" decimals="0">2055000</us-gaap:DeferredTaxAssetsStateTaxes>
  <!--Deferred Tax Assets, Deferred Income-->
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c20141231" unitRef="U001" decimals="0">92000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <!--Deferred Tax Assets, Deferred Income-->
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c20151231" unitRef="U001" decimals="0">1669000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <!--Current portion of deferred revenue-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20141231" unitRef="U001" decimals="0">602000</us-gaap:DeferredRevenueCurrent>
  <!--Current portion of deferred revenue-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20151231" unitRef="U001" decimals="0">602000</us-gaap:DeferredRevenueCurrent>
  <!--Long-term deferred revenue-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c20141231" unitRef="U001" decimals="0">4868000</us-gaap:DeferredRevenueNoncurrent>
  <!--Long-term deferred revenue-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c20151231" unitRef="U001" decimals="0">4266000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred Tax Assets, Net of Valuation Allowance-->
  <us-gaap:DeferredTaxAssetsNet contextRef="c20151231" unitRef="U001" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
  <!--Deferred Tax Assets, Net of Valuation Allowance-->
  <us-gaap:DeferredTaxAssetsNet contextRef="c20141231" unitRef="U001" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
  <!--Net operating loss carryforwards-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c20151231" unitRef="U001" decimals="0">68636000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <!--Net operating loss carryforwards-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c20141231" unitRef="U001" decimals="0">68263000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <!--Deferred Tax Assets, Gross-->
  <us-gaap:DeferredTaxAssetsGross contextRef="c20151231" unitRef="U001" decimals="0">79497000</us-gaap:DeferredTaxAssetsGross>
  <!--Deferred Tax Assets, Gross-->
  <us-gaap:DeferredTaxAssetsGross contextRef="c20141231" unitRef="U001" decimals="0">74300000</us-gaap:DeferredTaxAssetsGross>
  <!--Deferred Tax Assets, Other-->
  <us-gaap:DeferredTaxAssetsOther contextRef="c20151231" unitRef="U001" decimals="0">231000</us-gaap:DeferredTaxAssetsOther>
  <!--Deferred Tax Assets, Other-->
  <us-gaap:DeferredTaxAssetsOther contextRef="c20141231" unitRef="U001" decimals="0">231000</us-gaap:DeferredTaxAssetsOther>
  <!--Deferred Tax Assets, Tax Credit Carryforwards, General Business-->
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness contextRef="c20141231" unitRef="U001" decimals="0">2486000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
  <!--Deferred Tax Assets, Tax Credit Carryforwards, General Business-->
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness contextRef="c20151231" unitRef="U001" decimals="0">2497000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
  <!--Deferred Tax Liabilities, Derivatives-->
  <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="c20141231" unitRef="U001" decimals="0">92000</us-gaap:DeferredTaxLiabilitiesDerivatives>
  <!--Deferred Tax Liabilities, Derivatives-->
  <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="c20151231" unitRef="U001" decimals="0">92000</us-gaap:DeferredTaxLiabilitiesDerivatives>
  <!--Deferred Tax Assets, Valuation Allowance-->
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c20141231" unitRef="U001" decimals="0">74300000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <!--Deferred Tax Assets, Valuation Allowance-->
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c20151231" unitRef="U001" decimals="0">79497000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <!--Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost-->
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c20141231" unitRef="U001" decimals="0">542000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <!--Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost-->
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c20151231" unitRef="U001" decimals="0">3678000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <!--Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities-->
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c20151231" unitRef="U001" decimals="0">253000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <!--Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities-->
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c20141231" unitRef="U001" decimals="0">253000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <!--Deferred Tax Liabilities, Property, Plant and Equipment-->
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c20141231" unitRef="U001" decimals="0">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <!--Deferred Tax Liabilities, Property, Plant and Equipment-->
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c20151231" unitRef="U001" decimals="0">25000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <!--Maximum annual contribution per employee under 401(k) plan-->
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="c20150101to20151231" unitRef="U001" decimals="0">18000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
  <!--Maximum annual contribution per employee under 401(k) plan-->
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="c20140101to20141231" unitRef="U001" decimals="0">17500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
  <!--Company contributions under 401 (k) Plan-->
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</us-gaap:DefinedContributionPlanCostRecognized>
  <!--Company contributions under 401 (k) Plan-->
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="c20150101to20151231" unitRef="U001" decimals="0">0</us-gaap:DefinedContributionPlanCostRecognized>
  <!--Depreciation, Depletion and Amortization, Nonproduction-->
  <us-gaap:DepreciationAndAmortization contextRef="c20150101to20151231" unitRef="U001" decimals="0">13000</us-gaap:DepreciationAndAmortization>
  <!--Depreciation, Depletion and Amortization, Nonproduction-->
  <us-gaap:DepreciationAndAmortization contextRef="c20140101to20141231" unitRef="U001" decimals="0">2000</us-gaap:DepreciationAndAmortization>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20150101to20151231" unitRef="U001" decimals="0">551000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20140101to20141231" unitRef="U001" decimals="0">11000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Total gains (losses)-->
  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c20150101to20151231" unitRef="U001" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
  <!--Total gains (losses)-->
  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c20140101to20141231" unitRef="U001" decimals="0">-23110000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <!--Total gains (losses)-Recurring [Member]-->
  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c20150101to20151231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">3898000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <!--Total gains (losses)-Preferred Stock [Member]-Recurring [Member]-->
  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c20140101to20141231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_StatementClassOfStockAxis_PreferredStockMember" unitRef="U001" decimals="-3">-23110000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <!--Gain on derivative-->
  <us-gaap:DerivativeGainOnDerivative contextRef="c20130101to20131231" unitRef="U001" decimals="0">271000</us-gaap:DerivativeGainOnDerivative>
  <!--Disclosure of Compensation Related Costs, Share-based Payments [Text Block]-->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;NOTE 10 - STOCK OPTION PLANS&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px; text-indent: 13.5pt;"&gt;Our stock-based employee compensation plans described below:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px; text-indent: 13.5pt;"&gt;&lt;u&gt;2015 Equity Incentive Plan&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;We have a stock awards plan, (the 2015 Equity Incentive Plan), under which 5,000,000 shares of our authorized but unissued common stock were reserved for issuance to employees, consultants, or to non-employee members of the Board or to any board of directors (or similar governing authority) of any affiliate of the Company. The 2015 Equity Incentive Plan, approved by our shareholders on May 7, 2015, replaced the previously approved stock option plan (the 2005 Equity Incentive Plan).&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;For the 2015 Equity Incentive Plan, the fair value of options was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in fiscal 2015: dividend yield of 0%; volatility of 102%; risk-free interest rate of 0.86%; and expected lives of 5.0 years. The weighted average fair value of options granted was $6.90 per share during 2015.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Summarized information for the 2015 Equity Incentive Plan is as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;Weighted-&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;average&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Options&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;Outstanding options at January 1, 2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; width: 70%;"&gt;Granted, fair value of $5.18 per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 12%;"&gt;1,994,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right; width: 12%;"&gt;6.90&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;Outstanding options at December 31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,994,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;6.90&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;Exercisable at December 31, 2015&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;35,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;7.34&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;There was no intrinsic value related to the outstanding or exercisable options under this plan at December 31, 2015.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Further information regarding options outstanding under the 2015 Equity Incentive Plan at December 31, 2015 is summarized below:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 92%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;"&gt;Number of&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;Weighted average&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;"&gt;Number of&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;Weighted-average&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;options&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Remaining&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;options&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Remaining&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;Range of exercise prices&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;outstanding&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;life in years&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;exercisable&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;life in years&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: justify; width: 22%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: justify;"&gt;$4.38 - 7.34&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;1,994,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;9.0&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;6.90&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;35,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;9.0&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;7.34&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;2005 Equity Incentive Plan&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Under the 2005 Equity Incentive Plan, as amended, shares of our authorized but unissued common stock were reserved for issuance to employees, consultants, or to non-employee members of the Board or to any board of directors (or similar governing authority) of any affiliate of the Company. As of January 20, 2015 no additional shares were available for grant under the 2005 Equity Incentive Plan. A total of 330,084 options were outstanding and exercisable under this plan at December 31, 2015.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;For the 2005 Equity Incentive Plan, the fair value of options was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in fiscal 2015: dividend yield of 0%; volatility of 102%; risk-free interest rate of 1.41%; and expected lives of 4.6 years. The weighted average fair value of the options grants was $4.52 per share in 2015.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The assumptions for fiscal 2014 are: dividend yield of 0%; volatility of 102%; risk-free interest rate of 0.79%; and expected lives of 5.5 years. The weighted average fair value of the options granted was $14.50 per share in 2014.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Summarized information for the 2005 Equity Incentive Plan is as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 85%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;Weighted-&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;average&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Options&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td nowrap="nowrap" style="text-align: left; width: 74%;"&gt;Outstanding options at January 1, 2014&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right; width: 10%;"&gt;28,784&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right; width: 10%;"&gt;59.00&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Granted, fair value of $14.50 per share&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;212,500&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;18.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 1pt;"&gt;Expired/forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(31,200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;37.61&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Outstanding options at December 31, 2014&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;210,084&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;20.19&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt;"&gt;Granted, fair value of $4.52&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;120,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;3.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;Outstanding options at December 31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;330,084&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;13.49&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Exercisable at December 31, 2015&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;319,884&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;15.02&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The intrinsic value related to the outstanding or exercisable options under this plan at December 31, 2015 was $13,000 and $12,000, respectively. At December 31, 2014, the intrinsic value related to the outstanding or exercisable options was none.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Further information regarding options outstanding under the 2005 Equity Incentive Plan at December 31, 2015 is summarized below:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 92%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;"&gt;Number of&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;Weighted average&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;"&gt;Number of&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;Weighted-average&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;options&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Remaining&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;options&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Remaining&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;Range of exercise prices&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;outstanding&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;life in years&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;exercisable&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;life in years&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; width: 22%;"&gt;$3.25&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;120,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;4.0&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;3.25&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;110,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;4.0&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;3.25&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$11.50 - 18.50&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;200,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;7.7&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;18.33&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;199,800&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;7.7&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;18.32&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$30.50 - 42.50&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4.1&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;32.19&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4.1&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;32.19&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$69.00&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,400&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4.0&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;69.00&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,400&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4.0&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;69.00&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;$113.50 &amp;#8211; 157.50&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;4,684&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;119.99&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;4,684&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;119.99&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;330,084&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;319,884&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <!--Preferred stock dividends in dividends payable-Additional Paid-in Capital [Member]-->
  <us-gaap:DividendsPreferredStockCash contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">0</us-gaap:DividendsPreferredStockCash>
  <!--Preferred stock dividends in dividends payable-Series A Preferred Stock [Member]-->
  <us-gaap:DividendsPreferredStockCash contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:DividendsPreferredStockCash>
  <!--Preferred stock dividends in dividends payable-Treasury Stock [Member]-->
  <us-gaap:DividendsPreferredStockCash contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:DividendsPreferredStockCash>
  <!--Preferred stock dividends in dividends payable-->
  <us-gaap:DividendsPreferredStockCash contextRef="c20140101to20141231" unitRef="U001" decimals="0">2875000</us-gaap:DividendsPreferredStockCash>
  <!--Preferred stock dividends in dividends payable-Retained Earnings [Member]-->
  <us-gaap:DividendsPreferredStockCash contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">2875000</us-gaap:DividendsPreferredStockCash>
  <!--Preferred stock dividends in dividends payable-Series B Preferred Stock [Member]-->
  <us-gaap:DividendsPreferredStockCash contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:DividendsPreferredStockCash>
  <!--Preferred stock dividends in dividends payable-Common Stock [Member]-->
  <us-gaap:DividendsPreferredStockCash contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</us-gaap:DividendsPreferredStockCash>
  <!--Preferred stock dividends in dividends payable-->
  <us-gaap:DividendsPreferredStockCash contextRef="c20150101to20151231" unitRef="U001" decimals="0">0</us-gaap:DividendsPreferredStockCash>
  <!--Dividends Payable-Series A Preferred Stock [Member]-->
  <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c20141224_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">6913416</us-gaap:DividendsPayableCurrentAndNoncurrent>
  <!--Dividends Payable-Series B Preferred Stock [Member]-->
  <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c20141224_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">3046533</us-gaap:DividendsPayableCurrentAndNoncurrent>
  <!--Earnings Per Share, Policy [Policy Text Block]-->
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Income (Loss) Per Share&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt;"&gt;We have presented basic income (loss) per share, computed on the basis of the weighted average number of common shares outstanding during the year, and diluted income (loss) per share, computed on the basis of the weighted average number of common shares and all dilutive potential common shares outstanding during the year. Potential common shares result from stock options, preferred stock and warrants. Common equivalent shares have not been included in the net loss per share calculations for years ended December 31, 2015 and 2014 because the effect of including them would have been anti-dilutive.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;Basic and diluted net loss per share were determined as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;(in thousands, except share and per share amounts)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;For the year ended December 31,&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify; width: 64%;"&gt;Net loss allocable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;"&gt;(14,526&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;"&gt;(29,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;27,597,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,942,905&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Basic and diluted net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(0.53&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(15.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Net loss allocable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(14,526&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(29,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;We did not include the following securities in the table below in the computation of diluted net loss per common share because the securities were anti-dilutive during the periods presented:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;For the year ended December&lt;br /&gt; 31,&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify; width: 64%;"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;3,799,024&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;4,164,756&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; text-align: justify;"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,324,084&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;210,134&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;6,123,108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,374,890&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <!--Basic and diluted loss per common share (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20140101to20141231" unitRef="U003" decimals="2">-15.26</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Basic and diluted loss per common share (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20150101to20151231" unitRef="U003" decimals="2">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Tax benefit-->
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
  <!--Tax benefit-->
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
  <!--Fair Value Disclosures [Text Block]-->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;NOTE 7 - FAIR VALUE MEASUREMENTS&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;We calculate the fair value of our assets and liabilities which qualify as financial instruments and include additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments. The estimated fair value of receivables, accounts payable, short-term notes payable and payable to licensor approximate their carrying amounts due to the relatively short maturity of these instruments.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;U.S. GAAP define&amp;#8217;s fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 31.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family: Symbol; width: 18pt;"&gt;&amp;#183;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Level 1 &amp;#8211; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 31.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family: Symbol; width: 18pt;"&gt;&amp;#183;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Level 2 &amp;#8211; Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 31.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family: Symbol; width: 18pt;"&gt;&amp;#183;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Level 3 &amp;#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The guidance requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;We have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 and December 31, 2014 are summarized below:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;(in thousands)&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: justify;"&gt;Description&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;As of &lt;br /&gt;December 31,&lt;br /&gt; 2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 1&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 2&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 3&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Total Gains&lt;br /&gt; (Losses)&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-left: 0.25in; width: 35%; text-indent: -0.125in;"&gt;Contingent consideration&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;2,591&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;2,591&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;3,898&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;(in thousands)&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: justify;"&gt;Description&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;As of &lt;br /&gt;December 31, &lt;br /&gt; 2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 1&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 2&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 3&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Total Gains &lt;br /&gt; (Losses)&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0.25in; width: 35%; text-indent: -0.125in;"&gt;Derivative liability- preferred stock&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;(23,110&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;In order to calculate the Level 3 Derivative liability - preferred stock, we used the Monte Carlo simulation to estimate future stock prices. The use of valuation techniques requires the Company to make various key assumptions for inputs into the model, including assumptions about the expected future volatility of the price of the Company&amp;#8217;s stock. The preferred stock liability was converted into common stock on December 24, 2014.&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231" unitRef="U001" decimals="0">9000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20151231" unitRef="U001" decimals="0">547000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Net-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231" unitRef="U001" decimals="0">4991000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Finite-Lived Intangible Assets, Net-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20151231" unitRef="U001" decimals="0">6609000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Finite-Lived Intangible Assets, Amortization Expense, Year Three-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c20151231" unitRef="U001" decimals="-3">582000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231" unitRef="U001" decimals="0">5000000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20151231" unitRef="U001" decimals="0">7156000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Period of amortization of license-License Agreement Terms 1 [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20150101to20151231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTerms1Member">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Period of amortization of license-Gene Therapy [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20150101to20151231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTermsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Assets, Amortization Expense, Year Four-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c20151231" unitRef="U001" decimals="-3">582000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <!--Finite-Lived Intangible Assets, Amortization Expense, Year Five-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c20151231" unitRef="U001" decimals="-3">582000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <!--Finite-Lived Intangible Assets, Amortization Expense, Year Two-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c20151231" unitRef="U001" decimals="-3">582000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <!--Finite-Lived Intangible Assets, Amortization Expense, after Year Five-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c20151231" unitRef="U001" decimals="-3">3699000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
  <!--Finite-lived Intangible Assets Amortization Expense [Table Text Block]-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;The aggregate estimated amortization expense for intangible assets remaining as of December 31, 2015 is as follows:&lt;/div&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; width: 40%;"&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: right; width: 51%;"&gt;2016&lt;/td&gt;&lt;td style="font-weight: normal; width: 7%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 40%;"&gt;582&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2017&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;582&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2018&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;582&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2019&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;582&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2020&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;582&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;Thereafter&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;3,699&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: right;"&gt;Total&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;6,609&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
  <!--Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c20151231" unitRef="U001" decimals="-3">582000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <!--General and Administrative Expense-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20150101to20151231" unitRef="U001" decimals="0">14320000</us-gaap:GeneralAndAdministrativeExpense>
  <!--General and Administrative Expense-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20140101to20141231" unitRef="U001" decimals="0">3712000</us-gaap:GeneralAndAdministrativeExpense>
  <!--Goodwill-->
  <us-gaap:Goodwill contextRef="c20141231" unitRef="U001" decimals="0">0</us-gaap:Goodwill>
  <!--Goodwill-->
  <us-gaap:Goodwill contextRef="c20151231" unitRef="U001" decimals="0">32466000</us-gaap:Goodwill>
  <!--Goodwill-Business Acquisitions [Member]-->
  <us-gaap:Goodwill contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">32466000</us-gaap:Goodwill>
  <!--Goodwill and Intangible Assets, Policy [Policy Text Block]-->
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Goodwill&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;As of December 31, 2015, goodwill of $32.5 million was recorded on the Company's consolidated balance sheet. The implied fair value of goodwill represented the excess of the Abeona Ohio&amp;#8217;s value over and above the fair value of its tangible assets and identifiable intangible assets. In accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) No. 350 &amp;#8212; &lt;i&gt;Intangibles &amp;#8212; Goodwill and Other, &lt;/i&gt;goodwill is not amortized, but is rather tested annually for impairment and whenever changes in circumstances occur that would indicate impairment.&lt;/p&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <!--Income Tax Expense (Benefit)-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20150101to20151231" unitRef="U001" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income Tax Expense (Benefit)-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income Tax Disclosure [Text Block]-->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;NOTE 12 - INCOME TAXES&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Income tax expense differs from the statutory amounts as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table align="center" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 80%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; width: 64%;"&gt;Income taxes at U.S. statutory rate&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;(4,939,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;(9,105,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Current year reserve&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;6,257,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,254,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;Other&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;(1,318,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;7,851,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in;"&gt;Total tax expense&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Deferred taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities. The temporary differences that give rise to deferred tax assets were as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table align="center" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 80%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;2015&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;2014&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt; width: 64%;"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;68,636,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;68,263,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;General business credit carryforwards&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2,497,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2,486,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;State credits&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2,055,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2,061,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Property, equipment and goodwill&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;(25,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Stock options&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;3,678,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;542,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Derivatives&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;(92,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;(92,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Deferred revenue&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,669,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;92,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;595,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;464,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Accrued interest&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;253,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;253,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left; padding-left: 9pt;"&gt;Other&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;231,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;231,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;79,497,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;74,300,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;(79,497,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;(74,300,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 9pt;"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;At December 31, 2015, we had approximately $209,666,000 of net operating loss carryforwards and approximately $2,497,000 of general business credit carryforwards. These carryforwards expire as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 2in; width: 60%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Net operating&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;General business&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-size: 10pt; border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;l&lt;u style="text-decoration: none;"&gt;oss carryforwards&lt;/u&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;credit carryforwards&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;2016&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;2017&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; width: 44%;"&gt;2018&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 25%;"&gt;3,324,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 25%;"&gt;112,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;Thereafter&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;206,342,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;2,385,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; font-style: normal; text-align: left; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;209,666,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;2,497,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;As a result of a merger on January 25, 1996, a change in control occurred for federal income tax purposes, which limits the utilization of pre-merger net operating loss carryforwards of approximately $3,100,000 to approximately $530,000 per year.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Additionally, we acquired MacroChem Corporation on February 25, 2009 and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both corporations were loss companies at the time of the acquisition. Therefore, the net operating losses related to those acquisitions may be subject to annual limitations as provided by IRC Sec. 382.&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <!--Income Taxes-->
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;font style="font-size: 10pt; font-weight: normal;"&gt;We account for uncertain income tax positions in accordance with FASB ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;.&lt;/font&gt;&lt;font style="font-size: 10pt; font-weight: normal;"&gt;Interest costs and penalties related to income taxes are classified as interest expense and general and administrative costs, respectively, in our consolidated financial statements. For the years ended December 31, 2015 and 2014, we did not recognize any uncertain tax positions or interest or penalty expense related to income taxes. It is determined not to be reasonably likely for the amounts of unrecognized tax benefits to significantly increase or decrease within the next 12 months. We are currently subject to a three year statute of limitations by major tax jurisdictions for the years ended 2012, 2013 and 2014. We and our subsidiaries file income tax returns in the U.S. federal jurisdiction.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <!--Income taxes at U.S. statutory rate-->
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c20140101to20141231" unitRef="U001" decimals="0">-9105000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <!--Income taxes at U.S. statutory rate-->
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c20150101to20151231" unitRef="U001" decimals="0">-4939000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <!--Other-->
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c20140101to20141231" unitRef="U001" decimals="0">7851000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <!--Other-->
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c20150101to20151231" unitRef="U001" decimals="0">-1318000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <!--Accounts payable and accrued expenses-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20150101to20151231" unitRef="U001" decimals="0">-1174000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Accounts payable and accrued expenses-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20140101to20141231" unitRef="U001" decimals="0">33000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Increase (Decrease) in Other Noncurrent Assets-->
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <!--Increase (Decrease) in Other Noncurrent Assets-->
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c20150101to20151231" unitRef="U001" decimals="0">29000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <!--Deferred revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20150101to20151231" unitRef="U001" decimals="0">-602000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Deferred revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20140101to20141231" unitRef="U001" decimals="0">-349000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in Receivables-->
  <us-gaap:IncreaseDecreaseInReceivables contextRef="c20140101to20141231" unitRef="U001" decimals="0">-39000</us-gaap:IncreaseDecreaseInReceivables>
  <!--Increase (Decrease) in Receivables-->
  <us-gaap:IncreaseDecreaseInReceivables contextRef="c20150101to20151231" unitRef="U001" decimals="0">79000</us-gaap:IncreaseDecreaseInReceivables>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20150101to20151231" unitRef="U001" decimals="0">287000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20140101to20141231" unitRef="U001" decimals="0">-77000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Intangible Assets Disclosure [Text Block]-->
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;NOTE 4 &amp;#8211; LICENSED TECHNOLOGY&lt;/p&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On September 22, 2014, we entered into an exclusive, worldwide, licensing agreement with Licensor to obtain rights to utilize and to sub-license to other pharmaceuticals firms, its patented methods for the extraction of therapeutic biologics from human plasma.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On May 15, 2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children&amp;#8217;s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Licensed technology consists of the following:&lt;/p&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;December 31,&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 64%;"&gt;Licensed technology&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;7,156,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;547,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;9,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;Licensed technology, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;6,609,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,991,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Amortization on licensed technology was $538,000 and $9,000 for the years ended December 31, 2015 and 2014, respectively. The aggregate estimated amortization expense for intangible assets remaining as of December 31, 2015 is as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; width: 40%;"&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: right; width: 51%;"&gt;2016&lt;/td&gt;&lt;td style="font-weight: normal; width: 7%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 40%;"&gt;582&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2017&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;582&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2018&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;582&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2019&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;582&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2020&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;582&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;Thereafter&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;3,699&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: right;"&gt;Total&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;6,609&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <!--Interest and Debt Expense-->
  <us-gaap:InterestAndDebtExpense contextRef="c20150101to20151231" unitRef="U001" decimals="0">6000</us-gaap:InterestAndDebtExpense>
  <!--Interest and Debt Expense-->
  <us-gaap:InterestAndDebtExpense contextRef="c20140101to20141231" unitRef="U001" decimals="0">582000</us-gaap:InterestAndDebtExpense>
  <!--Interest Paid-->
  <us-gaap:InterestPaid contextRef="c20150101to20151231" unitRef="U001" decimals="0">7000</us-gaap:InterestPaid>
  <!--Interest Paid-->
  <us-gaap:InterestPaid contextRef="c20140101to20141231" unitRef="U001" decimals="0">7000</us-gaap:InterestPaid>
  <!--Investment Income, Nonoperating-->
  <us-gaap:InvestmentIncomeNonoperating contextRef="c20150101to20151231" unitRef="U001" decimals="0">4026000</us-gaap:InvestmentIncomeNonoperating>
  <!--Investment Income, Nonoperating-->
  <us-gaap:InvestmentIncomeNonoperating contextRef="c20140101to20141231" unitRef="U001" decimals="0">45000</us-gaap:InvestmentIncomeNonoperating>
  <!--Issuance of Stock and Warrants for Services or Claims-->
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c20150101to20151231" unitRef="U001" decimals="0">401000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <!--Issuance of Stock and Warrants for Services or Claims-->
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c20140101to20141231" unitRef="U001" decimals="0">349000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20141231" unitRef="U001" decimals="0">2898000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20151231" unitRef="U001" decimals="0">1477000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20141231" unitRef="U001" decimals="0">11766000</us-gaap:Liabilities>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20151231" unitRef="U001" decimals="0">12334000</us-gaap:Liabilities>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20141231" unitRef="U001" decimals="0">16582000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20151231" unitRef="U001" decimals="0">80055000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--License fee-License Agreement Terms 1 [Member]-->
  <us-gaap:LicenseCosts contextRef="c20150101to20151231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTerms1Member" unitRef="U001" decimals="-6">1000000</us-gaap:LicenseCosts>
  <!--License revenues-->
  <us-gaap:LicensesRevenue contextRef="c20140101to20141231" unitRef="U001" decimals="0">598000</us-gaap:LicensesRevenue>
  <!--License revenues-->
  <us-gaap:LicensesRevenue contextRef="c20150101to20151231" unitRef="U001" decimals="0">602000</us-gaap:LicensesRevenue>
  <!--Maturity date-Second Unsecured Grid Note [Member]-SCO Capital Partners LLC [Member]-->
  <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="c20140101to20141231_LongtermDebtTypeAxis_SecondUnsecuredGridNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember">2015-11-30</us-gaap:LineOfCreditFacilityExpirationDate1>
  <!--Maturity date-SCO Capital Partners LLC [Member]-Unsecured Debt [Member]-->
  <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="c20140101to20141231_LongtermDebtTypeAxis_UnsecuredDebtMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember">2015-08-31</us-gaap:LineOfCreditFacilityExpirationDate1>
  <!--Unsecured grid note amount-Unsecured Debt [Member]-SCO Capital Partners LLC [Member]-->
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c20140910_LongtermDebtTypeAxis_UnsecuredDebtMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember" unitRef="U001" decimals="0">250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <!--Unsecured grid note amount-SCO Capital Partners LLC [Member]-Second Unsecured Grid Note [Member]-->
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c20141201_LongtermDebtTypeAxis_SecondUnsecuredGridNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember" unitRef="U001" decimals="0">250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <!--Interest rate-Second Unsecured Grid Note [Member]-SCO Capital Partners LLC [Member]-->
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c20141231_LongtermDebtTypeAxis_SecondUnsecuredGridNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember" unitRef="U007" decimals="2">0.08</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <!--Interest rate-Unsecured Debt [Member]-SCO Capital Partners LLC [Member]-->
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c20141231_LongtermDebtTypeAxis_UnsecuredDebtMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember" unitRef="U007" decimals="2">0.08</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <!--Total amount drawn-Second Unsecured Grid Note [Member]-SCO Capital Partners LLC [Member]-->
  <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount contextRef="c20140101to20141231_LongtermDebtTypeAxis_SecondUnsecuredGridNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember" unitRef="U001" decimals="0">150000</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
  <!--Total amount drawn-SCO Capital Partners LLC [Member]-Unsecured Debt [Member]-->
  <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount contextRef="c20140101to20141231_LongtermDebtTypeAxis_UnsecuredDebtMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember" unitRef="U001" decimals="0">250000</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
  <!--Net Income (Loss) Available to Common Stockholders, Basic-->
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c20140101to20141231" unitRef="U001" decimals="0">-29653000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <!--Net Income (Loss) Available to Common Stockholders, Basic-->
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c20150101to20151231" unitRef="U001" decimals="0">-14526000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <!--Net Income (Loss) Available to Common Stockholders, Diluted-->
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-29653000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <!--Net Income (Loss) Available to Common Stockholders, Diluted-->
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c20150101to20151231" unitRef="U001" decimals="-3">-14526000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <!--Net Cash Provided by (Used in) Investing Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c20150101to20151231" unitRef="U001" decimals="0">3389000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <!--Net Cash Provided by (Used in) Investing Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <!--Net Cash Provided by (Used in) Operating Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c20150101to20151231" unitRef="U001" decimals="0">-10423000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <!--Net Cash Provided by (Used in) Operating Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c20140101to20141231" unitRef="U001" decimals="0">-1611000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <!--Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231" unitRef="U001" decimals="0">-26778000</us-gaap:NetIncomeLoss>
  <!--Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231" unitRef="U001" decimals="0">-14526000</us-gaap:NetIncomeLoss>
  <!--Net loss-Series A Preferred Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:NetIncomeLoss>
  <!--Net loss-Treasury Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:NetIncomeLoss>
  <!--Net loss-Treasury Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:NetIncomeLoss>
  <!--Net loss-Additional Paid-in Capital [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">0</us-gaap:NetIncomeLoss>
  <!--Net loss-Common Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</us-gaap:NetIncomeLoss>
  <!--Net loss-Series A Preferred Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:NetIncomeLoss>
  <!--Net loss-Retained Earnings [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">-14526000</us-gaap:NetIncomeLoss>
  <!--Net loss-Series B Preferred Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:NetIncomeLoss>
  <!--Net loss-Retained Earnings [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">-26778000</us-gaap:NetIncomeLoss>
  <!--Net loss-Common Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</us-gaap:NetIncomeLoss>
  <!--Net loss-Series B Preferred Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:NetIncomeLoss>
  <!--Net loss-Additional Paid-in Capital [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">0</us-gaap:NetIncomeLoss>
  <!--Net Cash Provided by (Used in) Financing Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c20150101to20151231" unitRef="U001" decimals="0">35652000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <!--Net Cash Provided by (Used in) Financing Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c20140101to20141231" unitRef="U001" decimals="0">12707000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <!--Recent Accounting Pronouncements-->
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;In May 2014, as part of its ongoing efforts to assist in the convergence of U.S. GAAP and International Financial Reporting Standards (&amp;#8220;IFRS&amp;#8221;), the FASB issued ASU 2014-09 related to revenue recognition. The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. In August 2015, the FASB issued ASU 2015-14 which defers the effective date of ASU 2014-09 one year making it effective for annual reporting periods beginning on or after December 15, 2017 while also providing for early adoption as of the original effective date. We are currently continuing to evaluate the impact that this standard will have on our consolidated financial statements as well as the appropriate method of adoption.&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20150101to20151231" unitRef="U001" decimals="0">4020000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20140101to20141231" unitRef="U001" decimals="0">-23647000</us-gaap:NonoperatingIncomeExpense>
  <!--Non-cancelable operating leases-Building2 [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="c20151231_PropertyPlantAndEquipmentByTypeAxis_Building2Member" unitRef="U001" decimals="0">7000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <!--Non-cancelable operating leases-Building [Member]-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="c20151231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember" unitRef="U001" decimals="0">171000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <!--Non-cancelable operating leases-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="c20151231" unitRef="U001" decimals="-3">349000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <!--Operating Leases, Income Statement, Lease Revenue-->
  <us-gaap:OperatingLeasesIncomeStatementLeaseRevenue contextRef="c20150101to20151231" unitRef="U001" decimals="0">2520000</us-gaap:OperatingLeasesIncomeStatementLeaseRevenue>
  <!--Rent expense-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c20150101to20151231" unitRef="U001" decimals="0">219000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Rent expense-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c20140101to20141231" unitRef="U001" decimals="0">178000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--2017-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c20151231" unitRef="U001" decimals="-3">241000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20140101to20141231" unitRef="U001" decimals="0">-3131000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20150101to20151231" unitRef="U001" decimals="0">-18546000</us-gaap:OperatingIncomeLoss>
  <!--Operating Leases, Future Minimum Payments Due-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="c20151231" unitRef="U001" decimals="-3">1922000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <!--2019-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="c20151231" unitRef="U001" decimals="-3">250000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <!--2020-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="c20151231" unitRef="U001" decimals="-3">836000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <!--Operating Loss Carryforwards-Latest Tax Year [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20151231_TaxPeriodAxis_LatestTaxYearMember" unitRef="U001" decimals="0">3324000</us-gaap:OperatingLossCarryforwards>
  <!--Operating Loss Carryforwards-Tax Year 2016 [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20151231_TaxPeriodAxis_TaxYear2016Member" unitRef="U001" decimals="0">0</us-gaap:OperatingLossCarryforwards>
  <!--Operating Loss Carryforwards-Pre merger [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20151231_StatementScenarioAxis_PreMergerMember" unitRef="U001" decimals="0">3100000</us-gaap:OperatingLossCarryforwards>
  <!--Operating Loss Carryforwards-Post merger [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20151231_StatementScenarioAxis_PostMergerMember" unitRef="U001" decimals="0">530000</us-gaap:OperatingLossCarryforwards>
  <!--Operating Loss Carryforwards-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20151231" unitRef="U001" decimals="0">209666000</us-gaap:OperatingLossCarryforwards>
  <!--Operating Loss Carryforwards-Tax Year Thereafter [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20151231_TaxPeriodAxis_TaxYearThereafterMember" unitRef="U001" decimals="0">206342000</us-gaap:OperatingLossCarryforwards>
  <!--Operating Loss Carryforwards-Tax Year 2017 [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20151231_TaxPeriodAxis_TaxYear2017Member" unitRef="U001" decimals="0">0</us-gaap:OperatingLossCarryforwards>
  <!--2018-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c20151231" unitRef="U001" decimals="-3">246000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <!--Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]-->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 63pt; text-indent: -63pt;"&gt;NOTE 1 - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;&lt;u&gt;Nature of Operations&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;Abeona Therapeutics Inc. (together with our subsidiaries, &amp;#8220;we&amp;#8221;, &amp;#8220;our&amp;#8221;, &amp;#8220;Abeona&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a Delaware corporation. We are focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA, respectively). We are also developing ABO-201 (AAV CLN3) gene therapy for Juvenile Neuronal Ceroid Lipofuscinoses (JNCL) also known as juvenile Batten disease; and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including PTB-101 SDF Alpha&amp;#8482; (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF&amp;#8482; (Salt Diafiltration) ethanol-free process.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Certain amounts have been reclassified to conform with current period classification.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;The consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Segments&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The Company operates in a single segment.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;&lt;u&gt;Cash and Cash Equivalents&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.&amp;#160;At December 31, 2015 and 2014, we had no such investments.&amp;#160;We maintain deposits primarily in two financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (FDIC).&amp;#160; We have not experienced any losses related to amounts in excess of FDIC limits.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Receivables&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Receivables are reported in the balance sheets at the outstanding amount net of an allowance for doubtful accounts.&amp;#160;We continually evaluate the creditworthiness of our customers and their financial condition and generally do not require collateral.&amp;#160;The allowance for doubtful accounts is based upon reviews of specific customer balances, historic losses, and general economic conditions.&amp;#160;As of December 31, 2015 and 2014, no allowance was recorded as all accounts are considered collectible.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Property and Equipment&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from three to five years. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned and the related accumulated depreciation are eliminated from the accounts and any gains or losses are recognized in the accompanying consolidated statements of operations of the respective period.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;font style="font-weight: normal;"&gt;&lt;u&gt;Licensed Technology&lt;/u&gt;&lt;/font&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;We maintain licensed technology on our consolidated balance sheet until either the licensed technology agreement underlying it is completed or the asset becomes impaired. When we determine that an asset has become impaired or we abandon a project, we write down the carrying value of the related intangible asset to its fair value and take an impairment charge in the period in which the impairment occurs.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;Generally licensed technology is amortized over the life of the patent or the agreement.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;We test our intangible assets for impairment on an annual basis, or more frequently if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate or new information regarding potential sales for the drug. In connection with each annual impairment assessment and any interim impairment assessment, we compare the fair value of the asset as of the date of the assessment with the carrying value of the asset on our consolidated balance sheet.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;In 2015, we did not impair any licensed technology.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Gene therapy license agreements&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On May 15, 2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children&amp;#8217;s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. This portfolio comprises 1 patent family: &amp;#8220;Products and methods for delivery of polynuleotides by adeno-associated virus for lysosomal storage disorders&amp;#8221;. Additionally, Abeona has secured FDA Orphan drug designation for both Sanfilippo A and B, which will provide 7 years of post-launch market exclusivity for both ABX-A and ABX-B in the U.S. Abeona will be seeking Orphan Drug Status within the EMA, which will grant 10 years of post-market exclusivity in the European Union.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The license is amortized over the life of the license of 20 years.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Plasma-based therapeutics license agreements&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On September 22, 2014, we entered into an exclusive, worldwide licensing agreement with Plasma Technologies LLC (&amp;#8220;Licensor&amp;#8221;) to obtain rights to utilize and to sub-license to other pharmaceuticals firms, its patented methods for the extraction of therapeutic biologics from human plasma. Under the terms of the licensing agreement, as amended on January 23, 2015, we paid a license fee of $1 million in cash, will pay $4,000,000 in cash or 1,096,151 shares of our common stock in 2017, a regulatory approval milestone payment of 513,375 shares of our common stock upon the first FDA regulatory approval of a drug derived from the Licensor&amp;#8217;s proprietary SDF process, and a tiered royalty on annual net sales of plasma fractions produced with Licensor&amp;#8217;s proprietary SDF process.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The license is amortized over the life of the patent of 11 years.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;License Revenues and Royalties&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Our revenues are generated from licensing, research and development agreements, royalties and product sales. We recognize revenue in accordance with SEC Staff Accounting Bulletin No. 104 (SAB 104), &lt;i&gt;Revenue Recognition&lt;/i&gt;. License revenue is recognized over the remaining life of the underlying patent. Research and development revenues are recognized as services are performed. Royalties and product sales are recognized in the period of sales.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Goodwill&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;As of December 31, 2015, goodwill of $32.5 million was recorded on the Company's consolidated balance sheet. The implied fair value of goodwill represented the excess of the Abeona Ohio&amp;#8217;s value over and above the fair value of its tangible assets and identifiable intangible assets. In accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) No. 350 &amp;#8212; &lt;i&gt;Intangibles &amp;#8212; Goodwill and Other, &lt;/i&gt;goodwill is not amortized, but is rather tested annually for impairment and whenever changes in circumstances occur that would indicate impairment.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Research and Development Expenses&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Research and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel expense, lab supplies, preclinical, development cost, clinical trial expense, outside manufacturing and consulting. The cost of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses are capitalized when acquired.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;General and administrative expense&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;General and administrative expenses primarily consist of personnel, contract personnel, personnel expenses to support our administrative and operating activities, facility costs and professional expenses (i.e., legal expenses), and investor relations fees.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Other Income&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;In 2015 and 2014, we recognized miscellaneous income of $4,026,000 and $45,000, respectively, due to the termination of the milestone recorded on the contingent consideration liability in 2015 and sales of platinum and monomers in 2014 and write-offs and settlements of other accounts payable for both years.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;In some of our license agreements we are responsible as agent for arranging the manufacture of MuGard (mucoadhesive oral wound rinse) and have entered into supply agreements with our license partners. Terms vary with each agreement but generally we arrange for the manufacture of MuGard with a third-party and receive a fee to cover our administration, handling and overhead costs. The income is recorded in other income.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;font style="font-size: 10pt; font-weight: normal;"&gt;We account for uncertain income tax positions in accordance with FASB ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;.&lt;/font&gt;&lt;font style="font-size: 10pt; font-weight: normal;"&gt;Interest costs and penalties related to income taxes are classified as interest expense and general and administrative costs, respectively, in our consolidated financial statements. For the years ended December 31, 2015 and 2014, we did not recognize any uncertain tax positions or interest or penalty expense related to income taxes. It is determined not to be reasonably likely for the amounts of unrecognized tax benefits to significantly increase or decrease within the next 12 months. We are currently subject to a three year statute of limitations by major tax jurisdictions for the years ended 2012, 2013 and 2014. We and our subsidiaries file income tax returns in the U.S. federal jurisdiction.&lt;/font&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Income (Loss) Per Share&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt;"&gt;We have presented basic income (loss) per share, computed on the basis of the weighted average number of common shares outstanding during the year, and diluted income (loss) per share, computed on the basis of the weighted average number of common shares and all dilutive potential common shares outstanding during the year. Potential common shares result from stock options, preferred stock and warrants. Common equivalent shares have not been included in the net loss per share calculations for years ended December 31, 2015 and 2014 because the effect of including them would have been anti-dilutive.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;Basic and diluted net loss per share were determined as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;(in thousands, except share and per share amounts)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;For the year ended December 31,&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify; width: 64%;"&gt;Net loss allocable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;"&gt;(14,526&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;"&gt;(29,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;27,597,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,942,905&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Basic and diluted net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(0.53&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(15.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Net loss allocable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(14,526&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(29,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;We did not include the following securities in the table below in the computation of diluted net loss per common share because the securities were anti-dilutive during the periods presented:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;For the year ended December&lt;br /&gt; 31,&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify; width: 64%;"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;3,799,024&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;4,164,756&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; text-align: justify;"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,324,084&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;210,134&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;6,123,108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,374,890&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Stock-Based Compensation&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;We account for stock based compensation expense in accordance with FASB ASC 718, &lt;i&gt;Stock Based Compensation&lt;/i&gt;. We have two stock-based compensation plans under which incentive and qualified stock options and restricted shares could be granted to employees, directors and consultants. Our 2015 Equity Incentive Plan was approved by shareholders in May 7, 2015. As of January 20, 2015, no further grants can be made under our old plan, the 2005 Equity Incentive Plan. We measure the cost of the employee/director/consultant services received in exchange for an award of equity instruments based on the grant date fair value for the employees and directors and vesting date fair value for consultants of the award. We use the Black-Scholes option pricing model to value our options.&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;The following table summarizes stock-based compensation for the years ended December 31, 2015 and 2014 which was allocated as follows (in thousands):&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 95%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;Year ended&lt;/p&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&lt;u style="text-decoration: none;"&gt;December 31, 2015&lt;/u&gt;&lt;/p&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;Year ended&lt;/p&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&lt;u style="text-decoration: none;"&gt;December 31, 2014&lt;/u&gt;&lt;/p&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; width: 64%;"&gt;Research and development&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;773&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;104&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;General and administrative&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;3,595&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;1,201&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left; padding-left: 0.375in; text-indent: -17.1pt;"&gt;Stock-based compensation expense included in operating expense&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;4,368&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;1,305&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4,368&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,305&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;Tax benefit&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in;"&gt;Stock-based compensation expense, net of tax&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;4,368&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;1,305&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;In May 2014, as part of its ongoing efforts to assist in the convergence of U.S. GAAP and International Financial Reporting Standards (&amp;#8220;IFRS&amp;#8221;), the FASB issued ASU 2014-09 related to revenue recognition. The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. In August 2015, the FASB issued ASU 2015-14 which defers the effective date of ASU 2014-09 one year making it effective for annual reporting periods beginning on or after December 15, 2017 while also providing for early adoption as of the original effective date. We are currently continuing to evaluate the impact that this standard will have on our consolidated financial statements as well as the appropriate method of adoption.&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <!--Other Assets-->
  <us-gaap:OtherAssets contextRef="c20151231" unitRef="U001" decimals="0">62000</us-gaap:OtherAssets>
  <!--Other Assets-->
  <us-gaap:OtherAssets contextRef="c20141231" unitRef="U001" decimals="0">32000</us-gaap:OtherAssets>
  <!--Miscellaneous income-->
  <us-gaap:OtherNonoperatingIncome contextRef="c20140101to20141231" unitRef="U001" decimals="0">45000</us-gaap:OtherNonoperatingIncome>
  <!--Miscellaneous income-->
  <us-gaap:OtherNonoperatingIncome contextRef="c20150101to20151231" unitRef="U001" decimals="0">4026000</us-gaap:OtherNonoperatingIncome>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20150101to20151231" unitRef="U001" decimals="0">308000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Pension and Other Postretirement Benefits Disclosure [Text Block]-->
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;NOTE 5 &amp;#8211; 401(k) PLAN&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;We have a tax-qualified employee savings and retirement plan (the 401(k) Plan) covering all our employees. Pursuant to the 401(k) Plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit ($18,000 in 2015 and $17,500 in 2014) and to have the amount of such reduction contributed to the 401(k) Plan. The 401(k) Plan is intended to qualify under Section 401 of the Internal Revenue Code so that contributions by employees or by us to the 401(k) Plan, and income earned on 401(k) Plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that contributions by us, if any, will be deductible by us when made. At the direction of each participant, we invest the assets of the 401(k) Plan in any of 60 investment options. Company contributions under the 401(k) Plan were $0 in 2015 and 2014.&lt;/p&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <!--Preferred Stock [Text Block]-->
  <us-gaap:PreferredStockTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;NOTE 8 &amp;#8211; PREFERRED STOCK&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&lt;u&gt;Series A Cumulative Convertible Preferred Stock&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;All Series A Preferred Stock, Series A dividends payable and interest on Series A Preferred Stock dividends payable were converted into 8,961,769 shares of common stock just prior to the closing of the financing on December 24, 2014.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&lt;u&gt;Derivative Liability&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;Effective January 1, 2009, we adopted the provisions of FASB ASC 815, &lt;i&gt;&amp;#8220;Derivatives and Hedging&amp;#8221;&lt;/i&gt; (FASB ASC 815) (previously EITF 07-5, &lt;i&gt;&amp;#8220;Determining Whether an Instrument (or an Embeded Feature) is Indexed to an Entity&amp;#8217;s Own Stock&amp;#8221;&lt;/i&gt;). As a result of adopting FASB ASC 815, warrants to purchase 77,091 of our common stock previously treated as equity pursuant to the derivative treatment exemption were no longer afforded equity treatment. These warrants had an exercise price of $175.00 and expired on November 10, 2013 and February 4, 2014.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;We determined that the anti-dilution provision built into the Series A Preferred Stock and warrants issued should be considered for derivative accounting.&amp;#160;FASB ASC 815 requires freestanding contracts that are settled in a company&amp;#8217;s own stock to be designated as an equity instrument, assets or liability. Under the provisions of FASB ASC 815, a contract designated as an asset or liability must be initially recorded and carried at fair value until the contract meets the requirements for classification as equity, until the contract is exercised or until the contract expires. We determined that the anti-dilution provision associated with the November 2007 and February 2008 preferred shares and warrants no longer met the criteria for equity accounting through the revised criteria in FASB ASC 815.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;Accordingly, at January 1, 2009, we determined that the warrants and the Series A Preferred Stock conversion feature should be accounted for as derivative liabilities. The preferred stock conversion feature was determined to have no fair market value at both issuance dates as well as each reporting period until the third quarter of 2010 since management asserted that the likelihood of issuing any new equity at a price that would trigger the anti-dilution effect to be nil. During the third quarter of 2010 we were actively raising capital. With our stock price below $150.00 a share it was possible that we would sell shares below $150.00 per share. Since this would require an adjustment to our convertible preferred stock we recorded a derivative liability and expense at September 30, 2010. The derivative liability and expense was revalued at December 31, 2013 was $1,190,000; and at December 24, 2014 was $24,300,000. The change in the fair value of the derivative was a loss of $23,110,000 in 2014. The Series A Preferred Stock was converted into common stock at December 24, 2014 and the amount of the derivative liability was reclassified to stockholders equity.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;The warrants were valued at issuance and each reporting period since using the Black-Scholes model. On January 1, 2009 we reclassified the fair value of the warrants from equity to liability as if these warrants were treated as a derivative liability since their issue date. We recorded derivative gain of $271,000 for the year ended December 31, 2013. Warrants to purchase 72,998 shares of our common stock expired November 10, 2013. The remaining 9,992 warrants expired February 4, 2014.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&lt;u&gt;Series B Cumulative Convertible Preferred Stock&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;All Series B Preferred Stock, Series B dividends payable, interest on Series B Preferred Stock dividends payable and liquidated damages were converted into 6,951,837 shares of common stock just prior to the closing of the financing on December 24, 2014.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&lt;u&gt;Liquidated Damages&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;Pursuant to the terms of an Investor Rights Agreement with the Purchasers of Series A Preferred Stock, we were required to maintain an effective registration statement. The Securities and Exchange Commission declared the registration statement effective November 13, 2008 relating to a portion of such securities, and as a result, we accrued $857,000 in potential liquidated damages as of December 31, 2013 and December 31, 2012. Potential liquidated damages were capped at 10% of each holder&amp;#8217;s investment.&amp;#160;The accrued liquidated damages of $857,000 were converted into common stock at December 24, 2014.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&lt;u&gt;Preferred Stock Dividends &amp;#8211; Series A&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;Unpaid preferred stock dividends and interest of $6,913,416 accrued at December 24, 2014 was converted into common stock at December 24, 2014.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;&lt;u&gt;Preferred Stock Dividends &amp;#8211; Series B&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"&gt;Unpaid preferred stock dividends and interest of $3,046,553 accrued at December 31, 2014 was converted into common stock at December 24, 2014.&lt;/p&gt;&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
  <!--Preferred Stock Dividends, Income Statement Impact-->
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="c20150101to20151231" unitRef="U001" decimals="0">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <!--Preferred Stock Dividends, Income Statement Impact-->
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="c20140101to20141231" unitRef="U001" decimals="0">2875000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <!--Prepaid Expense and Other Assets, Current-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20151231" unitRef="U001" decimals="0">315000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Prepaid Expense and Other Assets, Current-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20141231" unitRef="U001" decimals="0">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Proceeds from exercise of $5.00 warrants-->
  <us-gaap:ProceedsFromWarrantExercises contextRef="c20150101to20151231" unitRef="U001" decimals="0">4635000</us-gaap:ProceedsFromWarrantExercises>
  <!--Proceeds from exercise of $5.00 warrants-->
  <us-gaap:ProceedsFromWarrantExercises contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</us-gaap:ProceedsFromWarrantExercises>
  <!--Proceeds from Issuance or Sale of Equity-->
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c20141224to20141224" unitRef="U001" decimals="0">14035000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <!--Proceeds from Issuance of Private Placement-->
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c20150101to20150630" unitRef="U001" decimals="-5">4600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <!--Proceeds from Issuance of Private Placement-Private Placement [Member]-->
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c20150511to20150511_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="U001" decimals="-5">10000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <!--Proceeds from Issuance of Private Placement-Private Placement [Member]-->
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c20150423to20150423_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="U001" decimals="-6">7000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <!--Proceeds from Issuance of Private Placement-->
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c20150731to20150731" unitRef="U001" decimals="-5">15500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <!--Proceeds from $3.00 common stock issuances net of costs-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from $3.00 common stock issuances net of costs-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20150101to20151231" unitRef="U001" decimals="0">7001000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from Short-term Debt-->
  <us-gaap:ProceedsFromShortTermDebt contextRef="c20150101to20151231" unitRef="U001" decimals="0">-400000</us-gaap:ProceedsFromShortTermDebt>
  <!--Proceeds from Short-term Debt-->
  <us-gaap:ProceedsFromShortTermDebt contextRef="c20140101to20141231" unitRef="U001" decimals="0">400000</us-gaap:ProceedsFromShortTermDebt>
  <!--Cash from Abeona Ohio acquisition-->
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <!--Cash from Abeona Ohio acquisition-->
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c20150101to20151231" unitRef="U001" decimals="0">3697000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <!--Property, Plant and Equipment [Table Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;Property and equipment consists of the following:&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;December 31,&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 64%;"&gt;Equipment laboratory&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;139,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;209,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;14,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;Leasehold improvement&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;33,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;381,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;14,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;Less accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;31,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;350,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <!--Property, Plant and Equipment, Policy [Policy Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Property and Equipment&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from three to five years. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned and the related accumulated depreciation are eliminated from the accounts and any gains or losses are recognized in the accompanying consolidated statements of operations of the respective period.&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <!--Estimated useful lives of property and equipment-Maximum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20150101to20151231_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Estimated useful lives of property and equipment-Minimum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20150101to20151231_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Property and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20141231" unitRef="U001" decimals="0">4000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20151231" unitRef="U001" decimals="0">350000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property and equipment, gross-Leasehold Improvement [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20151231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U001" decimals="0">33000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property and equipment, gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231" unitRef="U001" decimals="0">14000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property and equipment, gross-Furniture and Office Equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="0">14000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property and equipment, gross-Equipment Laboratory [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" unitRef="U001" decimals="0">0</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property and equipment, gross-Equipment Laboratory [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20151231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" unitRef="U001" decimals="0">139000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property and equipment, gross-Leasehold Improvement [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U001" decimals="0">0</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property and equipment, gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20151231" unitRef="U001" decimals="0">381000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property and equipment, gross-Furniture and Office Equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20151231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="0">209000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment Disclosure [Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/p&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;Property and equipment consists of the following:&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;December 31,&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 64%;"&gt;Equipment laboratory&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;139,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;209,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;14,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;Leasehold improvement&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;33,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;381,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;14,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;Less accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;31,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;350,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Depreciation and amortization on property and equipment was $13,000 and $2,000 for the years ended December 31, 2015 and 2014, respectively.&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <!--Receivables-->
  <us-gaap:ReceivablesPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Receivables&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Receivables are reported in the balance sheets at the outstanding amount net of an allowance for doubtful accounts.&amp;#160;We continually evaluate the creditworthiness of our customers and their financial condition and generally do not require collateral.&amp;#160;The allowance for doubtful accounts is based upon reviews of specific customer balances, historic losses, and general economic conditions.&amp;#160;As of December 31, 2015 and 2014, no allowance was recorded as all accounts are considered collectible.&lt;/p&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <!--Receivables, Net, Current-->
  <us-gaap:ReceivablesNetCurrent contextRef="c20141231" unitRef="U001" decimals="0">35000</us-gaap:ReceivablesNetCurrent>
  <!--Receivables, Net, Current-->
  <us-gaap:ReceivablesNetCurrent contextRef="c20151231" unitRef="U001" decimals="0">115000</us-gaap:ReceivablesNetCurrent>
  <!--Related Party Transactions Disclosure [Text Block]-->
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;NOTE 2 - RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;On September 10, 2014, we entered into an Unsecured Grid Note, for up to $250,000 with SCO Capital Partners LLC (SCO). As of December 31, 2014 we had drawn a total of $250,000. The interest rate was 8% per annum and the maturity date was August 31, 2015 unless a financing of at least $5,000,000 occurred. The financing occurred December 24, 2014 and the Grid Note was paid in full on January 5, 2015.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;On September 10, 2014 we entered into a Share Exchange Agreement for Series B Preferred Stock between us and SCO and Beach Capital LLC whereby we agreed in connection with the consummation of the an offering for the Series B Preferred Stock to be converted into Common Stock. All Series B Preferred Stock dividends payable, interest on Series B Preferred Stock dividends payable and liquidated damages will be converted into Series B Preferred Stock just prior to an offering of at least $10 million. The Series B Preferred Stock, including the shares of Series B Preferred Stock issued upon conversion of all accrued dividends payable, interest on dividends payable and liquidated damages thereon, subject to a liquidation preference, will be exchanged for shares of Common Stock upon consummation of an offering at the offering price pursuant to a Share Exchange Agreement dated September 10, 2014. The conversion into Common Stock occurred on December 24, 2014.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On December 1, 2014, we entered into a second Unsecured Grid Note, for up to $250,000 with SCO. As of December 31, 2014 we had drawn a total of $150,000. The interest rate was 8% per annum and the maturity date was November 30, 2015 unless a financing of at least $5,000,000 occurred. The financing occurred December 24, 2014 and the Grid Note was paid in full on January 5, 2015.&lt;/p&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20140101to20141231" unitRef="U001" decimals="0">333000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20150101to20151231" unitRef="U001" decimals="0">4715000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and Development Expenses-->
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Research and Development Expenses&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Research and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel expense, lab supplies, preclinical, development cost, clinical trial expense, outside manufacturing and consulting. The cost of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses are capitalized when acquired.&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20151231" unitRef="U001" decimals="0">-310600000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20141231" unitRef="U001" decimals="0">-296074000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Revenue Recognition, Policy [Policy Text Block]-->
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;License Revenues and Royalties&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Our revenues are generated from licensing, research and development agreements, royalties and product sales. We recognize revenue in accordance with SEC Staff Accounting Bulletin No. 104 (SAB 104), &lt;i&gt;Revenue Recognition&lt;/i&gt;. License revenue is recognized over the remaining life of the underlying patent. Research and development revenues are recognized as services are performed. Royalties and product sales are recognized in the period of sales.&lt;/p&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <!--Royalties-->
  <us-gaap:RoyaltyRevenue contextRef="c20150101to20151231" unitRef="U001" decimals="0">438000</us-gaap:RoyaltyRevenue>
  <!--Royalties-->
  <us-gaap:RoyaltyRevenue contextRef="c20140101to20141231" unitRef="U001" decimals="0">327000</us-gaap:RoyaltyRevenue>
  <!--Options exercisable, Weighted average, Remaining life in years-Range Six [Member]-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeSixMember">P9Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options exercisable, Weighted average, Remaining life in years-Equity Incentive Plan 2005 [Member]-Range Three [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember">P4Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options exercisable, Weighted average, Remaining life in years-Equity Incentive Plan 2005 [Member]-Range Four [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember">P4Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options exercisable, Weighted average, Remaining life in years-Equity Incentive Plan 2005 [Member]-Range One [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember">P4Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options exercisable, Weighted average, Remaining life in years-Range Five [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options exercisable, Weighted average, Remaining life in years-Equity Incentive Plan 2005 [Member]-Range Two [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember">P7Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options exercisable, Weighted average, Exercise price (in dollars per share)-Equity Incentive Plan 2005 [Member]-Range One [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember" unitRef="U003" decimals="2">3.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <!--Options exercisable, Weighted average, Exercise price (in dollars per share)-Equity Incentive Plan 2005 [Member]-Range Five [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember" unitRef="U003" decimals="2">119.99</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <!--Options exercisable, Weighted average, Exercise price (in dollars per share)-Equity Incentive Plan 2005 [Member]-Range Four [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember" unitRef="U003" decimals="2">69.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <!--Options exercisable, Weighted average, Exercise price (in dollars per share)-Equity Incentive Plan 2005 [Member]-Range Three [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember" unitRef="U003" decimals="2">32.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <!--Options exercisable, Weighted average, Exercise price (in dollars per share)-Range Two [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember" unitRef="U003" decimals="2">18.32</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <!--Options exercisable, Weighted average, Exercise price (in dollars per share)-Equity Incentive Plan 2015 [Member]-Range Six [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeSixMember" unitRef="U003" decimals="2">7.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2005Member">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <!--Options outstanding, Weighted average, Remaining life in years-Equity Incentive Plan 2005 [Member]-Range One [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember">P4Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options outstanding, Weighted average, Remaining life in years-Range Six [Member]-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeSixMember">P9Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options outstanding, Weighted average, Remaining life in years-Range Five [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options outstanding, Weighted average, Remaining life in years-Equity Incentive Plan 2005 [Member]-Range Three [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember">P4Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options outstanding, Weighted average, Remaining life in years-Equity Incentive Plan 2005 [Member]-Range Two [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember">P7Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <!--Options outstanding, Weighted average, Remaining life in years-Equity Incentive Plan 2005 [Member]-Range Four [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember">P4Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <!--Intrinsic value of options exercisable-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U001" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <!--Intrinsic value of options exercisable-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U001" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <!--Intrinsic value of options exercisable-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U001" decimals="0">12000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <!--Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price-Equity Incentive Plan 2005 [Member]-Range Two [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember" unitRef="U003" decimals="2">18.33</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <!--Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price-Range Four [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember" unitRef="U003" decimals="2">69.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <!--Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price-Equity Incentive Plan 2015 [Member]-Range Six [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeSixMember" unitRef="U003" decimals="2">6.90</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <!--Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price-Range Three [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember" unitRef="U003" decimals="2">32.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <!--Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price-Equity Incentive Plan 2005 [Member]-Range Five [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember" unitRef="U003" decimals="2">119.99</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <!--Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price-Range One [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember" unitRef="U003" decimals="2">3.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20140101to20141231" unitRef="U001" decimals="0">925000</us-gaap:SalesRevenueNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20150101to20151231" unitRef="U001" decimals="0">1040000</us-gaap:SalesRevenueNet>
  <!--Schedule of purchase price allocation-->
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The following purchase price allocation is as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 70%;"&gt;&lt;tr style="height: 12px; vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 47%;"&gt;Total purchase price&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 20px; vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;"&gt;Initial consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;31,758,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;"&gt;Contingent consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;6,489,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;"&gt;Total purchase price&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 20%;"&gt;38,247,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 47%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 47%;"&gt;Allocation of the purchase price&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 47%;"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;3,697,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;28,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Property and equipment&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;51,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Other assets&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 20%;"&gt;(153,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Total tangible assets&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;3,625,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 47%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 47%;"&gt;Licensing agreement&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;2,156,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; width: 47%;"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 20%;"&gt;32,466,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 47%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 47%;"&gt;Total net asset value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 20%;"&gt;38,247,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <!--Financial assets and liabilities measured at fair value on recurring basis-->
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 and December 31, 2014 are summarized below:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;(in thousands)&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: justify;"&gt;Description&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;As of &lt;br /&gt;December 31,&lt;br /&gt; 2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 1&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 2&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 3&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Total Gains&lt;br /&gt; (Losses)&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-left: 0.25in; width: 35%; text-indent: -0.125in;"&gt;Contingent consideration&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;2,591&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;2,591&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;3,898&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;(in thousands)&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: justify;"&gt;Description&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;As of &lt;br /&gt;December 31, &lt;br /&gt; 2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 1&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 2&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Level 3&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Total Gains &lt;br /&gt; (Losses)&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0.25in; width: 35%; text-indent: -0.125in;"&gt;Derivative liability- preferred stock&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;(23,110&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <!--Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]-->
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;We did not include the following securities in the table below in the computation of diluted net loss per common share because the securities were anti-dilutive during the periods presented:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;For the year ended December&lt;br /&gt; 31,&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify; width: 64%;"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;3,799,024&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;4,164,756&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; text-align: justify;"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,324,084&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;210,134&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;6,123,108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,374,890&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <!--Summarized information of stock options-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Summarized information for the 2015 Equity Incentive Plan is as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;Weighted-&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;average&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Options&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;Outstanding options at January 1, 2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; width: 70%;"&gt;Granted, fair value of $5.18 per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 12%;"&gt;1,994,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right; width: 12%;"&gt;6.90&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;Outstanding options at December 31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,994,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;6.90&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;Exercisable at December 31, 2015&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;35,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;7.34&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <!--Summarized information of stock options-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Summarized information for the 2005 Equity Incentive Plan is as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 85%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;Weighted-&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;average&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="text-align: center;"&gt;exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;Options&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td nowrap="nowrap" style="text-align: left; width: 74%;"&gt;Outstanding options at January 1, 2014&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right; width: 10%;"&gt;28,784&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right; width: 10%;"&gt;59.00&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Granted, fair value of $14.50 per share&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;212,500&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;18.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 1pt;"&gt;Expired/forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(31,200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;37.61&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Outstanding options at December 31, 2014&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;210,084&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;20.19&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt;"&gt;Granted, fair value of $4.52&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;120,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;3.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;Outstanding options at December 31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;330,084&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;13.49&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Exercisable at December 31, 2015&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;319,884&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;15.02&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <!--Schedule of Finite-Lived Intangible Assets [Table Text Block]-->
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Licensed technology consists of the following:&lt;/p&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;December 31,&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left; width: 64%;"&gt;Licensed technology&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;7,156,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;547,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;9,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;Licensed technology, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;6,609,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,991,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <!--Income tax expense differs from statutory amounts-->
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Income tax expense differs from the statutory amounts as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table align="center" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 80%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; width: 64%;"&gt;Income taxes at U.S. statutory rate&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;(4,939,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;(9,105,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Current year reserve&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;6,257,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,254,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;Other&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;(1,318,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;7,851,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in;"&gt;Total tax expense&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <!--Temporary differences that give rise to deferred tax assets-->
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Deferred taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities. The temporary differences that give rise to deferred tax assets were as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table align="center" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 80%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;2015&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;2014&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt; width: 64%;"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;68,636,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;68,263,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;General business credit carryforwards&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2,497,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2,486,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;State credits&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2,055,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;2,061,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Property, equipment and goodwill&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;(25,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Stock options&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;3,678,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;542,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Derivatives&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;(92,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;(92,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Deferred revenue&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,669,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;92,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;595,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;464,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 9pt;"&gt;Accrued interest&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;253,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;253,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left; padding-left: 9pt;"&gt;Other&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;231,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;231,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;79,497,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;74,300,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;(79,497,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;(74,300,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 9pt;"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <!--Schedule of future minimum payments for operating leases-->
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;The five year lease payment schedule is (in thousands):&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; width: 40%;"&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;2016&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;349&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 16px; vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;2017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;241&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;2018&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;246&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;2019&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;250&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 1pt; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;836&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; width: 4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;"&gt;1,922&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <!--Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]-->
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;Basic and diluted net loss per share were determined as follows:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;(in thousands, except share and per share amounts)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;For the year ended December 31,&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2015&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;2014&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify; width: 64%;"&gt;Net loss allocable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;"&gt;(14,526&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;"&gt;(29,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;27,597,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,942,905&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Basic and diluted net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(0.53&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(15.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify;"&gt;Net loss allocable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(14,526&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(29,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <!--Stock-based compensation allocation-->
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;The following table summarizes stock-based compensation for the years ended December 31, 2015 and 2014 which was allocated as follows (in thousands):&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 95%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;Year ended&lt;/p&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&lt;u style="text-decoration: none;"&gt;December 31, 2015&lt;/u&gt;&lt;/p&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;Year ended&lt;/p&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&lt;u style="text-decoration: none;"&gt;December 31, 2014&lt;/u&gt;&lt;/p&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; width: 64%;"&gt;Research and development&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;773&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;104&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;General and administrative&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;3,595&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;1,201&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left; padding-left: 0.375in; text-indent: -17.1pt;"&gt;Stock-based compensation expense included in operating expense&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;4,368&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;1,305&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4,368&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,305&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;Tax benefit&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in;"&gt;Stock-based compensation expense, net of tax&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;4,368&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;1,305&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <!--Schedule of warrants outstanding at various exercise prices-->
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;The warrants had various exercise prices and terms as follows:&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="padding-bottom: 1pt; text-align: center;"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="padding-bottom: 1pt; text-align: center;"&gt;Exercise&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center;"&gt;Expiration&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;Summary of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center;"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center;"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;Date&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 49%;"&gt;2015 Financing 7/31/15 (a)&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 14%;"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 14%;"&gt;6.05&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; width: 16%;"&gt;07/31/20&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;2015 Financing 5/11/15 (b)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;625,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;11/11/17&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;2015 Financing 5/11/15 agent warrants (b)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;11.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;5/11/20&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;2014 Financing 12/24/14 (c)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,572,881&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;12/24/19&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;2014 Financing 12/24/14 agent warrants (c)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;87,500&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;12/18/19&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;2012 Series B private placement (d)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;400,001&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;25.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;10/24/18&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;2011 November private placement (e)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;42,898&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;100.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;11/10&amp;amp;30/16&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;2011 November placement agent warrants (e)&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;744&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right;"&gt;83.50&amp;amp;100.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center;"&gt;11/10&amp;amp;30/16&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center; text-decoration: none;"&gt;Total&lt;font style="text-underline-style: double;"&gt;&lt;u style="text-decoration: none;"&gt;&amp;#160;&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,799,024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&lt;/td&gt;&lt;td style="font-weight: normal; width: 18pt;"&gt;a)&lt;/td&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;In connection with the offering on July 31, 2015, the placement agent received warrants to purchase 20,000 share of common stock at $6.05 per share. The warrants are exercisable and expire on July 31. 2020.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&lt;/td&gt;&lt;td style="font-weight: normal; width: 18pt;"&gt;b)&lt;/td&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;In connection with the offering on May 11, 2015, warrants to purchase 625,000 shares of common stock at $10.00 per share were issued. All of the warrants exercisable and expire November 11, 2017.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;Also in connection with the offering on May 11, 2015, the placement agent received warrants to purchase 50,000 share of common stock at $11.00 per share. The warrants are exercisable and expire on May 11. 2020.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&lt;/td&gt;&lt;td style="font-weight: normal; width: 18pt;"&gt;c)&lt;/td&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;In connection with an offering on December 24, 2014, warrants to purchase 3,500,000 shares of common stock at $5.00 per share were purchased and issued for $0.01 per warrant. All of the warrants are exercisable immediately and expire on December 24, 2019. At December 31, 2015, 2,572,881 warrants are outstanding.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;Also in connection with the offering on December 24, 2014, the underwriter received warrants to purchase 87,500 shares of common stock at $5.00 per share. The warrants were exercisable on December 18, 2015 and expire on December 18, 2019.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&lt;/td&gt;&lt;td style="font-weight: normal; width: 18pt;"&gt;d)&lt;/td&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;In connection with a private placement offering on October 25, 2012, warrants to purchase 400,001 shares of common stock at $25.00 per share were issued. All of the warrants are exercisable immediately and expire on October 24, 2018.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&lt;/td&gt;&lt;td style="font-weight: normal; width: 18pt;"&gt;e)&lt;/td&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;In connection with a private placement offering on November 10 and 30, 2011, warrants to purchase 42,898 shares of common stock at $100.00 per share were issued. All of the warrants are exercisable immediately and 37,148 warrants expire November 10, 2016 and 5,750 warrants expire November 30, 2016.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <!--Information regarding options outstanding by range of exercise prices-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Further information regarding options outstanding under the 2015 Equity Incentive Plan at December 31, 2015 is summarized below:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 92%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;"&gt;Number of&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;Weighted average&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;"&gt;Number of&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;Weighted-average&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;options&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Remaining&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;options&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Remaining&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;Range of exercise prices&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;outstanding&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;life in years&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;exercisable&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;life in years&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: justify; width: 22%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: justify;"&gt;$4.38 - 7.34&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;1,994,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;9.0&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;6.90&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;35,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;9.0&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;7.34&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <!--Information regarding options outstanding by range of exercise prices-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Further information regarding options outstanding under the 2005 Equity Incentive Plan at December 31, 2015 is summarized below:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 92%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;"&gt;Number of&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;Weighted average&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;"&gt;Number of&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;Weighted-average&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;options&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Remaining&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;options&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Remaining&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Exercise&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;Range of exercise prices&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;outstanding&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;life in years&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;exercisable&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;life in years&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;price&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; width: 22%;"&gt;$3.25&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;120,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;4.0&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;3.25&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;110,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;4.0&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 10%;"&gt;3.25&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$11.50 - 18.50&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;200,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;7.7&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;18.33&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;199,800&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;7.7&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;18.32&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$30.50 - 42.50&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4.1&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;32.19&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4.1&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;32.19&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$69.00&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,400&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4.0&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;69.00&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,400&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4.0&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;69.00&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;$113.50 &amp;#8211; 157.50&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;4,684&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;119.99&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;4,684&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: right;"&gt;119.99&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;330,084&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;319,884&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <!--Segments-->
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Segments&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The Company operates in a single segment.&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <!--Selling, General and Administrative Expenses, Policy [Policy Text Block]-->
  <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;General and administrative expense&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;General and administrative expenses primarily consist of personnel, contract personnel, personnel expenses to support our administrative and operating activities, facility costs and professional expenses (i.e., legal expenses), and investor relations fees.&lt;/p&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
  <!--Stock option compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20140101to20141231" unitRef="U001" decimals="0">1305000</us-gaap:ShareBasedCompensation>
  <!--Stock option compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20150101to20151231" unitRef="U001" decimals="0">4368000</us-gaap:ShareBasedCompensation>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U002" decimals="INF">1994000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U002" decimals="INF">212500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U002" decimals="INF">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <!--Common stock price per share (in dollars per share)-->
  <us-gaap:SharePrice contextRef="c20151231" unitRef="U003" decimals="INF">3.00</us-gaap:SharePrice>
  <!--Common stock price per share (in dollars per share)-->
  <us-gaap:SharePrice contextRef="c20141231" unitRef="U003" decimals="INF">4.00</us-gaap:SharePrice>
  <!--Common stock price per share (in dollars per share)-Private Placement [Member]-->
  <us-gaap:SharePrice contextRef="c20150511_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="U003" decimals="2">8.00</us-gaap:SharePrice>
  <!--Common stock price per share (in dollars per share)-->
  <us-gaap:SharePrice contextRef="c20150731" unitRef="U003" decimals="2">5.50</us-gaap:SharePrice>
  <!--Common stock price per share (in dollars per share)-Private Placement [Member]-->
  <us-gaap:SharePrice contextRef="c20150423_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="U003" decimals="2">3.00</us-gaap:SharePrice>
  <!--Common stock price per share (in dollars per share)-->
  <us-gaap:SharePrice contextRef="c20141224" unitRef="U003" decimals="2">4.00</us-gaap:SharePrice>
  <!--Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U003" decimals="2">18.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U003" decimals="2">6.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U003" decimals="2">3.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Exercisable, end on period (in dollars per share)-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U003" decimals="2">7.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <!--Exercisable, end on period (in dollars per share)-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U003" decimals="2">15.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U007" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U007" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U007" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U002" decimals="INF">31200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <!--Exercisable, ending balance (in shares)-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U002" decimals="INF">319884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <!--Exercisable, ending balance (in shares)-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U002" decimals="INF">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <!--Expired/forfeited (in dollars per share)-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U003" decimals="2">37.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U007" decimals="2">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U007" decimals="2">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U007" decimals="2">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U002" decimals="INF">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U007" decimals="4">0.0086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U007" decimals="4">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U007" decimals="4">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <!--Stock-Based Compensation-->
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Stock-Based Compensation&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;We account for stock based compensation expense in accordance with FASB ASC 718, &lt;i&gt;Stock Based Compensation&lt;/i&gt;. We have two stock-based compensation plans under which incentive and qualified stock options and restricted shares could be granted to employees, directors and consultants. Our 2015 Equity Incentive Plan was approved by shareholders in May 7, 2015. As of January 20, 2015, no further grants can be made under our old plan, the 2005 Equity Incentive Plan. We measure the cost of the employee/director/consultant services received in exchange for an award of equity instruments based on the grant date fair value for the employees and directors and vesting date fair value for consultants of the award. We use the Black-Scholes option pricing model to value our options.&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;The following table summarizes stock-based compensation for the years ended December 31, 2015 and 2014 which was allocated as follows (in thousands):&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 95%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;Year ended&lt;/p&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&lt;u style="text-decoration: none;"&gt;December 31, 2015&lt;/u&gt;&lt;/p&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;Year ended&lt;/p&gt;&lt;p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&lt;u style="text-decoration: none;"&gt;December 31, 2014&lt;/u&gt;&lt;/p&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; width: 64%;"&gt;Research and development&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;773&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 15%;"&gt;104&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;General and administrative&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;3,595&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;1,201&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left; padding-left: 0.375in; text-indent: -17.1pt;"&gt;Stock-based compensation expense included in operating expense&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;4,368&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;1,305&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;4,368&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;1,305&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;Tax benefit&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in;"&gt;Stock-based compensation expense, net of tax&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;4,368&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;1,305&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U001" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U001" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U001" decimals="0">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20131231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U002" decimals="INF">28784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U002" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U002" decimals="INF">1994000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U002" decimals="INF">210084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U002" decimals="INF">330084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20131231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U003" decimals="2">59.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U003" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U003" decimals="2">6.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U003" decimals="2">13.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U003" decimals="2">20.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member" unitRef="U003" decimals="2">5.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U003" decimals="2">4.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U003" decimals="2">14.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Number of options outstanding (in shares)-Equity Incentive Plan 2005 [Member]-Range Three [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember" unitRef="U002" decimals="0">4000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <!--Number of options outstanding (in shares)-Equity Incentive Plan 2005 [Member]-Range Two [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember" unitRef="U002" decimals="0">200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <!--Number of options outstanding (in shares)-Range Six [Member]-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeSixMember" unitRef="U002" decimals="0">1994000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <!--Number of options outstanding (in shares)-Equity Incentive Plan 2005 [Member]-Range Four [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember" unitRef="U002" decimals="0">1400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <!--Number of options outstanding (in shares)-Equity Incentive Plan 2005 [Member]-Range One [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember" unitRef="U002" decimals="0">120000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <!--Number of options outstanding (in shares)-Range Five [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember" unitRef="U002" decimals="0">4684</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <!--Number of options outstanding (in shares)-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U002" decimals="0">330084</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <!--Number of options exercisable (in shares)-Equity Incentive Plan 2005 [Member]-Range Five [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember" unitRef="U002" decimals="0">4684</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <!--Number of options exercisable (in shares)-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member" unitRef="U002" decimals="0">319884</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <!--Number of options exercisable (in shares)-Equity Incentive Plan 2005 [Member]-Range One [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember" unitRef="U002" decimals="0">110000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <!--Number of options exercisable (in shares)-Range Four [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember" unitRef="U002" decimals="0">1400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <!--Number of options exercisable (in shares)-Equity Incentive Plan 2015 [Member]-Range Six [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2015Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeSixMember" unitRef="U002" decimals="0">35000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <!--Number of options exercisable (in shares)-Equity Incentive Plan 2005 [Member]-Range Two [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember" unitRef="U002" decimals="0">199800</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <!--Number of options exercisable (in shares)-Range Three [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember" unitRef="U002" decimals="0">4000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <!--Range of exercise prices, Upper range limit (in dollars per share)-Range Five [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember" unitRef="U003" decimals="2">157.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <!--Range of exercise prices, Upper range limit (in dollars per share)-Equity Incentive Plan 2005 [Member]-Range One [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember" unitRef="U003" decimals="2">3.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <!--Range of exercise prices, Upper range limit (in dollars per share)-Range Six [Member]-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeSixMember" unitRef="U003" decimals="2">7.34</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <!--Range of exercise prices, Upper range limit (in dollars per share)-Equity Incentive Plan 2005 [Member]-Range Three [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember" unitRef="U003" decimals="2">42.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <!--Range of exercise prices, Upper range limit (in dollars per share)-Equity Incentive Plan 2005 [Member]-Range Four [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember" unitRef="U003" decimals="2">69.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <!--Range of exercise prices, Upper range limit (in dollars per share)-Equity Incentive Plan 2005 [Member]-Range Two [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember" unitRef="U003" decimals="2">18.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <!--Range of exercise prices, Lower range limit (in dollars per share)-Range Five [Member]-Equity Incentive Plan 2005 [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember" unitRef="U003" decimals="2">113.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <!--Range of exercise prices, Lower range limit (in dollars per share)-Equity Incentive Plan 2005 [Member]-Range Three [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember" unitRef="U003" decimals="2">30.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <!--Range of exercise prices, Lower range limit (in dollars per share)-Range Six [Member]-Equity Incentive Plan 2015 [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2015Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeSixMember" unitRef="U003" decimals="2">4.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <!--Range of exercise prices, Lower range limit (in dollars per share)-Equity Incentive Plan 2005 [Member]-Range Two [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="c20150101to20151231_PlanNameAxis_EquityIncentivePlan2005Member_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember" unitRef="U003" decimals="2">11.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <!--Shares, Outstanding-Common Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c20131231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">514589</us-gaap:SharesOutstanding>
  <!--Shares, Outstanding-Series B Preferred Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c20131231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">1000</us-gaap:SharesOutstanding>
  <!--Shares, Outstanding-Series A Preferred Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c20131231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">2903.3617</us-gaap:SharesOutstanding>
  <!--Shares, Outstanding-Series B Preferred Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:SharesOutstanding>
  <!--Shares, Outstanding-Common Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">32743013</us-gaap:SharesOutstanding>
  <!--Shares, Outstanding-Series B Preferred Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:SharesOutstanding>
  <!--Shares, Outstanding-Series A Preferred Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:SharesOutstanding>
  <!--Shares, Outstanding-Series A Preferred Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:SharesOutstanding>
  <!--Shares, Outstanding-Common Stock [Member]-->
  <us-gaap:SharesOutstanding contextRef="c20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">19960801</us-gaap:SharesOutstanding>
  <!--Short-term Debt-->
  <us-gaap:ShortTermBorrowings contextRef="c20151231" unitRef="U001" decimals="0">0</us-gaap:ShortTermBorrowings>
  <!--Short-term Debt-->
  <us-gaap:ShortTermBorrowings contextRef="c20141231" unitRef="U001" decimals="0">400000</us-gaap:ShortTermBorrowings>
  <!--Common stock issued to Abeona Ohio holders-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <!--Common stock issued to Abeona Ohio holders-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <!--Common stock issued to Abeona Ohio holders-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">40000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <!--Common stock issued to Abeona Ohio holders-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <!--Common stock issued to Abeona Ohio holders-Treasury Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <!--Common stock issued to Abeona Ohio holders-->
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c20150101to20151231" unitRef="U001" decimals="0">31758000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <!--Common stock issued to Abeona Ohio holders-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">31718000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <!--Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">32000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20150101to20151231" unitRef="U001" decimals="0">32000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures-Treasury Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Stock Issued During Period, Value, Issued for Services-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20140101to20141231" unitRef="U001" decimals="0">349000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">400000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">349000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Treasury Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20150101to20151231" unitRef="U001" decimals="0">401000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Value, Issued for Services-Treasury Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <!--Stock Issued During Period, Shares, Reverse Stock Splits-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">6609</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
  <!--Stock Issued During Period, Shares, Reverse Stock Splits-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
  <!--Stock Issued During Period, Shares, Reverse Stock Splits-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
  <!--Restricted common stock issued to employees (in shares)-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
  <!--Restricted common stock issued to employees (in shares)-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
  <!--Restricted common stock issued to employees (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">1350000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
  <!--Stock Issued During Period, Value, New Issues-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Treasury Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">35000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">24000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Treasury Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20150101to20151231" unitRef="U001" decimals="0">7001000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">6977000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20140101to20141231" unitRef="U001" decimals="0">12307000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">12272000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Stock Issued During Period, Value, New Issues-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <!--Preferred stock converted into common stock-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <!--Preferred stock converted into common stock-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <!--Preferred stock converted into common stock-->
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <!--Preferred stock converted into common stock-Treasury Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <!--Preferred stock converted into common stock-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <!--Preferred stock converted into common stock-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <!--Preferred stock converted into common stock-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <!--Underwritten public offering (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">2333334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Underwritten public offering (in shares)-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Underwritten public offering (in shares)-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Underwritten public offering (in shares)-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Underwritten public offering (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">3500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Underwritten public offering (in shares)-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Underwritten public offering (in shares)-Private Placement [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20150423to20150423_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="U002" decimals="INF">2333333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Underwritten public offering (in shares)-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20141224to20141224" unitRef="U002" decimals="0">3500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Underwritten public offering (in shares)-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20150731to20150731" unitRef="U002" decimals="-4">2830000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Underwritten public offering (in shares)-Private Placement [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20150511to20150511_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="U002" decimals="INF">1250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <!--Stock Issued During Period, Shares, Conversion of Convertible Securities-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">4000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Stock Issued During Period, Shares, Conversion of Convertible Securities-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Stock Issued During Period, Shares, Conversion of Convertible Securities-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">-10.0000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <!--Restricted common stock issued to employees-->
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c20150101to20151231" unitRef="U001" decimals="0">4820000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <!--Restricted common stock issued to employees-Treasury Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <!--Restricted common stock issued to employees-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <!--Restricted common stock issued to employees-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <!--Restricted common stock issued to employees-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">4807000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <!--Restricted common stock issued to employees-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">13000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <!--Restricted common stock issued to employees-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <!--Common stock issued to Abeona Ohio holders (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">3979761</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <!--Common stock issued to Abeona Ohio holders (in shares)-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <!--Common stock issued to Abeona Ohio holders (in shares)-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <!--Common stock issued to Abeona Ohio holders (in shares)-Business Acquisitions [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c20150515to20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U002" decimals="0">3979761</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <!--Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <!--Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <!--Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">10000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <!--Stock Issued During Period, Shares, Issued for Services-Series B Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <!--Stock Issued During Period, Shares, Issued for Services-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <!--Stock Issued During Period, Shares, Issued for Services-Series A Preferred Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <!--Stock Issued During Period, Shares, Issued for Services-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">105177</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <!--Stock Issued During Period, Shares, Issued for Services-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">22000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <!--Stock Issued During Period, Shares, Issued for Services-License Agreement Terms 1 [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c20150101to20151231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTerms1Member" unitRef="U002" decimals="INF">1096151</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <!--Stockholders' Equity Note Disclosure [Text Block]-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;NOTE 9 &amp;#8211; STOCKHOLDERS&amp;#8217; EQUITY&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px; text-indent: 13.5pt;"&gt;&lt;u&gt;2015 Financing&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On July 31, 2015 we closed an upsized $15.5 million direct placement of registered common stock with institutional investors, including Soros Fund Management and Perceptive Life Science Fund, and two members of our Board of Directors. The financing was comprised of 2.83 million shares of our common stock at a price of $5.50 per share.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;During the second quarter we received additional financing of $4.6 million through Warrant exercises of our $5.00 warrants.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On May 11, 2015 we closed a $10 million private placement of common stock consisting of 1,250,000 shares of our common stock, at a price of $8.00 per share, and warrants to purchase 625,000 shares of our common stock with an exercise price of $10 per share.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.2pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.2pt;"&gt;Also in connection with the financing, the placement agent received warrants to purchase 50,000 shares of common stock at $11.00 per share and which are exercisable for five years from the closing date.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On April 23, 2015 we closed an upsized $7 million private placement of common stock consisting of 2,333,333 shares of our common stock, at a price of $3.00 per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On December 24, 2014, we closed an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of $4.00 per share and $.01 per warrant.&amp;#160;The warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance. The gross proceeds to the Company from this offering were $14,035,000, before deducting underwriting discounts and commissions and other estimated offering expenses.&amp;#160;All of the shares and warrants in the offering were sold by the Company. In addition the underwriter received warrants to purchase 87,500 shares of common stock at $5.00 per share. The warrants are exercisable on December 18, 2015 and expire on December 18, 2019.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Just before the financing closed on December 24, 2014, the Series A and Series B preferred stock and unpaid dividends and interest and liquidated damages were converted into common stock.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Warrants&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;There were warrants to purchase a total of 3,799,024 shares of common stock outstanding at December 31, 2015. All warrants were exercisable at December 31, 2015. The warrants had various exercise prices and terms as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 90%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="padding-bottom: 1pt; text-align: center;"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="padding-bottom: 1pt; text-align: center;"&gt;Exercise&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center;"&gt;Expiration&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;Summary of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center;"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center;"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;Date&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 49%;"&gt;2015 Financing 7/31/15 (a)&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 14%;"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 14%;"&gt;6.05&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; width: 16%;"&gt;07/31/20&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;2015 Financing 5/11/15 (b)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;625,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;11/11/17&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;2015 Financing 5/11/15 agent warrants (b)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;11.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;5/11/20&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;2014 Financing 12/24/14 (c)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,572,881&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;12/24/19&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;2014 Financing 12/24/14 agent warrants (c)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;87,500&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;12/18/19&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;2012 Series B private placement (d)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;400,001&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;25.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;10/24/18&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;2011 November private placement (e)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;42,898&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;100.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;11/10&amp;amp;30/16&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;2011 November placement agent warrants (e)&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;744&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right;"&gt;83.50&amp;amp;100.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center;"&gt;11/10&amp;amp;30/16&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center; text-decoration: none;"&gt;Total&lt;font style="text-underline-style: double;"&gt;&lt;u style="text-decoration: none;"&gt;&amp;#160;&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,799,024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&lt;/td&gt;&lt;td style="font-weight: normal; width: 18pt;"&gt;a)&lt;/td&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;In connection with the offering on July 31, 2015, the placement agent received warrants to purchase 20,000 share of common stock at $6.05 per share. The warrants are exercisable and expire on July 31. 2020.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&lt;/td&gt;&lt;td style="font-weight: normal; width: 18pt;"&gt;b)&lt;/td&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;In connection with the offering on May 11, 2015, warrants to purchase 625,000 shares of common stock at $10.00 per share were issued. All of the warrants exercisable and expire November 11, 2017.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;Also in connection with the offering on May 11, 2015, the placement agent received warrants to purchase 50,000 share of common stock at $11.00 per share. The warrants are exercisable and expire on May 11. 2020.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&lt;/td&gt;&lt;td style="font-weight: normal; width: 18pt;"&gt;c)&lt;/td&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;In connection with an offering on December 24, 2014, warrants to purchase 3,500,000 shares of common stock at $5.00 per share were purchased and issued for $0.01 per warrant. All of the warrants are exercisable immediately and expire on December 24, 2019. At December 31, 2015, 2,572,881 warrants are outstanding.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;Also in connection with the offering on December 24, 2014, the underwriter received warrants to purchase 87,500 shares of common stock at $5.00 per share. The warrants were exercisable on December 18, 2015 and expire on December 18, 2019.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&lt;/td&gt;&lt;td style="font-weight: normal; width: 18pt;"&gt;d)&lt;/td&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;In connection with a private placement offering on October 25, 2012, warrants to purchase 400,001 shares of common stock at $25.00 per share were issued. All of the warrants are exercisable immediately and expire on October 24, 2018.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt;&lt;/td&gt;&lt;td style="font-weight: normal; width: 18pt;"&gt;e)&lt;/td&gt;&lt;td style="font-weight: normal; text-align: justify;"&gt;In connection with a private placement offering on November 10 and 30, 2011, warrants to purchase 42,898 shares of common stock at $100.00 per share were issued. All of the warrants are exercisable immediately and 37,148 warrants expire November 10, 2016 and 5,750 warrants expire November 30, 2016.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;"&gt;Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 372 shares of common stock at $83.50 per share were issued. Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 372 shares of common stock at $100.00 per share were issued. All the placement agent warrants are exercisable immediately and 372 warrants expire November 10, 2016 and 372 warrants expire November 30, 2016.&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20141231" unitRef="U001" decimals="0">4816000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20151231" unitRef="U001" decimals="0">67721000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Series B Preferred Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20131231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Series A Preferred Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20131231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20131231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">251640000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20131231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">6000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20131231" unitRef="U001" decimals="0">-14779000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Treasury Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20131231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">-4000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Retained Earnings [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20131231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">-266421000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">328000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Retained Earnings [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">-296074000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Treasury Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Retained Earnings [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">-310600000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Series B Preferred Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">300690000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Series A Preferred Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Series B Preferred Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Treasury Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">200000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Series A Preferred Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">377993000</us-gaap:StockholdersEquity>
  <!--Tax Credit Carryforward, Amount-General business credit carryforward [Member]-Tax Year 2017 [Member]-->
  <us-gaap:TaxCreditCarryforwardAmount contextRef="c20151231_TaxCreditCarryforwardAxis_GeneralBusinessMember_TaxPeriodAxis_TaxYear2017Member" unitRef="U001" decimals="0">0</us-gaap:TaxCreditCarryforwardAmount>
  <!--Tax Credit Carryforward, Amount-Tax Year Thereafter [Member]-General business credit carryforward [Member]-->
  <us-gaap:TaxCreditCarryforwardAmount contextRef="c20151231_TaxCreditCarryforwardAxis_GeneralBusinessMember_TaxPeriodAxis_TaxYearThereafterMember" unitRef="U001" decimals="0">2385000</us-gaap:TaxCreditCarryforwardAmount>
  <!--Tax Credit Carryforward, Amount-General business credit carryforward [Member]-Latest Tax Year [Member]-->
  <us-gaap:TaxCreditCarryforwardAmount contextRef="c20151231_TaxCreditCarryforwardAxis_GeneralBusinessMember_TaxPeriodAxis_LatestTaxYearMember" unitRef="U001" decimals="0">112000</us-gaap:TaxCreditCarryforwardAmount>
  <!--Tax Credit Carryforward, Amount-General business credit carryforward [Member]-Tax Year 2016 [Member]-->
  <us-gaap:TaxCreditCarryforwardAmount contextRef="c20151231_TaxCreditCarryforwardAxis_GeneralBusinessMember_TaxPeriodAxis_TaxYear2016Member" unitRef="U001" decimals="0">0</us-gaap:TaxCreditCarryforwardAmount>
  <!--Tax Credit Carryforward, Amount-General business credit carryforward [Member]-->
  <us-gaap:TaxCreditCarryforwardAmount contextRef="c20151231_TaxCreditCarryforwardAxis_GeneralBusinessMember" unitRef="U001" decimals="0">2497000</us-gaap:TaxCreditCarryforwardAmount>
  <!--Treasury Stock, Shares, Retired-Series A Preferred Stock [Member]-->
  <us-gaap:TreasuryStockSharesRetired contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:TreasuryStockSharesRetired>
  <!--Treasury Stock, Shares, Retired-Common Stock [Member]-->
  <us-gaap:TreasuryStockSharesRetired contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">3</us-gaap:TreasuryStockSharesRetired>
  <!--Treasury Stock, Shares, Retired-Series B Preferred Stock [Member]-->
  <us-gaap:TreasuryStockSharesRetired contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</us-gaap:TreasuryStockSharesRetired>
  <!--Use of Estimates-->
  <us-gaap:UseOfEstimates contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <!--Weighted average shares outstanding (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20150101to20151231" unitRef="U002" decimals="0">27597434</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted average shares outstanding (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20140101to20141231" unitRef="U002" decimals="0">1942905</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted average number of common shares outstanding (in shares)-->
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20140101to20141231" unitRef="U002" decimals="0">1942905</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Weighted average number of common shares outstanding (in shares)-->
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20150101to20151231" unitRef="U002" decimals="0">27597434</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Payable due Licensor-->
  <accp:PayableDueLicensor contextRef="c20151231" unitRef="U001" decimals="0">4000000</accp:PayableDueLicensor>
  <!--Payable due Licensor-->
  <accp:PayableDueLicensor contextRef="c20141231" unitRef="U001" decimals="0">4000000</accp:PayableDueLicensor>
  <!--Lease extension period-->
  <accp:LeaseExtensionPeriod contextRef="c20150101to20151231">P5Y</accp:LeaseExtensionPeriod>
  <!--Total lease costs and unamortized tenant improvements-->
  <accp:TotalLeaseCostsAndUnamortizedTenantImprovements contextRef="c20150101to20151231" unitRef="U001" decimals="0">1744000</accp:TotalLeaseCostsAndUnamortizedTenantImprovements>
  <!--Debt Instrument, Covenant Compliance, Value-Unsecured Debt [Member]-SCO Capital Partners LLC [Member]-->
  <accp:DebtInstrumentCovenantComplianceValue contextRef="c20141231_LongtermDebtTypeAxis_UnsecuredDebtMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember" unitRef="U001" decimals="0">5000000</accp:DebtInstrumentCovenantComplianceValue>
  <!--Debt Instrument, Covenant Compliance, Value-Second Unsecured Grid Note [Member]-SCO Capital Partners LLC [Member]-->
  <accp:DebtInstrumentCovenantComplianceValue contextRef="c20141231_LongtermDebtTypeAxis_SecondUnsecuredGridNoteMember_RelatedPartyTransactionsByRelatedPartyAxis_ScoCapitalPartnersLlcMember" unitRef="U001" decimals="0">5000000</accp:DebtInstrumentCovenantComplianceValue>
  <!--Common stock issued to employees, directors and consultants-->
  <accp:CommonStockIssuedToEmployeesDirectorsAndConsultants contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</accp:CommonStockIssuedToEmployeesDirectorsAndConsultants>
  <!--Common stock issued to employees, directors and consultants-->
  <accp:CommonStockIssuedToEmployeesDirectorsAndConsultants contextRef="c20150101to20151231" unitRef="U001" decimals="0">-4852000</accp:CommonStockIssuedToEmployeesDirectorsAndConsultants>
  <!--Proceeds From Issuance Of Common Stock Net of Costs-->
  <accp:ProceedsFromIssuanceOfCommonStockNetOfCosts contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</accp:ProceedsFromIssuanceOfCommonStockNetOfCosts>
  <!--Proceeds From Issuance Of Common Stock Net of Costs-->
  <accp:ProceedsFromIssuanceOfCommonStockNetOfCosts contextRef="c20150101to20151231" unitRef="U001" decimals="0">9005000</accp:ProceedsFromIssuanceOfCommonStockNetOfCosts>
  <!--Proceeds From Issuance Of Common Stock One Net of Costs-->
  <accp:ProceedsFromIssuanceOfCommonStockOneNetOfCosts contextRef="c20150101to20151231" unitRef="U001" decimals="0">15411000</accp:ProceedsFromIssuanceOfCommonStockOneNetOfCosts>
  <!--Proceeds From Issuance Of Common Stock One Net of Costs-->
  <accp:ProceedsFromIssuanceOfCommonStockOneNetOfCosts contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</accp:ProceedsFromIssuanceOfCommonStockOneNetOfCosts>
  <!--Business Combination Contingent Consideration-->
  <accp:BusinessCombinationContingentConsideration contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</accp:BusinessCombinationContingentConsideration>
  <!--Business Combination Contingent Consideration-->
  <accp:BusinessCombinationContingentConsideration contextRef="c20150101to20151231" unitRef="U001" decimals="0">2591000</accp:BusinessCombinationContingentConsideration>
  <!--Noncash Or Part Noncash Acquisition Licensed Technology-->
  <accp:NoncashOrPartNoncashAcquisitionLicensedTecnology contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</accp:NoncashOrPartNoncashAcquisitionLicensedTecnology>
  <!--Noncash Or Part Noncash Acquisition Licensed Technology-->
  <accp:NoncashOrPartNoncashAcquisitionLicensedTecnology contextRef="c20150101to20151231" unitRef="U001" decimals="0">2156000</accp:NoncashOrPartNoncashAcquisitionLicensedTecnology>
  <!--Increase (Decrease) In Contingent Consideration Milestone-->
  <accp:IncreaseDecreaseInContingentConsiderationMilestone contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</accp:IncreaseDecreaseInContingentConsiderationMilestone>
  <!--Increase (Decrease) In Contingent Consideration Milestone-->
  <accp:IncreaseDecreaseInContingentConsiderationMilestone contextRef="c20150101to20151231" unitRef="U001" decimals="0">-3898000</accp:IncreaseDecreaseInContingentConsiderationMilestone>
  <!--Proceeds From Issuance Of Common Stock Two Net Of Costs-->
  <accp:ProceedsFromIssuanceOfCommonStockTwoNetOfCosts contextRef="c20140101to20141231" unitRef="U001" decimals="0">12307000</accp:ProceedsFromIssuanceOfCommonStockTwoNetOfCosts>
  <!--Proceeds From Issuance Of Common Stock Two Net Of Costs-->
  <accp:ProceedsFromIssuanceOfCommonStockTwoNetOfCosts contextRef="c20150101to20151231" unitRef="U001" decimals="0">0</accp:ProceedsFromIssuanceOfCommonStockTwoNetOfCosts>
  <!--Treasury Stock, Cancel-->
  <accp:TreasuryStockCancel contextRef="c20150101to20151231" unitRef="U001" decimals="0">0</accp:TreasuryStockCancel>
  <!--Treasury Stock, Cancel-->
  <accp:TreasuryStockCancel contextRef="c20140101to20141231" unitRef="U001" decimals="0">4000</accp:TreasuryStockCancel>
  <!--Increase Decrease in Interest Payable on Dividends-->
  <accp:IncreaseDecreaseInInterestPayableOnDividends contextRef="c20150101to20151231" unitRef="U001" decimals="0">0</accp:IncreaseDecreaseInInterestPayableOnDividends>
  <!--Increase Decrease in Interest Payable on Dividends-->
  <accp:IncreaseDecreaseInInterestPayableOnDividends contextRef="c20140101to20141231" unitRef="U001" decimals="0">592000</accp:IncreaseDecreaseInInterestPayableOnDividends>
  <!--Payable for future issuance of shares for licensed technology-->
  <accp:PayableForFutureIssuanceOfSharesForLicensedTechnology contextRef="c20150101to20151231" unitRef="U001" decimals="0">0</accp:PayableForFutureIssuanceOfSharesForLicensedTechnology>
  <!--Payable for future issuance of shares for licensed technology-->
  <accp:PayableForFutureIssuanceOfSharesForLicensedTechnology contextRef="c20140101to20141231" unitRef="U001" decimals="0">5000000</accp:PayableForFutureIssuanceOfSharesForLicensedTechnology>
  <!--Initial Conversion Price of Preferred Stock into Common Stock-Series A Preferred Stock [Member]-->
  <accp:InitialConversionPriceOfPreferredStockIntoCommonStock contextRef="c20151231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U003" decimals="2">150.00</accp:InitialConversionPriceOfPreferredStockIntoCommonStock>
  <!--Class of Warrants or Rights, Warrants Expired-Preferred Stock Offering 2008 [Member]-Warrants [Member]-->
  <accp:ClassOfWarrantsOrRightsWarrantsExpired contextRef="c20131109to20131110_FinancialInstrumentAxis_WarrantMember_StatementClassOfStockAxis_PreferredStockOffering2008Member" unitRef="U002" decimals="0">72998</accp:ClassOfWarrantsOrRightsWarrantsExpired>
  <!--Class of Warrants or Rights, Warrants Expired-Warrants [Member]-Preferred Stock Offering 2008 [Member]-->
  <accp:ClassOfWarrantsOrRightsWarrantsExpired contextRef="c20140204to20140204_FinancialInstrumentAxis_WarrantMember_StatementClassOfStockAxis_PreferredStockOffering2008Member" unitRef="U002" decimals="0">9992</accp:ClassOfWarrantsOrRightsWarrantsExpired>
  <!--Derivative liability preferred stock-Recurring [Member]-Preferred Stock [Member]-->
  <accp:DerivativeLiabilityPreferredStock contextRef="c20141231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_StatementClassOfStockAxis_PreferredStockMember" unitRef="U001" decimals="-3">0</accp:DerivativeLiabilityPreferredStock>
  <!--Derivative liability preferred stock-Recurring [Member]-Level 1 [Member]-Preferred Stock [Member]-->
  <accp:DerivativeLiabilityPreferredStock contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_StatementClassOfStockAxis_PreferredStockMember" unitRef="U001" decimals="-3">0</accp:DerivativeLiabilityPreferredStock>
  <!--Derivative liability preferred stock-Recurring [Member]-Preferred Stock [Member]-Level 2 [Member]-->
  <accp:DerivativeLiabilityPreferredStock contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_StatementClassOfStockAxis_PreferredStockMember" unitRef="U001" decimals="-3">0</accp:DerivativeLiabilityPreferredStock>
  <!--Derivative liability preferred stock-Recurring [Member]-Preferred Stock [Member]-Level 3 [Member]-->
  <accp:DerivativeLiabilityPreferredStock contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_StatementClassOfStockAxis_PreferredStockMember" unitRef="U001" decimals="-3">0</accp:DerivativeLiabilityPreferredStock>
  <!--Derivative liability preferred stock-->
  <accp:DerivativeLiabilityPreferredStock contextRef="c20131231" unitRef="U001" decimals="0">1190000</accp:DerivativeLiabilityPreferredStock>
  <!--Derivative liability preferred stock-->
  <accp:DerivativeLiabilityPreferredStock contextRef="c20141224" unitRef="U001" decimals="0">24300000</accp:DerivativeLiabilityPreferredStock>
  <!--Accrued Potential Liquidated Damages-->
  <accp:AccruedPotentialLiquidatedDamages contextRef="c20121231" unitRef="U001" decimals="0">857000</accp:AccruedPotentialLiquidatedDamages>
  <!--Accrued Potential Liquidated Damages-->
  <accp:AccruedPotentialLiquidatedDamages contextRef="c20131231" unitRef="U001" decimals="0">857000</accp:AccruedPotentialLiquidatedDamages>
  <!--Potential Liquidated Damages Capped at a Percentage of Each Holders Investment-->
  <accp:PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment contextRef="c20151231" unitRef="U007" decimals="1">0.1</accp:PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment>
  <!--Conversion of outstanding shares at dividends payable on preferred stock-Series B Preferred Stock [Member]-->
  <accp:ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock contextRef="c20140101to20141231_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="0">6951837</accp:ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock>
  <!--Conversion of outstanding shares at dividends payable on preferred stock-Series A Preferred Stock [Member]-->
  <accp:ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock contextRef="c20140101to20141231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">8961769</accp:ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock>
  <!--Stock Issued During Period Value New Issue-->
  <accp:StockIssuedDuringPeriodValueNewIssue contextRef="c20150101to20151231" unitRef="U001" decimals="0">9005000</accp:StockIssuedDuringPeriodValueNewIssue>
  <!--Stock Issued During Period Value New Issue-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssue contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueNewIssue>
  <!--Stock Issued During Period Value New Issue-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssue contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">13000</accp:StockIssuedDuringPeriodValueNewIssue>
  <!--Stock Issued During Period Value New Issue-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssue contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueNewIssue>
  <!--Stock Issued During Period Value New Issue-Retained Earnings [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssue contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueNewIssue>
  <!--Stock Issued During Period Value New Issue-Additional Paid-in Capital [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssue contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">8992000</accp:StockIssuedDuringPeriodValueNewIssue>
  <!--Stock Issued During Period Value New Issue-Treasury Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssue contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueNewIssue>
  <!--Stock Issued During Period Shares Reverse Stock Splits One-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesReverseStockSplitsOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">2270</accp:StockIssuedDuringPeriodSharesReverseStockSplitsOne>
  <!--Stock Issued During Period Shares Reverse Stock Splits One-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesReverseStockSplitsOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</accp:StockIssuedDuringPeriodSharesReverseStockSplitsOne>
  <!--Stock Issued During Period Shares Reverse Stock Splits One-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesReverseStockSplitsOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</accp:StockIssuedDuringPeriodSharesReverseStockSplitsOne>
  <!--Stock Issued During Period Shares New Issue-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesNewIssue contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">1250000</accp:StockIssuedDuringPeriodSharesNewIssue>
  <!--Stock Issued During Period Shares New Issue-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesNewIssue contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</accp:StockIssuedDuringPeriodSharesNewIssue>
  <!--Stock Issued During Period Shares New Issue-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesNewIssue contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</accp:StockIssuedDuringPeriodSharesNewIssue>
  <!--Stock Issued During Period Value New Issue One-->
  <accp:StockIssuedDuringPeriodValueNewIssueOne contextRef="c20150101to20151231" unitRef="U001" decimals="0">15411000</accp:StockIssuedDuringPeriodValueNewIssueOne>
  <!--Stock Issued During Period Value New Issue One-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssueOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">28000</accp:StockIssuedDuringPeriodValueNewIssueOne>
  <!--Stock Issued During Period Value New Issue One-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssueOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueNewIssueOne>
  <!--Stock Issued During Period Value New Issue One-Retained Earnings [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssueOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueNewIssueOne>
  <!--Stock Issued During Period Value New Issue One-Additional Paid-in Capital [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssueOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">15383000</accp:StockIssuedDuringPeriodValueNewIssueOne>
  <!--Stock Issued During Period Value New Issue One-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssueOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueNewIssueOne>
  <!--Stock Issued During Period Value New Issue One-Treasury Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueNewIssueOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueNewIssueOne>
  <!--Stock Issued During Period Shares New Issue One-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesNewIssueOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</accp:StockIssuedDuringPeriodSharesNewIssueOne>
  <!--Stock Issued During Period Shares New Issue One-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesNewIssueOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">2829091</accp:StockIssuedDuringPeriodSharesNewIssueOne>
  <!--Stock Issued During Period Shares New Issue One-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesNewIssueOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</accp:StockIssuedDuringPeriodSharesNewIssueOne>
  <!--Stock Issued During Period, Value, Warrants Exercised-Additional Paid-in Capital [Member]-->
  <accp:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">4626000</accp:StockIssuedDuringPeriodValueWarrantsExercised>
  <!--Stock Issued During Period, Value, Warrants Exercised-Retained Earnings [Member]-->
  <accp:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueWarrantsExercised>
  <!--Stock Issued During Period, Value, Warrants Exercised-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueWarrantsExercised>
  <!--Stock Issued During Period, Value, Warrants Exercised-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueWarrantsExercised>
  <!--Stock Issued During Period, Value, Warrants Exercised-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">9000</accp:StockIssuedDuringPeriodValueWarrantsExercised>
  <!--Stock Issued During Period, Value, Warrants Exercised-->
  <accp:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c20150101to20151231" unitRef="U001" decimals="0">4635000</accp:StockIssuedDuringPeriodValueWarrantsExercised>
  <!--Stock Issued During Period, Value, Warrants Exercised-Treasury Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueWarrantsExercised>
  <!--Stock Issued During Period Shares Warrants Exercised-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">0</accp:StockIssuedDuringPeriodSharesWarrantsExercised>
  <!--Stock Issued During Period Shares Warrants Exercised-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">927119</accp:StockIssuedDuringPeriodSharesWarrantsExercised>
  <!--Stock Issued During Period Shares Warrants Exercised-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</accp:StockIssuedDuringPeriodSharesWarrantsExercised>
  <!--Stock Issued During Period Value Reverse Stock Splits One-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplitsOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplitsOne>
  <!--Stock Issued During Period Value Reverse Stock Splits One-Retained Earnings [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplitsOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplitsOne>
  <!--Stock Issued During Period Value Reverse Stock Splits One-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplitsOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplitsOne>
  <!--Stock Issued During Period Value Reverse Stock Splits One-Additional Paid-in Capital [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplitsOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplitsOne>
  <!--Stock Issued During Period Value Reverse Stock Splits One-Treasury Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplitsOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplitsOne>
  <!--Stock Issued During Period Value Reverse Stock Splits One-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplitsOne contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplitsOne>
  <!--Stock Issued During Period Value Reverse Stock Splits One-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplitsOne contextRef="c20150101to20151231" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplitsOne>
  <!--Series B Preferred Stock Issued For Unpaid Liquidated Damages, Value-Series A Preferred Stock [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue>
  <!--Series B Preferred Stock Issued For Unpaid Liquidated Damages, Value-Common Stock [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue>
  <!--Series B Preferred Stock Issued For Unpaid Liquidated Damages, Value-Series B Preferred Stock [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue>
  <!--Series B Preferred Stock Issued For Unpaid Liquidated Damages, Value-Additional Paid-in Capital [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">857000</accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue>
  <!--Series B Preferred Stock Issued For Unpaid Liquidated Damages, Value-Treasury Stock [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue>
  <!--Series B Preferred Stock Issued For Unpaid Liquidated Damages, Value-Retained Earnings [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue>
  <!--Series B Preferred Stock Issued For Unpaid Liquidated Damages, Value-->
  <accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue contextRef="c20140101to20141231" unitRef="U001" decimals="0">857000</accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue>
  <!--Stock Issued For Series B Preferred Stock, Unpaid Dividends and Interest and Liquidated Damages, Shares-Series B Preferred Stock [Member]-->
  <accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">-1390</accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares>
  <!--Stock Issued For Series B Preferred Stock, Unpaid Dividends and Interest and Liquidated Damages, Shares-Common Stock [Member]-->
  <accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">6951837</accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares>
  <!--Stock Issued During Period, Value, Series A Preferred Stock-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">72000</accp:StockIssuedDuringPeriodValueSeriesAPreferredStock>
  <!--Stock Issued During Period, Value, Series A Preferred Stock-Retained Earnings [Member]-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueSeriesAPreferredStock>
  <!--Stock Issued During Period, Value, Series A Preferred Stock-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueSeriesAPreferredStock>
  <!--Stock Issued During Period, Value, Series A Preferred Stock-Additional Paid-in Capital [Member]-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">-72000</accp:StockIssuedDuringPeriodValueSeriesAPreferredStock>
  <!--Stock Issued During Period, Value, Series A Preferred Stock-Treasury Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueSeriesAPreferredStock>
  <!--Stock Issued During Period, Value, Series A Preferred Stock-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStock contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueSeriesAPreferredStock>
  <!--Stock Issued During Period, Value, Series A Preferred Stock-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueSeriesAPreferredStock>
  <!--Series B Preferred Stock Issued For Unpaid Series B Dividends and Interest, Shares-Series B Preferred Stock [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">304</accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares>
  <!--Stock Issued During Period, Value, Reverse Stock Splits-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplits contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplits>
  <!--Stock Issued During Period, Value, Reverse Stock Splits-Additional Paid-in Capital [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplits contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplits>
  <!--Stock Issued During Period, Value, Reverse Stock Splits-Treasury Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplits contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplits>
  <!--Stock Issued During Period, Value, Reverse Stock Splits-Retained Earnings [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplits contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplits>
  <!--Stock Issued During Period, Value, Reverse Stock Splits-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplits contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplits>
  <!--Stock Issued During Period, Value, Reverse Stock Splits-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplits contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplits>
  <!--Stock Issued During Period, Value, Reverse Stock Splits-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueReverseStockSplits contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueReverseStockSplits>
  <!--Series B Preferred Stock Issued For Unpaid Series B Dividends and Interest, Value-Additional Paid-in Capital [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">3047000</accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue>
  <!--Series B Preferred Stock Issued For Unpaid Series B Dividends and Interest, Value-->
  <accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue contextRef="c20140101to20141231" unitRef="U001" decimals="0">3047000</accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue>
  <!--Series B Preferred Stock Issued For Unpaid Series B Dividends and Interest, Value-Series A Preferred Stock [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue>
  <!--Series B Preferred Stock Issued For Unpaid Series B Dividends and Interest, Value-Common Stock [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue>
  <!--Series B Preferred Stock Issued For Unpaid Series B Dividends and Interest, Value-Treasury Stock [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue>
  <!--Series B Preferred Stock Issued For Unpaid Series B Dividends and Interest, Value-Retained Earnings [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue>
  <!--Series B Preferred Stock Issued For Unpaid Series B Dividends and Interest, Value-Series B Preferred Stock [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue>
  <!--Stock Issued During Period, Value, Series A Preferred Stock Unpaid Dividends and Interest-Additional Paid-in Capital [Member]-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">7066000</accp:StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest>
  <!--Stock Issued During Period, Value, Series A Preferred Stock Unpaid Dividends and Interest-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">17000</accp:StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest>
  <!--Stock Issued During Period, Value, Series A Preferred Stock Unpaid Dividends and Interest-Retained Earnings [Member]-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest>
  <!--Stock Issued During Period, Value, Series A Preferred Stock Unpaid Dividends and Interest-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest contextRef="c20140101to20141231" unitRef="U001" decimals="0">7083000</accp:StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest>
  <!--Stock Issued During Period, Value, Series A Preferred Stock Unpaid Dividends and Interest-Treasury Stock [Member]-->
  <accp:StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest>
  <!--Series B Preferred Stock Issued For Unpaid Liquidated Damages, Shares-Series B Preferred Stock [Member]-->
  <accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">86</accp:SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares>
  <!--Adjustments To Additional Paid In Capital Elimination of Derivative Liability, Preferred Stock-->
  <accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock contextRef="c20140101to20141231" unitRef="U001" decimals="0">24300000</accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock>
  <!--Adjustments To Additional Paid In Capital Elimination of Derivative Liability, Preferred Stock-Series B Preferred Stock [Member]-->
  <accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock>
  <!--Adjustments To Additional Paid In Capital Elimination of Derivative Liability, Preferred Stock-Retained Earnings [Member]-->
  <accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock>
  <!--Adjustments To Additional Paid In Capital Elimination of Derivative Liability, Preferred Stock-Common Stock [Member]-->
  <accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock>
  <!--Adjustments To Additional Paid In Capital Elimination of Derivative Liability, Preferred Stock-Treasury Stock [Member]-->
  <accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock>
  <!--Adjustments To Additional Paid In Capital Elimination of Derivative Liability, Preferred Stock-Series A Preferred Stock [Member]-->
  <accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock>
  <!--Adjustments To Additional Paid In Capital Elimination of Derivative Liability, Preferred Stock-Additional Paid-in Capital [Member]-->
  <accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">24300000</accp:AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock>
  <!--Treasury Stock, Value, Retired-Retained Earnings [Member]-->
  <accp:TreasuryStockValueRetired contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:TreasuryStockValueRetired>
  <!--Treasury Stock, Value, Retired-Treasury Stock [Member]-->
  <accp:TreasuryStockValueRetired contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">4000</accp:TreasuryStockValueRetired>
  <!--Treasury Stock, Value, Retired-Additional Paid-in Capital [Member]-->
  <accp:TreasuryStockValueRetired contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">-4000</accp:TreasuryStockValueRetired>
  <!--Treasury Stock, Value, Retired-Common Stock [Member]-->
  <accp:TreasuryStockValueRetired contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">0</accp:TreasuryStockValueRetired>
  <!--Treasury Stock, Value, Retired-Series A Preferred Stock [Member]-->
  <accp:TreasuryStockValueRetired contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">0</accp:TreasuryStockValueRetired>
  <!--Treasury Stock, Value, Retired-->
  <accp:TreasuryStockValueRetired contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</accp:TreasuryStockValueRetired>
  <!--Treasury Stock, Value, Retired-Series B Preferred Stock [Member]-->
  <accp:TreasuryStockValueRetired contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:TreasuryStockValueRetired>
  <!--Stock Issued During Period, Shares, Series A Preferred Stock Unpaid Dividends and Interest-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">1728365</accp:StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest>
  <!--Stock Issued During Period, Shares, Series A Preferred Stock-Series A Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesSeriesAPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="INF">-2893.3617</accp:StockIssuedDuringPeriodSharesSeriesAPreferredStock>
  <!--Stock Issued During Period, Shares, Series A Preferred Stock-Series B Preferred Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesSeriesAPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U002" decimals="INF">0</accp:StockIssuedDuringPeriodSharesSeriesAPreferredStock>
  <!--Stock Issued During Period, Shares, Series A Preferred Stock-Common Stock [Member]-->
  <accp:StockIssuedDuringPeriodSharesSeriesAPreferredStock contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF">7233404</accp:StockIssuedDuringPeriodSharesSeriesAPreferredStock>
  <!--Stock Issued For Series B Preferred Stock, Unpaid Dividends and Interest and Liquidated Damages, Value-Retained Earnings [Member]-->
  <accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="0">0</accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue>
  <!--Stock Issued For Series B Preferred Stock, Unpaid Dividends and Interest and Liquidated Damages, Value-Additional Paid-in Capital [Member]-->
  <accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="0">-70000</accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue>
  <!--Stock Issued For Series B Preferred Stock, Unpaid Dividends and Interest and Liquidated Damages, Value-Series B Preferred Stock [Member]-->
  <accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_SeriesBPreferredStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue>
  <!--Stock Issued For Series B Preferred Stock, Unpaid Dividends and Interest and Liquidated Damages, Value-->
  <accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue contextRef="c20140101to20141231" unitRef="U001" decimals="0">0</accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue>
  <!--Stock Issued For Series B Preferred Stock, Unpaid Dividends and Interest and Liquidated Damages, Value-Treasury Stock [Member]-->
  <accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">0</accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue>
  <!--Stock Issued For Series B Preferred Stock, Unpaid Dividends and Interest and Liquidated Damages, Value-Common Stock [Member]-->
  <accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">70000</accp:StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue>
  <!--New issues share one price per share-->
  <accp:NewIssuesShareOnePricePerShare contextRef="c20151231" unitRef="U003" decimals="INF">5.50</accp:NewIssuesShareOnePricePerShare>
  <!--New issues share price per share-->
  <accp:NewIssuesSharePricePerShare contextRef="c20151231" unitRef="U003" decimals="INF">8.00</accp:NewIssuesSharePricePerShare>
  <!--Number of investment options-->
  <accp:NumberOfInvestmentOptions contextRef="c20150101to20151231" unitRef="U008" decimals="INF">60</accp:NumberOfInvestmentOptions>
  <!--Summary Of Operating Loss Carryforwards and General Business Credit Carryforwards [Table Text Block]-->
  <accp:SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;These carryforwards expire as follows:&lt;/div&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 2in; width: 60%;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;Net operating&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;"&gt;General business&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap" style="font-weight: bold; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="font-size: 10pt; border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;l&lt;u style="text-decoration: none;"&gt;oss carryforwards&lt;/u&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;"&gt;credit carryforwards&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;2016&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;2017&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; text-align: left; width: 44%;"&gt;2018&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 25%;"&gt;3,324,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; text-align: right; width: 25%;"&gt;112,000&lt;/td&gt;&lt;td style="font-weight: normal; text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;Thereafter&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;206,342,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;"&gt;2,385,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; font-style: normal; text-align: left; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;209,666,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;"&gt;2,497,000&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</accp:SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock>
  <!--Income Tax Reconciliation Current Year Reserve-->
  <accp:IncomeTaxReconciliationCurrentYearReserve contextRef="c20150101to20151231" unitRef="U001" decimals="0">6257000</accp:IncomeTaxReconciliationCurrentYearReserve>
  <!--Income Tax Reconciliation Current Year Reserve-->
  <accp:IncomeTaxReconciliationCurrentYearReserve contextRef="c20140101to20141231" unitRef="U001" decimals="0">1254000</accp:IncomeTaxReconciliationCurrentYearReserve>
  <!--Number of Years Subject to Statute of Limitations-->
  <accp:NumberOfYearsSubjectToStatuteOfLimitations contextRef="c20150101to20151231">P3Y</accp:NumberOfYearsSubjectToStatuteOfLimitations>
  <!--Regulatory approval milestone payment-License Agreement Terms 1 [Member]-->
  <accp:RegulatoryApprovalMilestonePayment contextRef="c20151231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTerms1Member" unitRef="U002" decimals="INF">513375</accp:RegulatoryApprovalMilestonePayment>
  <!--Remaining Payable For Future Issuance Of Shares For Licensed Technology-License Agreement Terms 1 [Member]-->
  <accp:RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology contextRef="c20151231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTerms1Member" unitRef="U001" decimals="0">4000000</accp:RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology>
  <!--Number of Stock Based Compensation Plans-->
  <accp:NumberOfStockBasedCompensationPlans contextRef="c20150101to20151231" unitRef="U006" decimals="INF">2</accp:NumberOfStockBasedCompensationPlans>
  <!--Number of Financial Institutions Deposits are Primarily Maintained-->
  <accp:NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained contextRef="c20150101to20151231" unitRef="U004" decimals="INF">2</accp:NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained>
  <!--Number of patent family-Gene Therapy [Member]-->
  <accp:NumberOfPatentFamily contextRef="c20150101to20151231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTermsMember" unitRef="U005" decimals="INF">1</accp:NumberOfPatentFamily>
  <!--Other Income [Policy Text Block]-->
  <accp:OtherIncomePolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Other Income&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;In 2015 and 2014, we recognized miscellaneous income of $4,026,000 and $45,000, respectively, due to the termination of the milestone recorded on the contingent consideration liability in 2015 and sales of platinum and monomers in 2014 and write-offs and settlements of other accounts payable for both years.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;In some of our license agreements we are responsible as agent for arranging the manufacture of MuGard (mucoadhesive oral wound rinse) and have entered into supply agreements with our license partners. Terms vary with each agreement but generally we arrange for the manufacture of MuGard with a third-party and receive a fee to cover our administration, handling and overhead costs. The income is recorded in other income.&lt;/p&gt;&lt;/div&gt;</accp:OtherIncomePolicyTextBlock>
  <!--Nature of Operations [Policy Text Block]-->
  <accp:NatureOfOperationsPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;&lt;u&gt;Nature of Operations&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"&gt;Abeona Therapeutics Inc. (together with our subsidiaries, &amp;#8220;we&amp;#8221;, &amp;#8220;our&amp;#8221;, &amp;#8220;Abeona&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a Delaware corporation. We are focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA, respectively). We are also developing ABO-201 (AAV CLN3) gene therapy for Juvenile Neuronal Ceroid Lipofuscinoses (JNCL) also known as juvenile Batten disease; and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including PTB-101 SDF Alpha&amp;#8482; (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF&amp;#8482; (Salt Diafiltration) ethanol-free process.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;Certain amounts have been reclassified to conform with current period classification.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:&lt;/p&gt;&lt;/div&gt;</accp:NatureOfOperationsPolicyTextBlock>
  <!--Licensed technology [Policy Text Block]-->
  <accp:LicensedTechnologyPolicyTextBlock contextRef="c20150101to20151231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;font style="font-weight: normal;"&gt;&lt;u&gt;Licensed Technology&lt;/u&gt;&lt;/font&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;We maintain licensed technology on our consolidated balance sheet until either the licensed technology agreement underlying it is completed or the asset becomes impaired. When we determine that an asset has become impaired or we abandon a project, we write down the carrying value of the related intangible asset to its fair value and take an impairment charge in the period in which the impairment occurs.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;Generally licensed technology is amortized over the life of the patent or the agreement.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;We test our intangible assets for impairment on an annual basis, or more frequently if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate or new information regarding potential sales for the drug. In connection with each annual impairment assessment and any interim impairment assessment, we compare the fair value of the asset as of the date of the assessment with the carrying value of the asset on our consolidated balance sheet.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;"&gt;In 2015, we did not impair any licensed technology.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Gene therapy license agreements&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On May 15, 2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children&amp;#8217;s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. This portfolio comprises 1 patent family: &amp;#8220;Products and methods for delivery of polynuleotides by adeno-associated virus for lysosomal storage disorders&amp;#8221;. Additionally, Abeona has secured FDA Orphan drug designation for both Sanfilippo A and B, which will provide 7 years of post-launch market exclusivity for both ABX-A and ABX-B in the U.S. Abeona will be seeking Orphan Drug Status within the EMA, which will grant 10 years of post-market exclusivity in the European Union.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The license is amortized over the life of the license of 20 years.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&lt;u&gt;Plasma-based therapeutics license agreements&lt;/u&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;On September 22, 2014, we entered into an exclusive, worldwide licensing agreement with Plasma Technologies LLC (&amp;#8220;Licensor&amp;#8221;) to obtain rights to utilize and to sub-license to other pharmaceuticals firms, its patented methods for the extraction of therapeutic biologics from human plasma. Under the terms of the licensing agreement, as amended on January 23, 2015, we paid a license fee of $1 million in cash, will pay $4,000,000 in cash or 1,096,151 shares of our common stock in 2017, a regulatory approval milestone payment of 513,375 shares of our common stock upon the first FDA regulatory approval of a drug derived from the Licensor&amp;#8217;s proprietary SDF process, and a tiered royalty on annual net sales of plasma fractions produced with Licensor&amp;#8217;s proprietary SDF process.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"&gt;The license is amortized over the life of the patent of 11 years.&lt;/p&gt;&lt;/div&gt;</accp:LicensedTechnologyPolicyTextBlock>
  <!--Class of Warrants Or Right Expiration Date-Public Offering [Member]-->
  <accp:ClassOfWarrantsOrRightExpirationDate contextRef="c20150101to20151231_ClassOfWarrantOrRightAxis_PublicOfferingMember" id="Item-18">2019-12-24</accp:ClassOfWarrantsOrRightExpirationDate>
  <!--Class of Warrants Or Right Expiration Date-May Financing 2015 [Member]-->
  <accp:ClassOfWarrantsOrRightExpirationDate contextRef="c20150101to20151231_ClassOfWarrantOrRightAxis_MayFinancing2015Member" id="Item-19">2017-11-11</accp:ClassOfWarrantsOrRightExpirationDate>
  <!--Class of Warrants Or Right Expiration Date-May Financing Agent Warrants 2015 [Member]-->
  <accp:ClassOfWarrantsOrRightExpirationDate contextRef="c20150101to20151231_ClassOfWarrantOrRightAxis_MayFinancingAgentWarrants2015Member" id="Item-20">2020-05-11</accp:ClassOfWarrantsOrRightExpirationDate>
  <!--Class of Warrants Or Right Expiration Date-Warrants [Member]-Private Placement 1 [Member]-->
  <accp:ClassOfWarrantsOrRightExpirationDate contextRef="c20150101to20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member_FinancialInstrumentAxis_WarrantMember">2016-11-10</accp:ClassOfWarrantsOrRightExpirationDate>
  <!--Class of Warrants Or Right Expiration Date-Private Placement 1 [Member]-Warrant2 [Member]-->
  <accp:ClassOfWarrantsOrRightExpirationDate contextRef="c20150101to20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member_FinancialInstrumentAxis_Warrant2Member">2016-11-30</accp:ClassOfWarrantsOrRightExpirationDate>
  <!--Class of Warrants Or Right Expiration Date-July Financing 2015 [Member]-->
  <accp:ClassOfWarrantsOrRightExpirationDate contextRef="c20150101to20151231_ClassOfWarrantOrRightAxis_JulyFinancing2015Member" id="Item-21">2020-07-31</accp:ClassOfWarrantsOrRightExpirationDate>
  <!--Class of Warrants Or Right Expiration Date-Public Offering Agent Warrants [Member]-->
  <accp:ClassOfWarrantsOrRightExpirationDate contextRef="c20150101to20151231_ClassOfWarrantOrRightAxis_PublicOfferingAgentWarrantsMember" id="Item-22">2019-12-18</accp:ClassOfWarrantsOrRightExpirationDate>
  <!--Class of Warrants Or Right Expiration Date-2012 Series B private placement [Member]-->
  <accp:ClassOfWarrantsOrRightExpirationDate contextRef="c20150101to20151231_ClassOfWarrantOrRightAxis_SeriesBPrivatePlacementMember" id="Item-23">2018-10-24</accp:ClassOfWarrantsOrRightExpirationDate>
  <!--Warrants issued price-->
  <accp:WarrantsIssuedPrice contextRef="c20141224to20141224" unitRef="U003" decimals="2">0.01</accp:WarrantsIssuedPrice>
  <!--Term of warrant-Placement Agent [Member]-->
  <accp:TermOfWarrant contextRef="c20150511to20150511_SubsidiarySaleOfStockAxis_PlacementAgentMember">P5Y</accp:TermOfWarrant>
  <!--Class of Warrants Or Rights Exercisable Period-->
  <accp:ClassOfWarrantsOrRightsExercisablePeriod contextRef="c20141224to20141224">P5Y</accp:ClassOfWarrantsOrRightsExercisablePeriod>
  <!--Number of Board of Directors-->
  <accp:NumberOfBoardOfDirectors contextRef="c20150731to20150731" unitRef="U009" decimals="INF">2</accp:NumberOfBoardOfDirectors>
  <!--Class of Warrants Or Rights Expiration Date-Placement Agent Warrants 1 [Member]-->
  <accp:ClassOfWarrantsOrRightsExpirationDate contextRef="c20150101to20151231_ClassOfWarrantOrRightAxis_PlacementAgentWarrants1Member" id="Item-24">11/10 &amp; 30/16</accp:ClassOfWarrantsOrRightsExpirationDate>
  <!--Class of Warrants Or Rights Expiration Date-Private Placement 1 [Member]-->
  <accp:ClassOfWarrantsOrRightsExpirationDate contextRef="c20150101to20151231_ClassOfWarrantOrRightAxis_PrivatePlacement1Member" id="Item-25">11/10 &amp; 30/16</accp:ClassOfWarrantsOrRightsExpirationDate>
  <!--Number of milestones-Business Acquisitions [Member]-->
  <accp:NumberOfMilestones contextRef="c20150515to20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U010" decimals="INF">3</accp:NumberOfMilestones>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets-Business Acquisitions [Member]-->
  <accp:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets contextRef="c20150515_BusinessAcquisitionAxis_BusinessAcquisitionsMember" unitRef="U001" decimals="0">3625000</accp:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:footnote xlink:label="Footnote-Item-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In connection with a private placement offering on October 25, 2012, warrants to purchase 400,001 shares of common stock at $25.00 per share were issued. All of the warrants are exercisable immediately and expire on October 24, 2018.</link:footnote>
    <link:loc xlink:href="#Item-1" xlink:label="Item-1_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-1_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-11" xlink:label="Item-11_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-11_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-23" xlink:label="Item-23_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-23_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:footnote xlink:label="Footnote-Item-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In connection with the offering on May 11, 2015, warrants to purchase 625,000 shares of common stock at $10.00 per share were issued. All of the warrants exercisable and expire November 11, 2017.

Also in connection with the offering on May 11, 2015, the placement agent received warrants to purchase 50,000 share of common stock at $11.00 per share. The warrants are exercisable and expire on May 11. 2020.</link:footnote>
    <link:loc xlink:href="#Item-2" xlink:label="Item-2_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-2_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-8" xlink:label="Item-8_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-8_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-13" xlink:label="Item-13_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-13_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-16" xlink:label="Item-16_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-16_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-19" xlink:label="Item-19_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-19_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-20" xlink:label="Item-20_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-20_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:footnote xlink:label="Footnote-Item-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In connection with a private placement offering on November 10 and 30, 2011, warrants to purchase 42,898 shares of common stock at $100.00 per share were issued. All of the warrants are exercisable immediately and 37,148 warrants expire November 10, 2016 and 5,750 warrants expire November 30, 2016.

Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 372 shares of common stock at $83.50 per share were issued. Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 372 shares of common stock at $100.00 per share were issued. All the placement agent warrants are exercisable immediately and 372 warrants expire November 10, 2016 and 372 warrants expire November 30, 2016.</link:footnote>
    <link:loc xlink:href="#Item-3" xlink:label="Item-3_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-3_lbl" xlink:to="Footnote-Item-3" xlink:type="arc" />
    <link:loc xlink:href="#Item-5" xlink:label="Item-5_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-5_lbl" xlink:to="Footnote-Item-3" xlink:type="arc" />
    <link:loc xlink:href="#Item-9" xlink:label="Item-9_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-9_lbl" xlink:to="Footnote-Item-3" xlink:type="arc" />
    <link:loc xlink:href="#Item-10" xlink:label="Item-10_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-10_lbl" xlink:to="Footnote-Item-3" xlink:type="arc" />
    <link:loc xlink:href="#Item-14" xlink:label="Item-14_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-14_lbl" xlink:to="Footnote-Item-3" xlink:type="arc" />
    <link:loc xlink:href="#Item-24" xlink:label="Item-24_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-24_lbl" xlink:to="Footnote-Item-3" xlink:type="arc" />
    <link:loc xlink:href="#Item-25" xlink:label="Item-25_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-25_lbl" xlink:to="Footnote-Item-3" xlink:type="arc" />
    <link:footnote xlink:label="Footnote-Item-4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In connection with an offering on December 24, 2014, warrants to purchase 3,500,000 shares of common stock at $5.00 per share were purchased and issued for $0.01 per warrant. All of the warrants are exercisable immediately and expire on December 24, 2019. At December 31, 2015, 2,572,881 warrants are outstanding.

Also in connection with the offering on December 24, 2014, the underwriter received warrants to purchase 87,500 shares of common stock at $5.00 per share. The warrants were exercisable on December 18, 2015 and expire on December 18, 2019.</link:footnote>
    <link:loc xlink:href="#Item-4" xlink:label="Item-4_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-4_lbl" xlink:to="Footnote-Item-4" xlink:type="arc" />
    <link:loc xlink:href="#Item-7" xlink:label="Item-7_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-7_lbl" xlink:to="Footnote-Item-4" xlink:type="arc" />
    <link:loc xlink:href="#Item-12" xlink:label="Item-12_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-12_lbl" xlink:to="Footnote-Item-4" xlink:type="arc" />
    <link:loc xlink:href="#Item-15" xlink:label="Item-15_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-15_lbl" xlink:to="Footnote-Item-4" xlink:type="arc" />
    <link:loc xlink:href="#Item-18" xlink:label="Item-18_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-18_lbl" xlink:to="Footnote-Item-4" xlink:type="arc" />
    <link:loc xlink:href="#Item-22" xlink:label="Item-22_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-22_lbl" xlink:to="Footnote-Item-4" xlink:type="arc" />
    <link:footnote xlink:label="Footnote-Item-5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In connection with the offering on July 31, 2015, the placement agent received warrants to purchase 20,000 share of common stock at $6.05 per share. The warrants are exercisable and expire on July 31. 2020.</link:footnote>
    <link:loc xlink:href="#Item-6" xlink:label="Item-6_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-6_lbl" xlink:to="Footnote-Item-5" xlink:type="arc" />
    <link:loc xlink:href="#Item-17" xlink:label="Item-17_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-17_lbl" xlink:to="Footnote-Item-5" xlink:type="arc" />
    <link:loc xlink:href="#Item-21" xlink:label="Item-21_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-21_lbl" xlink:to="Footnote-Item-5" xlink:type="arc" />
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>accp-20151231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.0.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<xs:schema targetNamespace="http://accesspharma.com/20151231" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:accp="http://accesspharma.com/20151231" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="accp-20151231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="accp-20151231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="accp-20151231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="accp-20151231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://accesspharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: CONSOLIDATED BALANCE SHEETS-->
        <link:definition>010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>030000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" id="ConsolidatedStatementsOfStockholdersEquityParenthetical">
        <!--Parent Role: CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY-->
        <link:definition>030100 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical">
        <!--Parent Role: CONSOLIDATED STATEMENTS OF CASH FLOWS-->
        <link:definition>040100 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPolicies">
        <link:definition>060100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>060200 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>060300 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/LicensedTechnology" id="LicensedTechnology">
        <link:definition>060400 - Disclosure - LICENSED TECHNOLOGY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/KPlan" id="KPlan">
        <link:definition>060500 - Disclosure - 401(k) PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>060600 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>060700 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/PreferredStock" id="PreferredStock">
        <link:definition>060800 - Disclosure - PREFERRED STOCK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>060900 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/StockOptionPlans" id="StockOptionPlans">
        <link:definition>061000 - Disclosure - STOCK OPTION PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisition" id="AbeonaTherapeuticsLlcAcquisition">
        <link:definition>061100 - Disclosure - ABEONA THERAPEUTICS LLC ACQUISITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>061200 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>070100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>080100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <!--Parent Role: PROPERTY AND EQUIPMENT-->
        <link:definition>080300 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/LicensedTechnologyTables" id="LicensedTechnologyTables">
        <!--Parent Role: LICENSED TECHNOLOGY-->
        <link:definition>080400 - Disclosure - LICENSED TECHNOLOGY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <!--Parent Role: COMMITMENTS AND CONTINGENCIES-->
        <link:definition>080600 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <!--Parent Role: FAIR VALUE MEASUREMENTS-->
        <link:definition>080700 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>080900 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/StockOptionPlansTables" id="StockOptionPlansTables">
        <!--Parent Role: STOCK OPTION PLANS-->
        <link:definition>081000 - Disclosure - STOCK OPTION PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionTables" id="AbeonaTherapeuticsLlcAcquisitionTables">
        <!--Parent Role: ABEONA THERAPEUTICS LLC ACQUISITION-->
        <link:definition>081100 - Disclosure - ABEONA THERAPEUTICS LLC ACQUISITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <!--Parent Role: INCOME TAXES-->
        <link:definition>081200 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails">
        <!--Parent Role: NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <!--Parent Role: RELATED PARTY TRANSACTIONS-->
        <link:definition>090200 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <!--Parent Role: PROPERTY AND EQUIPMENT-->
        <link:definition>090300 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/LicensedTechnologyDetails" id="LicensedTechnologyDetails">
        <!--Parent Role: LICENSED TECHNOLOGY-->
        <link:definition>090400 - Disclosure - LICENSED TECHNOLOGY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/LicensedTechnologyDetailsCalc2" id="LicensedTechnologyDetailsCalc2">
        <!--Parent Role: LICENSED TECHNOLOGY (Details)-->
        <link:definition>090402 - Disclosure - LICENSED TECHNOLOGY (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/KPlanDetails" id="KPlanDetails">
        <!--Parent Role: 401(k) PLAN-->
        <link:definition>090500 - Disclosure - 401(k) PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: COMMITMENTS AND CONTINGENCIES-->
        <link:definition>090600 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
        <!--Parent Role: FAIR VALUE MEASUREMENTS-->
        <link:definition>090700 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/PreferredStockDetails" id="PreferredStockDetails">
        <!--Parent Role: PREFERRED STOCK-->
        <link:definition>090800 - Disclosure - PREFERRED STOCK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090900 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/StockOptionPlansDetails" id="StockOptionPlansDetails">
        <!--Parent Role: STOCK OPTION PLANS-->
        <link:definition>091000 - Disclosure - STOCK OPTION PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionDetails" id="AbeonaTherapeuticsLlcAcquisitionDetails">
        <!--Parent Role: ABEONA THERAPEUTICS LLC ACQUISITION-->
        <link:definition>091100 - Disclosure - ABEONA THERAPEUTICS LLC ACQUISITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://accesspharma.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <!--Parent Role: INCOME TAXES-->
        <link:definition>091200 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:element name="EquityIncentivePlan2005Member" id="accp_EquityIncentivePlan2005Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlan2015Member" id="accp_EquityIncentivePlan2015Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RangeTwoMember" id="accp_RangeTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RangeSixMember" id="accp_RangeSixMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RangeThreeMember" id="accp_RangeThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RangeFiveMember" id="accp_RangeFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RangeFourMember" id="accp_RangeFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RangeOneMember" id="accp_RangeOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PayableDueLicensor" id="accp_PayableDueLicensor" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LeaseExtensionPeriod" id="accp_LeaseExtensionPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TotalLeaseCostsAndUnamortizedTenantImprovements" id="accp_TotalLeaseCostsAndUnamortizedTenantImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="Building2Member" id="accp_Building2Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="Building3Member" id="accp_Building3Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PreferredStockAbstract" id="accp_PreferredStockAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentCovenantComplianceValue" id="accp_DebtInstrumentCovenantComplianceValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="SecondUnsecuredGridNoteMember" id="accp_SecondUnsecuredGridNoteMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ScoCapitalPartnersLlcMember" id="accp_ScoCapitalPartnersLlcMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonStockIssuedToEmployeesDirectorsAndConsultants" id="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ProceedsFromIssuanceOfCommonStockNetOfCosts" id="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" id="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="BusinessCombinationContingentConsideration" id="accp_BusinessCombinationContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="NoncashOrPartNoncashAcquisitionLicensedTecnology" id="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="IncreaseDecreaseInContingentConsiderationMilestone" id="accp_IncreaseDecreaseInContingentConsiderationMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" id="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="TreasuryStockCancel" id="accp_TreasuryStockCancel" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="IncreaseDecreaseInInterestPayableOnDividends" id="accp_IncreaseDecreaseInInterestPayableOnDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="PayableForFutureIssuanceOfSharesForLicensedTechnology" id="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" id="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" id="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InitialConversionPriceOfPreferredStockIntoCommonStock" id="accp_InitialConversionPriceOfPreferredStockIntoCommonStock" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ClassOfWarrantsOrRightsWarrantsExpired" id="accp_ClassOfWarrantsOrRightsWarrantsExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DerivativeLiabilityPreferredStock" id="accp_DerivativeLiabilityPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedPotentialLiquidatedDamages" id="accp_AccruedPotentialLiquidatedDamages" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" id="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" id="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PreferredStockOffering2008Member" id="accp_PreferredStockOffering2008Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueNewIssue" id="accp_StockIssuedDuringPeriodValueNewIssue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesReverseStockSplitsOne" id="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesNewIssue" id="accp_StockIssuedDuringPeriodSharesNewIssue" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueNewIssueOne" id="accp_StockIssuedDuringPeriodValueNewIssueOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesNewIssueOne" id="accp_StockIssuedDuringPeriodSharesNewIssueOne" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="accp_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="accp_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueReverseStockSplitsOne" id="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" id="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" id="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueSeriesAPreferredStock" id="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" id="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueReverseStockSplits" id="accp_StockIssuedDuringPeriodValueReverseStockSplits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" id="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" id="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" id="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" id="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="TreasuryStockValueRetired" id="accp_TreasuryStockValueRetired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" id="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesSeriesAPreferredStock" id="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" id="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NewIssuesShareOnePricePerShare" id="accp_NewIssuesShareOnePricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NewIssuesSharePricePerShare" id="accp_NewIssuesSharePricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfInvestmentOptions" id="accp_NumberOfInvestmentOptions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" id="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TaxYear2016Member" id="accp_TaxYear2016Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxYear2017Member" id="accp_TaxYear2017Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PreMergerMember" id="accp_PreMergerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PostMergerMember" id="accp_PostMergerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncomeTaxReconciliationCurrentYearReserve" id="accp_IncomeTaxReconciliationCurrentYearReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="TaxYearThereafterMember" id="accp_TaxYearThereafterMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfYearsSubjectToStatuteOfLimitations" id="accp_NumberOfYearsSubjectToStatuteOfLimitations" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RegulatoryApprovalMilestonePayment" id="accp_RegulatoryApprovalMilestonePayment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="LicenseAgreementTerms1Member" id="accp_LicenseAgreementTerms1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" id="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NumberOfStockBasedCompensationPlans" id="accp_NumberOfStockBasedCompensationPlans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" id="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="GoodwillAbstract" id="accp_GoodwillAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfPatentFamily" id="accp_NumberOfPatentFamily" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DocumentAndEntityInformationAbstract" id="accp_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OtherIncomePolicyTextBlock" id="accp_OtherIncomePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NatureOfOperationsPolicyTextBlock" id="accp_NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LicensedTechnologyPolicyTextBlock" id="accp_LicensedTechnologyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantsOrRightExpirationDate" id="accp_ClassOfWarrantsOrRightExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WarrantsIssuedPrice" id="accp_WarrantsIssuedPrice" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TermOfWarrant" id="accp_TermOfWarrant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantsOrRightsExercisablePeriod" id="accp_ClassOfWarrantsOrRightsExercisablePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfBoardOfDirectors" id="accp_NumberOfBoardOfDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlacementAgentWarrants1Member" id="accp_PlacementAgentWarrants1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrivatePlacement1Member" id="accp_PrivatePlacement1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PublicOfferingMember" id="accp_PublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeriesBPrivatePlacementMember" id="accp_SeriesBPrivatePlacementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MayFinancing2015Member" id="accp_MayFinancing2015Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="Warrant2Member" id="accp_Warrant2Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantsOrRightsExpirationDate" id="accp_ClassOfWarrantsOrRightsExpirationDate" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlacementAgentMember" id="accp_PlacementAgentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MayFinancingAgentWarrants2015Member" id="accp_MayFinancingAgentWarrants2015Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PublicOfferingAgentWarrantsMember" id="accp_PublicOfferingAgentWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="JulyFinancing2015Member" id="accp_JulyFinancing2015Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BusinessAcquisitionsMember" id="accp_BusinessAcquisitionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfMilestones" id="accp_NumberOfMilestones" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" id="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>accp-20151231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.0.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://accesspharma.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#AbeonaTherapeuticsLlcAcquisitionDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/LicensedTechnologyDetailsCalc2" xlink:type="simple" xlink:href="accp-20151231.xsd#LicensedTechnologyDetailsCalc2" />
  <link:roleRef roleURI="http://accesspharma.com/role/LicensedTechnologyDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#LicensedTechnologyDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="Goodwill" xlink:title="calculation: Assets to Goodwill" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="ReceivablesNetCurrent" xlink:title="ReceivablesNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="ReceivablesNetCurrent" xlink:title="calculation: AssetsCurrent to ReceivablesNetCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssets" xlink:label="OtherAssets" xlink:title="OtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssets" xlink:title="calculation: Assets to OtherAssets" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="calculation: Assets to FiniteLivedIntangibleAssetsNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DeferredRevenueCurrent" xlink:title="calculation: LiabilitiesCurrent to DeferredRevenueCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="ShortTermBorrowings" xlink:title="ShortTermBorrowings" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ShortTermBorrowings" xlink:title="calculation: LiabilitiesCurrent to ShortTermBorrowings" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DeferredRevenueNoncurrent" xlink:title="calculation: Liabilities to DeferredRevenueNoncurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="calculation: Liabilities to BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PayableDueLicensor" xlink:label="PayableDueLicensor" xlink:title="PayableDueLicensor" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="PayableDueLicensor" xlink:title="calculation: Liabilities to PayableDueLicensor" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="PreferredStockDividendsIncomeStatementImpact" xlink:title="PreferredStockDividendsIncomeStatementImpact" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="PreferredStockDividendsIncomeStatementImpact" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to PreferredStockDividendsIncomeStatementImpact" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="calculation: NonoperatingIncomeExpense to DerivativeGainLossOnDerivativeNet" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="InvestmentIncomeNonoperating" xlink:title="InvestmentIncomeNonoperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InvestmentIncomeNonoperating" xlink:title="calculation: NonoperatingIncomeExpense to InvestmentIncomeNonoperating" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="InterestAndDebtExpense" xlink:title="InterestAndDebtExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestAndDebtExpense" xlink:title="calculation: NonoperatingIncomeExpense to InterestAndDebtExpense" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: NetIncomeLoss to NonoperatingIncomeExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: CostsAndExpenses to GeneralAndAdministrativeExpense" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: CostsAndExpenses to DepreciationDepletionAndAmortization" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: CostsAndExpenses to ResearchAndDevelopmentExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="CostsAndExpenses" xlink:title="calculation: OperatingIncomeLoss to CostsAndExpenses" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="LicensesRevenue" xlink:title="calculation: SalesRevenueNet to LicensesRevenue" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="RoyaltyRevenue" xlink:title="calculation: SalesRevenueNet to RoyaltyRevenue" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="SalesRevenueNet" xlink:title="calculation: OperatingIncomeLoss to SalesRevenueNet" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OperatingIncomeLoss" xlink:title="calculation: NetIncomeLoss to OperatingIncomeLoss" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="NetIncomeLoss" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to NetIncomeLoss" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:label="CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:title="CommonStockIssuedToEmployeesDirectorsAndConsultants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to CommonStockIssuedToEmployeesDirectorsAndConsultants" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_IncreaseDecreaseInContingentConsiderationMilestone" xlink:label="IncreaseDecreaseInContingentConsiderationMilestone" xlink:title="IncreaseDecreaseInContingentConsiderationMilestone" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInContingentConsiderationMilestone" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInContingentConsiderationMilestone" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="IncreaseDecreaseInOtherNoncurrentAssets" xlink:title="IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInOtherNoncurrentAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInOtherNoncurrentAssets" order="16.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to DepreciationDepletionAndAmortization" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to NetIncomeLoss" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="13.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="IncreaseDecreaseInReceivables" xlink:title="IncreaseDecreaseInReceivables" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInReceivables" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInReceivables" order="11.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IssuanceOfStockAndWarrantsForServicesOrClaims" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="17.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to DerivativeGainLossOnDerivativeNet" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInDeferredRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInDeferredRevenue" order="20.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ShareBasedCompensation" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_IncreaseDecreaseInInterestPayableOnDividends" xlink:label="IncreaseDecreaseInInterestPayableOnDividends" xlink:title="IncreaseDecreaseInInterestPayableOnDividends" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInInterestPayableOnDividends" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInInterestPayableOnDividends" order="18.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to ProceedsFromSaleOfPropertyPlantAndEquipment" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:label="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:title="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfCommonStockOneNetOfCosts" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:label="ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:title="ProceedsFromIssuanceOfCommonStockNetOfCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfCommonStockNetOfCosts" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromWarrantExercises" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromWarrantExercises" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:label="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:title="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfCommonStock" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="ProceedsFromShortTermDebt" xlink:title="ProceedsFromShortTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromShortTermDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromShortTermDebt" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/LicensedTechnologyDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsGross" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/LicensedTechnologyDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="OperatingLeasesFutureMinimumPaymentsDue" xlink:title="OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="calculation: OperatingLeasesFutureMinimumPaymentsDue to OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="calculation: OperatingLeasesFutureMinimumPaymentsDue to OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="calculation: OperatingLeasesFutureMinimumPaymentsDue to OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="calculation: OperatingLeasesFutureMinimumPaymentsDue to OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="calculation: OperatingLeasesFutureMinimumPaymentsDue to OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="BusinessCombinationConsiderationTransferred1" xlink:title="BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:title="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationConsiderationTransferred1" xlink:to="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:title="calculation: BusinessCombinationConsiderationTransferred1 to BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:title="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationConsiderationTransferred1" xlink:to="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:title="calculation: BusinessCombinationConsiderationTransferred1 to BusinessCombinationConsiderationTransferredLiabilitiesIncurred" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="calculation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet to BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="calculation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="calculation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:title="calculation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="calculation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="calculation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="calculation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:title="calculation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="calculation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="Goodwill" xlink:title="calculation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet to Goodwill" order="4.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsValuationAllowance" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOther" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOther" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="DeferredTaxAssetsStateTaxes" xlink:title="DeferredTaxAssetsStateTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsStateTaxes" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsStateTaxes" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="DeferredTaxAssetsDeferredIncome" xlink:title="DeferredTaxAssetsDeferredIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsDeferredIncome" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsDeferredIncome" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="DeferredTaxLiabilitiesDerivatives" xlink:title="DeferredTaxLiabilitiesDerivatives" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxLiabilitiesDerivatives" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxLiabilitiesDerivatives" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsGoodwillAndIntangibleAssets" order="7.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsGross" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsGross" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_IncomeTaxReconciliationCurrentYearReserve" xlink:label="IncomeTaxReconciliationCurrentYearReserve" xlink:title="IncomeTaxReconciliationCurrentYearReserve" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationCurrentYearReserve" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationCurrentYearReserve" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="IncomeTaxReconciliationOtherReconcilingItems" xlink:title="IncomeTaxReconciliationOtherReconcilingItems" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationOtherReconcilingItems" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationOtherReconcilingItems" order="4.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>accp-20151231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.0.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://accesspharma.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#AbeonaTherapeuticsLlcAcquisitionDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockOptionPlansDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#StockOptionPlansDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#StockholdersEquityDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/PreferredStockDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#PreferredStockDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#FairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/KPlanDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#KPlanDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/LicensedTechnologyDetailsCalc2" xlink:type="simple" xlink:href="accp-20151231.xsd#LicensedTechnologyDetailsCalc2" />
  <link:roleRef roleURI="http://accesspharma.com/role/LicensedTechnologyDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#LicensedTechnologyDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="accp-20151231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionTables" xlink:type="simple" xlink:href="accp-20151231.xsd#AbeonaTherapeuticsLlcAcquisitionTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockOptionPlansTables" xlink:type="simple" xlink:href="accp-20151231.xsd#StockOptionPlansTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="accp-20151231.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="accp-20151231.xsd#FairValueMeasurementsTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/CommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="accp-20151231.xsd#CommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/LicensedTechnologyTables" xlink:type="simple" xlink:href="accp-20151231.xsd#LicensedTechnologyTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="accp-20151231.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="accp-20151231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="accp-20151231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://accesspharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="accp-20151231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisition" xlink:type="simple" xlink:href="accp-20151231.xsd#AbeonaTherapeuticsLlcAcquisition" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockOptionPlans" xlink:type="simple" xlink:href="accp-20151231.xsd#StockOptionPlans" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockholdersEquity" xlink:type="simple" xlink:href="accp-20151231.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://accesspharma.com/role/PreferredStock" xlink:type="simple" xlink:href="accp-20151231.xsd#PreferredStock" />
  <link:roleRef roleURI="http://accesspharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="accp-20151231.xsd#FairValueMeasurements" />
  <link:roleRef roleURI="http://accesspharma.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="accp-20151231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://accesspharma.com/role/KPlan" xlink:type="simple" xlink:href="accp-20151231.xsd#KPlan" />
  <link:roleRef roleURI="http://accesspharma.com/role/LicensedTechnology" xlink:type="simple" xlink:href="accp-20151231.xsd#LicensedTechnology" />
  <link:roleRef roleURI="http://accesspharma.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="accp-20151231.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://accesspharma.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="accp-20151231.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="accp-20151231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfStockholdersEquity" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://accesspharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="accp-20151231.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedBalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueIssuedForServices" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="StockIssuedDuringPeriodValueReverseStockSplits" xlink:title="StockIssuedDuringPeriodValueReverseStockSplits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueReverseStockSplits" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueReverseStockSplits" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesReverseStockSplits" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TreasuryStockValueRetired" xlink:label="TreasuryStockValueRetired" xlink:title="TreasuryStockValueRetired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TreasuryStockValueRetired" xlink:title="definition: StatementLineItems to TreasuryStockValueRetired" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="TreasuryStockSharesRetired" xlink:title="TreasuryStockSharesRetired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TreasuryStockSharesRetired" xlink:title="definition: StatementLineItems to TreasuryStockSharesRetired" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueShareBasedCompensation" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesShareBasedCompensation" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueWarrantsExercised" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesWarrantsExercised" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssues" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueNewIssue" xlink:label="StockIssuedDuringPeriodValueNewIssue" xlink:title="StockIssuedDuringPeriodValueNewIssue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssue" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssue" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesNewIssue" xlink:label="StockIssuedDuringPeriodSharesNewIssue" xlink:title="StockIssuedDuringPeriodSharesNewIssue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssue" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssue" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueNewIssueOne" xlink:label="StockIssuedDuringPeriodValueNewIssueOne" xlink:title="StockIssuedDuringPeriodValueNewIssueOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssueOne" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssueOne" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesNewIssueOne" xlink:label="StockIssuedDuringPeriodSharesNewIssueOne" xlink:title="StockIssuedDuringPeriodSharesNewIssueOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssueOne" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssueOne" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:label="StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:title="StockIssuedDuringPeriodValueSeriesAPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueSeriesAPreferredStock" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:label="StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:title="StockIssuedDuringPeriodSharesSeriesAPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesSeriesAPreferredStock" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:label="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:title="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:label="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:title="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:label="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:title="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:label="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:title="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:title="definition: StatementLineItems to SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:label="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:title="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:title="definition: StatementLineItems to SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:label="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:title="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:title="definition: StatementLineItems to SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:label="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:title="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:title="definition: StatementLineItems to SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:label="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:title="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:title="definition: StatementLineItems to StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:label="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:title="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:title="definition: StatementLineItems to StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueAcquisitions" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:label="StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:title="StockIssuedDuringPeriodValueReverseStockSplitsOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueReverseStockSplitsOne" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplitsOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesReverseStockSplitsOne" order="37.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="38.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DividendsPreferredStockCash" xlink:title="definition: StatementLineItems to DividendsPreferredStockCash" order="39.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="41.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: EquityComponentDomain to SeriesAPreferredStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="SeriesBPreferredStockMember" xlink:title="definition: EquityComponentDomain to SeriesBPreferredStockMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="TreasuryStockMember" xlink:title="TreasuryStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="TreasuryStockMember" xlink:title="definition: EquityComponentDomain to TreasuryStockMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="6.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="ConversionOfStockLineItems" xlink:title="ConversionOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConversionOfStockLineItems" xlink:to="ConversionOfStockAmountConverted1" xlink:title="definition: ConversionOfStockLineItems to ConversionOfStockAmountConverted1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="ConversionOfStockTable" xlink:title="ConversionOfStockTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ConversionOfStockLineItems" xlink:to="ConversionOfStockTable" xlink:title="definition: ConversionOfStockLineItems to ConversionOfStockTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConversionOfStockTable" xlink:to="ConversionOfStockByUniqueDescriptionAxis" xlink:title="definition: ConversionOfStockTable to ConversionOfStockByUniqueDescriptionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain" xlink:title="definition: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain_2" xlink:title="ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain_2" xlink:title="definition: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:label="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:title="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConversionOfStockNameDomain" xlink:to="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:title="definition: ConversionOfStockNameDomain to ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:label="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:title="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConversionOfStockNameDomain" xlink:to="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:title="definition: ConversionOfStockNameDomain to ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/RelatedPartyTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PropertyAndEquipment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/LicensedTechnology" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/KPlan" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/FairValueMeasurements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PreferredStock" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockOptionPlans" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisition" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PropertyAndEquipmentTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/LicensedTechnologyTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/CommitmentsAndContingenciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/FairValueMeasurementsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockholdersEquityTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockOptionPlansTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_EquityIncentivePlan2015Member" xlink:label="EquityIncentivePlan2015Member" xlink:title="EquityIncentivePlan2015Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2015Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2015Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_EquityIncentivePlan2005Member" xlink:label="EquityIncentivePlan2005Member" xlink:title="EquityIncentivePlan2005Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2005Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2005Member" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/IncomeTaxesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:title="EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="AllocatedShareBasedCompensationExpenseNetOfTax" xlink:title="AllocatedShareBasedCompensationExpenseNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpenseNetOfTax" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpenseNetOfTax" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="OperatingExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to OperatingExpenseMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfStockBasedCompensationPlans" xlink:label="NumberOfStockBasedCompensationPlans" xlink:title="NumberOfStockBasedCompensationPlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfStockBasedCompensationPlans" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfStockBasedCompensationPlans" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to SeriesAPreferredStockMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="SeriesBPreferredStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to SeriesBPreferredStockMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfPatentFamily" xlink:label="NumberOfPatentFamily" xlink:title="NumberOfPatentFamily" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="NumberOfPatentFamily" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems to NumberOfPatentFamily" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="LicenseCosts" xlink:title="LicenseCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="LicenseCosts" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems to LicenseCosts" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:label="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:title="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems to RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems to FiniteLivedIntangibleAssetUsefulLife" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RegulatoryApprovalMilestonePayment" xlink:label="RegulatoryApprovalMilestonePayment" xlink:title="RegulatoryApprovalMilestonePayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="RegulatoryApprovalMilestonePayment" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems to RegulatoryApprovalMilestonePayment" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:title="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems to ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="definition: ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable to ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="LicenseAgreementTermsMember" xlink:title="LicenseAgreementTermsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="LicenseAgreementTermsMember" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to LicenseAgreementTermsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_LicenseAgreementTerms1Member" xlink:label="LicenseAgreementTerms1Member" xlink:title="LicenseAgreementTerms1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="LicenseAgreementTerms1Member" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to LicenseAgreementTerms1Member" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ConversionOfStockAmountConverted1" xlink:title="definition: RelatedPartyTransactionLineItems to ConversionOfStockAmountConverted1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="definition: RelatedPartyTransactionLineItems to LineOfCreditFacilityMaximumBorrowingCapacity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:title="LineOfCreditFacilityMaximumMonthendOutstandingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:title="definition: RelatedPartyTransactionLineItems to LineOfCreditFacilityMaximumMonthendOutstandingAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:title="LineOfCreditFacilityInterestRateAtPeriodEnd" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:title="definition: RelatedPartyTransactionLineItems to LineOfCreditFacilityInterestRateAtPeriodEnd" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="LineOfCreditFacilityExpirationDate1" xlink:title="LineOfCreditFacilityExpirationDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="LineOfCreditFacilityExpirationDate1" xlink:title="definition: RelatedPartyTransactionLineItems to LineOfCreditFacilityExpirationDate1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_DebtInstrumentCovenantComplianceValue" xlink:label="DebtInstrumentCovenantComplianceValue" xlink:title="DebtInstrumentCovenantComplianceValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentCovenantComplianceValue" xlink:title="definition: RelatedPartyTransactionLineItems to DebtInstrumentCovenantComplianceValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ScoCapitalPartnersLlcMember" xlink:label="ScoCapitalPartnersLlcMember" xlink:title="ScoCapitalPartnersLlcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="ScoCapitalPartnersLlcMember" xlink:title="definition: RelatedPartyDomain to ScoCapitalPartnersLlcMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to LongtermDebtTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="UnsecuredDebtMember" xlink:title="UnsecuredDebtMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="UnsecuredDebtMember" xlink:title="definition: LongtermDebtTypeDomain to UnsecuredDebtMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SecondUnsecuredGridNoteMember" xlink:label="SecondUnsecuredGridNoteMember" xlink:title="SecondUnsecuredGridNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="SecondUnsecuredGridNoteMember" xlink:title="definition: LongtermDebtTypeDomain to SecondUnsecuredGridNoteMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to StatementClassOfStockAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBPreferredStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetByTypeAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationAndAmortization" xlink:title="definition: PropertyPlantAndEquipmentLineItems to DepreciationAndAmortization" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/LicensedTechnologyDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/LicensedTechnologyDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/KPlanDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="OperatingLeasedAssetsLineItems" xlink:title="OperatingLeasedAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="LeasesOperatingAbstract" xlink:title="LeasesOperatingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="LeasesOperatingAbstract" xlink:title="definition: OperatingLeasedAssetsLineItems to LeasesOperatingAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="definition: OperatingLeasedAssetsLineItems to OperatingLeasesFutureMinimumPaymentsDueAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="OperatingLeasesRentExpenseNet" xlink:title="OperatingLeasesRentExpenseNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesRentExpenseNet" xlink:title="definition: OperatingLeasedAssetsLineItems to OperatingLeasesRentExpenseNet" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="definition: OperatingLeasedAssetsLineItems to OperatingLeasesFutureMinimumPaymentsDueCurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="definition: OperatingLeasedAssetsLineItems to OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="definition: OperatingLeasedAssetsLineItems to OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="definition: OperatingLeasedAssetsLineItems to OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="definition: OperatingLeasedAssetsLineItems to OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="OperatingLeasesFutureMinimumPaymentsDue" xlink:title="OperatingLeasesFutureMinimumPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesFutureMinimumPaymentsDue" xlink:title="definition: OperatingLeasedAssetsLineItems to OperatingLeasesFutureMinimumPaymentsDue" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementLeaseRevenue" xlink:label="OperatingLeasesIncomeStatementLeaseRevenue" xlink:title="OperatingLeasesIncomeStatementLeaseRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesIncomeStatementLeaseRevenue" xlink:title="definition: OperatingLeasedAssetsLineItems to OperatingLeasesIncomeStatementLeaseRevenue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_LeaseExtensionPeriod" xlink:label="LeaseExtensionPeriod" xlink:title="LeaseExtensionPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="LeaseExtensionPeriod" xlink:title="definition: OperatingLeasedAssetsLineItems to LeaseExtensionPeriod" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TotalLeaseCostsAndUnamortizedTenantImprovements" xlink:label="TotalLeaseCostsAndUnamortizedTenantImprovements" xlink:title="TotalLeaseCostsAndUnamortizedTenantImprovements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="TotalLeaseCostsAndUnamortizedTenantImprovements" xlink:title="definition: OperatingLeasedAssetsLineItems to TotalLeaseCostsAndUnamortizedTenantImprovements" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="ScheduleOfOperatingLeasedAssetsTable" xlink:title="ScheduleOfOperatingLeasedAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="ScheduleOfOperatingLeasedAssetsTable" xlink:title="definition: OperatingLeasedAssetsLineItems to ScheduleOfOperatingLeasedAssetsTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfOperatingLeasedAssetsTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfOperatingLeasedAssetsTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to BuildingMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_Building2Member" xlink:label="Building2Member" xlink:title="Building2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="Building2Member" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to Building2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_Building3Member" xlink:label="Building3Member" xlink:title="Building3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="Building3Member" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to Building3Member" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_DerivativeLiabilityPreferredStock" xlink:label="DerivativeLiabilityPreferredStock" xlink:title="DerivativeLiabilityPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="DerivativeLiabilityPreferredStock" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to DerivativeLiabilityPreferredStock" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to DerivativeGainLossOnDerivativeNet" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="PreferredStockMember" xlink:title="definition: ClassOfStockDomain to PreferredStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:label="InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:title="InitialConversionPriceOfPreferredStockIntoCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:title="definition: ClassOfStockLineItems to InitialConversionPriceOfPreferredStockIntoCommonStock" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_DerivativeLiabilityPreferredStock" xlink:label="DerivativeLiabilityPreferredStock" xlink:title="DerivativeLiabilityPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="DerivativeLiabilityPreferredStock" xlink:title="definition: ClassOfStockLineItems to DerivativeLiabilityPreferredStock" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="definition: ClassOfStockLineItems to DerivativeGainLossOnDerivativeNet" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="DerivativeGainOnDerivative" xlink:title="DerivativeGainOnDerivative" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="DerivativeGainOnDerivative" xlink:title="definition: ClassOfStockLineItems to DerivativeGainOnDerivative" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightsWarrantsExpired" xlink:label="ClassOfWarrantsOrRightsWarrantsExpired" xlink:title="ClassOfWarrantsOrRightsWarrantsExpired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantsOrRightsWarrantsExpired" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantsOrRightsWarrantsExpired" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_AccruedPotentialLiquidatedDamages" xlink:label="AccruedPotentialLiquidatedDamages" xlink:title="AccruedPotentialLiquidatedDamages" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="AccruedPotentialLiquidatedDamages" xlink:title="definition: ClassOfStockLineItems to AccruedPotentialLiquidatedDamages" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:label="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:title="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:title="definition: ClassOfStockLineItems to PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:label="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:title="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:title="definition: ClassOfStockLineItems to ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="DividendsPayableCurrentAndNoncurrent" xlink:title="DividendsPayableCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="DividendsPayableCurrentAndNoncurrent" xlink:title="definition: ClassOfStockLineItems to DividendsPayableCurrentAndNoncurrent" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBPreferredStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PreferredStockOffering2008Member" xlink:label="PreferredStockOffering2008Member" xlink:title="PreferredStockOffering2008Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="PreferredStockOffering2008Member" xlink:title="definition: ClassOfStockDomain to PreferredStockOffering2008Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfStockByClassTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="SubsidiariesMember" xlink:title="SubsidiariesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="SubsidiariesMember" xlink:title="definition: RelatedPartyDomain to SubsidiariesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: ScheduleOfStockByClassTable to FinancialInstrumentAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="definition: ClassOfWarrantOrRightLineItems to ProceedsFromIssuanceOfPrivatePlacement" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfBoardOfDirectors" xlink:label="NumberOfBoardOfDirectors" xlink:title="NumberOfBoardOfDirectors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="NumberOfBoardOfDirectors" xlink:title="definition: ClassOfWarrantOrRightLineItems to NumberOfBoardOfDirectors" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="SharePrice" xlink:title="definition: ClassOfWarrantOrRightLineItems to SharePrice" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: ClassOfWarrantOrRightLineItems to StockIssuedDuringPeriodSharesNewIssues" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TermOfWarrant" xlink:label="TermOfWarrant" xlink:title="TermOfWarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="TermOfWarrant" xlink:title="definition: ClassOfWarrantOrRightLineItems to TermOfWarrant" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_WarrantsIssuedPrice" xlink:label="WarrantsIssuedPrice" xlink:title="WarrantsIssuedPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsIssuedPrice" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsIssuedPrice" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightsExercisablePeriod" xlink:label="ClassOfWarrantsOrRightsExercisablePeriod" xlink:title="ClassOfWarrantsOrRightsExercisablePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantsOrRightsExercisablePeriod" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantsOrRightsExercisablePeriod" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="definition: ClassOfWarrantOrRightLineItems to ProceedsFromIssuanceOrSaleOfEquity" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightOutstanding" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightsExpirationDate" xlink:label="ClassOfWarrantsOrRightsExpirationDate" xlink:title="ClassOfWarrantsOrRightsExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantsOrRightsExpirationDate" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantsOrRightsExpirationDate" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightExpirationDate" xlink:label="ClassOfWarrantsOrRightExpirationDate" xlink:title="ClassOfWarrantsOrRightExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantsOrRightExpirationDate" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantsOrRightExpirationDate" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightTable" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightTable" order="15.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_JulyFinancing2015Member" xlink:label="JulyFinancing2015Member" xlink:title="JulyFinancing2015Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="JulyFinancing2015Member" xlink:title="definition: ClassOfWarrantOrRightDomain to JulyFinancing2015Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_MayFinancing2015Member" xlink:label="MayFinancing2015Member" xlink:title="MayFinancing2015Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayFinancing2015Member" xlink:title="definition: ClassOfWarrantOrRightDomain to MayFinancing2015Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_MayFinancingAgentWarrants2015Member" xlink:label="MayFinancingAgentWarrants2015Member" xlink:title="MayFinancingAgentWarrants2015Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayFinancingAgentWarrants2015Member" xlink:title="definition: ClassOfWarrantOrRightDomain to MayFinancingAgentWarrants2015Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PublicOfferingMember" xlink:label="PublicOfferingMember" xlink:title="PublicOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PublicOfferingMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PublicOfferingMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PublicOfferingAgentWarrantsMember" xlink:label="PublicOfferingAgentWarrantsMember" xlink:title="PublicOfferingAgentWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PublicOfferingAgentWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PublicOfferingAgentWarrantsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPrivatePlacementMember" xlink:label="SeriesBPrivatePlacementMember" xlink:title="SeriesBPrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeriesBPrivatePlacementMember" xlink:title="definition: ClassOfWarrantOrRightDomain to SeriesBPrivatePlacementMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PrivatePlacement1Member" xlink:label="PrivatePlacement1Member" xlink:title="PrivatePlacement1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PrivatePlacement1Member" xlink:title="definition: ClassOfWarrantOrRightDomain to PrivatePlacement1Member" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PlacementAgentWarrants1Member" xlink:label="PlacementAgentWarrants1Member" xlink:title="PlacementAgentWarrants1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PlacementAgentWarrants1Member" xlink:title="definition: ClassOfWarrantOrRightDomain to PlacementAgentWarrants1Member" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: ClassOfWarrantOrRightTable to FinancialInstrumentAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_Warrant2Member" xlink:label="Warrant2Member" xlink:title="Warrant2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="Warrant2Member" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to Warrant2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: ClassOfWarrantOrRightTable to SubsidiarySaleOfStockAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="PrivatePlacementMember" xlink:title="PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="PrivatePlacementMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to PrivatePlacementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PlacementAgentMember" xlink:label="PlacementAgentMember" xlink:title="PlacementAgentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="PlacementAgentMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to PlacementAgentMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockOptionPlansDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="28.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_EquityIncentivePlan2015Member" xlink:label="EquityIncentivePlan2015Member" xlink:title="EquityIncentivePlan2015Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2015Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2015Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_EquityIncentivePlan2005Member" xlink:label="EquityIncentivePlan2005Member" xlink:title="EquityIncentivePlan2005Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2005Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2005Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeSixMember" xlink:label="RangeSixMember" xlink:title="RangeSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeSixMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeSixMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeOneMember" xlink:label="RangeOneMember" xlink:title="RangeOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeOneMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeOneMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeTwoMember" xlink:label="RangeTwoMember" xlink:title="RangeTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeTwoMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeTwoMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeThreeMember" xlink:label="RangeThreeMember" xlink:title="RangeThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeThreeMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeThreeMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeFourMember" xlink:label="RangeFourMember" xlink:title="RangeFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeFourMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeFourMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeFiveMember" xlink:label="RangeFiveMember" xlink:title="RangeFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeFiveMember" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeFiveMember" order="6.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="BusinessAcquisitionSharePrice" xlink:title="BusinessAcquisitionSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionSharePrice" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionSharePrice" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfMilestones" xlink:label="NumberOfMilestones" xlink:title="NumberOfMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="NumberOfMilestones" xlink:title="definition: BusinessAcquisitionLineItems to NumberOfMilestones" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationConsiderationTransferredAbstract" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationConsiderationTransferredAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:title="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:title="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationConsiderationTransferredLiabilitiesIncurred" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="BusinessCombinationConsiderationTransferred1" xlink:title="BusinessCombinationConsiderationTransferred1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationConsiderationTransferred1" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationConsiderationTransferred1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="Goodwill" xlink:title="definition: BusinessAcquisitionLineItems to Goodwill" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="22.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_BusinessAcquisitionsMember" xlink:label="BusinessAcquisitionsMember" xlink:title="BusinessAcquisitionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="BusinessAcquisitionsMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to BusinessAcquisitionsMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://accesspharma.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="TaxCreditCarryforwardLineItems" xlink:title="TaxCreditCarryforwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardAmount" xlink:title="definition: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardAmount" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="TaxCreditCarryforwardTable" xlink:title="TaxCreditCarryforwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardTable" xlink:title="definition: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxCreditCarryforwardAxis" xlink:title="definition: TaxCreditCarryforwardTable to TaxCreditCarryforwardAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain_2" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain_2" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="GeneralBusinessMember" xlink:title="GeneralBusinessMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="GeneralBusinessMember" xlink:title="definition: TaxCreditCarryforwardNameDomain to GeneralBusinessMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxPeriodAxis" xlink:title="definition: TaxCreditCarryforwardTable to TaxPeriodAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain_2" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain_2" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TaxYear2016Member" xlink:label="TaxYear2016Member" xlink:title="TaxYear2016Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2016Member" xlink:title="definition: TaxPeriodDomain to TaxYear2016Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TaxYear2017Member" xlink:label="TaxYear2017Member" xlink:title="TaxYear2017Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2017Member" xlink:title="definition: TaxPeriodDomain to TaxYear2017Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="LatestTaxYearMember" xlink:title="LatestTaxYearMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="LatestTaxYearMember" xlink:title="definition: TaxPeriodDomain to LatestTaxYearMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TaxYearThereafterMember" xlink:label="TaxYearThereafterMember" xlink:title="TaxYearThereafterMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYearThereafterMember" xlink:title="definition: TaxPeriodDomain to TaxYearThereafterMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsTable" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxPeriodAxis" xlink:title="definition: OperatingLossCarryforwardsTable to TaxPeriodAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="StatementScenarioAxis" xlink:title="definition: OperatingLossCarryforwardsTable to StatementScenarioAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PreMergerMember" xlink:label="PreMergerMember" xlink:title="PreMergerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="PreMergerMember" xlink:title="definition: ScenarioUnspecifiedDomain to PreMergerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PostMergerMember" xlink:label="PostMergerMember" xlink:title="PostMergerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="PostMergerMember" xlink:title="definition: ScenarioUnspecifiedDomain to PostMergerMember" order="2.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>accp-20151231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.0.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="dei_EntityPublicFloat_lbl">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:title="label: EntityPublicFloat to dei_EntityPublicFloat_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl">Additional paid-in capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl1">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl1" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl">Stock option compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="AllocatedShareBasedCompensationExpenseNetOfTax" xlink:title="AllocatedShareBasedCompensationExpenseNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl">Stock-based compensation expense, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xlink:title="label: AllocatedShareBasedCompensationExpenseNetOfTax to us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="AllowanceForDoubtfulAccountsReceivable" xlink:title="AllowanceForDoubtfulAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" id="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl">Allowance for doubtful accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:title="label: AllowanceForDoubtfulAccountsReceivable to us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl">Amortization on licensed technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl1">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Antidilutive securities not included in computation of diluted net income (loss) per common share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BuildingMember_lbl" xml:lang="en-US" id="us-gaap_BuildingMember_lbl">New York Office [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" xlink:title="label: BuildingMember to us-gaap_BuildingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BuildingMember_lbl1" xml:lang="en-US" id="us-gaap_BuildingMember_lbl1">Building [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingMember" xlink:to="us-gaap_BuildingMember_lbl1" xlink:title="label: BuildingMember to us-gaap_BuildingMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl">Acquisition transaction cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:title="label: BusinessAcquisitionCostOfAcquiredEntityTransactionCosts to us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="BusinessCombinationConsiderationTransferred1" xlink:title="BusinessCombinationConsiderationTransferred1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferred1_lbl">Total purchase price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:title="label: BusinessCombinationConsiderationTransferred1 to us-gaap_BusinessCombinationConsiderationTransferred1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationConsiderationTransferred1_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferred1_lbl1">Business Combination, Consideration Transferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl1" xlink:title="label: BusinessCombinationConsiderationTransferred1 to us-gaap_BusinessCombinationConsiderationTransferred1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl">Number of shares issued to company (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued to us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued to us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionAcquireeDomain_lbl">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:title="label: BusinessAcquisitionAcquireeDomain to us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:title="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl">Contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xlink:title="label: BusinessCombinationConsiderationTransferredLiabilitiesIncurred to us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl1">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl1" xlink:title="label: BusinessCombinationConsiderationTransferredLiabilitiesIncurred to us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:title="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl">Shares issued to holders of Abeona Ohio for acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:title="label: BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable to us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl1">Initial consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl1" xlink:title="label: BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable to us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl">Licensing agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionAxis_lbl">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:title="label: BusinessAcquisitionAxis to us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl">Contingent consideration liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:title="label: BusinessCombinationContingentConsiderationLiabilityNoncurrent to us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl1">Contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl1" xlink:title="label: BusinessCombinationContingentConsiderationLiabilityNoncurrent to us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl2" xml:lang="en-US" id="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl2">Contingent consideration liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl2" xlink:title="label: BusinessCombinationContingentConsiderationLiabilityNoncurrent to us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationsAbstract_lbl">ABEONA THERAPEUTICS LLC ACQUISITION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xlink:title="label: BusinessCombinationsAbstract to us-gaap_BusinessCombinationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="BusinessAcquisitionSharePrice" xlink:title="BusinessAcquisitionSharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionSharePrice_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionSharePrice_lbl">Business acquisition, share price (in dollars per shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:title="label: BusinessAcquisitionSharePrice to us-gaap_BusinessAcquisitionSharePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionLineItems_lbl">Business Acquisition [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:title="label: BusinessAcquisitionLineItems to us-gaap_BusinessAcquisitionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl">Total purchase price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" xlink:title="label: BusinessCombinationConsiderationTransferredAbstract to us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xlink:title="label: BusinessCombinationConsiderationTransferredAbstract to us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="BusinessCombinationDisclosureTextBlock" xlink:title="BusinessCombinationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationDisclosureTextBlock_lbl">ABEONA THERAPEUTICS LLC ACQUISITION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:title="label: BusinessCombinationDisclosureTextBlock to us-gaap_BusinessCombinationDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl">Allocation of the purchase price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl1">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl">Total net asset value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl1">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl">Cash and Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValueAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">Cash and cash equivalents at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2">Cash and cash equivalents at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue_lbl">Highly liquid investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue_lbl1">Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl">Warrants exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1">Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2">Exercise price of warrants (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightDomain_lbl">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:title="label: ClassOfWarrantOrRightDomain to us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl">Warrants exercisable date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:title="label: ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable to us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl1">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl1" xlink:title="label: ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable to us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightAxis_lbl">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:title="label: ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Warrants granted to acquire shares of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1">Warrant issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightLineItems_lbl">Class of Warrant or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:title="label: ClassOfWarrantOrRightLineItems to us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl">Warrants Outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightTable_lbl">Class of Warrant or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:title="label: ClassOfWarrantOrRightTable to us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl1" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">COMMITMENTS AND CONTINGENCIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common stock - $.01 par value; authorized 200,000,000 shares; issued 32,743,013 at December 31, 2015; issued 19,960,801 at December 31, 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl">401(k) PLAN [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:title="label: CompensationAndRetirementDisclosureAbstract to us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl">Components of temporary differences that give rise to deferred tax assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:title="label: ComponentsOfDeferredTaxAssetsAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl1">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl1" xlink:title="label: ComponentsOfDeferredTaxAssetsAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ConsolidationPolicyTextBlock_lbl">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:title="label: ConsolidationPolicyTextBlock to us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xml:lang="en-US" id="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xlink:title="label: ConversionOfStockByUniqueDescriptionAxis to us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="ConversionOfStockLineItems" xlink:title="ConversionOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConversionOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_ConversionOfStockLineItems_lbl">Conversion of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockLineItems" xlink:to="us-gaap_ConversionOfStockLineItems_lbl" xlink:title="label: ConversionOfStockLineItems to us-gaap_ConversionOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="us-gaap_ConversionOfStockAmountConverted1_lbl">Preferred stock dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:title="label: ConversionOfStockAmountConverted1 to us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConversionOfStockAmountConverted1_lbl1" xml:lang="en-US" id="us-gaap_ConversionOfStockAmountConverted1_lbl1">Conversion of Stock, Amount Converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl1" xlink:title="label: ConversionOfStockAmountConverted1 to us-gaap_ConversionOfStockAmountConverted1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="ConversionOfStockTable" xlink:title="ConversionOfStockTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConversionOfStockTable_lbl" xml:lang="en-US" id="us-gaap_ConversionOfStockTable_lbl">Conversion of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockTable" xlink:to="us-gaap_ConversionOfStockTable_lbl" xlink:title="label: ConversionOfStockTable to us-gaap_ConversionOfStockTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConversionOfStockNameDomain_lbl" xml:lang="en-US" id="us-gaap_ConversionOfStockNameDomain_lbl">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain_lbl" xlink:title="label: ConversionOfStockNameDomain to us-gaap_ConversionOfStockNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_CostsAndExpensesAbstract_lbl">Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:title="label: CostsAndExpensesAbstract to us-gaap_CostsAndExpensesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="us-gaap_CostsAndExpenses_lbl">Total expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:title="label: CostsAndExpenses to us-gaap_CostsAndExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostsAndExpenses_lbl1" xml:lang="en-US" id="us-gaap_CostsAndExpenses_lbl1">Costs and Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl1" xlink:title="label: CostsAndExpenses to us-gaap_CostsAndExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:title="label: DeferredTaxAssetsGoodwillAndIntangibleAssets to us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" xlink:title="label: DeferredTaxAssetsGoodwillAndIntangibleAssets to us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="DeferredTaxAssetsStateTaxes" xlink:title="DeferredTaxAssetsStateTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsStateTaxes_lbl">State credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsStateTaxes" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xlink:title="label: DeferredTaxAssetsStateTaxes to us-gaap_DeferredTaxAssetsStateTaxes_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="DeferredTaxAssetsDeferredIncome" xlink:title="DeferredTaxAssetsDeferredIncome" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsDeferredIncome_lbl">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:title="label: DeferredTaxAssetsDeferredIncome to us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsDeferredIncome_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsDeferredIncome_lbl1">Deferred Tax Assets, Deferred Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl1" xlink:title="label: DeferredTaxAssetsDeferredIncome to us-gaap_DeferredTaxAssetsDeferredIncome_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueCurrent_lbl">Current portion of deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:title="label: DeferredRevenueCurrent to us-gaap_DeferredRevenueCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueNoncurrent_lbl">Long-term deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:title="label: DeferredRevenueNoncurrent to us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="DeferredTaxAssetsGrossAbstract" xlink:title="DeferredTaxAssetsGrossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGrossAbstract_lbl">Deferred tax assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:title="label: DeferredTaxAssetsGrossAbstract to us-gaap_DeferredTaxAssetsGrossAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl">Net deferred taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl1">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl">Gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl1">Deferred Tax Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOther_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:title="label: DeferredTaxAssetsOther to us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOther_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOther_lbl1">Deferred Tax Assets, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl1" xlink:title="label: DeferredTaxAssetsOther to us-gaap_DeferredTaxAssetsOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl">General business credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness to us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl1">Deferred Tax Assets, Tax Credit Carryforwards, General Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl1" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness to us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="DeferredTaxLiabilitiesDerivatives" xlink:title="DeferredTaxLiabilitiesDerivatives" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl">Derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesDerivatives" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xlink:title="label: DeferredTaxLiabilitiesDerivatives to us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl1">Deferred Tax Liabilities, Derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesDerivatives" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl1" xlink:title="label: DeferredTaxLiabilitiesDerivatives to us-gaap_DeferredTaxLiabilitiesDerivatives_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl">Stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl">Accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities to us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl1">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl1" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities to us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl">Property, equipment and goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:title="label: DeferredTaxLiabilitiesPropertyPlantAndEquipment to us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" xlink:title="label: DeferredTaxLiabilitiesPropertyPlantAndEquipment to us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:title="DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" id="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl">Maximum annual contribution per employee under 401(k) plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:title="label: DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount to us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="DefinedContributionPlanCostRecognized" xlink:title="DefinedContributionPlanCostRecognized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" id="us-gaap_DefinedContributionPlanCostRecognized_lbl">Company contributions under 401 (k) Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:title="label: DefinedContributionPlanCostRecognized to us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization_lbl">Depreciation and amortization on property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationAndAmortization_lbl1" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization_lbl1">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl1" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" id="us-gaap_DerivativeGainLossOnDerivativeNet_lbl">Gain (loss) on derivative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:title="label: DerivativeGainLossOnDerivativeNet to us-gaap_DerivativeGainLossOnDerivativeNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DerivativeGainLossOnDerivativeNet_lbl1" xml:lang="en-US" id="us-gaap_DerivativeGainLossOnDerivativeNet_lbl1">Loss on change in fair value of derivative-preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl1" xlink:title="label: DerivativeGainLossOnDerivativeNet to us-gaap_DerivativeGainLossOnDerivativeNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DerivativeGainLossOnDerivativeNet_lbl2" xml:lang="en-US" id="us-gaap_DerivativeGainLossOnDerivativeNet_lbl2">Loss on change in fair value of derivative-preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl2" xlink:title="label: DerivativeGainLossOnDerivativeNet to us-gaap_DerivativeGainLossOnDerivativeNet_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeGainLossOnDerivativeNet_lbl3" xml:lang="en-US" id="us-gaap_DerivativeGainLossOnDerivativeNet_lbl3">Total gains (losses)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl3" xlink:title="label: DerivativeGainLossOnDerivativeNet to us-gaap_DerivativeGainLossOnDerivativeNet_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="DerivativeGainOnDerivative" xlink:title="DerivativeGainOnDerivative" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeGainOnDerivative_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeGainOnDerivative_lbl" xml:lang="en-US" id="us-gaap_DerivativeGainOnDerivative_lbl">Gain on derivative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_lbl" xlink:title="label: DerivativeGainOnDerivative to us-gaap_DerivativeGainOnDerivative_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl">STOCK OPTION PLANS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl">STOCK OPTION PLANS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DividendsPreferredStockCash_lbl" xml:lang="en-US" id="us-gaap_DividendsPreferredStockCash_lbl">Preferred stock dividends in dividends payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl" xlink:title="label: DividendsPreferredStockCash to us-gaap_DividendsPreferredStockCash_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStockCash_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DividendsPreferredStockCash_lbl1" xml:lang="en-US" id="us-gaap_DividendsPreferredStockCash_lbl1">Preferred dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl1" xlink:title="label: DividendsPreferredStockCash to us-gaap_DividendsPreferredStockCash_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="DividendsPayableCurrentAndNoncurrent" xlink:title="DividendsPayableCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl">Preferred stock dividends accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:title="label: DividendsPayableCurrentAndNoncurrent to us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl1">Dividends Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl1" xlink:title="label: DividendsPayableCurrentAndNoncurrent to us-gaap_DividendsPayableCurrentAndNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl">Income (Loss) Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="EarningsPerShareBasicAndDilutedAbstract" xlink:title="EarningsPerShareBasicAndDilutedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl">Basic and diluted net loss per share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:title="label: EarningsPerShareBasicAndDilutedAbstract to us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl1">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl1" xlink:title="label: EarningsPerShareBasicAndDilutedAbstract to us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAndDiluted_lbl">Basic and diluted loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:title="label: EarningsPerShareBasicAndDiluted to us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAndDiluted_lbl1">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl1" xlink:title="label: EarningsPerShareBasicAndDiluted to us-gaap_EarningsPerShareBasicAndDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl">Income (Loss) Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl1">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl1" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockOptionMember_lbl1" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl1">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl1" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:title="EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl">Tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense to us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="us-gaap_EquipmentMember_lbl">Equipment Laboratory [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:title="label: EquipmentMember to us-gaap_EquipmentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember_lbl">Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract_lbl">FAIR VALUE MEASUREMENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByMeasurementFrequencyAxis_lbl">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:title="label: FairValueByMeasurementFrequencyAxis to us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl1">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementFrequencyDomain_lbl">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:title="label: FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl">Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl1">Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl1" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_FinancialInstrumentAxis_lbl">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:title="label: FinancialInstrumentAxis to us-gaap_FinancialInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl">Less accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl">Amortization expense for intangible assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl1">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl">Licensed technology, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1">Licensed technology, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2">Finite-Lived Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl">2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearThree to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearThree to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl">Licensed technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1">Finite-Lived Intangible Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl">Licensed Technology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl">Period of amortization of license</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:title="label: FiniteLivedIntangibleAssetUsefulLife to us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl">2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearFour to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearFour to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearFive to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearFive to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl">2017</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl1">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl">Amortization expense for intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl1">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl">2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember_lbl">Furniture and Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="GeneralBusinessMember" xlink:title="GeneralBusinessMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralBusinessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralBusinessMember_lbl" xml:lang="en-US" id="us-gaap_GeneralBusinessMember_lbl">General business credit carryforward [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralBusinessMember" xlink:to="us-gaap_GeneralBusinessMember_lbl" xlink:title="label: GeneralBusinessMember to us-gaap_GeneralBusinessMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl">General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Goodwill_lbl" xml:lang="en-US" id="us-gaap_Goodwill_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:title="label: Goodwill to us-gaap_Goodwill_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:title="label: GoodwillAndIntangibleAssetsPolicyTextBlock to us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl1">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl1" xlink:title="label: GoodwillAndIntangibleAssetsPolicyTextBlock to us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl">LICENSED TECHNOLOGY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis_lbl">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">INCOME TAXES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl">Income tax expense differs from the statutory amounts [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:title="label: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl">Total tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl1">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl">Income taxes at U.S. statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:title="label: IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate to us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="IncomeTaxReconciliationOtherReconcilingItems" xlink:title="IncomeTaxReconciliationOtherReconcilingItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:title="label: IncomeTaxReconciliationOtherReconcilingItems to us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="IncreaseDecreaseInOtherNoncurrentAssets" xlink:title="IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:title="label: IncreaseDecreaseInOtherNoncurrentAssets to us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl1">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl1" xlink:title="label: IncreaseDecreaseInOtherNoncurrentAssets to us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:title="label: IncreaseDecreaseInDeferredRevenue to us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Change in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="IncreaseDecreaseInReceivables" xlink:title="IncreaseDecreaseInReceivables" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInReceivables_lbl">Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:title="label: IncreaseDecreaseInReceivables to us-gaap_IncreaseDecreaseInReceivables_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInReceivables_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInReceivables_lbl1">Increase (Decrease) in Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl1" xlink:title="label: IncreaseDecreaseInReceivables to us-gaap_IncreaseDecreaseInReceivables_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl">LICENSED TECHNOLOGY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="InterestAndDebtExpense" xlink:title="InterestAndDebtExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US" id="us-gaap_InterestAndDebtExpense_lbl">Interest and other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:title="label: InterestAndDebtExpense to us-gaap_InterestAndDebtExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestAndDebtExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestAndDebtExpense_lbl1" xml:lang="en-US" id="us-gaap_InterestAndDebtExpense_lbl1">Interest and Debt Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl1" xlink:title="label: InterestAndDebtExpense to us-gaap_InterestAndDebtExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="us-gaap_InterestPaid_lbl">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:title="label: InterestPaid to us-gaap_InterestPaid_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaid_lbl1" xml:lang="en-US" id="us-gaap_InterestPaid_lbl1">Interest Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="us-gaap_InterestPaid_lbl1" xlink:title="label: InterestPaid to us-gaap_InterestPaid_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="InvestmentIncomeNonoperating" xlink:title="InvestmentIncomeNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US" id="us-gaap_InvestmentIncomeNonoperating_lbl">Interest and miscellaneous income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:title="label: InvestmentIncomeNonoperating to us-gaap_InvestmentIncomeNonoperating_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeNonoperating_lbl1" xml:lang="en-US" id="us-gaap_InvestmentIncomeNonoperating_lbl1">Investment Income, Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl1" xlink:title="label: InvestmentIncomeNonoperating to us-gaap_InvestmentIncomeNonoperating_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" id="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl">Stock issued for services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:title="label: IssuanceOfStockAndWarrantsForServicesOrClaims to us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1" xml:lang="en-US" id="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1" xlink:title="label: IssuanceOfStockAndWarrantsForServicesOrClaims to us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="LatestTaxYearMember" xlink:title="LatestTaxYearMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LatestTaxYearMember_lbl" xml:lang="en-US" id="us-gaap_LatestTaxYearMember_lbl">2018 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl" xlink:title="label: LatestTaxYearMember to us-gaap_LatestTaxYearMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LatestTaxYearMember_lbl1" xml:lang="en-US" id="us-gaap_LatestTaxYearMember_lbl1">Latest Tax Year [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl1" xlink:title="label: LatestTaxYearMember to us-gaap_LatestTaxYearMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="us-gaap_LongtermDebtTypeAxis_lbl">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:title="label: LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="us-gaap_LongtermDebtTypeDomain_lbl">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xlink:title="label: LongtermDebtTypeDomain to us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsMember_lbl">Leasehold Improvement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:title="label: LeaseholdImprovementsMember to us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="LeasesOperatingAbstract" xlink:title="LeasesOperatingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US" id="us-gaap_LeasesOperatingAbstract_lbl">Operating Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" xlink:title="label: LeasesOperatingAbstract to us-gaap_LeasesOperatingAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="LicenseAgreementTermsMember" xlink:title="LicenseAgreementTermsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" id="us-gaap_LicenseAgreementTermsMember_lbl">Gene Therapy [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl" xlink:title="label: LicenseAgreementTermsMember to us-gaap_LicenseAgreementTermsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="LicenseCosts" xlink:title="LicenseCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LicenseCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LicenseCosts_lbl" xml:lang="en-US" id="us-gaap_LicenseCosts_lbl">License fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseCosts" xlink:to="us-gaap_LicenseCosts_lbl" xlink:title="label: LicenseCosts to us-gaap_LicenseCosts_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="us-gaap_LicensesRevenue_lbl">License revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl" xlink:title="label: LicensesRevenue to us-gaap_LicensesRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="LineOfCreditFacilityExpirationDate1" xlink:title="LineOfCreditFacilityExpirationDate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityExpirationDate1_lbl">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:title="label: LineOfCreditFacilityExpirationDate1 to us-gaap_LineOfCreditFacilityExpirationDate1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl">Unsecured grid note amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:title="label: LineOfCreditFacilityMaximumBorrowingCapacity to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:title="LineOfCreditFacilityInterestRateAtPeriodEnd" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xlink:title="label: LineOfCreditFacilityInterestRateAtPeriodEnd to us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:title="LineOfCreditFacilityMaximumMonthendOutstandingAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_lbl">Total amount drawn</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_lbl" xlink:title="label: LineOfCreditFacilityMaximumMonthendOutstandingAmount to us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="us-gaap_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:title="label: MaximumMember to us-gaap_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="us-gaap_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:title="label: MinimumMember to us-gaap_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl">Net loss allocable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1">Net loss allocable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl2">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl2" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl">Net loss allocable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersDiluted to us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl1">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersDiluted to us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl">Supplemental disclosure of noncash transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:title="label: NoncashInvestingAndFinancingItemsAbstract to us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl">Total non operating income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl">Non-cancelable operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueCurrent to us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl1">2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueCurrent to us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl">Operating Leases, Lease Payment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueAbstract to us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementLeaseRevenue" xlink:label="OperatingLeasesIncomeStatementLeaseRevenue" xlink:title="OperatingLeasesIncomeStatementLeaseRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesIncomeStatementLeaseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeasesIncomeStatementLeaseRevenue_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasesIncomeStatementLeaseRevenue_lbl">Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesIncomeStatementLeaseRevenue" xlink:to="us-gaap_OperatingLeasesIncomeStatementLeaseRevenue_lbl" xlink:title="label: OperatingLeasesIncomeStatementLeaseRevenue to us-gaap_OperatingLeasesIncomeStatementLeaseRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesIncomeStatementLeaseRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasesIncomeStatementLeaseRevenue_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeasesIncomeStatementLeaseRevenue_lbl1">Operating Leases, Income Statement, Lease Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesIncomeStatementLeaseRevenue" xlink:to="us-gaap_OperatingLeasesIncomeStatementLeaseRevenue_lbl1" xlink:title="label: OperatingLeasesIncomeStatementLeaseRevenue to us-gaap_OperatingLeasesIncomeStatementLeaseRevenue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="OperatingLeasesRentExpenseNet" xlink:title="OperatingLeasesRentExpenseNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasesRentExpenseNet_lbl">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:title="label: OperatingLeasesRentExpenseNet to us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl">2017</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInTwoYears to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenseMember_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenseMember_lbl">Operating Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl" xlink:title="label: OperatingExpenseMember to us-gaap_OperatingExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsTable_lbl">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:title="label: OperatingLossCarryforwardsTable to us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsLineItems_lbl">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:title="label: OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="OperatingLeasesFutureMinimumPaymentsDue" xlink:title="OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDue to us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl1">Operating Leases, Future Minimum Payments Due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl1" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDue to us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl">2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInFourYears to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="OperatingLeasedAssetsLineItems" xlink:title="OperatingLeasedAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasedAssetsLineItems_lbl">Operating Leased Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:title="label: OperatingLeasedAssetsLineItems to us-gaap_OperatingLeasedAssetsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInFiveYears to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards_lbl">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwards_lbl1" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards_lbl1">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl1" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl">2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInThreeYears to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl1">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl1" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="OtherIncomeAbstract" xlink:title="OtherIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherIncomeAbstract_lbl">Other Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl" xlink:title="label: OtherIncomeAbstract to us-gaap_OtherIncomeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssets" xlink:label="OtherAssets" xlink:title="OtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherAssets_lbl" xml:lang="en-US" id="us-gaap_OtherAssets_lbl">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:title="label: OtherAssets to us-gaap_OtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssets_lbl1" xml:lang="en-US" id="us-gaap_OtherAssets_lbl1">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssets" xlink:to="us-gaap_OtherAssets_lbl1" xlink:title="label: OtherAssets to us-gaap_OtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncome_lbl">Miscellaneous income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:title="label: OtherNonoperatingIncome to us-gaap_OtherNonoperatingIncome_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Capital expenditures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl">401(k) PLAN</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="PreferredStockTextBlock" xlink:title="PreferredStockTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" id="us-gaap_PreferredStockTextBlock_lbl">PREFERRED STOCK</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" xlink:title="label: PreferredStockTextBlock to us-gaap_PreferredStockTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockTextBlock_lbl1">Preferred Stock [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl1" xlink:title="label: PreferredStockTextBlock to us-gaap_PreferredStockTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="PreferredStockDividendsIncomeStatementImpact" xlink:title="PreferredStockDividendsIncomeStatementImpact" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl">Less preferred stock dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:title="label: PreferredStockDividendsIncomeStatementImpact to us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl1">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl1" xlink:title="label: PreferredStockDividendsIncomeStatementImpact to us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_PreferredStockMember_lbl">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:title="label: PreferredStockMember to us-gaap_PreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="PrivatePlacementMember" xlink:title="PrivatePlacementMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" id="us-gaap_PrivatePlacementMember_lbl">Private Placement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:title="label: PrivatePlacementMember to us-gaap_PrivatePlacementMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromWarrantExercises_lbl">Proceeds from exercise of $5.00 warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:title="label: ProceedsFromWarrantExercises to us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl">Gross proceeds from offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquity to us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl1">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl1" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquity to us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl">Proceed from sale of stock from private placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:title="label: ProceedsFromIssuanceOfPrivatePlacement to us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xlink:title="label: ProceedsFromIssuanceOfPrivatePlacement to us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Proceeds from $3.00 common stock issuances net of costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="ProceedsFromShortTermDebt" xlink:title="ProceedsFromShortTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromShortTermDebt_lbl">Proceeds/payment of short-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:title="label: ProceedsFromShortTermDebt to us-gaap_ProceedsFromShortTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromShortTermDebt_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromShortTermDebt_lbl1">Proceeds from Short-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl1" xlink:title="label: ProceedsFromShortTermDebt to us-gaap_ProceedsFromShortTermDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl">Cash from Abeona Ohio acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract_lbl">PROPERTY AND EQUIPMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract_lbl1">Property and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl1" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl">Estimated useful lives of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl">Components of property and equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentNetByTypeAbstract to us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems_lbl">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RangeMember_lbl" xml:lang="en-US" id="us-gaap_RangeMember_lbl">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="us-gaap_RangeMember_lbl" xlink:title="label: RangeMember to us-gaap_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="us-gaap_RangeAxis_lbl">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:title="label: RangeAxis to us-gaap_RangeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock_lbl">Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="ReceivablesNetCurrent" xlink:title="ReceivablesNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" id="us-gaap_ReceivablesNetCurrent_lbl">Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xlink:title="label: ReceivablesNetCurrent to us-gaap_ReceivablesNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReceivablesNetCurrent_lbl1" xml:lang="en-US" id="us-gaap_ReceivablesNetCurrent_lbl1">Receivables, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl1" xlink:title="label: ReceivablesNetCurrent to us-gaap_ReceivablesNetCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionLineItems_lbl">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:title="label: RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyDomain_lbl">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsAbstract_lbl">RELATED PARTY TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:title="label: RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:title="label: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:title="label: ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:title="label: ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems to us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">Accumulated (deficit) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl1" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock_lbl">License Revenues and Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RoyaltyRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" id="us-gaap_RoyaltyRevenue_lbl">Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl" xlink:title="label: RoyaltyRevenue to us-gaap_RoyaltyRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl">Options exercisable, Weighted average, Remaining life in years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl">Options exercisable, Weighted average, Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl">Expected lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl">Options outstanding, Weighted average, Remaining life in years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl">Intrinsic value of options exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl">Options outstanding, Weighted average, Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="us-gaap_SaleOfStockNameOfTransactionDomain_lbl">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:title="label: SaleOfStockNameOfTransactionDomain to us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="SalesRevenueNetAbstract" xlink:title="SalesRevenueNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US" id="us-gaap_SalesRevenueNetAbstract_lbl">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl" xlink:title="label: SalesRevenueNetAbstract to us-gaap_SalesRevenueNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SalesRevenueNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_SalesRevenueNetAbstract_lbl1">Revenue, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl1" xlink:title="label: SalesRevenueNetAbstract to us-gaap_SalesRevenueNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" id="us-gaap_SalesRevenueNet_lbl">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:title="label: SalesRevenueNet to us-gaap_SalesRevenueNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SalesRevenueNet_lbl1" xml:lang="en-US" id="us-gaap_SalesRevenueNet_lbl1">Revenue, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl1" xlink:title="label: SalesRevenueNet to us-gaap_SalesRevenueNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="us-gaap_ScenarioUnspecifiedDomain_lbl">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:title="label: ScenarioUnspecifiedDomain to us-gaap_ScenarioUnspecifiedDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:title="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl">Schedule of purchase price allocation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:title="label: ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock to us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl">Financial assets and liabilities measured at fair value on recurring basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:title="label: ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl">Summarized information of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl">Schedule of licensed technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl">Income tax expense differs from statutory amounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl">Temporary differences that give rise to deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:title="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl">Schedule of future minimum payments for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:title="label: ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock to us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl">Basic and diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:title="label: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" xlink:title="label: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:title="label: ScheduleOfBusinessAcquisitionsByAcquisitionTable to us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="ScheduleOfOperatingLeasedAssetsTable" xlink:title="ScheduleOfOperatingLeasedAssetsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl">Schedule of Operating Leased Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:title="label: ScheduleOfOperatingLeasedAssetsTable to us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl">Stock-based compensation allocation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:title="label: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable_lbl">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl">Schedule of warrants outstanding at various exercise prices</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:title="label: ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock to us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl">Information regarding options outstanding by range of exercise prices</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:title="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:title="label: ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable to us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:title="label: SegmentReportingPolicyPolicyTextBlock to us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl">General and administrative expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember_lbl">Series A Cumulative Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember_lbl1">Preferred Stock - A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeriesAPreferredStockMember_lbl2" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember_lbl2">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl2" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_SeriesBPreferredStockMember_lbl">Series B Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:title="label: SeriesBPreferredStockMember to us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SeriesBPreferredStockMember_lbl1" xml:lang="en-US" id="us-gaap_SeriesBPreferredStockMember_lbl1">Preferred Stock - B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl1" xlink:title="label: SeriesBPreferredStockMember to us-gaap_SeriesBPreferredStockMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeriesBPreferredStockMember_lbl2" xml:lang="en-US" id="us-gaap_SeriesBPreferredStockMember_lbl2">Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl2" xlink:title="label: SeriesBPreferredStockMember to us-gaap_SeriesBPreferredStockMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl1">Share-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock option compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl">Weighted- average exercise price [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SharePrice_lbl" xml:lang="en-US" id="us-gaap_SharePrice_lbl">Common stock issued, net of costs (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharePrice_lbl1" xml:lang="en-US" id="us-gaap_SharePrice_lbl1">Common stock price per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl1" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl">Exercisable, end on period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl">Expired/forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl">Exercisable, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl">Expired/forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl">Shares authorized but unissued common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl">Intrinsic value of options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl">Outstanding options, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1">Outstanding options, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl">Outstanding options, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1">Outstanding options, beginning of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl">Options [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl">Weighted average fair value of options granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl">Information regarding options outstanding by range of exercise prices [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl">Number of options outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl">Number of options exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl">Range of exercise prices, Upper range limit (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl">Range of exercise prices, Lower range limit (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="ShortTermBorrowings" xlink:title="ShortTermBorrowings" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" id="us-gaap_ShortTermBorrowings_lbl">Short-terms note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:title="label: ShortTermBorrowings to us-gaap_ShortTermBorrowings_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShortTermBorrowings_lbl1" xml:lang="en-US" id="us-gaap_ShortTermBorrowings_lbl1">Short-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl1" xlink:title="label: ShortTermBorrowings to us-gaap_ShortTermBorrowings_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl1" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl1">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl1" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="us-gaap_StatementScenarioAxis_lbl">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:title="label: StatementScenarioAxis to us-gaap_StatementScenarioAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl">Common stock issued to Abeona Ohio holders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl">Common stock issued to employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:title="label: StockIssuedDuringPeriodValueShareBasedCompensation to us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1" xlink:title="label: StockIssuedDuringPeriodValueShareBasedCompensation to us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl">Common stock issued for services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl">Additional adjustments for reverse stock split (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:title="label: StockIssuedDuringPeriodSharesReverseStockSplits to us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1">Stock Issued During Period, Shares, Reverse Stock Splits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesReverseStockSplits to us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl">Restricted common stock issued to employees (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardGross to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl">Common stock issued, net of costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl">Preferred stock converted into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:title="label: StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl">Underwritten public offering (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1">Common stock issued, net of costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl">Preferred stock converted into common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl">Restricted common stock issued to employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:title="label: StockIssuedDuringPeriodValueRestrictedStockAwardGross to us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl">Common stock issued to Abeona Ohio holders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1">Stock issued in acquisition (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl">Common stock issued to employees (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensation to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensation to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl">Common stock issued for services (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1">Common stock shares in lieu of cash (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">Stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteAbstract_lbl">STOCKHOLDERS' EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:title="label: StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="SubsidiariesMember" xlink:title="SubsidiariesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiariesMember_lbl" xml:lang="en-US" id="us-gaap_SubsidiariesMember_lbl">SCO Capital Partners LLC and Affiliates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiariesMember" xlink:to="us-gaap_SubsidiariesMember_lbl" xlink:title="label: SubsidiariesMember to us-gaap_SubsidiariesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockAxis_lbl">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:title="label: SubsidiarySaleOfStockAxis to us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">Supplemental cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAxis_lbl">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:title="label: TaxCreditCarryforwardAxis to us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="TaxCreditCarryforwardTable" xlink:title="TaxCreditCarryforwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardTable_lbl">Tax Credit Carryforward [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:title="label: TaxCreditCarryforwardTable to us-gaap_TaxCreditCarryforwardTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US" id="us-gaap_TaxPeriodAxis_lbl">Tax Period [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:title="label: TaxPeriodAxis to us-gaap_TaxPeriodAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US" id="us-gaap_TaxPeriodDomain_lbl">Tax Period [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" xlink:title="label: TaxPeriodDomain to us-gaap_TaxPeriodDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAmount_lbl">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:title="label: TaxCreditCarryforwardAmount to us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardNameDomain_lbl">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:title="label: TaxCreditCarryforwardNameDomain to us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="TaxCreditCarryforwardLineItems" xlink:title="TaxCreditCarryforwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardLineItems_lbl">Tax Credit Carryforward [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:title="label: TaxCreditCarryforwardLineItems to us-gaap_TaxCreditCarryforwardLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" id="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:title="label: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="TreasuryStockSharesRetired" xlink:title="TreasuryStockSharesRetired" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US" id="us-gaap_TreasuryStockSharesRetired_lbl">Cancel treasury stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl" xlink:title="label: TreasuryStockSharesRetired to us-gaap_TreasuryStockSharesRetired_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TreasuryStockSharesRetired_lbl1" xml:lang="en-US" id="us-gaap_TreasuryStockSharesRetired_lbl1">Treasury Stock, Shares, Retired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl1" xlink:title="label: TreasuryStockSharesRetired to us-gaap_TreasuryStockSharesRetired_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="TreasuryStockMember" xlink:title="TreasuryStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US" id="us-gaap_TreasuryStockMember_lbl">Treasury stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:title="label: TreasuryStockMember to us-gaap_TreasuryStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TreasuryStockMember_lbl1" xml:lang="en-US" id="us-gaap_TreasuryStockMember_lbl1">Treasury Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl1" xlink:title="label: TreasuryStockMember to us-gaap_TreasuryStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="UnsecuredDebtMember" xlink:title="UnsecuredDebtMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UnsecuredDebtMember_lbl" xml:lang="en-US" id="us-gaap_UnsecuredDebtMember_lbl">Unsecured Grid Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl" xlink:title="label: UnsecuredDebtMember to us-gaap_UnsecuredDebtMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnsecuredDebtMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnsecuredDebtMember_lbl1" xml:lang="en-US" id="us-gaap_UnsecuredDebtMember_lbl1">Unsecured Debt [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl1" xlink:title="label: UnsecuredDebtMember to us-gaap_UnsecuredDebtMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl">Weighted average number of common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_EquityIncentivePlan2005Member" xlink:label="EquityIncentivePlan2005Member" xlink:title="EquityIncentivePlan2005Member" />
    <link:label xlink:type="resource" xlink:label="accp_EquityIncentivePlan2005Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_EquityIncentivePlan2005Member_lbl" xml:lang="en-US" id="accp_EquityIncentivePlan2005Member_lbl">Equity Incentive Plan Agreement ("Agreement") is a legal contract between a Corporation and its employees to provide the employee with an interest in the Corporation. The purpose of an Equity Incentive Plan is to strengthen the financials of the Corporation by providing incentive stock options to its employees. The Plan serves as a means to attract, retain, and motivate corporate personnel. Generally, the Plan is administered by a Compensation Committee composed of members selected by, and serving at the pleasure of, the Board of Directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2005Member" xlink:to="accp_EquityIncentivePlan2005Member_lbl" xlink:title="label: EquityIncentivePlan2005Member to accp_EquityIncentivePlan2005Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_EquityIncentivePlan2005Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_EquityIncentivePlan2005Member_lbl1" xml:lang="en-US" id="accp_EquityIncentivePlan2005Member_lbl1">Equity Incentive Plan 2005 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2005Member" xlink:to="accp_EquityIncentivePlan2005Member_lbl1" xlink:title="label: EquityIncentivePlan2005Member to accp_EquityIncentivePlan2005Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_EquityIncentivePlan2005Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_EquityIncentivePlan2005Member_lbl2" xml:lang="en-US" id="accp_EquityIncentivePlan2005Member_lbl2">2005 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2005Member" xlink:to="accp_EquityIncentivePlan2005Member_lbl2" xlink:title="label: EquityIncentivePlan2005Member to accp_EquityIncentivePlan2005Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_EquityIncentivePlan2015Member" xlink:label="EquityIncentivePlan2015Member" xlink:title="EquityIncentivePlan2015Member" />
    <link:label xlink:type="resource" xlink:label="accp_EquityIncentivePlan2015Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_EquityIncentivePlan2015Member_lbl" xml:lang="en-US" id="accp_EquityIncentivePlan2015Member_lbl">Equity Incentive Plan Agreement ("Agreement") is a legal contract between a Corporation and its employees to provide the employee with an interest in the Corporation. The purpose of an Equity Incentive Plan is to strengthen the financials of the Corporation by providing incentive stock options to its employees. The Plan serves as a means to attract, retain, and motivate corporate personnel. Generally, the Plan is administered by a Compensation Committee composed of members selected by, and serving at the pleasure of, the Board of Directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2015Member" xlink:to="accp_EquityIncentivePlan2015Member_lbl" xlink:title="label: EquityIncentivePlan2015Member to accp_EquityIncentivePlan2015Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_EquityIncentivePlan2015Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_EquityIncentivePlan2015Member_lbl1" xml:lang="en-US" id="accp_EquityIncentivePlan2015Member_lbl1">Equity Incentive Plan 2015 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2015Member" xlink:to="accp_EquityIncentivePlan2015Member_lbl1" xlink:title="label: EquityIncentivePlan2015Member to accp_EquityIncentivePlan2015Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_EquityIncentivePlan2015Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_EquityIncentivePlan2015Member_lbl2" xml:lang="en-US" id="accp_EquityIncentivePlan2015Member_lbl2">2015 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2015Member" xlink:to="accp_EquityIncentivePlan2015Member_lbl2" xlink:title="label: EquityIncentivePlan2015Member to accp_EquityIncentivePlan2015Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeTwoMember" xlink:label="RangeTwoMember" xlink:title="RangeTwoMember" />
    <link:label xlink:type="resource" xlink:label="accp_RangeTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_RangeTwoMember_lbl" xml:lang="en-US" id="accp_RangeTwoMember_lbl">Range two of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeTwoMember" xlink:to="accp_RangeTwoMember_lbl" xlink:title="label: RangeTwoMember to accp_RangeTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_RangeTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_RangeTwoMember_lbl1" xml:lang="en-US" id="accp_RangeTwoMember_lbl1">Range Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeTwoMember" xlink:to="accp_RangeTwoMember_lbl1" xlink:title="label: RangeTwoMember to accp_RangeTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_RangeTwoMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_RangeTwoMember_lbl2" xml:lang="en-US" id="accp_RangeTwoMember_lbl2">$11.50 - 18.50 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeTwoMember" xlink:to="accp_RangeTwoMember_lbl2" xlink:title="label: RangeTwoMember to accp_RangeTwoMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeSixMember" xlink:label="RangeSixMember" xlink:title="RangeSixMember" />
    <link:label xlink:type="resource" xlink:label="accp_RangeSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_RangeSixMember_lbl" xml:lang="en-US" id="accp_RangeSixMember_lbl">Range six of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeSixMember" xlink:to="accp_RangeSixMember_lbl" xlink:title="label: RangeSixMember to accp_RangeSixMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_RangeSixMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_RangeSixMember_lbl1" xml:lang="en-US" id="accp_RangeSixMember_lbl1">Range Six [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeSixMember" xlink:to="accp_RangeSixMember_lbl1" xlink:title="label: RangeSixMember to accp_RangeSixMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_RangeSixMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_RangeSixMember_lbl2" xml:lang="en-US" id="accp_RangeSixMember_lbl2">$4.38 - 7.34 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeSixMember" xlink:to="accp_RangeSixMember_lbl2" xlink:title="label: RangeSixMember to accp_RangeSixMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeThreeMember" xlink:label="RangeThreeMember" xlink:title="RangeThreeMember" />
    <link:label xlink:type="resource" xlink:label="accp_RangeThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_RangeThreeMember_lbl" xml:lang="en-US" id="accp_RangeThreeMember_lbl">Range three of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeThreeMember" xlink:to="accp_RangeThreeMember_lbl" xlink:title="label: RangeThreeMember to accp_RangeThreeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_RangeThreeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_RangeThreeMember_lbl1" xml:lang="en-US" id="accp_RangeThreeMember_lbl1">Range Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeThreeMember" xlink:to="accp_RangeThreeMember_lbl1" xlink:title="label: RangeThreeMember to accp_RangeThreeMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_RangeThreeMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_RangeThreeMember_lbl2" xml:lang="en-US" id="accp_RangeThreeMember_lbl2">$30.50 - 42.50 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeThreeMember" xlink:to="accp_RangeThreeMember_lbl2" xlink:title="label: RangeThreeMember to accp_RangeThreeMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeFiveMember" xlink:label="RangeFiveMember" xlink:title="RangeFiveMember" />
    <link:label xlink:type="resource" xlink:label="accp_RangeFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_RangeFiveMember_lbl" xml:lang="en-US" id="accp_RangeFiveMember_lbl">Range five of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeFiveMember" xlink:to="accp_RangeFiveMember_lbl" xlink:title="label: RangeFiveMember to accp_RangeFiveMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_RangeFiveMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_RangeFiveMember_lbl1" xml:lang="en-US" id="accp_RangeFiveMember_lbl1">Range Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeFiveMember" xlink:to="accp_RangeFiveMember_lbl1" xlink:title="label: RangeFiveMember to accp_RangeFiveMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_RangeFiveMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_RangeFiveMember_lbl2" xml:lang="en-US" id="accp_RangeFiveMember_lbl2">$113.50 - 157.50 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeFiveMember" xlink:to="accp_RangeFiveMember_lbl2" xlink:title="label: RangeFiveMember to accp_RangeFiveMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeFourMember" xlink:label="RangeFourMember" xlink:title="RangeFourMember" />
    <link:label xlink:type="resource" xlink:label="accp_RangeFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_RangeFourMember_lbl" xml:lang="en-US" id="accp_RangeFourMember_lbl">Range four of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeFourMember" xlink:to="accp_RangeFourMember_lbl" xlink:title="label: RangeFourMember to accp_RangeFourMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_RangeFourMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_RangeFourMember_lbl1" xml:lang="en-US" id="accp_RangeFourMember_lbl1">Range Four [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeFourMember" xlink:to="accp_RangeFourMember_lbl1" xlink:title="label: RangeFourMember to accp_RangeFourMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_RangeFourMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_RangeFourMember_lbl2" xml:lang="en-US" id="accp_RangeFourMember_lbl2">$69.00 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeFourMember" xlink:to="accp_RangeFourMember_lbl2" xlink:title="label: RangeFourMember to accp_RangeFourMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeOneMember" xlink:label="RangeOneMember" xlink:title="RangeOneMember" />
    <link:label xlink:type="resource" xlink:label="accp_RangeOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_RangeOneMember_lbl" xml:lang="en-US" id="accp_RangeOneMember_lbl">Range one of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOneMember" xlink:to="accp_RangeOneMember_lbl" xlink:title="label: RangeOneMember to accp_RangeOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_RangeOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_RangeOneMember_lbl1" xml:lang="en-US" id="accp_RangeOneMember_lbl1">Range One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOneMember" xlink:to="accp_RangeOneMember_lbl1" xlink:title="label: RangeOneMember to accp_RangeOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_RangeOneMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_RangeOneMember_lbl2" xml:lang="en-US" id="accp_RangeOneMember_lbl2">$3.25 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOneMember" xlink:to="accp_RangeOneMember_lbl2" xlink:title="label: RangeOneMember to accp_RangeOneMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PayableDueLicensor" xlink:label="PayableDueLicensor" xlink:title="PayableDueLicensor" />
    <link:label xlink:type="resource" xlink:label="accp_PayableDueLicensor_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PayableDueLicensor_lbl" xml:lang="en-US" id="accp_PayableDueLicensor_lbl">Amount payable due licensor.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayableDueLicensor" xlink:to="accp_PayableDueLicensor_lbl" xlink:title="label: PayableDueLicensor to accp_PayableDueLicensor_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PayableDueLicensor_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PayableDueLicensor_lbl1" xml:lang="en-US" id="accp_PayableDueLicensor_lbl1">Payable due Licensor</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayableDueLicensor" xlink:to="accp_PayableDueLicensor_lbl1" xlink:title="label: PayableDueLicensor to accp_PayableDueLicensor_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_LeaseExtensionPeriod" xlink:label="LeaseExtensionPeriod" xlink:title="LeaseExtensionPeriod" />
    <link:label xlink:type="resource" xlink:label="accp_LeaseExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_LeaseExtensionPeriod_lbl" xml:lang="en-US" id="accp_LeaseExtensionPeriod_lbl">Represents extend the lease for an additional five years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseExtensionPeriod" xlink:to="accp_LeaseExtensionPeriod_lbl" xlink:title="label: LeaseExtensionPeriod to accp_LeaseExtensionPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_LeaseExtensionPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_LeaseExtensionPeriod_lbl1" xml:lang="en-US" id="accp_LeaseExtensionPeriod_lbl1">Lease extension period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseExtensionPeriod" xlink:to="accp_LeaseExtensionPeriod_lbl1" xlink:title="label: LeaseExtensionPeriod to accp_LeaseExtensionPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TotalLeaseCostsAndUnamortizedTenantImprovements" xlink:label="TotalLeaseCostsAndUnamortizedTenantImprovements" xlink:title="TotalLeaseCostsAndUnamortizedTenantImprovements" />
    <link:label xlink:type="resource" xlink:label="accp_TotalLeaseCostsAndUnamortizedTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_TotalLeaseCostsAndUnamortizedTenantImprovements_lbl" xml:lang="en-US" id="accp_TotalLeaseCostsAndUnamortizedTenantImprovements_lbl">Represents total lease costs and unamortized improvements having a life longer than one year that were made for the benefit of one or more tenants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalLeaseCostsAndUnamortizedTenantImprovements" xlink:to="accp_TotalLeaseCostsAndUnamortizedTenantImprovements_lbl" xlink:title="label: TotalLeaseCostsAndUnamortizedTenantImprovements to accp_TotalLeaseCostsAndUnamortizedTenantImprovements_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_TotalLeaseCostsAndUnamortizedTenantImprovements_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_TotalLeaseCostsAndUnamortizedTenantImprovements_lbl1" xml:lang="en-US" id="accp_TotalLeaseCostsAndUnamortizedTenantImprovements_lbl1">Total lease costs and unamortized tenant improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalLeaseCostsAndUnamortizedTenantImprovements" xlink:to="accp_TotalLeaseCostsAndUnamortizedTenantImprovements_lbl1" xlink:title="label: TotalLeaseCostsAndUnamortizedTenantImprovements to accp_TotalLeaseCostsAndUnamortizedTenantImprovements_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_Building2Member" xlink:label="Building2Member" xlink:title="Building2Member" />
    <link:label xlink:type="resource" xlink:label="accp_Building2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_Building2Member_lbl" xml:lang="en-US" id="accp_Building2Member_lbl">Facility held for productive use including, but not limited to, office, and distribution facilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Building2Member" xlink:to="accp_Building2Member_lbl" xlink:title="label: Building2Member to accp_Building2Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_Building2Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_Building2Member_lbl1" xml:lang="en-US" id="accp_Building2Member_lbl1">Building2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Building2Member" xlink:to="accp_Building2Member_lbl1" xlink:title="label: Building2Member to accp_Building2Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_Building2Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_Building2Member_lbl2" xml:lang="en-US" id="accp_Building2Member_lbl2">Dallas Office [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Building2Member" xlink:to="accp_Building2Member_lbl2" xlink:title="label: Building2Member to accp_Building2Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_Building3Member" xlink:label="Building3Member" xlink:title="Building3Member" />
    <link:label xlink:type="resource" xlink:label="accp_Building3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_Building3Member_lbl" xml:lang="en-US" id="accp_Building3Member_lbl">Facility held for productive use including, but not limited to, office, and distribution facilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Building3Member" xlink:to="accp_Building3Member_lbl" xlink:title="label: Building3Member to accp_Building3Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_Building3Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_Building3Member_lbl1" xml:lang="en-US" id="accp_Building3Member_lbl1">Building3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Building3Member" xlink:to="accp_Building3Member_lbl1" xlink:title="label: Building3Member to accp_Building3Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_Building3Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_Building3Member_lbl2" xml:lang="en-US" id="accp_Building3Member_lbl2">Cleveland Office [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Building3Member" xlink:to="accp_Building3Member_lbl2" xlink:title="label: Building3Member to accp_Building3Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PreferredStockAbstract" xlink:label="PreferredStockAbstract" xlink:title="PreferredStockAbstract" />
    <link:label xlink:type="resource" xlink:label="accp_PreferredStockAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PreferredStockAbstract_lbl1" xml:lang="en-US" id="accp_PreferredStockAbstract_lbl1">PREFERRED STOCK [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockAbstract" xlink:to="accp_PreferredStockAbstract_lbl1" xlink:title="label: PreferredStockAbstract to accp_PreferredStockAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_DebtInstrumentCovenantComplianceValue" xlink:label="DebtInstrumentCovenantComplianceValue" xlink:title="DebtInstrumentCovenantComplianceValue" />
    <link:label xlink:type="resource" xlink:label="accp_DebtInstrumentCovenantComplianceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_DebtInstrumentCovenantComplianceValue_lbl" xml:lang="en-US" id="accp_DebtInstrumentCovenantComplianceValue_lbl">States the value associated with the debt covenants throughout the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCovenantComplianceValue" xlink:to="accp_DebtInstrumentCovenantComplianceValue_lbl" xlink:title="label: DebtInstrumentCovenantComplianceValue to accp_DebtInstrumentCovenantComplianceValue_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_DebtInstrumentCovenantComplianceValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_DebtInstrumentCovenantComplianceValue_lbl1" xml:lang="en-US" id="accp_DebtInstrumentCovenantComplianceValue_lbl1">Debt Instrument, Covenant Compliance, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCovenantComplianceValue" xlink:to="accp_DebtInstrumentCovenantComplianceValue_lbl1" xlink:title="label: DebtInstrumentCovenantComplianceValue to accp_DebtInstrumentCovenantComplianceValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_DebtInstrumentCovenantComplianceValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_DebtInstrumentCovenantComplianceValue_lbl2" xml:lang="en-US" id="accp_DebtInstrumentCovenantComplianceValue_lbl2">Total amount required</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCovenantComplianceValue" xlink:to="accp_DebtInstrumentCovenantComplianceValue_lbl2" xlink:title="label: DebtInstrumentCovenantComplianceValue to accp_DebtInstrumentCovenantComplianceValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SecondUnsecuredGridNoteMember" xlink:label="SecondUnsecuredGridNoteMember" xlink:title="SecondUnsecuredGridNoteMember" />
    <link:label xlink:type="resource" xlink:label="accp_SecondUnsecuredGridNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_SecondUnsecuredGridNoteMember_lbl" xml:lang="en-US" id="accp_SecondUnsecuredGridNoteMember_lbl">Other debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondUnsecuredGridNoteMember" xlink:to="accp_SecondUnsecuredGridNoteMember_lbl" xlink:title="label: SecondUnsecuredGridNoteMember to accp_SecondUnsecuredGridNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_SecondUnsecuredGridNoteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_SecondUnsecuredGridNoteMember_lbl1" xml:lang="en-US" id="accp_SecondUnsecuredGridNoteMember_lbl1">Second Unsecured Grid Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondUnsecuredGridNoteMember" xlink:to="accp_SecondUnsecuredGridNoteMember_lbl1" xlink:title="label: SecondUnsecuredGridNoteMember to accp_SecondUnsecuredGridNoteMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ScoCapitalPartnersLlcMember" xlink:label="ScoCapitalPartnersLlcMember" xlink:title="ScoCapitalPartnersLlcMember" />
    <link:label xlink:type="resource" xlink:label="accp_ScoCapitalPartnersLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ScoCapitalPartnersLlcMember_lbl" xml:lang="en-US" id="accp_ScoCapitalPartnersLlcMember_lbl">Owner that controls majority of the voting interest in the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScoCapitalPartnersLlcMember" xlink:to="accp_ScoCapitalPartnersLlcMember_lbl" xlink:title="label: ScoCapitalPartnersLlcMember to accp_ScoCapitalPartnersLlcMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ScoCapitalPartnersLlcMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ScoCapitalPartnersLlcMember_lbl1" xml:lang="en-US" id="accp_ScoCapitalPartnersLlcMember_lbl1">SCO Capital Partners LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScoCapitalPartnersLlcMember" xlink:to="accp_ScoCapitalPartnersLlcMember_lbl1" xlink:title="label: ScoCapitalPartnersLlcMember to accp_ScoCapitalPartnersLlcMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ScoCapitalPartnersLlcMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_ScoCapitalPartnersLlcMember_lbl2" xml:lang="en-US" id="accp_ScoCapitalPartnersLlcMember_lbl2">SCO Capital Partners LLC (SCO) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScoCapitalPartnersLlcMember" xlink:to="accp_ScoCapitalPartnersLlcMember_lbl2" xlink:title="label: ScoCapitalPartnersLlcMember to accp_ScoCapitalPartnersLlcMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:label="CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:title="CommonStockIssuedToEmployeesDirectorsAndConsultants" />
    <link:label xlink:type="resource" xlink:label="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl" xml:lang="en-US" id="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl">Equity impact of common stock issued to employees, directors and consultants by an entity during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:to="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl" xlink:title="label: CommonStockIssuedToEmployeesDirectorsAndConsultants to accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl1" xml:lang="en-US" id="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl1">Common stock issued to employees, directors and consultants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:to="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl1" xlink:title="label: CommonStockIssuedToEmployeesDirectorsAndConsultants to accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl2" xml:lang="en-US" id="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl2">Stock issued to directors, employees and consultants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:to="accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl2" xlink:title="label: CommonStockIssuedToEmployeesDirectorsAndConsultants to accp_CommonStockIssuedToEmployeesDirectorsAndConsultants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:label="ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:title="ProceedsFromIssuanceOfCommonStockNetOfCosts" />
    <link:label xlink:type="resource" xlink:label="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl" xml:lang="en-US" id="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl">The cash inflow from the additional capital contribution to the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:to="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStockNetOfCosts to accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl1" xml:lang="en-US" id="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl1">Proceeds From Issuance Of Common Stock Net of Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:to="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStockNetOfCosts to accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl2" xml:lang="en-US" id="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl2">Proceeds from $8.00 common stock issuances net of costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:to="accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl2" xlink:title="label: ProceedsFromIssuanceOfCommonStockNetOfCosts to accp_ProceedsFromIssuanceOfCommonStockNetOfCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:label="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:title="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" />
    <link:label xlink:type="resource" xlink:label="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl" xml:lang="en-US" id="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl">The cash inflow from the additional capital contribution to the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:to="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStockOneNetOfCosts to accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl1" xml:lang="en-US" id="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl1">Proceeds From Issuance Of Common Stock One Net of Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:to="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStockOneNetOfCosts to accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl2" xml:lang="en-US" id="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl2">Proceeds from $5.50 common stock issuances net of costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:to="accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl2" xlink:title="label: ProceedsFromIssuanceOfCommonStockOneNetOfCosts to accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_BusinessCombinationContingentConsideration" xlink:label="BusinessCombinationContingentConsideration" xlink:title="BusinessCombinationContingentConsideration" />
    <link:label xlink:type="resource" xlink:label="accp_BusinessCombinationContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_BusinessCombinationContingentConsideration_lbl" xml:lang="en-US" id="accp_BusinessCombinationContingentConsideration_lbl">Amount of increase (decrease) in the value of contingent consideration in a noncash (or part of noncash) acquisition. Noncash is defined as information about all investing and financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsideration" xlink:to="accp_BusinessCombinationContingentConsideration_lbl" xlink:title="label: BusinessCombinationContingentConsideration to accp_BusinessCombinationContingentConsideration_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_BusinessCombinationContingentConsideration_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_BusinessCombinationContingentConsideration_lbl1" xml:lang="en-US" id="accp_BusinessCombinationContingentConsideration_lbl1">Business Combination Contingent Consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsideration" xlink:to="accp_BusinessCombinationContingentConsideration_lbl1" xlink:title="label: BusinessCombinationContingentConsideration to accp_BusinessCombinationContingentConsideration_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_BusinessCombinationContingentConsideration_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_BusinessCombinationContingentConsideration_lbl2" xml:lang="en-US" id="accp_BusinessCombinationContingentConsideration_lbl2">Contingent milestones to Abeona Ohio members</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsideration" xlink:to="accp_BusinessCombinationContingentConsideration_lbl2" xlink:title="label: BusinessCombinationContingentConsideration to accp_BusinessCombinationContingentConsideration_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NoncashOrPartNoncashAcquisitionLicensedTecnology" xlink:label="NoncashOrPartNoncashAcquisitionLicensedTecnology" xlink:title="NoncashOrPartNoncashAcquisitionLicensedTecnology" />
    <link:label xlink:type="resource" xlink:label="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl" xml:lang="en-US" id="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl">The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionLicensedTecnology" xlink:to="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl" xlink:title="label: NoncashOrPartNoncashAcquisitionLicensedTecnology to accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl1" xml:lang="en-US" id="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl1">Noncash Or Part Noncash Acquisition Licensed Technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionLicensedTecnology" xlink:to="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl1" xlink:title="label: NoncashOrPartNoncashAcquisitionLicensedTecnology to accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl2" xml:lang="en-US" id="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl2">Licensed technology from Abeona Ohio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionLicensedTecnology" xlink:to="accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl2" xlink:title="label: NoncashOrPartNoncashAcquisitionLicensedTecnology to accp_NoncashOrPartNoncashAcquisitionLicensedTecnology_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_IncreaseDecreaseInContingentConsiderationMilestone" xlink:label="IncreaseDecreaseInContingentConsiderationMilestone" xlink:title="IncreaseDecreaseInContingentConsiderationMilestone" />
    <link:label xlink:type="resource" xlink:label="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl" xml:lang="en-US" id="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl">Amount of increase (decrease) of liability recognized arising from contingent consideration during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContingentConsiderationMilestone" xlink:to="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl" xlink:title="label: IncreaseDecreaseInContingentConsiderationMilestone to accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl1" xml:lang="en-US" id="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl1">Increase (Decrease) In Contingent Consideration Milestone</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContingentConsiderationMilestone" xlink:to="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl1" xlink:title="label: IncreaseDecreaseInContingentConsiderationMilestone to accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl2" xml:lang="en-US" id="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl2">Contingent consideration milestone</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContingentConsiderationMilestone" xlink:to="accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl2" xlink:title="label: IncreaseDecreaseInContingentConsiderationMilestone to accp_IncreaseDecreaseInContingentConsiderationMilestone_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:label="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:title="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" />
    <link:label xlink:type="resource" xlink:label="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl" xml:lang="en-US" id="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl">The cash inflow from the additional capital contribution to the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:to="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStockTwoNetOfCosts to accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl1" xml:lang="en-US" id="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl1">Proceeds From Issuance Of Common Stock Two Net Of Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:to="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStockTwoNetOfCosts to accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl2" xml:lang="en-US" id="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl2">Proceeds from $4.00 common stock net of costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:to="accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl2" xlink:title="label: ProceedsFromIssuanceOfCommonStockTwoNetOfCosts to accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TreasuryStockCancel" xlink:label="TreasuryStockCancel" xlink:title="TreasuryStockCancel" />
    <link:label xlink:type="resource" xlink:label="accp_TreasuryStockCancel_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_TreasuryStockCancel_lbl" xml:lang="en-US" id="accp_TreasuryStockCancel_lbl">value of the stock cancel in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockCancel" xlink:to="accp_TreasuryStockCancel_lbl" xlink:title="label: TreasuryStockCancel to accp_TreasuryStockCancel_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_TreasuryStockCancel_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_TreasuryStockCancel_lbl1" xml:lang="en-US" id="accp_TreasuryStockCancel_lbl1">Treasury Stock, Cancel</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockCancel" xlink:to="accp_TreasuryStockCancel_lbl1" xlink:title="label: TreasuryStockCancel to accp_TreasuryStockCancel_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_TreasuryStockCancel_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_TreasuryStockCancel_lbl2" xml:lang="en-US" id="accp_TreasuryStockCancel_lbl2">Cancel treasury stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockCancel" xlink:to="accp_TreasuryStockCancel_lbl2" xlink:title="label: TreasuryStockCancel to accp_TreasuryStockCancel_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_IncreaseDecreaseInInterestPayableOnDividends" xlink:label="IncreaseDecreaseInInterestPayableOnDividends" xlink:title="IncreaseDecreaseInInterestPayableOnDividends" />
    <link:label xlink:type="resource" xlink:label="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl" xml:lang="en-US" id="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl">The increase (decrease) during the reporting period in interest payable on dividends declared but unpaid on equity securities issued by the entity and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInterestPayableOnDividends" xlink:to="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl" xlink:title="label: IncreaseDecreaseInInterestPayableOnDividends to accp_IncreaseDecreaseInInterestPayableOnDividends_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl1" xml:lang="en-US" id="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl1">Increase Decrease in Interest Payable on Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInterestPayableOnDividends" xlink:to="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl1" xlink:title="label: IncreaseDecreaseInInterestPayableOnDividends to accp_IncreaseDecreaseInInterestPayableOnDividends_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl2" xml:lang="en-US" id="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl2">Interest on dividends payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInterestPayableOnDividends" xlink:to="accp_IncreaseDecreaseInInterestPayableOnDividends_lbl2" xlink:title="label: IncreaseDecreaseInInterestPayableOnDividends to accp_IncreaseDecreaseInInterestPayableOnDividends_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:label="PayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:title="PayableForFutureIssuanceOfSharesForLicensedTechnology" />
    <link:label xlink:type="resource" xlink:label="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl" xml:lang="en-US" id="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl">Amount of payable for future issuance of shares for licensed technology as of balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:to="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl" xlink:title="label: PayableForFutureIssuanceOfSharesForLicensedTechnology to accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl1" xml:lang="en-US" id="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl1">Payable for future issuance of shares for licensed technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:to="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl1" xlink:title="label: PayableForFutureIssuanceOfSharesForLicensedTechnology to accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl2" xml:lang="en-US" id="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl2">Payable in cash or future issuance of common shares for licensed technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:to="accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl2" xlink:title="label: PayableForFutureIssuanceOfSharesForLicensedTechnology to accp_PayableForFutureIssuanceOfSharesForLicensedTechnology_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:label="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:title="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" />
    <link:label xlink:type="resource" xlink:label="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl" xml:lang="en-US" id="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl">Conversion of Series B Preferred stock unpaid dividends and interest and liquidation damages into shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:to="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl" xlink:title="label: ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember to accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl1" xml:lang="en-US" id="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl1">Conversion of Series B Preferred stock unpaid dividends and interest and liquidation damages into shares of common stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:to="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl1" xlink:title="label: ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember to accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl2" xml:lang="en-US" id="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl2">Conversion of Series B Preferred Stock Unpaid Dividends and Interest and Liquidation Damages into Shares of Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:to="accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl2" xlink:title="label: ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember to accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:label="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:title="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" />
    <link:label xlink:type="resource" xlink:label="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl" xml:lang="en-US" id="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl">Conversion Of Series A Preferred Stock Unpaid Dividends And Interest And Liquidation Damages Into Shares Of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:to="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl" xlink:title="label: ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember to accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl1" xml:lang="en-US" id="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl1">Conversion Of Series A Preferred Stock Unpaid Dividends And Interest And Liquidation Damages Into Shares Of Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:to="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl1" xlink:title="label: ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember to accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl2" xml:lang="en-US" id="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl2">Conversion of Series A Preferred Stock Unpaid Dividends and Interest and Liquidation Damages into Shares of Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:to="accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl2" xlink:title="label: ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember to accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:label="InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:title="InitialConversionPriceOfPreferredStockIntoCommonStock" />
    <link:label xlink:type="resource" xlink:label="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl" xml:lang="en-US" id="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl">Initial conversion price of preferred stock into common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:to="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl" xlink:title="label: InitialConversionPriceOfPreferredStockIntoCommonStock to accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl1" xml:lang="en-US" id="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl1">Initial Conversion Price of Preferred Stock into Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:to="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl1" xlink:title="label: InitialConversionPriceOfPreferredStockIntoCommonStock to accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl2" xml:lang="en-US" id="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl2">Initial conversion price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:to="accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl2" xlink:title="label: InitialConversionPriceOfPreferredStockIntoCommonStock to accp_InitialConversionPriceOfPreferredStockIntoCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightsWarrantsExpired" xlink:label="ClassOfWarrantsOrRightsWarrantsExpired" xlink:title="ClassOfWarrantsOrRightsWarrantsExpired" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl">Aggregate number of warrants or rights expired during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightsWarrantsExpired" xlink:to="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl" xlink:title="label: ClassOfWarrantsOrRightsWarrantsExpired to accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl1" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl1">Class of Warrants or Rights, Warrants Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightsWarrantsExpired" xlink:to="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl1" xlink:title="label: ClassOfWarrantsOrRightsWarrantsExpired to accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl2" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl2">Warrants expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightsWarrantsExpired" xlink:to="accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl2" xlink:title="label: ClassOfWarrantsOrRightsWarrantsExpired to accp_ClassOfWarrantsOrRightsWarrantsExpired_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_DerivativeLiabilityPreferredStock" xlink:label="DerivativeLiabilityPreferredStock" xlink:title="DerivativeLiabilityPreferredStock" />
    <link:label xlink:type="resource" xlink:label="accp_DerivativeLiabilityPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_DerivativeLiabilityPreferredStock_lbl" xml:lang="en-US" id="accp_DerivativeLiabilityPreferredStock_lbl">Fair values as of the balance sheet date of liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments related to preferred stock, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilityPreferredStock" xlink:to="accp_DerivativeLiabilityPreferredStock_lbl" xlink:title="label: DerivativeLiabilityPreferredStock to accp_DerivativeLiabilityPreferredStock_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_DerivativeLiabilityPreferredStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_DerivativeLiabilityPreferredStock_lbl1" xml:lang="en-US" id="accp_DerivativeLiabilityPreferredStock_lbl1">Derivative liability preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilityPreferredStock" xlink:to="accp_DerivativeLiabilityPreferredStock_lbl1" xlink:title="label: DerivativeLiabilityPreferredStock to accp_DerivativeLiabilityPreferredStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_DerivativeLiabilityPreferredStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_DerivativeLiabilityPreferredStock_lbl2" xml:lang="en-US" id="accp_DerivativeLiabilityPreferredStock_lbl2">Derivative liability - preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilityPreferredStock" xlink:to="accp_DerivativeLiabilityPreferredStock_lbl2" xlink:title="label: DerivativeLiabilityPreferredStock to accp_DerivativeLiabilityPreferredStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_AccruedPotentialLiquidatedDamages" xlink:label="AccruedPotentialLiquidatedDamages" xlink:title="AccruedPotentialLiquidatedDamages" />
    <link:label xlink:type="resource" xlink:label="accp_AccruedPotentialLiquidatedDamages_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_AccruedPotentialLiquidatedDamages_lbl" xml:lang="en-US" id="accp_AccruedPotentialLiquidatedDamages_lbl">Accrued potential liquidated damages.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedPotentialLiquidatedDamages" xlink:to="accp_AccruedPotentialLiquidatedDamages_lbl" xlink:title="label: AccruedPotentialLiquidatedDamages to accp_AccruedPotentialLiquidatedDamages_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_AccruedPotentialLiquidatedDamages_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_AccruedPotentialLiquidatedDamages_lbl1" xml:lang="en-US" id="accp_AccruedPotentialLiquidatedDamages_lbl1">Accrued Potential Liquidated Damages</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedPotentialLiquidatedDamages" xlink:to="accp_AccruedPotentialLiquidatedDamages_lbl1" xlink:title="label: AccruedPotentialLiquidatedDamages to accp_AccruedPotentialLiquidatedDamages_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_AccruedPotentialLiquidatedDamages_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_AccruedPotentialLiquidatedDamages_lbl2" xml:lang="en-US" id="accp_AccruedPotentialLiquidatedDamages_lbl2">Accrued potential liquidated damages</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedPotentialLiquidatedDamages" xlink:to="accp_AccruedPotentialLiquidatedDamages_lbl2" xlink:title="label: AccruedPotentialLiquidatedDamages to accp_AccruedPotentialLiquidatedDamages_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:label="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:title="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" />
    <link:label xlink:type="resource" xlink:label="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl" xml:lang="en-US" id="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl">Potential liquidated damages are capped at a certain percentage of each holder's investment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:to="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl" xlink:title="label: PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment to accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl1" xml:lang="en-US" id="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl1">Potential Liquidated Damages Capped at a Percentage of Each Holders Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:to="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl1" xlink:title="label: PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment to accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl2" xml:lang="en-US" id="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl2">Potential liquidated damages</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:to="accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl2" xlink:title="label: PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment to accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:label="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:title="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" />
    <link:label xlink:type="resource" xlink:label="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl" xml:lang="en-US" id="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl">Conversion of number of outstanding shares at dividends payable on preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:to="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl" xlink:title="label: ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock to accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl1" xml:lang="en-US" id="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl1">Conversion of outstanding shares at dividends payable on preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:to="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl1" xlink:title="label: ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock to accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl2" xml:lang="en-US" id="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl2">Conversion of outstanding shares at dividends payable on preferred stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:to="accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl2" xlink:title="label: ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock to accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PreferredStockOffering2008Member" xlink:label="PreferredStockOffering2008Member" xlink:title="PreferredStockOffering2008Member" />
    <link:label xlink:type="resource" xlink:label="accp_PreferredStockOffering2008Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PreferredStockOffering2008Member_lbl" xml:lang="en-US" id="accp_PreferredStockOffering2008Member_lbl">Warrants issued in connection with preferred stock offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockOffering2008Member" xlink:to="accp_PreferredStockOffering2008Member_lbl" xlink:title="label: PreferredStockOffering2008Member to accp_PreferredStockOffering2008Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PreferredStockOffering2008Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PreferredStockOffering2008Member_lbl1" xml:lang="en-US" id="accp_PreferredStockOffering2008Member_lbl1">Preferred Stock Offering 2008 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockOffering2008Member" xlink:to="accp_PreferredStockOffering2008Member_lbl1" xlink:title="label: PreferredStockOffering2008Member to accp_PreferredStockOffering2008Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueNewIssue" xlink:label="StockIssuedDuringPeriodValueNewIssue" xlink:title="StockIssuedDuringPeriodValueNewIssue" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueNewIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodValueNewIssue_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueNewIssue_lbl">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssue" xlink:to="accp_StockIssuedDuringPeriodValueNewIssue_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssue to accp_StockIssuedDuringPeriodValueNewIssue_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueNewIssue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodValueNewIssue_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueNewIssue_lbl1">Stock Issued During Period Value New Issue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssue" xlink:to="accp_StockIssuedDuringPeriodValueNewIssue_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssue to accp_StockIssuedDuringPeriodValueNewIssue_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueNewIssue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_StockIssuedDuringPeriodValueNewIssue_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueNewIssue_lbl2">Common stock issued for $8.00 share net of costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssue" xlink:to="accp_StockIssuedDuringPeriodValueNewIssue_lbl2" xlink:title="label: StockIssuedDuringPeriodValueNewIssue to accp_StockIssuedDuringPeriodValueNewIssue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplitsOne" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl">Reduction in the number of shares during the period as a result of a reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:to="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl" xlink:title="label: StockIssuedDuringPeriodSharesReverseStockSplitsOne to accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl1">Stock Issued During Period Shares Reverse Stock Splits One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:to="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesReverseStockSplitsOne to accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl2">Transfer agent correction 2014 reverse stock split (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:to="accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesReverseStockSplitsOne to accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesNewIssue" xlink:label="StockIssuedDuringPeriodSharesNewIssue" xlink:title="StockIssuedDuringPeriodSharesNewIssue" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesNewIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodSharesNewIssue_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesNewIssue_lbl">Number of new stock issued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssue" xlink:to="accp_StockIssuedDuringPeriodSharesNewIssue_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssue to accp_StockIssuedDuringPeriodSharesNewIssue_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesNewIssue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodSharesNewIssue_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesNewIssue_lbl1">Stock Issued During Period Shares New Issue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssue" xlink:to="accp_StockIssuedDuringPeriodSharesNewIssue_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssue to accp_StockIssuedDuringPeriodSharesNewIssue_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesNewIssue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_StockIssuedDuringPeriodSharesNewIssue_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesNewIssue_lbl2">Common stock issued for $8.00 share net of costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssue" xlink:to="accp_StockIssuedDuringPeriodSharesNewIssue_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssue to accp_StockIssuedDuringPeriodSharesNewIssue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueNewIssueOne" xlink:label="StockIssuedDuringPeriodValueNewIssueOne" xlink:title="StockIssuedDuringPeriodValueNewIssueOne" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssueOne" xlink:to="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssueOne to accp_StockIssuedDuringPeriodValueNewIssueOne_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl1">Stock Issued During Period Value New Issue One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssueOne" xlink:to="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssueOne to accp_StockIssuedDuringPeriodValueNewIssueOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl2">Common stock issued for $5.50 share net of costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssueOne" xlink:to="accp_StockIssuedDuringPeriodValueNewIssueOne_lbl2" xlink:title="label: StockIssuedDuringPeriodValueNewIssueOne to accp_StockIssuedDuringPeriodValueNewIssueOne_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesNewIssueOne" xlink:label="StockIssuedDuringPeriodSharesNewIssueOne" xlink:title="StockIssuedDuringPeriodSharesNewIssueOne" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl">Number of new stock issued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssueOne" xlink:to="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssueOne to accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl1">Stock Issued During Period Shares New Issue One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssueOne" xlink:to="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssueOne to accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl2">Common stock issued for $5.50 share net of costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssueOne" xlink:to="accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssueOne to accp_StockIssuedDuringPeriodSharesNewIssueOne_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl">Value of stock issued as a result of the exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl1">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl2">Exercise of $5.00 warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl2" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to accp_StockIssuedDuringPeriodValueWarrantsExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl">Number of warrants (or share units) exercised during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesWarrantsExercised to accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl1">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesWarrantsExercised to accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl2">Exercise of $5.00 warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesWarrantsExercised to accp_StockIssuedDuringPeriodSharesWarrantsExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:label="StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:title="StockIssuedDuringPeriodValueReverseStockSplitsOne" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl">Value of common stock issued for reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:to="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl" xlink:title="label: StockIssuedDuringPeriodValueReverseStockSplitsOne to accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl1">Stock Issued During Period Value Reverse Stock Splits One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:to="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl1" xlink:title="label: StockIssuedDuringPeriodValueReverseStockSplitsOne to accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl2">Transfer agent correction 2014 reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:to="accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl2" xlink:title="label: StockIssuedDuringPeriodValueReverseStockSplitsOne to accp_StockIssuedDuringPeriodValueReverseStockSplitsOne_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:label="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:title="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl">Value of Series B preferred stock issued for unpaid liquidated damages during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue to accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl1" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl1">Series B Preferred Stock Issued For Unpaid Liquidated Damages, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl1" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue to accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl2" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl2">Series B preferred stock issued for unpaid liquidated damages</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl2" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue to accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:label="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:title="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl" xml:lang="en-US" id="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl">Number of stock issued for Series B preferred stock, unpaid dividends and interest and liquidated damages during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:to="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl" xlink:title="label: StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares to accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl1" xml:lang="en-US" id="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl1">Stock Issued For Series B Preferred Stock, Unpaid Dividends and Interest and Liquidated Damages, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:to="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl1" xlink:title="label: StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares to accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl2" xml:lang="en-US" id="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl2">Common stock issued for Series B preferred stock, unpaid dividends and interest and liquidated damages (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:to="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl2" xlink:title="label: StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares to accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:label="StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:title="StockIssuedDuringPeriodValueSeriesAPreferredStock" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl">Value of stock issued for series A preferred stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:to="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl" xlink:title="label: StockIssuedDuringPeriodValueSeriesAPreferredStock to accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl1">Stock Issued During Period, Value, Series A Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:to="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl1" xlink:title="label: StockIssuedDuringPeriodValueSeriesAPreferredStock to accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl2">Common stock issued for Series A preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:to="accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl2" xlink:title="label: StockIssuedDuringPeriodValueSeriesAPreferredStock to accp_StockIssuedDuringPeriodValueSeriesAPreferredStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:label="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:title="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl">Number of Series B preferred stock issued for unpaid Series B dividends and interest during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares to accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl1" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl1">Series B Preferred Stock Issued For Unpaid Series B Dividends and Interest, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl1" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares to accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl2" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl2">Series B preferred stock issued for unpaid Series B dividends and interest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl2" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares to accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="StockIssuedDuringPeriodValueReverseStockSplits" xlink:title="StockIssuedDuringPeriodValueReverseStockSplits" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl">Value of common stock issued for reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xlink:title="label: StockIssuedDuringPeriodValueReverseStockSplits to accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl1">Stock Issued During Period, Value, Reverse Stock Splits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl1" xlink:title="label: StockIssuedDuringPeriodValueReverseStockSplits to accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl2">Additional adjustments for reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl2" xlink:title="label: StockIssuedDuringPeriodValueReverseStockSplits to accp_StockIssuedDuringPeriodValueReverseStockSplits_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:label="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:title="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl">Value of Series B preferred stock issued for unpaid Series B dividends and interest during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue to accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl1" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl1">Series B Preferred Stock Issued For Unpaid Series B Dividends and Interest, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl1" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue to accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl2" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl2">Series B preferred stock issued for unpaid Series B dividends and interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl2" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue to accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:label="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:title="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl">Stock issued for series A preferred stock unpaid dividends and interest during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:to="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl" xlink:title="label: StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest to accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl1">Stock Issued During Period, Value, Series A Preferred Stock Unpaid Dividends and Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:to="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl1" xlink:title="label: StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest to accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl2">Common stock issued for Series A preferred stock unpaid dividends and interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:to="accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl2" xlink:title="label: StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest to accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:label="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:title="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl">Number of Series B preferred stock issued for unpaid liquidated damages during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares to accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl1" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl1">Series B Preferred Stock Issued For Unpaid Liquidated Damages, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl1" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares to accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl2" xml:lang="en-US" id="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl2">Series B preferred stock issued for unpaid liquidated damages (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:to="accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl2" xlink:title="label: SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares to accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:label="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:title="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" />
    <link:label xlink:type="resource" xlink:label="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl" xml:lang="en-US" id="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl">Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in elimination of derivative liability - preferred stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:to="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock to accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl1" xml:lang="en-US" id="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl1">Adjustments To Additional Paid In Capital Elimination of Derivative Liability, Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:to="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock to accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl2" xml:lang="en-US" id="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl2">Elimination of derivative liability - preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:to="accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock to accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TreasuryStockValueRetired" xlink:label="TreasuryStockValueRetired" xlink:title="TreasuryStockValueRetired" />
    <link:label xlink:type="resource" xlink:label="accp_TreasuryStockValueRetired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_TreasuryStockValueRetired_lbl" xml:lang="en-US" id="accp_TreasuryStockValueRetired_lbl">Value of common and preferred stock retired from treasury during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockValueRetired" xlink:to="accp_TreasuryStockValueRetired_lbl" xlink:title="label: TreasuryStockValueRetired to accp_TreasuryStockValueRetired_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_TreasuryStockValueRetired_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_TreasuryStockValueRetired_lbl1" xml:lang="en-US" id="accp_TreasuryStockValueRetired_lbl1">Treasury Stock, Value, Retired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockValueRetired" xlink:to="accp_TreasuryStockValueRetired_lbl1" xlink:title="label: TreasuryStockValueRetired to accp_TreasuryStockValueRetired_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_TreasuryStockValueRetired_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_TreasuryStockValueRetired_lbl2" xml:lang="en-US" id="accp_TreasuryStockValueRetired_lbl2">Cancel treasury stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockValueRetired" xlink:to="accp_TreasuryStockValueRetired_lbl2" xlink:title="label: TreasuryStockValueRetired to accp_TreasuryStockValueRetired_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:label="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:title="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl">Number of stock issued for series a preferred stock unpaid dividends and interest during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:to="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl" xlink:title="label: StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest to accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl1">Stock Issued During Period, Shares, Series A Preferred Stock Unpaid Dividends and Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:to="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest to accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl2">Common stock issued for Series A preferred stock unpaid dividends and interest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:to="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest to accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:label="StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:title="StockIssuedDuringPeriodSharesSeriesAPreferredStock" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl">Number of stock issued for series A preferred stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:to="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl" xlink:title="label: StockIssuedDuringPeriodSharesSeriesAPreferredStock to accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl1" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl1">Stock Issued During Period, Shares, Series A Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:to="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesSeriesAPreferredStock to accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl2" xml:lang="en-US" id="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl2">Common stock issued for Series A preferred stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:to="accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesSeriesAPreferredStock to accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:label="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:title="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl" xml:lang="en-US" id="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl">Value of common stock issued for Series B preferred stock, unpaid dividends and interest and liquidated damages during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:to="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl" xlink:title="label: StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue to accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl1" xml:lang="en-US" id="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl1">Stock Issued For Series B Preferred Stock, Unpaid Dividends and Interest and Liquidated Damages, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:to="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl1" xlink:title="label: StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue to accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl2" xml:lang="en-US" id="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl2">Common stock issued for Series B preferred stock, unpaid dividends and interest and liquidated damages</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:to="accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl2" xlink:title="label: StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue to accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NewIssuesShareOnePricePerShare" xlink:label="NewIssuesShareOnePricePerShare" xlink:title="NewIssuesShareOnePricePerShare" />
    <link:label xlink:type="resource" xlink:label="accp_NewIssuesShareOnePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NewIssuesShareOnePricePerShare_lbl" xml:lang="en-US" id="accp_NewIssuesShareOnePricePerShare_lbl">Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewIssuesShareOnePricePerShare" xlink:to="accp_NewIssuesShareOnePricePerShare_lbl" xlink:title="label: NewIssuesShareOnePricePerShare to accp_NewIssuesShareOnePricePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NewIssuesShareOnePricePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NewIssuesShareOnePricePerShare_lbl1" xml:lang="en-US" id="accp_NewIssuesShareOnePricePerShare_lbl1">New issues share one price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewIssuesShareOnePricePerShare" xlink:to="accp_NewIssuesShareOnePricePerShare_lbl1" xlink:title="label: NewIssuesShareOnePricePerShare to accp_NewIssuesShareOnePricePerShare_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_NewIssuesShareOnePricePerShare_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_NewIssuesShareOnePricePerShare_lbl2" xml:lang="en-US" id="accp_NewIssuesShareOnePricePerShare_lbl2">Common stock issued, net of costs (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewIssuesShareOnePricePerShare" xlink:to="accp_NewIssuesShareOnePricePerShare_lbl2" xlink:title="label: NewIssuesShareOnePricePerShare to accp_NewIssuesShareOnePricePerShare_lbl2" />
    <link:label xlink:type="resource" xlink:label="accp_NewIssuesShareOnePricePerShare_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_NewIssuesShareOnePricePerShare_lbl3" xml:lang="en-US" id="accp_NewIssuesShareOnePricePerShare_lbl3">Common stock , net of costs (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewIssuesShareOnePricePerShare" xlink:to="accp_NewIssuesShareOnePricePerShare_lbl3" xlink:title="label: NewIssuesShareOnePricePerShare to accp_NewIssuesShareOnePricePerShare_lbl3" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NewIssuesSharePricePerShare" xlink:label="NewIssuesSharePricePerShare" xlink:title="NewIssuesSharePricePerShare" />
    <link:label xlink:type="resource" xlink:label="accp_NewIssuesSharePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NewIssuesSharePricePerShare_lbl" xml:lang="en-US" id="accp_NewIssuesSharePricePerShare_lbl">Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewIssuesSharePricePerShare" xlink:to="accp_NewIssuesSharePricePerShare_lbl" xlink:title="label: NewIssuesSharePricePerShare to accp_NewIssuesSharePricePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NewIssuesSharePricePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NewIssuesSharePricePerShare_lbl1" xml:lang="en-US" id="accp_NewIssuesSharePricePerShare_lbl1">New issues share price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewIssuesSharePricePerShare" xlink:to="accp_NewIssuesSharePricePerShare_lbl1" xlink:title="label: NewIssuesSharePricePerShare to accp_NewIssuesSharePricePerShare_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_NewIssuesSharePricePerShare_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_NewIssuesSharePricePerShare_lbl2" xml:lang="en-US" id="accp_NewIssuesSharePricePerShare_lbl2">Common stock , net of costs (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewIssuesSharePricePerShare" xlink:to="accp_NewIssuesSharePricePerShare_lbl2" xlink:title="label: NewIssuesSharePricePerShare to accp_NewIssuesSharePricePerShare_lbl2" />
    <link:label xlink:type="resource" xlink:label="accp_NewIssuesSharePricePerShare_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_NewIssuesSharePricePerShare_lbl3" xml:lang="en-US" id="accp_NewIssuesSharePricePerShare_lbl3">Common stock , net of costs (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewIssuesSharePricePerShare" xlink:to="accp_NewIssuesSharePricePerShare_lbl3" xlink:title="label: NewIssuesSharePricePerShare to accp_NewIssuesSharePricePerShare_lbl3" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfInvestmentOptions" xlink:label="NumberOfInvestmentOptions" xlink:title="NumberOfInvestmentOptions" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfInvestmentOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NumberOfInvestmentOptions_lbl" xml:lang="en-US" id="accp_NumberOfInvestmentOptions_lbl">The number of investment options at the direction of each participant to invest in the assets of the 401(k) plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInvestmentOptions" xlink:to="accp_NumberOfInvestmentOptions_lbl" xlink:title="label: NumberOfInvestmentOptions to accp_NumberOfInvestmentOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfInvestmentOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NumberOfInvestmentOptions_lbl1" xml:lang="en-US" id="accp_NumberOfInvestmentOptions_lbl1">Number of investment options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInvestmentOptions" xlink:to="accp_NumberOfInvestmentOptions_lbl1" xlink:title="label: NumberOfInvestmentOptions to accp_NumberOfInvestmentOptions_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfInvestmentOptions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_NumberOfInvestmentOptions_lbl2" xml:lang="en-US" id="accp_NumberOfInvestmentOptions_lbl2">Number of investment options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInvestmentOptions" xlink:to="accp_NumberOfInvestmentOptions_lbl2" xlink:title="label: NumberOfInvestmentOptions to accp_NumberOfInvestmentOptions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" xlink:label="SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" xlink:title="SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl" xml:lang="en-US" id="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl">Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards and general business credit carryforwards, including an assessment of the likelihood of utilization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" xlink:to="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl" xlink:title="label: SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock to accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl1" xml:lang="en-US" id="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl1">Summary Of Operating Loss Carryforwards and General Business Credit Carryforwards [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" xlink:to="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl1" xlink:title="label: SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock to accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl2" xml:lang="en-US" id="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl2">Net operating loss carryforwards and general business credits expiration dates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" xlink:to="accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl2" xlink:title="label: SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock to accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TaxYear2016Member" xlink:label="TaxYear2016Member" xlink:title="TaxYear2016Member" />
    <link:label xlink:type="resource" xlink:label="accp_TaxYear2016Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_TaxYear2016Member_lbl" xml:lang="en-US" id="accp_TaxYear2016Member_lbl">Identified as tax year 2016.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2016Member" xlink:to="accp_TaxYear2016Member_lbl" xlink:title="label: TaxYear2016Member to accp_TaxYear2016Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_TaxYear2016Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_TaxYear2016Member_lbl1" xml:lang="en-US" id="accp_TaxYear2016Member_lbl1">Tax Year 2016 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2016Member" xlink:to="accp_TaxYear2016Member_lbl1" xlink:title="label: TaxYear2016Member to accp_TaxYear2016Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_TaxYear2016Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_TaxYear2016Member_lbl2" xml:lang="en-US" id="accp_TaxYear2016Member_lbl2">2016 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2016Member" xlink:to="accp_TaxYear2016Member_lbl2" xlink:title="label: TaxYear2016Member to accp_TaxYear2016Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TaxYear2017Member" xlink:label="TaxYear2017Member" xlink:title="TaxYear2017Member" />
    <link:label xlink:type="resource" xlink:label="accp_TaxYear2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_TaxYear2017Member_lbl" xml:lang="en-US" id="accp_TaxYear2017Member_lbl">Identified as tax year 2017.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2017Member" xlink:to="accp_TaxYear2017Member_lbl" xlink:title="label: TaxYear2017Member to accp_TaxYear2017Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_TaxYear2017Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_TaxYear2017Member_lbl1" xml:lang="en-US" id="accp_TaxYear2017Member_lbl1">Tax Year 2017 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2017Member" xlink:to="accp_TaxYear2017Member_lbl1" xlink:title="label: TaxYear2017Member to accp_TaxYear2017Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_TaxYear2017Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_TaxYear2017Member_lbl2" xml:lang="en-US" id="accp_TaxYear2017Member_lbl2">2017 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2017Member" xlink:to="accp_TaxYear2017Member_lbl2" xlink:title="label: TaxYear2017Member to accp_TaxYear2017Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PreMergerMember" xlink:label="PreMergerMember" xlink:title="PreMergerMember" />
    <link:label xlink:type="resource" xlink:label="accp_PreMergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PreMergerMember_lbl" xml:lang="en-US" id="accp_PreMergerMember_lbl">Relating to issues pre merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerMember" xlink:to="accp_PreMergerMember_lbl" xlink:title="label: PreMergerMember to accp_PreMergerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PreMergerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PreMergerMember_lbl1" xml:lang="en-US" id="accp_PreMergerMember_lbl1">Pre merger [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerMember" xlink:to="accp_PreMergerMember_lbl1" xlink:title="label: PreMergerMember to accp_PreMergerMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PostMergerMember" xlink:label="PostMergerMember" xlink:title="PostMergerMember" />
    <link:label xlink:type="resource" xlink:label="accp_PostMergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PostMergerMember_lbl" xml:lang="en-US" id="accp_PostMergerMember_lbl">Relating to issues after the merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostMergerMember" xlink:to="accp_PostMergerMember_lbl" xlink:title="label: PostMergerMember to accp_PostMergerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PostMergerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PostMergerMember_lbl1" xml:lang="en-US" id="accp_PostMergerMember_lbl1">Post merger [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostMergerMember" xlink:to="accp_PostMergerMember_lbl1" xlink:title="label: PostMergerMember to accp_PostMergerMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_IncomeTaxReconciliationCurrentYearReserve" xlink:label="IncomeTaxReconciliationCurrentYearReserve" xlink:title="IncomeTaxReconciliationCurrentYearReserve" />
    <link:label xlink:type="resource" xlink:label="accp_IncomeTaxReconciliationCurrentYearReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_IncomeTaxReconciliationCurrentYearReserve_lbl" xml:lang="en-US" id="accp_IncomeTaxReconciliationCurrentYearReserve_lbl">The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to current year reserve.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationCurrentYearReserve" xlink:to="accp_IncomeTaxReconciliationCurrentYearReserve_lbl" xlink:title="label: IncomeTaxReconciliationCurrentYearReserve to accp_IncomeTaxReconciliationCurrentYearReserve_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_IncomeTaxReconciliationCurrentYearReserve_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_IncomeTaxReconciliationCurrentYearReserve_lbl1" xml:lang="en-US" id="accp_IncomeTaxReconciliationCurrentYearReserve_lbl1">Income Tax Reconciliation Current Year Reserve</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationCurrentYearReserve" xlink:to="accp_IncomeTaxReconciliationCurrentYearReserve_lbl1" xlink:title="label: IncomeTaxReconciliationCurrentYearReserve to accp_IncomeTaxReconciliationCurrentYearReserve_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_IncomeTaxReconciliationCurrentYearReserve_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_IncomeTaxReconciliationCurrentYearReserve_lbl2" xml:lang="en-US" id="accp_IncomeTaxReconciliationCurrentYearReserve_lbl2">Current year reserve</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationCurrentYearReserve" xlink:to="accp_IncomeTaxReconciliationCurrentYearReserve_lbl2" xlink:title="label: IncomeTaxReconciliationCurrentYearReserve to accp_IncomeTaxReconciliationCurrentYearReserve_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TaxYearThereafterMember" xlink:label="TaxYearThereafterMember" xlink:title="TaxYearThereafterMember" />
    <link:label xlink:type="resource" xlink:label="accp_TaxYearThereafterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_TaxYearThereafterMember_lbl" xml:lang="en-US" id="accp_TaxYearThereafterMember_lbl">Identified as tax year Thereafter 2016.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYearThereafterMember" xlink:to="accp_TaxYearThereafterMember_lbl" xlink:title="label: TaxYearThereafterMember to accp_TaxYearThereafterMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_TaxYearThereafterMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_TaxYearThereafterMember_lbl1" xml:lang="en-US" id="accp_TaxYearThereafterMember_lbl1">Tax Year Thereafter [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYearThereafterMember" xlink:to="accp_TaxYearThereafterMember_lbl1" xlink:title="label: TaxYearThereafterMember to accp_TaxYearThereafterMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_TaxYearThereafterMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_TaxYearThereafterMember_lbl2" xml:lang="en-US" id="accp_TaxYearThereafterMember_lbl2">Thereafter [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYearThereafterMember" xlink:to="accp_TaxYearThereafterMember_lbl2" xlink:title="label: TaxYearThereafterMember to accp_TaxYearThereafterMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfYearsSubjectToStatuteOfLimitations" xlink:label="NumberOfYearsSubjectToStatuteOfLimitations" xlink:title="NumberOfYearsSubjectToStatuteOfLimitations" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl" xml:lang="en-US" id="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl">Number of years subject to statute of limitations by major tax jurisdiction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfYearsSubjectToStatuteOfLimitations" xlink:to="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl" xlink:title="label: NumberOfYearsSubjectToStatuteOfLimitations to accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl1" xml:lang="en-US" id="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl1">Number of Years Subject to Statute of Limitations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfYearsSubjectToStatuteOfLimitations" xlink:to="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl1" xlink:title="label: NumberOfYearsSubjectToStatuteOfLimitations to accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl2" xml:lang="en-US" id="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl2">Number of years subject to statute of limitations by major tax jurisdiction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfYearsSubjectToStatuteOfLimitations" xlink:to="accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl2" xlink:title="label: NumberOfYearsSubjectToStatuteOfLimitations to accp_NumberOfYearsSubjectToStatuteOfLimitations_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RegulatoryApprovalMilestonePayment" xlink:label="RegulatoryApprovalMilestonePayment" xlink:title="RegulatoryApprovalMilestonePayment" />
    <link:label xlink:type="resource" xlink:label="accp_RegulatoryApprovalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_RegulatoryApprovalMilestonePayment_lbl" xml:lang="en-US" id="accp_RegulatoryApprovalMilestonePayment_lbl">Regulatory approval milestone payment in shares of our common stock upon the first FDA regulatory approval of a drug derived from the Licensor's proprietary SDF process, and a tiered royalty on annual net sales of plasma fractions produced with Licensor's proprietary SDF process.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RegulatoryApprovalMilestonePayment" xlink:to="accp_RegulatoryApprovalMilestonePayment_lbl" xlink:title="label: RegulatoryApprovalMilestonePayment to accp_RegulatoryApprovalMilestonePayment_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_RegulatoryApprovalMilestonePayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_RegulatoryApprovalMilestonePayment_lbl1" xml:lang="en-US" id="accp_RegulatoryApprovalMilestonePayment_lbl1">Regulatory approval milestone payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RegulatoryApprovalMilestonePayment" xlink:to="accp_RegulatoryApprovalMilestonePayment_lbl1" xlink:title="label: RegulatoryApprovalMilestonePayment to accp_RegulatoryApprovalMilestonePayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_RegulatoryApprovalMilestonePayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_RegulatoryApprovalMilestonePayment_lbl2" xml:lang="en-US" id="accp_RegulatoryApprovalMilestonePayment_lbl2">Regulatory approval milestone payment (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RegulatoryApprovalMilestonePayment" xlink:to="accp_RegulatoryApprovalMilestonePayment_lbl2" xlink:title="label: RegulatoryApprovalMilestonePayment to accp_RegulatoryApprovalMilestonePayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_LicenseAgreementTerms1Member" xlink:label="LicenseAgreementTerms1Member" xlink:title="LicenseAgreementTerms1Member" />
    <link:label xlink:type="resource" xlink:label="accp_LicenseAgreementTerms1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_LicenseAgreementTerms1Member_lbl" xml:lang="en-US" id="accp_LicenseAgreementTerms1Member_lbl">Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAgreementTerms1Member" xlink:to="accp_LicenseAgreementTerms1Member_lbl" xlink:title="label: LicenseAgreementTerms1Member to accp_LicenseAgreementTerms1Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_LicenseAgreementTerms1Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_LicenseAgreementTerms1Member_lbl1" xml:lang="en-US" id="accp_LicenseAgreementTerms1Member_lbl1">License Agreement Terms 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAgreementTerms1Member" xlink:to="accp_LicenseAgreementTerms1Member_lbl1" xlink:title="label: LicenseAgreementTerms1Member to accp_LicenseAgreementTerms1Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_LicenseAgreementTerms1Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_LicenseAgreementTerms1Member_lbl2" xml:lang="en-US" id="accp_LicenseAgreementTerms1Member_lbl2">Plasma-based Therapeutics [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAgreementTerms1Member" xlink:to="accp_LicenseAgreementTerms1Member_lbl2" xlink:title="label: LicenseAgreementTerms1Member to accp_LicenseAgreementTerms1Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:label="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:title="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" />
    <link:label xlink:type="resource" xlink:label="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl" xml:lang="en-US" id="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl">Payable For Future Issuance Of Shares For Licensed Technology outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:to="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl" xlink:title="label: RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology to accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl1" xml:lang="en-US" id="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl1">Remaining Payable For Future Issuance Of Shares For Licensed Technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:to="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl1" xlink:title="label: RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology to accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl2" xml:lang="en-US" id="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl2">License fee payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:to="accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl2" xlink:title="label: RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology to accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfStockBasedCompensationPlans" xlink:label="NumberOfStockBasedCompensationPlans" xlink:title="NumberOfStockBasedCompensationPlans" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfStockBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NumberOfStockBasedCompensationPlans_lbl" xml:lang="en-US" id="accp_NumberOfStockBasedCompensationPlans_lbl">Refers to number of stock based compensation plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfStockBasedCompensationPlans" xlink:to="accp_NumberOfStockBasedCompensationPlans_lbl" xlink:title="label: NumberOfStockBasedCompensationPlans to accp_NumberOfStockBasedCompensationPlans_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfStockBasedCompensationPlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NumberOfStockBasedCompensationPlans_lbl1" xml:lang="en-US" id="accp_NumberOfStockBasedCompensationPlans_lbl1">Number of Stock Based Compensation Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfStockBasedCompensationPlans" xlink:to="accp_NumberOfStockBasedCompensationPlans_lbl1" xlink:title="label: NumberOfStockBasedCompensationPlans to accp_NumberOfStockBasedCompensationPlans_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfStockBasedCompensationPlans_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_NumberOfStockBasedCompensationPlans_lbl2" xml:lang="en-US" id="accp_NumberOfStockBasedCompensationPlans_lbl2">Number of stock based compensation plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfStockBasedCompensationPlans" xlink:to="accp_NumberOfStockBasedCompensationPlans_lbl2" xlink:title="label: NumberOfStockBasedCompensationPlans to accp_NumberOfStockBasedCompensationPlans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" xlink:label="NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" xlink:title="NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl" xml:lang="en-US" id="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl">Number of financial institutions where the deposits are primarily maintained.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" xlink:to="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl" xlink:title="label: NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained to accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl1" xml:lang="en-US" id="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl1">Number of Financial Institutions Deposits are Primarily Maintained</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" xlink:to="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl1" xlink:title="label: NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained to accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl2" xml:lang="en-US" id="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl2">Number of financial institutions deposits are primarily maintained</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" xlink:to="accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl2" xlink:title="label: NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained to accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_GoodwillAbstract" xlink:label="GoodwillAbstract" xlink:title="GoodwillAbstract" />
    <link:label xlink:type="resource" xlink:label="accp_GoodwillAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_GoodwillAbstract_lbl1" xml:lang="en-US" id="accp_GoodwillAbstract_lbl1">Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAbstract" xlink:to="accp_GoodwillAbstract_lbl1" xlink:title="label: GoodwillAbstract to accp_GoodwillAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_GoodwillAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_GoodwillAbstract_lbl2" xml:lang="en-US" id="accp_GoodwillAbstract_lbl2">Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAbstract" xlink:to="accp_GoodwillAbstract_lbl2" xlink:title="label: GoodwillAbstract to accp_GoodwillAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfPatentFamily" xlink:label="NumberOfPatentFamily" xlink:title="NumberOfPatentFamily" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfPatentFamily_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NumberOfPatentFamily_lbl" xml:lang="en-US" id="accp_NumberOfPatentFamily_lbl">Refers to the number of marketed products licensed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPatentFamily" xlink:to="accp_NumberOfPatentFamily_lbl" xlink:title="label: NumberOfPatentFamily to accp_NumberOfPatentFamily_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfPatentFamily_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NumberOfPatentFamily_lbl1" xml:lang="en-US" id="accp_NumberOfPatentFamily_lbl1">Number of patent family</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPatentFamily" xlink:to="accp_NumberOfPatentFamily_lbl1" xlink:title="label: NumberOfPatentFamily to accp_NumberOfPatentFamily_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="accp_DocumentAndEntityInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_DocumentAndEntityInformationAbstract_lbl1" xml:lang="en-US" id="accp_DocumentAndEntityInformationAbstract_lbl1">Document and Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="accp_DocumentAndEntityInformationAbstract_lbl1" xlink:title="label: DocumentAndEntityInformationAbstract to accp_DocumentAndEntityInformationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_OtherIncomePolicyTextBlock" xlink:label="OtherIncomePolicyTextBlock" xlink:title="OtherIncomePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="accp_OtherIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_OtherIncomePolicyTextBlock_lbl" xml:lang="en-US" id="accp_OtherIncomePolicyTextBlock_lbl">Disclosure of accounting policy for other income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomePolicyTextBlock" xlink:to="accp_OtherIncomePolicyTextBlock_lbl" xlink:title="label: OtherIncomePolicyTextBlock to accp_OtherIncomePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_OtherIncomePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_OtherIncomePolicyTextBlock_lbl1" xml:lang="en-US" id="accp_OtherIncomePolicyTextBlock_lbl1">Other Income [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomePolicyTextBlock" xlink:to="accp_OtherIncomePolicyTextBlock_lbl1" xlink:title="label: OtherIncomePolicyTextBlock to accp_OtherIncomePolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_OtherIncomePolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_OtherIncomePolicyTextBlock_lbl2" xml:lang="en-US" id="accp_OtherIncomePolicyTextBlock_lbl2">Other Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomePolicyTextBlock" xlink:to="accp_OtherIncomePolicyTextBlock_lbl2" xlink:title="label: OtherIncomePolicyTextBlock to accp_OtherIncomePolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NatureOfOperationsPolicyTextBlock" xlink:label="NatureOfOperationsPolicyTextBlock" xlink:title="NatureOfOperationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="accp_NatureOfOperationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US" id="accp_NatureOfOperationsPolicyTextBlock_lbl">Disclosure of accounting policy for business description. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperationsPolicyTextBlock" xlink:to="accp_NatureOfOperationsPolicyTextBlock_lbl" xlink:title="label: NatureOfOperationsPolicyTextBlock to accp_NatureOfOperationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NatureOfOperationsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NatureOfOperationsPolicyTextBlock_lbl1" xml:lang="en-US" id="accp_NatureOfOperationsPolicyTextBlock_lbl1">Nature of Operations [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperationsPolicyTextBlock" xlink:to="accp_NatureOfOperationsPolicyTextBlock_lbl1" xlink:title="label: NatureOfOperationsPolicyTextBlock to accp_NatureOfOperationsPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_NatureOfOperationsPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_NatureOfOperationsPolicyTextBlock_lbl2" xml:lang="en-US" id="accp_NatureOfOperationsPolicyTextBlock_lbl2">Nature of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperationsPolicyTextBlock" xlink:to="accp_NatureOfOperationsPolicyTextBlock_lbl2" xlink:title="label: NatureOfOperationsPolicyTextBlock to accp_NatureOfOperationsPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_LicensedTechnologyPolicyTextBlock" xlink:label="LicensedTechnologyPolicyTextBlock" xlink:title="LicensedTechnologyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="accp_LicensedTechnologyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_LicensedTechnologyPolicyTextBlock_lbl" xml:lang="en-US" id="accp_LicensedTechnologyPolicyTextBlock_lbl">Disclosure of accounting policy for licensed technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensedTechnologyPolicyTextBlock" xlink:to="accp_LicensedTechnologyPolicyTextBlock_lbl" xlink:title="label: LicensedTechnologyPolicyTextBlock to accp_LicensedTechnologyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_LicensedTechnologyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_LicensedTechnologyPolicyTextBlock_lbl1" xml:lang="en-US" id="accp_LicensedTechnologyPolicyTextBlock_lbl1">Licensed technology [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensedTechnologyPolicyTextBlock" xlink:to="accp_LicensedTechnologyPolicyTextBlock_lbl1" xlink:title="label: LicensedTechnologyPolicyTextBlock to accp_LicensedTechnologyPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_LicensedTechnologyPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_LicensedTechnologyPolicyTextBlock_lbl2" xml:lang="en-US" id="accp_LicensedTechnologyPolicyTextBlock_lbl2">Licensed Technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensedTechnologyPolicyTextBlock" xlink:to="accp_LicensedTechnologyPolicyTextBlock_lbl2" xlink:title="label: LicensedTechnologyPolicyTextBlock to accp_LicensedTechnologyPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightExpirationDate" xlink:label="ClassOfWarrantsOrRightExpirationDate" xlink:title="ClassOfWarrantsOrRightExpirationDate" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ClassOfWarrantsOrRightExpirationDate_lbl" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightExpirationDate_lbl">Expiration date of each class of warrants or rights outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightExpirationDate" xlink:to="accp_ClassOfWarrantsOrRightExpirationDate_lbl" xlink:title="label: ClassOfWarrantsOrRightExpirationDate to accp_ClassOfWarrantsOrRightExpirationDate_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightExpirationDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ClassOfWarrantsOrRightExpirationDate_lbl1" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightExpirationDate_lbl1">Class of Warrants Or Right Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightExpirationDate" xlink:to="accp_ClassOfWarrantsOrRightExpirationDate_lbl1" xlink:title="label: ClassOfWarrantsOrRightExpirationDate to accp_ClassOfWarrantsOrRightExpirationDate_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightExpirationDate_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_ClassOfWarrantsOrRightExpirationDate_lbl2" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightExpirationDate_lbl2">Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightExpirationDate" xlink:to="accp_ClassOfWarrantsOrRightExpirationDate_lbl2" xlink:title="label: ClassOfWarrantsOrRightExpirationDate to accp_ClassOfWarrantsOrRightExpirationDate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_WarrantsIssuedPrice" xlink:label="WarrantsIssuedPrice" xlink:title="WarrantsIssuedPrice" />
    <link:label xlink:type="resource" xlink:label="accp_WarrantsIssuedPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_WarrantsIssuedPrice_lbl" xml:lang="en-US" id="accp_WarrantsIssuedPrice_lbl">Price of a single warrant issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedPrice" xlink:to="accp_WarrantsIssuedPrice_lbl" xlink:title="label: WarrantsIssuedPrice to accp_WarrantsIssuedPrice_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_WarrantsIssuedPrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_WarrantsIssuedPrice_lbl1" xml:lang="en-US" id="accp_WarrantsIssuedPrice_lbl1">Warrants issued price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedPrice" xlink:to="accp_WarrantsIssuedPrice_lbl1" xlink:title="label: WarrantsIssuedPrice to accp_WarrantsIssuedPrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_WarrantsIssuedPrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_WarrantsIssuedPrice_lbl2" xml:lang="en-US" id="accp_WarrantsIssuedPrice_lbl2">Warrants issued price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedPrice" xlink:to="accp_WarrantsIssuedPrice_lbl2" xlink:title="label: WarrantsIssuedPrice to accp_WarrantsIssuedPrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TermOfWarrant" xlink:label="TermOfWarrant" xlink:title="TermOfWarrant" />
    <link:label xlink:type="resource" xlink:label="accp_TermOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_TermOfWarrant_lbl" xml:lang="en-US" id="accp_TermOfWarrant_lbl">The warrants have an exercise price per share and are exercisable for this duration from the closing date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfWarrant" xlink:to="accp_TermOfWarrant_lbl" xlink:title="label: TermOfWarrant to accp_TermOfWarrant_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_TermOfWarrant_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_TermOfWarrant_lbl1" xml:lang="en-US" id="accp_TermOfWarrant_lbl1">Term of warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfWarrant" xlink:to="accp_TermOfWarrant_lbl1" xlink:title="label: TermOfWarrant to accp_TermOfWarrant_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightsExercisablePeriod" xlink:label="ClassOfWarrantsOrRightsExercisablePeriod" xlink:title="ClassOfWarrantsOrRightsExercisablePeriod" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl">Exercisable period of warrants and rights outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightsExercisablePeriod" xlink:to="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl" xlink:title="label: ClassOfWarrantsOrRightsExercisablePeriod to accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl1" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl1">Class of Warrants Or Rights Exercisable Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightsExercisablePeriod" xlink:to="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl1" xlink:title="label: ClassOfWarrantsOrRightsExercisablePeriod to accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl2" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl2">Exercisable period of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightsExercisablePeriod" xlink:to="accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl2" xlink:title="label: ClassOfWarrantsOrRightsExercisablePeriod to accp_ClassOfWarrantsOrRightsExercisablePeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfBoardOfDirectors" xlink:label="NumberOfBoardOfDirectors" xlink:title="NumberOfBoardOfDirectors" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfBoardOfDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NumberOfBoardOfDirectors_lbl" xml:lang="en-US" id="accp_NumberOfBoardOfDirectors_lbl">Refers to number of board of directors in a company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardOfDirectors" xlink:to="accp_NumberOfBoardOfDirectors_lbl" xlink:title="label: NumberOfBoardOfDirectors to accp_NumberOfBoardOfDirectors_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfBoardOfDirectors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NumberOfBoardOfDirectors_lbl1" xml:lang="en-US" id="accp_NumberOfBoardOfDirectors_lbl1">Number of Board of Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardOfDirectors" xlink:to="accp_NumberOfBoardOfDirectors_lbl1" xlink:title="label: NumberOfBoardOfDirectors to accp_NumberOfBoardOfDirectors_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfBoardOfDirectors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_NumberOfBoardOfDirectors_lbl2" xml:lang="en-US" id="accp_NumberOfBoardOfDirectors_lbl2">Number of board of directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardOfDirectors" xlink:to="accp_NumberOfBoardOfDirectors_lbl2" xlink:title="label: NumberOfBoardOfDirectors to accp_NumberOfBoardOfDirectors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PlacementAgentWarrants1Member" xlink:label="PlacementAgentWarrants1Member" xlink:title="PlacementAgentWarrants1Member" />
    <link:label xlink:type="resource" xlink:label="accp_PlacementAgentWarrants1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PlacementAgentWarrants1Member_lbl" xml:lang="en-US" id="accp_PlacementAgentWarrants1Member_lbl">Warrants issued as a placement agent warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementAgentWarrants1Member" xlink:to="accp_PlacementAgentWarrants1Member_lbl" xlink:title="label: PlacementAgentWarrants1Member to accp_PlacementAgentWarrants1Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PlacementAgentWarrants1Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PlacementAgentWarrants1Member_lbl1" xml:lang="en-US" id="accp_PlacementAgentWarrants1Member_lbl1">Placement Agent Warrants 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementAgentWarrants1Member" xlink:to="accp_PlacementAgentWarrants1Member_lbl1" xlink:title="label: PlacementAgentWarrants1Member to accp_PlacementAgentWarrants1Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_PlacementAgentWarrants1Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_PlacementAgentWarrants1Member_lbl2" xml:lang="en-US" id="accp_PlacementAgentWarrants1Member_lbl2">2011 November Placement Agent Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementAgentWarrants1Member" xlink:to="accp_PlacementAgentWarrants1Member_lbl2" xlink:title="label: PlacementAgentWarrants1Member to accp_PlacementAgentWarrants1Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PrivatePlacement1Member" xlink:label="PrivatePlacement1Member" xlink:title="PrivatePlacement1Member" />
    <link:label xlink:type="resource" xlink:label="accp_PrivatePlacement1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PrivatePlacement1Member_lbl" xml:lang="en-US" id="accp_PrivatePlacement1Member_lbl">Warrants issued through private placement of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacement1Member" xlink:to="accp_PrivatePlacement1Member_lbl" xlink:title="label: PrivatePlacement1Member to accp_PrivatePlacement1Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PrivatePlacement1Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PrivatePlacement1Member_lbl1" xml:lang="en-US" id="accp_PrivatePlacement1Member_lbl1">Private Placement 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacement1Member" xlink:to="accp_PrivatePlacement1Member_lbl1" xlink:title="label: PrivatePlacement1Member to accp_PrivatePlacement1Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_PrivatePlacement1Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_PrivatePlacement1Member_lbl2" xml:lang="en-US" id="accp_PrivatePlacement1Member_lbl2">2011 November Private Placement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacement1Member" xlink:to="accp_PrivatePlacement1Member_lbl2" xlink:title="label: PrivatePlacement1Member to accp_PrivatePlacement1Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PublicOfferingMember" xlink:label="PublicOfferingMember" xlink:title="PublicOfferingMember" />
    <link:label xlink:type="resource" xlink:label="accp_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PublicOfferingMember_lbl" xml:lang="en-US" id="accp_PublicOfferingMember_lbl">Warrants issued through public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicOfferingMember" xlink:to="accp_PublicOfferingMember_lbl" xlink:title="label: PublicOfferingMember to accp_PublicOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PublicOfferingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PublicOfferingMember_lbl1" xml:lang="en-US" id="accp_PublicOfferingMember_lbl1">Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicOfferingMember" xlink:to="accp_PublicOfferingMember_lbl1" xlink:title="label: PublicOfferingMember to accp_PublicOfferingMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_PublicOfferingMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_PublicOfferingMember_lbl2" xml:lang="en-US" id="accp_PublicOfferingMember_lbl2">2014 December Financing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicOfferingMember" xlink:to="accp_PublicOfferingMember_lbl2" xlink:title="label: PublicOfferingMember to accp_PublicOfferingMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPrivatePlacementMember" xlink:label="SeriesBPrivatePlacementMember" xlink:title="SeriesBPrivatePlacementMember" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_SeriesBPrivatePlacementMember_lbl" xml:lang="en-US" id="accp_SeriesBPrivatePlacementMember_lbl">Warrants issued as a investor relation advisory services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPrivatePlacementMember" xlink:to="accp_SeriesBPrivatePlacementMember_lbl" xlink:title="label: SeriesBPrivatePlacementMember to accp_SeriesBPrivatePlacementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPrivatePlacementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_SeriesBPrivatePlacementMember_lbl1" xml:lang="en-US" id="accp_SeriesBPrivatePlacementMember_lbl1">2012 Series B private placement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPrivatePlacementMember" xlink:to="accp_SeriesBPrivatePlacementMember_lbl1" xlink:title="label: SeriesBPrivatePlacementMember to accp_SeriesBPrivatePlacementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_SeriesBPrivatePlacementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_SeriesBPrivatePlacementMember_lbl2" xml:lang="en-US" id="accp_SeriesBPrivatePlacementMember_lbl2">2012 Series B Private Placement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPrivatePlacementMember" xlink:to="accp_SeriesBPrivatePlacementMember_lbl2" xlink:title="label: SeriesBPrivatePlacementMember to accp_SeriesBPrivatePlacementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_MayFinancing2015Member" xlink:label="MayFinancing2015Member" xlink:title="MayFinancing2015Member" />
    <link:label xlink:type="resource" xlink:label="accp_MayFinancing2015Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_MayFinancing2015Member_lbl" xml:lang="en-US" id="accp_MayFinancing2015Member_lbl">Warrants issued through private placement of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayFinancing2015Member" xlink:to="accp_MayFinancing2015Member_lbl" xlink:title="label: MayFinancing2015Member to accp_MayFinancing2015Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_MayFinancing2015Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_MayFinancing2015Member_lbl1" xml:lang="en-US" id="accp_MayFinancing2015Member_lbl1">May Financing 2015 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayFinancing2015Member" xlink:to="accp_MayFinancing2015Member_lbl1" xlink:title="label: MayFinancing2015Member to accp_MayFinancing2015Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_MayFinancing2015Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_MayFinancing2015Member_lbl2" xml:lang="en-US" id="accp_MayFinancing2015Member_lbl2">2015 May Financing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayFinancing2015Member" xlink:to="accp_MayFinancing2015Member_lbl2" xlink:title="label: MayFinancing2015Member to accp_MayFinancing2015Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_Warrant2Member" xlink:label="Warrant2Member" xlink:title="Warrant2Member" />
    <link:label xlink:type="resource" xlink:label="accp_Warrant2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_Warrant2Member_lbl" xml:lang="en-US" id="accp_Warrant2Member_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Warrant2Member" xlink:to="accp_Warrant2Member_lbl" xlink:title="label: Warrant2Member to accp_Warrant2Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_Warrant2Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_Warrant2Member_lbl1" xml:lang="en-US" id="accp_Warrant2Member_lbl1">Warrant2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Warrant2Member" xlink:to="accp_Warrant2Member_lbl1" xlink:title="label: Warrant2Member to accp_Warrant2Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightsExpirationDate" xlink:label="ClassOfWarrantsOrRightsExpirationDate" xlink:title="ClassOfWarrantsOrRightsExpirationDate" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_ClassOfWarrantsOrRightsExpirationDate_lbl" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightsExpirationDate_lbl">Expiration date of each class of warrants or rights outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightsExpirationDate" xlink:to="accp_ClassOfWarrantsOrRightsExpirationDate_lbl" xlink:title="label: ClassOfWarrantsOrRightsExpirationDate to accp_ClassOfWarrantsOrRightsExpirationDate_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightsExpirationDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_ClassOfWarrantsOrRightsExpirationDate_lbl1" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightsExpirationDate_lbl1">Class of Warrants Or Rights Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightsExpirationDate" xlink:to="accp_ClassOfWarrantsOrRightsExpirationDate_lbl1" xlink:title="label: ClassOfWarrantsOrRightsExpirationDate to accp_ClassOfWarrantsOrRightsExpirationDate_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_ClassOfWarrantsOrRightsExpirationDate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_ClassOfWarrantsOrRightsExpirationDate_lbl2" xml:lang="en-US" id="accp_ClassOfWarrantsOrRightsExpirationDate_lbl2">Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightsExpirationDate" xlink:to="accp_ClassOfWarrantsOrRightsExpirationDate_lbl2" xlink:title="label: ClassOfWarrantsOrRightsExpirationDate to accp_ClassOfWarrantsOrRightsExpirationDate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PlacementAgentMember" xlink:label="PlacementAgentMember" xlink:title="PlacementAgentMember" />
    <link:label xlink:type="resource" xlink:label="accp_PlacementAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PlacementAgentMember_lbl" xml:lang="en-US" id="accp_PlacementAgentMember_lbl">A placement agent is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementAgentMember" xlink:to="accp_PlacementAgentMember_lbl" xlink:title="label: PlacementAgentMember to accp_PlacementAgentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PlacementAgentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PlacementAgentMember_lbl1" xml:lang="en-US" id="accp_PlacementAgentMember_lbl1">Placement Agent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementAgentMember" xlink:to="accp_PlacementAgentMember_lbl1" xlink:title="label: PlacementAgentMember to accp_PlacementAgentMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_MayFinancingAgentWarrants2015Member" xlink:label="MayFinancingAgentWarrants2015Member" xlink:title="MayFinancingAgentWarrants2015Member" />
    <link:label xlink:type="resource" xlink:label="accp_MayFinancingAgentWarrants2015Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_MayFinancingAgentWarrants2015Member_lbl" xml:lang="en-US" id="accp_MayFinancingAgentWarrants2015Member_lbl">Warrants issued as a placement agent warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayFinancingAgentWarrants2015Member" xlink:to="accp_MayFinancingAgentWarrants2015Member_lbl" xlink:title="label: MayFinancingAgentWarrants2015Member to accp_MayFinancingAgentWarrants2015Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_MayFinancingAgentWarrants2015Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_MayFinancingAgentWarrants2015Member_lbl1" xml:lang="en-US" id="accp_MayFinancingAgentWarrants2015Member_lbl1">May Financing Agent Warrants 2015 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayFinancingAgentWarrants2015Member" xlink:to="accp_MayFinancingAgentWarrants2015Member_lbl1" xlink:title="label: MayFinancingAgentWarrants2015Member to accp_MayFinancingAgentWarrants2015Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_MayFinancingAgentWarrants2015Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_MayFinancingAgentWarrants2015Member_lbl2" xml:lang="en-US" id="accp_MayFinancingAgentWarrants2015Member_lbl2">2015 May Financing Agent Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MayFinancingAgentWarrants2015Member" xlink:to="accp_MayFinancingAgentWarrants2015Member_lbl2" xlink:title="label: MayFinancingAgentWarrants2015Member to accp_MayFinancingAgentWarrants2015Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PublicOfferingAgentWarrantsMember" xlink:label="PublicOfferingAgentWarrantsMember" xlink:title="PublicOfferingAgentWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="accp_PublicOfferingAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_PublicOfferingAgentWarrantsMember_lbl" xml:lang="en-US" id="accp_PublicOfferingAgentWarrantsMember_lbl">Warrants issued as a placement agent warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicOfferingAgentWarrantsMember" xlink:to="accp_PublicOfferingAgentWarrantsMember_lbl" xlink:title="label: PublicOfferingAgentWarrantsMember to accp_PublicOfferingAgentWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_PublicOfferingAgentWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_PublicOfferingAgentWarrantsMember_lbl1" xml:lang="en-US" id="accp_PublicOfferingAgentWarrantsMember_lbl1">Public Offering Agent Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicOfferingAgentWarrantsMember" xlink:to="accp_PublicOfferingAgentWarrantsMember_lbl1" xlink:title="label: PublicOfferingAgentWarrantsMember to accp_PublicOfferingAgentWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_PublicOfferingAgentWarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_PublicOfferingAgentWarrantsMember_lbl2" xml:lang="en-US" id="accp_PublicOfferingAgentWarrantsMember_lbl2">2014 December Financing Agent Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicOfferingAgentWarrantsMember" xlink:to="accp_PublicOfferingAgentWarrantsMember_lbl2" xlink:title="label: PublicOfferingAgentWarrantsMember to accp_PublicOfferingAgentWarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_JulyFinancing2015Member" xlink:label="JulyFinancing2015Member" xlink:title="JulyFinancing2015Member" />
    <link:label xlink:type="resource" xlink:label="accp_JulyFinancing2015Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_JulyFinancing2015Member_lbl" xml:lang="en-US" id="accp_JulyFinancing2015Member_lbl">Warrants issued through private placement of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyFinancing2015Member" xlink:to="accp_JulyFinancing2015Member_lbl" xlink:title="label: JulyFinancing2015Member to accp_JulyFinancing2015Member_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_JulyFinancing2015Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_JulyFinancing2015Member_lbl1" xml:lang="en-US" id="accp_JulyFinancing2015Member_lbl1">July Financing 2015 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyFinancing2015Member" xlink:to="accp_JulyFinancing2015Member_lbl1" xlink:title="label: JulyFinancing2015Member to accp_JulyFinancing2015Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_JulyFinancing2015Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_JulyFinancing2015Member_lbl2" xml:lang="en-US" id="accp_JulyFinancing2015Member_lbl2">2015 July Financing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyFinancing2015Member" xlink:to="accp_JulyFinancing2015Member_lbl2" xlink:title="label: JulyFinancing2015Member to accp_JulyFinancing2015Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_BusinessAcquisitionsMember" xlink:label="BusinessAcquisitionsMember" xlink:title="BusinessAcquisitionsMember" />
    <link:label xlink:type="resource" xlink:label="accp_BusinessAcquisitionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_BusinessAcquisitionsMember_lbl" xml:lang="en-US" id="accp_BusinessAcquisitionsMember_lbl">Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionsMember" xlink:to="accp_BusinessAcquisitionsMember_lbl" xlink:title="label: BusinessAcquisitionsMember to accp_BusinessAcquisitionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_BusinessAcquisitionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_BusinessAcquisitionsMember_lbl1" xml:lang="en-US" id="accp_BusinessAcquisitionsMember_lbl1">Business Acquisitions [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionsMember" xlink:to="accp_BusinessAcquisitionsMember_lbl1" xlink:title="label: BusinessAcquisitionsMember to accp_BusinessAcquisitionsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_BusinessAcquisitionsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="accp_BusinessAcquisitionsMember_lbl2" xml:lang="en-US" id="accp_BusinessAcquisitionsMember_lbl2">Abeona Therapeutics LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionsMember" xlink:to="accp_BusinessAcquisitionsMember_lbl2" xlink:title="label: BusinessAcquisitionsMember to accp_BusinessAcquisitionsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfMilestones" xlink:label="NumberOfMilestones" xlink:title="NumberOfMilestones" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_NumberOfMilestones_lbl" xml:lang="en-US" id="accp_NumberOfMilestones_lbl">Refers to contingent valuation of number of milestones acquired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestones" xlink:to="accp_NumberOfMilestones_lbl" xlink:title="label: NumberOfMilestones to accp_NumberOfMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_NumberOfMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_NumberOfMilestones_lbl1" xml:lang="en-US" id="accp_NumberOfMilestones_lbl1">Number of milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestones" xlink:to="accp_NumberOfMilestones_lbl1" xlink:title="label: NumberOfMilestones to accp_NumberOfMilestones_lbl1" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" />
    <link:label xlink:type="resource" xlink:label="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl" xml:lang="en-US" id="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl">Amount of tangible assets acquired at the acquisition date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets to accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl1" xml:lang="en-US" id="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets to accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl2" xml:lang="en-US" id="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl2">Total tangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl2" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets to accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>accp-20151231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.0.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://accesspharma.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#AbeonaTherapeuticsLlcAcquisitionDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockOptionPlansDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#StockOptionPlansDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#StockholdersEquityDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/PreferredStockDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#PreferredStockDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#FairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/KPlanDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#KPlanDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/LicensedTechnologyDetailsCalc2" xlink:type="simple" xlink:href="accp-20151231.xsd#LicensedTechnologyDetailsCalc2" />
  <link:roleRef roleURI="http://accesspharma.com/role/LicensedTechnologyDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#LicensedTechnologyDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="accp-20151231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://accesspharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="accp-20151231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionTables" xlink:type="simple" xlink:href="accp-20151231.xsd#AbeonaTherapeuticsLlcAcquisitionTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockOptionPlansTables" xlink:type="simple" xlink:href="accp-20151231.xsd#StockOptionPlansTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="accp-20151231.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="accp-20151231.xsd#FairValueMeasurementsTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/CommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="accp-20151231.xsd#CommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/LicensedTechnologyTables" xlink:type="simple" xlink:href="accp-20151231.xsd#LicensedTechnologyTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="accp-20151231.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="accp-20151231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="accp-20151231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://accesspharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="accp-20151231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisition" xlink:type="simple" xlink:href="accp-20151231.xsd#AbeonaTherapeuticsLlcAcquisition" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockOptionPlans" xlink:type="simple" xlink:href="accp-20151231.xsd#StockOptionPlans" />
  <link:roleRef roleURI="http://accesspharma.com/role/StockholdersEquity" xlink:type="simple" xlink:href="accp-20151231.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://accesspharma.com/role/PreferredStock" xlink:type="simple" xlink:href="accp-20151231.xsd#PreferredStock" />
  <link:roleRef roleURI="http://accesspharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="accp-20151231.xsd#FairValueMeasurements" />
  <link:roleRef roleURI="http://accesspharma.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="accp-20151231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://accesspharma.com/role/KPlan" xlink:type="simple" xlink:href="accp-20151231.xsd#KPlan" />
  <link:roleRef roleURI="http://accesspharma.com/role/LicensedTechnology" xlink:type="simple" xlink:href="accp-20151231.xsd#LicensedTechnology" />
  <link:roleRef roleURI="http://accesspharma.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="accp-20151231.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://accesspharma.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="accp-20151231.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="accp-20151231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfStockholdersEquity" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://accesspharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="accp-20151231.xsd#ConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://accesspharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="accp-20151231.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCentralIndexKey" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityWellKnownSeasonedIssuer" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityVoluntaryFilers" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCurrentReportingStatus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityFilerCategory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityPublicFloat" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalYearFocus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalPeriodFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentType" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentType" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentFlag" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentPeriodEndDate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="ReceivablesNetCurrent" xlink:title="ReceivablesNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="ReceivablesNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to ReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: AssetsAbstract to FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Goodwill" xlink:title="presentation: AssetsAbstract to Goodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssets" xlink:label="OtherAssets" xlink:title="OtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssets" xlink:title="presentation: AssetsAbstract to OtherAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="ShortTermBorrowings" xlink:title="ShortTermBorrowings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ShortTermBorrowings" xlink:title="presentation: LiabilitiesCurrentAbstract to ShortTermBorrowings" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DeferredRevenueCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DeferredRevenueCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PayableDueLicensor" xlink:label="PayableDueLicensor" xlink:title="PayableDueLicensor" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="PayableDueLicensor" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to PayableDueLicensor" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRevenueNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRevenueNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="SalesRevenueNetAbstract" xlink:title="SalesRevenueNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="LicensesRevenue" xlink:title="presentation: SalesRevenueNetAbstract to LicensesRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="RoyaltyRevenue" xlink:title="presentation: SalesRevenueNetAbstract to RoyaltyRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="SalesRevenueNet" xlink:title="presentation: SalesRevenueNetAbstract to SalesRevenueNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="SalesRevenueNetAbstract" xlink:title="presentation: IncomeStatementAbstract to SalesRevenueNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: CostsAndExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: CostsAndExpensesAbstract to DepreciationDepletionAndAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="CostsAndExpenses" xlink:title="presentation: CostsAndExpensesAbstract to CostsAndExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="CostsAndExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to CostsAndExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="InvestmentIncomeNonoperating" xlink:title="InvestmentIncomeNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="InvestmentIncomeNonoperating" xlink:title="presentation: IncomeStatementAbstract to InvestmentIncomeNonoperating" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="InterestAndDebtExpense" xlink:title="InterestAndDebtExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="InterestAndDebtExpense" xlink:title="presentation: IncomeStatementAbstract to InterestAndDebtExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="presentation: IncomeStatementAbstract to DerivativeGainLossOnDerivativeNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="PreferredStockDividendsIncomeStatementImpact" xlink:title="PreferredStockDividendsIncomeStatementImpact" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="PreferredStockDividendsIncomeStatementImpact" xlink:title="presentation: IncomeStatementAbstract to PreferredStockDividendsIncomeStatementImpact" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasicAndDiluted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: StatementEquityComponentsAxis to SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="SeriesBPreferredStockMember" xlink:title="presentation: StatementEquityComponentsAxis to SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="TreasuryStockMember" xlink:title="TreasuryStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="TreasuryStockMember" xlink:title="presentation: StatementEquityComponentsAxis to TreasuryStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="presentation: StatementLineItems to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="presentation: StatementLineItems to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueIssuedForServices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="StockIssuedDuringPeriodValueReverseStockSplits" xlink:title="StockIssuedDuringPeriodValueReverseStockSplits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueReverseStockSplits" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueReverseStockSplits" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesReverseStockSplits" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TreasuryStockValueRetired" xlink:label="TreasuryStockValueRetired" xlink:title="TreasuryStockValueRetired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TreasuryStockValueRetired" xlink:title="presentation: StatementLineItems to TreasuryStockValueRetired" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="TreasuryStockSharesRetired" xlink:title="TreasuryStockSharesRetired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TreasuryStockSharesRetired" xlink:title="presentation: StatementLineItems to TreasuryStockSharesRetired" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueShareBasedCompensation" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesShareBasedCompensation" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueWarrantsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesWarrantsExercised" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueNewIssues" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueNewIssue" xlink:label="StockIssuedDuringPeriodValueNewIssue" xlink:title="StockIssuedDuringPeriodValueNewIssue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssue" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueNewIssue" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesNewIssue" xlink:label="StockIssuedDuringPeriodSharesNewIssue" xlink:title="StockIssuedDuringPeriodSharesNewIssue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssue" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesNewIssue" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueNewIssueOne" xlink:label="StockIssuedDuringPeriodValueNewIssueOne" xlink:title="StockIssuedDuringPeriodValueNewIssueOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssueOne" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueNewIssueOne" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesNewIssueOne" xlink:label="StockIssuedDuringPeriodSharesNewIssueOne" xlink:title="StockIssuedDuringPeriodSharesNewIssueOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssueOne" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesNewIssueOne" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:label="StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:title="StockIssuedDuringPeriodValueSeriesAPreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSeriesAPreferredStock" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueSeriesAPreferredStock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:label="StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:title="StockIssuedDuringPeriodSharesSeriesAPreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesSeriesAPreferredStock" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesSeriesAPreferredStock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:label="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:title="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:label="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:title="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:label="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:title="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" xlink:title="presentation: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:label="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:title="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" xlink:title="presentation: StatementLineItems to SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:label="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:title="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" xlink:title="presentation: StatementLineItems to SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:label="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:title="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" xlink:title="presentation: StatementLineItems to SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:label="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:title="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" xlink:title="presentation: StatementLineItems to SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:label="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:title="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" xlink:title="presentation: StatementLineItems to StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:label="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:title="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" xlink:title="presentation: StatementLineItems to StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueAcquisitions" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:label="StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:title="StockIssuedDuringPeriodValueReverseStockSplitsOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueReverseStockSplitsOne" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueReverseStockSplitsOne" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplitsOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesReverseStockSplitsOne" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesReverseStockSplitsOne" order="36.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DividendsPreferredStockCash" xlink:title="presentation: StatementLineItems to DividendsPreferredStockCash" order="38.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="presentation: StatementLineItems to NetIncomeLoss" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockholdersEquity_2" xlink:title="presentation: StatementLineItems to StockholdersEquity" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharesOutstanding_2" xlink:title="presentation: StatementLineItems to SharesOutstanding" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: StatementOfStockholdersEquityAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="SharePrice" xlink:title="presentation: StatementOfStockholdersEquityAbstract to SharePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NewIssuesSharePricePerShare" xlink:label="NewIssuesSharePricePerShare" xlink:title="NewIssuesSharePricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="NewIssuesSharePricePerShare" xlink:title="presentation: StatementOfStockholdersEquityAbstract to NewIssuesSharePricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NewIssuesShareOnePricePerShare" xlink:label="NewIssuesShareOnePricePerShare" xlink:title="NewIssuesShareOnePricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="NewIssuesShareOnePricePerShare" xlink:title="presentation: StatementOfStockholdersEquityAbstract to NewIssuesShareOnePricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DerivativeGainLossOnDerivativeNet" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:label="CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:title="CommonStockIssuedToEmployeesDirectorsAndConsultants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="CommonStockIssuedToEmployeesDirectorsAndConsultants" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to CommonStockIssuedToEmployeesDirectorsAndConsultants" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IssuanceOfStockAndWarrantsForServicesOrClaims" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="IncreaseDecreaseInReceivables" xlink:title="IncreaseDecreaseInReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInReceivables" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="IncreaseDecreaseInOtherNoncurrentAssets" xlink:title="IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherNoncurrentAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherNoncurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_IncreaseDecreaseInInterestPayableOnDividends" xlink:label="IncreaseDecreaseInInterestPayableOnDividends" xlink:title="IncreaseDecreaseInInterestPayableOnDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInterestPayableOnDividends" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInterestPayableOnDividends" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_IncreaseDecreaseInContingentConsiderationMilestone" xlink:label="IncreaseDecreaseInContingentConsiderationMilestone" xlink:title="IncreaseDecreaseInContingentConsiderationMilestone" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInContingentConsiderationMilestone" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInContingentConsiderationMilestone" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDeferredRevenue" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDeferredRevenue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:label="ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:title="ProceedsFromIssuanceOfCommonStockNetOfCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockNetOfCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStockNetOfCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:label="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:title="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockOneNetOfCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStockOneNetOfCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromWarrantExercises" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromWarrantExercises" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:label="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:title="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStockTwoNetOfCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="ProceedsFromShortTermDebt" xlink:title="ProceedsFromShortTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromShortTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromShortTermDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsPeriodIncreaseDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAtCarryingValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAtCarryingValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaid" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:title="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_BusinessCombinationContingentConsideration" xlink:label="BusinessCombinationContingentConsideration" xlink:title="BusinessCombinationContingentConsideration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="BusinessCombinationContingentConsideration" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to BusinessCombinationContingentConsideration" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NoncashOrPartNoncashAcquisitionLicensedTecnology" xlink:label="NoncashOrPartNoncashAcquisitionLicensedTecnology" xlink:title="NoncashOrPartNoncashAcquisitionLicensedTecnology" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionLicensedTecnology" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashAcquisitionLicensedTecnology" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TreasuryStockCancel" xlink:label="TreasuryStockCancel" xlink:title="TreasuryStockCancel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="TreasuryStockCancel" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to TreasuryStockCancel" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:label="PayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:title="PayableForFutureIssuanceOfSharesForLicensedTechnology" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="PayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to PayableForFutureIssuanceOfSharesForLicensedTechnology" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="DividendsPreferredStockCash" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to DividendsPreferredStockCash" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="ConversionOfStockTable" xlink:title="ConversionOfStockTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:label="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:title="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfStockNameDomain" xlink:to="ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:title="presentation: ConversionOfStockNameDomain to ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:label="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:title="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfStockNameDomain" xlink:to="ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" xlink:title="presentation: ConversionOfStockNameDomain to ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain" xlink:title="presentation: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfStockTable" xlink:to="ConversionOfStockByUniqueDescriptionAxis" xlink:title="presentation: ConversionOfStockTable to ConversionOfStockByUniqueDescriptionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="ConversionOfStockLineItems" xlink:title="ConversionOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfStockLineItems" xlink:to="ConversionOfStockAmountConverted1" xlink:title="presentation: ConversionOfStockLineItems to ConversionOfStockAmountConverted1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfStockTable" xlink:to="ConversionOfStockLineItems" xlink:title="presentation: ConversionOfStockTable to ConversionOfStockLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfStockTable" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to ConversionOfStockTable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NoncashInvestingAndFinancingItemsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SharePrice" xlink:title="presentation: StatementOfCashFlowsAbstract to SharePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NewIssuesSharePricePerShare" xlink:label="NewIssuesSharePricePerShare" xlink:title="NewIssuesSharePricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NewIssuesSharePricePerShare" xlink:title="presentation: StatementOfCashFlowsAbstract to NewIssuesSharePricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NewIssuesShareOnePricePerShare" xlink:label="NewIssuesShareOnePricePerShare" xlink:title="NewIssuesShareOnePricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NewIssuesShareOnePricePerShare" xlink:title="presentation: StatementOfCashFlowsAbstract to NewIssuesShareOnePricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: StatementOfCashFlowsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/RelatedPartyTransactions">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: RelatedPartyTransactionsAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PropertyAndEquipment">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/LicensedTechnology">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/KPlan">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/FairValueMeasurements">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PreferredStock">
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PreferredStockAbstract" xlink:label="PreferredStockAbstract" xlink:title="PreferredStockAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="PreferredStockTextBlock" xlink:title="PreferredStockTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockAbstract" xlink:to="PreferredStockTextBlock" xlink:title="presentation: PreferredStockAbstract to PreferredStockTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockOptionPlans">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisition">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="BusinessCombinationDisclosureTextBlock" xlink:title="BusinessCombinationDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="BusinessCombinationDisclosureTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to BusinessCombinationDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NatureOfOperationsPolicyTextBlock" xlink:label="NatureOfOperationsPolicyTextBlock" xlink:title="NatureOfOperationsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureOfOperationsPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NatureOfOperationsPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ConsolidationPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="SegmentReportingPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to SegmentReportingPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ReceivablesPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ReceivablesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_LicensedTechnologyPolicyTextBlock" xlink:label="LicensedTechnologyPolicyTextBlock" xlink:title="LicensedTechnologyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="LicensedTechnologyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to LicensedTechnologyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="RevenueRecognitionPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to RevenueRecognitionPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to GoodwillAndIntangibleAssetsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ResearchAndDevelopmentExpensePolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_OtherIncomePolicyTextBlock" xlink:label="OtherIncomePolicyTextBlock" xlink:title="OtherIncomePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OtherIncomePolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OtherIncomePolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to IncomeTaxPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PropertyAndEquipmentTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/LicensedTechnologyTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/CommitmentsAndContingenciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:title="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/FairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockholdersEquityTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockOptionPlansTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_EquityIncentivePlan2015Member" xlink:label="EquityIncentivePlan2015Member" xlink:title="EquityIncentivePlan2015Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2015Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2015Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_EquityIncentivePlan2005Member" xlink:label="EquityIncentivePlan2005Member" xlink:title="EquityIncentivePlan2005Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2005Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2005Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:title="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/IncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" xlink:label="SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" xlink:title="SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="CashEquivalentsAtCarryingValue" xlink:title="presentation: CashAndCashEquivalentsAtCarryingValueAbstract to CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" xlink:label="NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" xlink:title="NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" xlink:title="presentation: CashAndCashEquivalentsAtCarryingValueAbstract to NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to CashAndCashEquivalentsAtCarryingValueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="AllowanceForDoubtfulAccountsReceivable" xlink:title="AllowanceForDoubtfulAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="AllowanceForDoubtfulAccountsReceivable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to AllowanceForDoubtfulAccountsReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:title="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="LicenseAgreementTermsMember" xlink:title="LicenseAgreementTermsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="LicenseAgreementTermsMember" xlink:title="presentation: ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to LicenseAgreementTermsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_LicenseAgreementTerms1Member" xlink:label="LicenseAgreementTerms1Member" xlink:title="LicenseAgreementTerms1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="LicenseAgreementTerms1Member" xlink:title="presentation: ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to LicenseAgreementTerms1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="presentation: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="presentation: ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable to ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfPatentFamily" xlink:label="NumberOfPatentFamily" xlink:title="NumberOfPatentFamily" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="NumberOfPatentFamily" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to NumberOfPatentFamily" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="LicenseCosts" xlink:title="LicenseCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="LicenseCosts" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to LicenseCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:label="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:title="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to StockIssuedDuringPeriodSharesIssuedForServices" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetUsefulLife" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RegulatoryApprovalMilestonePayment" xlink:label="RegulatoryApprovalMilestonePayment" xlink:title="RegulatoryApprovalMilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="RegulatoryApprovalMilestonePayment" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to RegulatoryApprovalMilestonePayment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="presentation: ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:title="presentation: ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable to ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="PropertyPlantAndEquipmentAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to PropertyPlantAndEquipmentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_GoodwillAbstract" xlink:label="GoodwillAbstract" xlink:title="GoodwillAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAbstract" xlink:to="Goodwill" xlink:title="presentation: GoodwillAbstract to Goodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="GoodwillAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to GoodwillAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="OtherIncomeAbstract" xlink:title="OtherIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeAbstract" xlink:to="OtherNonoperatingIncome" xlink:title="presentation: OtherIncomeAbstract to OtherNonoperatingIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OtherIncomeAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OtherIncomeAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfYearsSubjectToStatuteOfLimitations" xlink:label="NumberOfYearsSubjectToStatuteOfLimitations" xlink:title="NumberOfYearsSubjectToStatuteOfLimitations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NumberOfYearsSubjectToStatuteOfLimitations" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NumberOfYearsSubjectToStatuteOfLimitations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="EarningsPerShareBasicAndDilutedAbstract" xlink:title="EarningsPerShareBasicAndDilutedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to EarningsPerShareBasicAndDiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to NetIncomeLossAvailableToCommonStockholdersDiluted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasicAndDilutedAbstract" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasicAndDilutedAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to SeriesAPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="SeriesBPreferredStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to SeriesBPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to EarningsPerShareAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfStockBasedCompensationPlans" xlink:label="NumberOfStockBasedCompensationPlans" xlink:title="NumberOfStockBasedCompensationPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfStockBasedCompensationPlans" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfStockBasedCompensationPlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: ShareBasedCompensationAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="OperatingExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to OperatingExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:title="EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="AllocatedShareBasedCompensationExpenseNetOfTax" xlink:title="AllocatedShareBasedCompensationExpenseNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpenseNetOfTax" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpenseNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: ShareBasedCompensationAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ShareBasedCompensationAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ScoCapitalPartnersLlcMember" xlink:label="ScoCapitalPartnersLlcMember" xlink:title="ScoCapitalPartnersLlcMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="ScoCapitalPartnersLlcMember" xlink:title="presentation: RelatedPartyDomain to ScoCapitalPartnersLlcMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="UnsecuredDebtMember" xlink:title="UnsecuredDebtMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="UnsecuredDebtMember" xlink:title="presentation: LongtermDebtTypeDomain to UnsecuredDebtMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SecondUnsecuredGridNoteMember" xlink:label="SecondUnsecuredGridNoteMember" xlink:title="SecondUnsecuredGridNoteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="SecondUnsecuredGridNoteMember" xlink:title="presentation: LongtermDebtTypeDomain to SecondUnsecuredGridNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to LongtermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesBPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesBPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ConversionOfStockAmountConverted1" xlink:title="presentation: RelatedPartyTransactionLineItems to ConversionOfStockAmountConverted1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="presentation: RelatedPartyTransactionLineItems to LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:title="LineOfCreditFacilityMaximumMonthendOutstandingAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:title="presentation: RelatedPartyTransactionLineItems to LineOfCreditFacilityMaximumMonthendOutstandingAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:title="LineOfCreditFacilityInterestRateAtPeriodEnd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:title="presentation: RelatedPartyTransactionLineItems to LineOfCreditFacilityInterestRateAtPeriodEnd" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="LineOfCreditFacilityExpirationDate1" xlink:title="LineOfCreditFacilityExpirationDate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="LineOfCreditFacilityExpirationDate1" xlink:title="presentation: RelatedPartyTransactionLineItems to LineOfCreditFacilityExpirationDate1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_DebtInstrumentCovenantComplianceValue" xlink:label="DebtInstrumentCovenantComplianceValue" xlink:title="DebtInstrumentCovenantComplianceValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentCovenantComplianceValue" xlink:title="presentation: RelatedPartyTransactionLineItems to DebtInstrumentCovenantComplianceValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: RelatedPartyTransactionsAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentNetByTypeAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentNetByTypeAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentNetByTypeAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="DepreciationAndAmortization" xlink:title="presentation: PropertyPlantAndEquipmentNetByTypeAbstract to DepreciationAndAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetByTypeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/LicensedTechnologyDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/LicensedTechnologyDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/KPlanDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:title="DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfInvestmentOptions" xlink:label="NumberOfInvestmentOptions" xlink:title="NumberOfInvestmentOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="NumberOfInvestmentOptions" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to NumberOfInvestmentOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="DefinedContributionPlanCostRecognized" xlink:title="DefinedContributionPlanCostRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="DefinedContributionPlanCostRecognized" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to DefinedContributionPlanCostRecognized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="ScheduleOfOperatingLeasedAssetsTable" xlink:title="ScheduleOfOperatingLeasedAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to BuildingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_Building2Member" xlink:label="Building2Member" xlink:title="Building2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="Building2Member" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to Building2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_Building3Member" xlink:label="Building3Member" xlink:title="Building3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="Building3Member" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to Building3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasedAssetsTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfOperatingLeasedAssetsTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="OperatingLeasedAssetsLineItems" xlink:title="OperatingLeasedAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="LeasesOperatingAbstract" xlink:title="LeasesOperatingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesOperatingAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="presentation: LeasesOperatingAbstract to OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementLeaseRevenue" xlink:label="OperatingLeasesIncomeStatementLeaseRevenue" xlink:title="OperatingLeasesIncomeStatementLeaseRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesOperatingAbstract" xlink:to="OperatingLeasesIncomeStatementLeaseRevenue" xlink:title="presentation: LeasesOperatingAbstract to OperatingLeasesIncomeStatementLeaseRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_LeaseExtensionPeriod" xlink:label="LeaseExtensionPeriod" xlink:title="LeaseExtensionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesOperatingAbstract" xlink:to="LeaseExtensionPeriod" xlink:title="presentation: LeasesOperatingAbstract to LeaseExtensionPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TotalLeaseCostsAndUnamortizedTenantImprovements" xlink:label="TotalLeaseCostsAndUnamortizedTenantImprovements" xlink:title="TotalLeaseCostsAndUnamortizedTenantImprovements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesOperatingAbstract" xlink:to="TotalLeaseCostsAndUnamortizedTenantImprovements" xlink:title="presentation: LeasesOperatingAbstract to TotalLeaseCostsAndUnamortizedTenantImprovements" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="LeasesOperatingAbstract" xlink:title="presentation: OperatingLeasedAssetsLineItems to LeasesOperatingAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="presentation: OperatingLeasesFutureMinimumPaymentsDueAbstract to OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="presentation: OperatingLeasesFutureMinimumPaymentsDueAbstract to OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="presentation: OperatingLeasesFutureMinimumPaymentsDueAbstract to OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="presentation: OperatingLeasesFutureMinimumPaymentsDueAbstract to OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:title="presentation: OperatingLeasesFutureMinimumPaymentsDueAbstract to OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="OperatingLeasesFutureMinimumPaymentsDue" xlink:title="OperatingLeasesFutureMinimumPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentsDue" xlink:title="presentation: OperatingLeasesFutureMinimumPaymentsDueAbstract to OperatingLeasesFutureMinimumPaymentsDue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="presentation: OperatingLeasedAssetsLineItems to OperatingLeasesFutureMinimumPaymentsDueAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="OperatingLeasesRentExpenseNet" xlink:title="OperatingLeasesRentExpenseNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasedAssetsLineItems" xlink:to="OperatingLeasesRentExpenseNet" xlink:title="presentation: OperatingLeasedAssetsLineItems to OperatingLeasesRentExpenseNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasedAssetsTable" xlink:to="OperatingLeasedAssetsLineItems" xlink:title="presentation: ScheduleOfOperatingLeasedAssetsTable to OperatingLeasedAssetsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfOperatingLeasedAssetsTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to ScheduleOfOperatingLeasedAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="PreferredStockMember" xlink:title="presentation: ClassOfStockDomain to PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract to BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_DerivativeLiabilityPreferredStock" xlink:label="DerivativeLiabilityPreferredStock" xlink:title="DerivativeLiabilityPreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="DerivativeLiabilityPreferredStock" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract to DerivativeLiabilityPreferredStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract to DerivativeGainLossOnDerivativeNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/PreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PreferredStockAbstract" xlink:label="PreferredStockAbstract" xlink:title="PreferredStockAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesBPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PreferredStockOffering2008Member" xlink:label="PreferredStockOffering2008Member" xlink:title="PreferredStockOffering2008Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="PreferredStockOffering2008Member" xlink:title="presentation: ClassOfStockDomain to PreferredStockOffering2008Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="SubsidiariesMember" xlink:title="SubsidiariesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="SubsidiariesMember" xlink:title="presentation: RelatedPartyDomain to SubsidiariesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfStockByClassTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: ScheduleOfStockByClassTable to FinancialInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: ClassOfStockLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:label="InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:title="InitialConversionPriceOfPreferredStockIntoCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="InitialConversionPriceOfPreferredStockIntoCommonStock" xlink:title="presentation: ClassOfStockLineItems to InitialConversionPriceOfPreferredStockIntoCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: ClassOfStockLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_DerivativeLiabilityPreferredStock" xlink:label="DerivativeLiabilityPreferredStock" xlink:title="DerivativeLiabilityPreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="DerivativeLiabilityPreferredStock" xlink:title="presentation: ClassOfStockLineItems to DerivativeLiabilityPreferredStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="presentation: ClassOfStockLineItems to DerivativeGainLossOnDerivativeNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="DerivativeGainOnDerivative" xlink:title="DerivativeGainOnDerivative" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="DerivativeGainOnDerivative" xlink:title="presentation: ClassOfStockLineItems to DerivativeGainOnDerivative" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightsWarrantsExpired" xlink:label="ClassOfWarrantsOrRightsWarrantsExpired" xlink:title="ClassOfWarrantsOrRightsWarrantsExpired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantsOrRightsWarrantsExpired" xlink:title="presentation: ClassOfStockLineItems to ClassOfWarrantsOrRightsWarrantsExpired" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_AccruedPotentialLiquidatedDamages" xlink:label="AccruedPotentialLiquidatedDamages" xlink:title="AccruedPotentialLiquidatedDamages" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="AccruedPotentialLiquidatedDamages" xlink:title="presentation: ClassOfStockLineItems to AccruedPotentialLiquidatedDamages" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:label="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:title="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" xlink:title="presentation: ClassOfStockLineItems to PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:label="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:title="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" xlink:title="presentation: ClassOfStockLineItems to ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="DividendsPayableCurrentAndNoncurrent" xlink:title="DividendsPayableCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="DividendsPayableCurrentAndNoncurrent" xlink:title="presentation: ClassOfStockLineItems to DividendsPayableCurrentAndNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: PreferredStockAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_JulyFinancing2015Member" xlink:label="JulyFinancing2015Member" xlink:title="JulyFinancing2015Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="JulyFinancing2015Member" xlink:title="presentation: ClassOfWarrantOrRightDomain to JulyFinancing2015Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_MayFinancing2015Member" xlink:label="MayFinancing2015Member" xlink:title="MayFinancing2015Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayFinancing2015Member" xlink:title="presentation: ClassOfWarrantOrRightDomain to MayFinancing2015Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_MayFinancingAgentWarrants2015Member" xlink:label="MayFinancingAgentWarrants2015Member" xlink:title="MayFinancingAgentWarrants2015Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="MayFinancingAgentWarrants2015Member" xlink:title="presentation: ClassOfWarrantOrRightDomain to MayFinancingAgentWarrants2015Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PublicOfferingMember" xlink:label="PublicOfferingMember" xlink:title="PublicOfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PublicOfferingMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PublicOfferingMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PublicOfferingAgentWarrantsMember" xlink:label="PublicOfferingAgentWarrantsMember" xlink:title="PublicOfferingAgentWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PublicOfferingAgentWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PublicOfferingAgentWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_SeriesBPrivatePlacementMember" xlink:label="SeriesBPrivatePlacementMember" xlink:title="SeriesBPrivatePlacementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeriesBPrivatePlacementMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to SeriesBPrivatePlacementMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PrivatePlacement1Member" xlink:label="PrivatePlacement1Member" xlink:title="PrivatePlacement1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PrivatePlacement1Member" xlink:title="presentation: ClassOfWarrantOrRightDomain to PrivatePlacement1Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PlacementAgentWarrants1Member" xlink:label="PlacementAgentWarrants1Member" xlink:title="PlacementAgentWarrants1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PlacementAgentWarrants1Member" xlink:title="presentation: ClassOfWarrantOrRightDomain to PlacementAgentWarrants1Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_Warrant2Member" xlink:label="Warrant2Member" xlink:title="Warrant2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="Warrant2Member" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to Warrant2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="PrivatePlacementMember" xlink:title="PrivatePlacementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="PrivatePlacementMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to PrivatePlacementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PlacementAgentMember" xlink:label="PlacementAgentMember" xlink:title="PlacementAgentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="PlacementAgentMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to PlacementAgentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ProceedsFromIssuanceOfPrivatePlacement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfBoardOfDirectors" xlink:label="NumberOfBoardOfDirectors" xlink:title="NumberOfBoardOfDirectors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="NumberOfBoardOfDirectors" xlink:title="presentation: ClassOfWarrantOrRightLineItems to NumberOfBoardOfDirectors" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="SharePrice" xlink:title="presentation: ClassOfWarrantOrRightLineItems to SharePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: ClassOfWarrantOrRightLineItems to StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TermOfWarrant" xlink:label="TermOfWarrant" xlink:title="TermOfWarrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="TermOfWarrant" xlink:title="presentation: ClassOfWarrantOrRightLineItems to TermOfWarrant" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_WarrantsIssuedPrice" xlink:label="WarrantsIssuedPrice" xlink:title="WarrantsIssuedPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsIssuedPrice" xlink:title="presentation: ClassOfWarrantOrRightLineItems to WarrantsIssuedPrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightsExercisablePeriod" xlink:label="ClassOfWarrantsOrRightsExercisablePeriod" xlink:title="ClassOfWarrantsOrRightsExercisablePeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantsOrRightsExercisablePeriod" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ClassOfWarrantsOrRightsExercisablePeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ProceedsFromIssuanceOrSaleOfEquity" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightsExpirationDate" xlink:label="ClassOfWarrantsOrRightsExpirationDate" xlink:title="ClassOfWarrantsOrRightsExpirationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantsOrRightsExpirationDate" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ClassOfWarrantsOrRightsExpirationDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_ClassOfWarrantsOrRightExpirationDate" xlink:label="ClassOfWarrantsOrRightExpirationDate" xlink:title="ClassOfWarrantsOrRightExpirationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantsOrRightExpirationDate" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ClassOfWarrantsOrRightExpirationDate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightLineItems" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ClassOfWarrantOrRightTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ClassOfWarrantOrRightTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/StockOptionPlansDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_EquityIncentivePlan2015Member" xlink:label="EquityIncentivePlan2015Member" xlink:title="EquityIncentivePlan2015Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2015Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2015Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_EquityIncentivePlan2005Member" xlink:label="EquityIncentivePlan2005Member" xlink:title="EquityIncentivePlan2005Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2005Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2005Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeSixMember" xlink:label="RangeSixMember" xlink:title="RangeSixMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeSixMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeSixMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeOneMember" xlink:label="RangeOneMember" xlink:title="RangeOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeOneMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeTwoMember" xlink:label="RangeTwoMember" xlink:title="RangeTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeTwoMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeThreeMember" xlink:label="RangeThreeMember" xlink:title="RangeThreeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeThreeMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeFourMember" xlink:label="RangeFourMember" xlink:title="RangeFourMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeFourMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_RangeFiveMember" xlink:label="RangeFiveMember" xlink:title="RangeFiveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="RangeFiveMember" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to RangeFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_BusinessAcquisitionsMember" xlink:label="BusinessAcquisitionsMember" xlink:title="BusinessAcquisitionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="BusinessAcquisitionsMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to BusinessAcquisitionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: BusinessAcquisitionLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="BusinessAcquisitionSharePrice" xlink:title="BusinessAcquisitionSharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionSharePrice" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessAcquisitionSharePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_NumberOfMilestones" xlink:label="NumberOfMilestones" xlink:title="NumberOfMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="NumberOfMilestones" xlink:title="presentation: BusinessAcquisitionLineItems to NumberOfMilestones" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:title="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:title="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to BusinessCombinationConsiderationTransferredLiabilitiesIncurred" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="BusinessCombinationConsiderationTransferred1" xlink:title="BusinessCombinationConsiderationTransferred1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="BusinessCombinationConsiderationTransferred1" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to BusinessCombinationConsiderationTransferred1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="Goodwill" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to Goodwill" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationConsiderationTransferredAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessCombinationConsiderationTransferredAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://accesspharma.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_IncomeTaxReconciliationCurrentYearReserve" xlink:label="IncomeTaxReconciliationCurrentYearReserve" xlink:title="IncomeTaxReconciliationCurrentYearReserve" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationCurrentYearReserve" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationCurrentYearReserve" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="IncomeTaxReconciliationOtherReconcilingItems" xlink:title="IncomeTaxReconciliationOtherReconcilingItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationOtherReconcilingItems" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationOtherReconcilingItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="DeferredTaxAssetsGrossAbstract" xlink:title="DeferredTaxAssetsGrossAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="DeferredTaxAssetsStateTaxes" xlink:title="DeferredTaxAssetsStateTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsStateTaxes" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsStateTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="DeferredTaxLiabilitiesDerivatives" xlink:title="DeferredTaxLiabilitiesDerivatives" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxLiabilitiesDerivatives" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxLiabilitiesDerivatives" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="DeferredTaxAssetsDeferredIncome" xlink:title="DeferredTaxAssetsDeferredIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsDeferredIncome" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsDeferredIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsGoodwillAndIntangibleAssets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsOther" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsOther" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsGrossAbstract" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsGrossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsGross" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsNet" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to ComponentsOfDeferredTaxAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TaxYear2016Member" xlink:label="TaxYear2016Member" xlink:title="TaxYear2016Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2016Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2016Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TaxYear2017Member" xlink:label="TaxYear2017Member" xlink:title="TaxYear2017Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2017Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2017Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="LatestTaxYearMember" xlink:title="LatestTaxYearMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="LatestTaxYearMember" xlink:title="presentation: TaxPeriodDomain to LatestTaxYearMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_TaxYearThereafterMember" xlink:label="TaxYearThereafterMember" xlink:title="TaxYearThereafterMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYearThereafterMember" xlink:title="presentation: TaxPeriodDomain to TaxYearThereafterMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="presentation: TaxPeriodAxis to TaxPeriodDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxPeriodAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to TaxPeriodAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PreMergerMember" xlink:label="PreMergerMember" xlink:title="PreMergerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="PreMergerMember" xlink:title="presentation: ScenarioUnspecifiedDomain to PreMergerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="accp-20151231.xsd#accp_PostMergerMember" xlink:label="PostMergerMember" xlink:title="PostMergerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="PostMergerMember" xlink:title="presentation: ScenarioUnspecifiedDomain to PostMergerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="presentation: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="OperatingLossCarryforwardsLineItems" xlink:title="presentation: OperatingLossCarryforwardsTable to OperatingLossCarryforwardsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="OperatingLossCarryforwardsTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to OperatingLossCarryforwardsTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="TaxCreditCarryforwardTable" xlink:title="TaxCreditCarryforwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="GeneralBusinessMember" xlink:title="GeneralBusinessMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="GeneralBusinessMember" xlink:title="presentation: TaxCreditCarryforwardNameDomain to GeneralBusinessMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="presentation: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxCreditCarryforwardAxis" xlink:title="presentation: TaxCreditCarryforwardTable to TaxCreditCarryforwardAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxPeriodAxis" xlink:title="presentation: TaxCreditCarryforwardTable to TaxPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="TaxCreditCarryforwardLineItems" xlink:title="TaxCreditCarryforwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardAmount" xlink:title="presentation: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxCreditCarryforwardLineItems" xlink:title="presentation: TaxCreditCarryforwardTable to TaxCreditCarryforwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="TaxCreditCarryforwardTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to TaxCreditCarryforwardTable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828651824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABEONA THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,743,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828866544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 40,138,000<span></span>
</td>
<td class="nump">$ 11,520,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">315,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">40,568,000<span></span>
</td>
<td class="nump">11,555,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Licensed technology, net</a></td>
<td class="nump">6,609,000<span></span>
</td>
<td class="nump">4,991,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">32,466,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">62,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">80,055,000<span></span>
</td>
<td class="nump">16,582,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">875,000<span></span>
</td>
<td class="nump">1,896,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-terms note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">602,000<span></span>
</td>
<td class="nump">602,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,477,000<span></span>
</td>
<td class="nump">2,898,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability</a></td>
<td class="nump">2,591,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_PayableDueLicensor', window );">Payable due Licensor</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">4,266,000<span></span>
</td>
<td class="nump">4,868,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 12,334,000<span></span>
</td>
<td class="nump">$ 11,766,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $.01 par value; authorized 200,000,000 shares; issued 32,743,013 at December 31, 2015; issued 19,960,801 at December 31, 2014</a></td>
<td class="nump">$ 328,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">377,993,000<span></span>
</td>
<td class="nump">300,690,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(310,600,000)<span></span>
</td>
<td class="num">(296,074,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">67,721,000<span></span>
</td>
<td class="nump">4,816,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 80,055,000<span></span>
</td>
<td class="nump">$ 16,582,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_PayableDueLicensor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable due licensor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_PayableDueLicensor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 10<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),16(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 13<br> -Subparagraph 2, 3<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6763858848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">32,743,013<span></span>
</td>
<td class="nump">19,960,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828857952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenues</a></td>
<td class="nump">$ 602,000<span></span>
</td>
<td class="nump">$ 598,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalties</a></td>
<td class="nump">438,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
<td class="nump">1,040,000<span></span>
</td>
<td class="nump">925,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,715,000<span></span>
</td>
<td class="nump">333,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,320,000<span></span>
</td>
<td class="nump">3,712,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">551,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">19,586,000<span></span>
</td>
<td class="nump">4,056,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,546,000)<span></span>
</td>
<td class="num">(3,131,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest and miscellaneous income</a></td>
<td class="nump">4,026,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest and other expense</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(582,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on change in fair value of derivative-preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,110,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non operating income (expense)</a></td>
<td class="nump">4,020,000<span></span>
</td>
<td class="num">(23,647,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,526,000)<span></span>
</td>
<td class="num">(26,778,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less preferred stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,875,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss allocable to common stockholders</a></td>
<td class="num">$ (14,526,000)<span></span>
</td>
<td class="num">$ (29,653,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (15.26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">27,597,434<span></span>
</td>
<td class="nump">1,942,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6830901696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Preferred Stock - A [Member]</div></th>
<th class="th"><div>Preferred Stock - B [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Treasury stock [Member]</div></th>
<th class="th"><div>Accumulated (deficit) [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 251,640,000<span></span>
</td>
<td class="num">$ (4,000)<span></span>
</td>
<td class="num">$ (266,421,000)<span></span>
</td>
<td class="num">$ (14,779,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2013</a></td>
<td class="nump">514,589<span></span>
</td>
<td class="nump">2,903.3617<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">349,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">349,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in shares)</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Preferred stock converted into common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred stock converted into common stock (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="num">(10.0000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodValueReverseStockSplits', window );">Additional adjustments for reverse stock split</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Additional adjustments for reverse stock split (in shares)</a></td>
<td class="nump">6,609<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_TreasuryStockValueRetired', window );">Cancel treasury stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Cancel treasury stock (in shares)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, net of costs</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">12,272,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,307,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of costs (in shares)</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodValueSeriesAPreferredStock', window );">Common stock issued for Series A preferred stock</a></td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(72,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock', window );">Common stock issued for Series A preferred stock (in shares)</a></td>
<td class="nump">7,233,404<span></span>
</td>
<td class="num">(2,893.3617)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest', window );">Common stock issued for Series A preferred stock unpaid dividends and interest</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,066,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,083,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest', window );">Common stock issued for Series A preferred stock unpaid dividends and interest (in shares)</a></td>
<td class="nump">1,728,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock', window );">Elimination of derivative liability - preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue', window );">Series B preferred stock issued for unpaid Series B dividends and interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,047,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,047,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares', window );">Series B preferred stock issued for unpaid Series B dividends and interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue', window );">Series B preferred stock issued for unpaid liquidated damages</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">857,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">857,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares', window );">Series B preferred stock issued for unpaid liquidated damages (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue', window );">Common stock issued for Series B preferred stock, unpaid dividends and interest and liquidated damages</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(70,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares', window );">Common stock issued for Series B preferred stock, unpaid dividends and interest and liquidated damages (in shares)</a></td>
<td class="nump">6,951,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,305,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,305,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,875,000)<span></span>
</td>
<td class="num">(2,875,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(26,778,000)<span></span>
</td>
<td class="num">(26,778,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">300,690,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(296,074,000)<span></span>
</td>
<td class="nump">4,816,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="nump">19,960,801<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">401,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in shares)</a></td>
<td class="nump">105,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued to employees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued to employees (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted common stock issued to employees</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,807,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,820,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock issued to employees (in shares)</a></td>
<td class="nump">1,350,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of $5.00 warrants</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,626,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,635,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of $5.00 warrants (in shares)</a></td>
<td class="nump">927,119<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, net of costs</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,977,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,001,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of costs (in shares)</a></td>
<td class="nump">2,333,334<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodValueNewIssue', window );">Common stock issued for $8.00 share net of costs</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,992,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,005,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodSharesNewIssue', window );">Common stock issued for $8.00 share net of costs (in shares)</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodValueNewIssueOne', window );">Common stock issued for $5.50 share net of costs</a></td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">15,383,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,411,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodSharesNewIssueOne', window );">Common stock issued for $5.50 share net of costs (in shares)</a></td>
<td class="nump">2,829,091<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Common stock issued to Abeona Ohio holders</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,718,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,758,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common stock issued to Abeona Ohio holders (in shares)</a></td>
<td class="nump">3,979,761<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodValueReverseStockSplitsOne', window );">Transfer agent correction 2014 reverse stock split</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne', window );">Transfer agent correction 2014 reverse stock split (in shares)</a></td>
<td class="num">(2,270)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,368,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,368,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,526,000)<span></span>
</td>
<td class="num">(14,526,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 328,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 377,993,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (310,600,000)<span></span>
</td>
<td class="nump">$ 67,721,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="nump">32,743,013<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in elimination of derivative liability - preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_AdjustmentsToAdditionalPaidInCapitalEliminationOfDerivativeLiabilityPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Series B preferred stock issued for unpaid liquidated damages during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of Series B preferred stock issued for unpaid liquidated damages during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_SeriesBPreferredStockIssuedForUnpaidLiquidatedDamagesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Series B preferred stock issued for unpaid Series B dividends and interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of Series B preferred stock issued for unpaid Series B dividends and interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_SeriesBPreferredStockIssuedForUnpaidSeriesBDividendsAndInterestValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodSharesNewIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodSharesNewIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodSharesNewIssueOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodSharesNewIssueOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodSharesReverseStockSplitsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued for series A preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodSharesSeriesAPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued for series a preferred stock unpaid dividends and interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodSharesSeriesAPreferredStockUnpaidDividendsAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodValueNewIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodValueNewIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodValueNewIssueOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodValueNewIssueOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued for reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodValueReverseStockSplitsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued for reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodValueReverseStockSplitsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodValueSeriesAPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for series A preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodValueSeriesAPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for series A preferred stock unpaid dividends and interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodValueSeriesAPreferredStockUnpaidDividendsAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued for Series B preferred stock, unpaid dividends and interest and liquidated damages during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued for Series B preferred stock, unpaid dividends and interest and liquidated damages during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_StockIssuedForSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidatedDamagesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_TreasuryStockValueRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_TreasuryStockValueRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828970000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 24, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock issued, net of costs (in dollars per share)</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NewIssuesSharePricePerShare', window );">Common stock , net of costs (in dollars per share)</a></td>
<td class="nump">8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NewIssuesShareOnePricePerShare', window );">Common stock issued, net of costs (in dollars per share)</a></td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NewIssuesShareOnePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NewIssuesShareOnePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NewIssuesSharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NewIssuesSharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6831282256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,526,000)<span></span>
</td>
<td class="num">$ (26,778,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on change in fair value of derivative-preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">551,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation expense</a></td>
<td class="nump">4,368,000<span></span>
</td>
<td class="nump">1,305,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_CommonStockIssuedToEmployeesDirectorsAndConsultants', window );">Stock issued to directors, employees and consultants</a></td>
<td class="nump">4,852,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock issued for services</a></td>
<td class="nump">401,000<span></span>
</td>
<td class="nump">349,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(79,000)<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(287,000)<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(29,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,174,000)<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_IncreaseDecreaseInInterestPayableOnDividends', window );">Interest on dividends payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">592,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_IncreaseDecreaseInContingentConsiderationMilestone', window );">Contingent consideration milestone</a></td>
<td class="num">(3,898,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(602,000)<span></span>
</td>
<td class="num">(349,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(10,423,000)<span></span>
</td>
<td class="num">(1,611,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(308,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Cash from Abeona Ohio acquisition</a></td>
<td class="nump">3,697,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by investing activities</a></td>
<td class="nump">3,389,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from $3.00 common stock issuances net of costs</a></td>
<td class="nump">7,001,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ProceedsFromIssuanceOfCommonStockNetOfCosts', window );">Proceeds from $8.00 common stock issuances net of costs</a></td>
<td class="nump">9,005,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts', window );">Proceeds from $5.50 common stock issuances net of costs</a></td>
<td class="nump">15,411,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of $5.00 warrants</a></td>
<td class="nump">4,635,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts', window );">Proceeds from $4.00 common stock net of costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,307,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds/payment of short-term debt</a></td>
<td class="num">(400,000)<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">35,652,000<span></span>
</td>
<td class="nump">12,707,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">28,618,000<span></span>
</td>
<td class="nump">11,096,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">11,520,000<span></span>
</td>
<td class="nump">424,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">40,138,000<span></span>
</td>
<td class="nump">11,520,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Shares issued to holders of Abeona Ohio for acquisition</a></td>
<td class="nump">31,758,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_BusinessCombinationContingentConsideration', window );">Contingent milestones to Abeona Ohio members</a></td>
<td class="nump">2,591,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NoncashOrPartNoncashAcquisitionLicensedTecnology', window );">Licensed technology from Abeona Ohio</a></td>
<td class="nump">2,156,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_TreasuryStockCancel', window );">Cancel treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_PayableForFutureIssuanceOfSharesForLicensedTechnology', window );">Payable in cash or future issuance of common shares for licensed technology</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock dividends in dividends payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,875,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember', window );">Conversion of Series A Preferred Stock Unpaid Dividends and Interest and Liquidation Damages into Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Stock, Amount Converted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,081,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember', window );">Conversion of Series B Preferred Stock Unpaid Dividends and Interest and Liquidation Damages into Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Stock, Amount Converted</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,094,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_BusinessCombinationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of contingent consideration in a noncash (or part of noncash) acquisition. Noncash is defined as information about all investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_BusinessCombinationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_CommonStockIssuedToEmployeesDirectorsAndConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of common stock issued to employees, directors and consultants by an entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_CommonStockIssuedToEmployeesDirectorsAndConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_IncreaseDecreaseInContingentConsiderationMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of liability recognized arising from contingent consideration during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_IncreaseDecreaseInContingentConsiderationMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_IncreaseDecreaseInInterestPayableOnDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable on dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_IncreaseDecreaseInInterestPayableOnDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NoncashOrPartNoncashAcquisitionLicensedTecnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NoncashOrPartNoncashAcquisitionLicensedTecnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_PayableForFutureIssuanceOfSharesForLicensedTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable for future issuance of shares for licensed technology as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_PayableForFutureIssuanceOfSharesForLicensedTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_ProceedsFromIssuanceOfCommonStockNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_ProceedsFromIssuanceOfCommonStockNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_ProceedsFromIssuanceOfCommonStockOneNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_ProceedsFromIssuanceOfCommonStockTwoNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_TreasuryStockCancel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>value of the stock cancel in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_TreasuryStockCancel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=accp_ConversionOfSeriesAPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=accp_ConversionOfSeriesBPreferredStockUnpaidDividendsAndInterestAndLiquidationDamagesIntoSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6769123376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 24, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock issued, net of costs (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NewIssuesSharePricePerShare', window );">Common stock , net of costs (in dollars per share)</a></td>
<td class="nump">8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NewIssuesShareOnePricePerShare', window );">Common stock , net of costs (in dollars per share)</a></td>
<td class="nump">5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NewIssuesShareOnePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NewIssuesShareOnePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NewIssuesSharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NewIssuesSharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6762152384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 63pt; text-indent: -63pt;">NOTE 1 - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"><u>Nature of Operations</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">Abeona Therapeutics Inc. (together with our subsidiaries, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;Abeona&#8221; or the &#8220;Company&#8221;) is a Delaware corporation. We are focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA, respectively). We are also developing ABO-201 (AAV CLN3) gene therapy for Juvenile Neuronal Ceroid Lipofuscinoses (JNCL) also known as juvenile Batten disease; and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including PTB-101 SDF Alpha&#8482; (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF&#8482; (Salt Diafiltration) ethanol-free process.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Certain amounts have been reclassified to conform with current period classification.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Principles of Consolidation</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">The consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"><u>Use of Estimates</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Segments</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The Company operates in a single segment.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"><u>Cash and Cash Equivalents</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.&#160;At December 31, 2015 and 2014, we had no such investments.&#160;We maintain deposits primarily in two financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (FDIC).&#160; We have not experienced any losses related to amounts in excess of FDIC limits.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Receivables</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Receivables are reported in the balance sheets at the outstanding amount net of an allowance for doubtful accounts.&#160;We continually evaluate the creditworthiness of our customers and their financial condition and generally do not require collateral.&#160;The allowance for doubtful accounts is based upon reviews of specific customer balances, historic losses, and general economic conditions.&#160;As of December 31, 2015 and 2014, no allowance was recorded as all accounts are considered collectible.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Property and Equipment</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from three to five years. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned and the related accumulated depreciation are eliminated from the accounts and any gains or losses are recognized in the accompanying consolidated statements of operations of the respective period.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><font style="font-weight: normal;"><u>Licensed Technology</u></font>&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">We maintain licensed technology on our consolidated balance sheet until either the licensed technology agreement underlying it is completed or the asset becomes impaired. When we determine that an asset has become impaired or we abandon a project, we write down the carrying value of the related intangible asset to its fair value and take an impairment charge in the period in which the impairment occurs.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">Generally licensed technology is amortized over the life of the patent or the agreement.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">We test our intangible assets for impairment on an annual basis, or more frequently if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate or new information regarding potential sales for the drug. In connection with each annual impairment assessment and any interim impairment assessment, we compare the fair value of the asset as of the date of the assessment with the carrying value of the asset on our consolidated balance sheet.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">In 2015, we did not impair any licensed technology.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Gene therapy license agreements</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On May 15, 2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children&#8217;s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. This portfolio comprises 1 patent family: &#8220;Products and methods for delivery of polynuleotides by adeno-associated virus for lysosomal storage disorders&#8221;. Additionally, Abeona has secured FDA Orphan drug designation for both Sanfilippo A and B, which will provide 7 years of post-launch market exclusivity for both ABX-A and ABX-B in the U.S. Abeona will be seeking Orphan Drug Status within the EMA, which will grant 10 years of post-market exclusivity in the European Union.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The license is amortized over the life of the license of 20 years.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Plasma-based therapeutics license agreements</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On September 22, 2014, we entered into an exclusive, worldwide licensing agreement with Plasma Technologies LLC (&#8220;Licensor&#8221;) to obtain rights to utilize and to sub-license to other pharmaceuticals firms, its patented methods for the extraction of therapeutic biologics from human plasma. Under the terms of the licensing agreement, as amended on January 23, 2015, we paid a license fee of $1 million in cash, will pay $4,000,000 in cash or 1,096,151 shares of our common stock in 2017, a regulatory approval milestone payment of 513,375 shares of our common stock upon the first FDA regulatory approval of a drug derived from the Licensor&#8217;s proprietary SDF process, and a tiered royalty on annual net sales of plasma fractions produced with Licensor&#8217;s proprietary SDF process.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The license is amortized over the life of the patent of 11 years.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>License Revenues and Royalties</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Our revenues are generated from licensing, research and development agreements, royalties and product sales. We recognize revenue in accordance with SEC Staff Accounting Bulletin No. 104 (SAB 104), <i>Revenue Recognition</i>. License revenue is recognized over the remaining life of the underlying patent. Research and development revenues are recognized as services are performed. Royalties and product sales are recognized in the period of sales.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Goodwill</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">As of December 31, 2015, goodwill of $32.5 million was recorded on the Company's consolidated balance sheet. The implied fair value of goodwill represented the excess of the Abeona Ohio&#8217;s value over and above the fair value of its tangible assets and identifiable intangible assets. In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) No. 350 &#8212; <i>Intangibles &#8212; Goodwill and Other, </i>goodwill is not amortized, but is rather tested annually for impairment and whenever changes in circumstances occur that would indicate impairment.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Research and Development Expenses</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Research and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel expense, lab supplies, preclinical, development cost, clinical trial expense, outside manufacturing and consulting. The cost of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses are capitalized when acquired.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>General and administrative expense</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">General and administrative expenses primarily consist of personnel, contract personnel, personnel expenses to support our administrative and operating activities, facility costs and professional expenses (i.e., legal expenses), and investor relations fees.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Other Income</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">In 2015 and 2014, we recognized miscellaneous income of $4,026,000 and $45,000, respectively, due to the termination of the milestone recorded on the contingent consideration liability in 2015 and sales of platinum and monomers in 2014 and write-offs and settlements of other accounts payable for both years.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">In some of our license agreements we are responsible as agent for arranging the manufacture of MuGard (mucoadhesive oral wound rinse) and have entered into supply agreements with our license partners. Terms vary with each agreement but generally we arrange for the manufacture of MuGard with a third-party and receive a fee to cover our administration, handling and overhead costs. The income is recorded in other income.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Income Taxes</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><font style="font-size: 10pt; font-weight: normal;">We account for uncertain income tax positions in accordance with FASB ASC 740, <i>Income Taxes</i>.</font><font style="font-size: 10pt; font-weight: normal;">Interest costs and penalties related to income taxes are classified as interest expense and general and administrative costs, respectively, in our consolidated financial statements. For the years ended December 31, 2015 and 2014, we did not recognize any uncertain tax positions or interest or penalty expense related to income taxes. It is determined not to be reasonably likely for the amounts of unrecognized tax benefits to significantly increase or decrease within the next 12 months. We are currently subject to a three year statute of limitations by major tax jurisdictions for the years ended 2012, 2013 and 2014. We and our subsidiaries file income tax returns in the U.S. federal jurisdiction.</font></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Income (Loss) Per Share</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt;">We have presented basic income (loss) per share, computed on the basis of the weighted average number of common shares outstanding during the year, and diluted income (loss) per share, computed on the basis of the weighted average number of common shares and all dilutive potential common shares outstanding during the year. Potential common shares result from stock options, preferred stock and warrants. Common equivalent shares have not been included in the net loss per share calculations for years ended December 31, 2015 and 2014 because the effect of including them would have been anti-dilutive.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">Basic and diluted net loss per share were determined as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">(in thousands, except share and per share amounts)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">For the year ended December 31,</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: justify; width: 64%;">Net loss allocable to common stockholders</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;">(14,526</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">)</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;">(29,653</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: justify;">Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">27,597,434</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">1,942,905</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: justify;">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(0.53</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(15.26</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: justify;">Net loss allocable to common stockholders</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(14,526</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(29,653</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">We did not include the following securities in the table below in the computation of diluted net loss per common share because the securities were anti-dilutive during the periods presented:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">For the year ended December<br /> 31,</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify; width: 64%;">Warrants</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 15%;">3,799,024</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 15%;">4,164,756</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; text-align: justify;">Stock options</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">2,324,084</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">210,134</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: justify;">Total</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">6,123,108</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">4,374,890</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Stock-Based Compensation</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">We account for stock based compensation expense in accordance with FASB ASC 718, <i>Stock Based Compensation</i>. We have two stock-based compensation plans under which incentive and qualified stock options and restricted shares could be granted to employees, directors and consultants. Our 2015 Equity Incentive Plan was approved by shareholders in May 7, 2015. As of January 20, 2015, no further grants can be made under our old plan, the 2005 Equity Incentive Plan. We measure the cost of the employee/director/consultant services received in exchange for an award of equity instruments based on the grant date fair value for the employees and directors and vesting date fair value for consultants of the award. We use the Black-Scholes option pricing model to value our options.&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">The following table summarizes stock-based compensation for the years ended December 31, 2015 and 2014 which was allocated as follows (in thousands):</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 95%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt; text-align: left;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;">Year ended</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"><u style="text-decoration: none;">December 31, 2015</u></p></td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;">Year ended</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"><u style="text-decoration: none;">December 31, 2014</u></p></td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; width: 64%;">Research and development</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">773</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">104</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">General and administrative</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">3,595</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">1,201</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left; padding-left: 0.375in; text-indent: -17.1pt;">Stock-based compensation expense included in operating expense</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">4,368</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">1,305</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">Total stock-based compensation expense</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4,368</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,305</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">Tax benefit</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in;">Stock-based compensation expense, net of tax</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">4,368</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">1,305</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Recent Accounting Pronouncements</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">In May 2014, as part of its ongoing efforts to assist in the convergence of U.S. GAAP and International Financial Reporting Standards (&#8220;IFRS&#8221;), the FASB issued ASU 2014-09 related to revenue recognition. The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. In August 2015, the FASB issued ASU 2015-14 which defers the effective date of ASU 2014-09 one year making it effective for annual reporting periods beginning on or after December 15, 2017 while also providing for early adoption as of the original effective date. We are currently continuing to evaluate the impact that this standard will have on our consolidated financial statements as well as the appropriate method of adoption.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6003-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6751973824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">NOTE 2 - RELATED PARTY TRANSACTIONS</p><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">On September 10, 2014, we entered into an Unsecured Grid Note, for up to $250,000 with SCO Capital Partners LLC (SCO). As of December 31, 2014 we had drawn a total of $250,000. The interest rate was 8% per annum and the maturity date was August 31, 2015 unless a financing of at least $5,000,000 occurred. The financing occurred December 24, 2014 and the Grid Note was paid in full on January 5, 2015.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">On September 10, 2014 we entered into a Share Exchange Agreement for Series B Preferred Stock between us and SCO and Beach Capital LLC whereby we agreed in connection with the consummation of the an offering for the Series B Preferred Stock to be converted into Common Stock. All Series B Preferred Stock dividends payable, interest on Series B Preferred Stock dividends payable and liquidated damages will be converted into Series B Preferred Stock just prior to an offering of at least $10 million. The Series B Preferred Stock, including the shares of Series B Preferred Stock issued upon conversion of all accrued dividends payable, interest on dividends payable and liquidated damages thereon, subject to a liquidation preference, will be exchanged for shares of Common Stock upon consummation of an offering at the offering price pursuant to a Share Exchange Agreement dated September 10, 2014. The conversion into Common Stock occurred on December 24, 2014.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On December 1, 2014, we entered into a second Unsecured Grid Note, for up to $250,000 with SCO. As of December 31, 2014 we had drawn a total of $150,000. The interest rate was 8% per annum and the maturity date was November 30, 2015 unless a financing of at least $5,000,000 occurred. The financing occurred December 24, 2014 and the Grid Note was paid in full on January 5, 2015.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph b<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6761160976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">NOTE 3 - PROPERTY AND EQUIPMENT</p><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="padding-bottom: 1pt;">Property and equipment consists of the following:</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">December 31,</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 64%;">Equipment laboratory</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">139,000</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">-</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Furniture and office equipment</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">209,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">14,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 1pt; text-align: left;">Leasehold improvement</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">33,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">-</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">381,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">14,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; text-align: left;">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">31,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">10,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: left;">Property and equipment, net</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">350,000</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">4,000</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Depreciation and amortization on property and equipment was $13,000 and $2,000 for the years ended December 31, 2015 and 2014, respectively.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6751973824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSED TECHNOLOGY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>LICENSED TECHNOLOGY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">LICENSED TECHNOLOGY</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">NOTE 4 &#8211; LICENSED TECHNOLOGY</p><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On September 22, 2014, we entered into an exclusive, worldwide, licensing agreement with Licensor to obtain rights to utilize and to sub-license to other pharmaceuticals firms, its patented methods for the extraction of therapeutic biologics from human plasma.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On May 15, 2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children&#8217;s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Licensed technology consists of the following:</p><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">December 31,</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 64%;">Licensed technology</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">7,156,000</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">5,000,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; text-align: left;">Less accumulated amortization</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">547,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">9,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: left;">Licensed technology, net</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">6,609,000</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">4,991,000</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Amortization on licensed technology was $538,000 and $9,000 for the years ended December 31, 2015 and 2014, respectively. The aggregate estimated amortization expense for intangible assets remaining as of December 31, 2015 is as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; width: 40%;"><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: right; width: 51%;">2016</td><td style="font-weight: normal; width: 7%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 40%;">582</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: right;">2017</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">582</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: right;">2018</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">582</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: right;">2019</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">582</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: right;">2020</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">582</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">Thereafter</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">3,699</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: right;">Total</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">6,609</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6608292384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>401(k) PLAN [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) PLAN</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">NOTE 5 &#8211; 401(k) PLAN</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">We have a tax-qualified employee savings and retirement plan (the 401(k) Plan) covering all our employees. Pursuant to the 401(k) Plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit ($18,000 in 2015 and $17,500 in 2014) and to have the amount of such reduction contributed to the 401(k) Plan. The 401(k) Plan is intended to qualify under Section 401 of the Internal Revenue Code so that contributions by employees or by us to the 401(k) Plan, and income earned on 401(k) Plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that contributions by us, if any, will be deductible by us when made. At the direction of each participant, we invest the assets of the 401(k) Plan in any of 60 investment options. Company contributions under the 401(k) Plan were $0 in 2015 and 2014.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49170332&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6829333968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">NOTE 6 &#8211; COMMITMENTS AND CONTINGENCIES</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Operating Leases</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">At December 31, 2015, we had a commitment under a non-cancelable operating lease for our New York office until December 31, 2016 totaling $171,000. We also had a non-cancelable operating lease for our Dallas office and lab until August 31, 2016 totaling $7,000. We had an operating lease for our Cleveland office and lab until December 31, 2025 totaling $2,520,000. We have the option to extend the lease for an additional five years. We can also terminate the lease early at December 31, 2020, at the end of year five, and pay for unamortized tenant improvements. Our total lease costs and unamortized tenant improvements would total $1,744,000 with the termination provision.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">The five year lease payment schedule is (in thousands):</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; width: 40%;"><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">2016</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">349</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr><tr style="height: 16px; vertical-align: bottom; background-color: white;"><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">2017</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">241</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">2018</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">246</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">2019</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">250</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 1pt; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">2020</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">836</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">Total</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">1,922</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; clear: both; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Rent expense for the years ended December 31, 2015 and 2014 was $219,000 and $178,000, respectively.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Legal</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">We are not currently subject to any material pending legal proceedings.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6830971184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">NOTE 7 - FAIR VALUE MEASUREMENTS</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">We calculate the fair value of our assets and liabilities which qualify as financial instruments and include additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments. The estimated fair value of receivables, accounts payable, short-term notes payable and payable to licensor approximate their carrying amounts due to the relatively short maturity of these instruments.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">U.S. GAAP define&#8217;s fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 31.5pt;"></td><td style="font-family: Symbol; width: 18pt;">&#183;</td><td style="text-align: justify;">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr></table><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 31.5pt;"></td><td style="font-family: Symbol; width: 18pt;">&#183;</td><td style="text-align: justify;">Level 2 &#8211; Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</td></tr></table><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 31.5pt;"></td><td style="font-family: Symbol; width: 18pt;">&#183;</td><td style="text-align: justify;">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The guidance requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">We have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 and December 31, 2014 are summarized below:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>(in thousands)</u></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 90%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: justify;">Description</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">As of <br />December 31,<br /> 2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 1</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 2</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 3</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Total Gains<br /> (Losses)</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify;">Liabilities:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-left: 0.25in; width: 35%; text-indent: -0.125in;">Contingent consideration</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">2,591</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">2,591</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">3,898</td><td style="text-align: left; width: 1%;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>(in thousands)</u></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 90%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: justify;">Description</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">As of <br />December 31, <br /> 2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 1</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 2</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 3</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Total Gains <br /> (Losses)</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify;">Liabilities:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0.25in; width: 35%; text-indent: -0.125in;">Derivative liability- preferred stock</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">(23,110</td><td style="text-align: left; width: 1%;">)</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">In order to calculate the Level 3 Derivative liability - preferred stock, we used the Monte Carlo simulation to estimate future stock prices. The use of valuation techniques requires the Company to make various key assumptions for inputs into the model, including assumptions about the expected future volatility of the price of the Company&#8217;s stock. The preferred stock liability was converted into common stock on December 24, 2014.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6761456752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREFERRED STOCK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_PreferredStockAbstract', window );"><strong>PREFERRED STOCK [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">PREFERRED STOCK</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">NOTE 8 &#8211; PREFERRED STOCK</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"><u>Series A Cumulative Convertible Preferred Stock</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">All Series A Preferred Stock, Series A dividends payable and interest on Series A Preferred Stock dividends payable were converted into 8,961,769 shares of common stock just prior to the closing of the financing on December 24, 2014.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"><u>Derivative Liability</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">Effective January 1, 2009, we adopted the provisions of FASB ASC 815, <i>&#8220;Derivatives and Hedging&#8221;</i> (FASB ASC 815) (previously EITF 07-5, <i>&#8220;Determining Whether an Instrument (or an Embeded Feature) is Indexed to an Entity&#8217;s Own Stock&#8221;</i>). As a result of adopting FASB ASC 815, warrants to purchase 77,091 of our common stock previously treated as equity pursuant to the derivative treatment exemption were no longer afforded equity treatment. These warrants had an exercise price of $175.00 and expired on November 10, 2013 and February 4, 2014.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">We determined that the anti-dilution provision built into the Series A Preferred Stock and warrants issued should be considered for derivative accounting.&#160;FASB ASC 815 requires freestanding contracts that are settled in a company&#8217;s own stock to be designated as an equity instrument, assets or liability. Under the provisions of FASB ASC 815, a contract designated as an asset or liability must be initially recorded and carried at fair value until the contract meets the requirements for classification as equity, until the contract is exercised or until the contract expires. We determined that the anti-dilution provision associated with the November 2007 and February 2008 preferred shares and warrants no longer met the criteria for equity accounting through the revised criteria in FASB ASC 815.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">Accordingly, at January 1, 2009, we determined that the warrants and the Series A Preferred Stock conversion feature should be accounted for as derivative liabilities. The preferred stock conversion feature was determined to have no fair market value at both issuance dates as well as each reporting period until the third quarter of 2010 since management asserted that the likelihood of issuing any new equity at a price that would trigger the anti-dilution effect to be nil. During the third quarter of 2010 we were actively raising capital. With our stock price below $150.00 a share it was possible that we would sell shares below $150.00 per share. Since this would require an adjustment to our convertible preferred stock we recorded a derivative liability and expense at September 30, 2010. The derivative liability and expense was revalued at December 31, 2013 was $1,190,000; and at December 24, 2014 was $24,300,000. The change in the fair value of the derivative was a loss of $23,110,000 in 2014. The Series A Preferred Stock was converted into common stock at December 24, 2014 and the amount of the derivative liability was reclassified to stockholders equity.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">The warrants were valued at issuance and each reporting period since using the Black-Scholes model. On January 1, 2009 we reclassified the fair value of the warrants from equity to liability as if these warrants were treated as a derivative liability since their issue date. We recorded derivative gain of $271,000 for the year ended December 31, 2013. Warrants to purchase 72,998 shares of our common stock expired November 10, 2013. The remaining 9,992 warrants expired February 4, 2014.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"><u>Series B Cumulative Convertible Preferred Stock</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">All Series B Preferred Stock, Series B dividends payable, interest on Series B Preferred Stock dividends payable and liquidated damages were converted into 6,951,837 shares of common stock just prior to the closing of the financing on December 24, 2014.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"><u>Liquidated Damages</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">Pursuant to the terms of an Investor Rights Agreement with the Purchasers of Series A Preferred Stock, we were required to maintain an effective registration statement. The Securities and Exchange Commission declared the registration statement effective November 13, 2008 relating to a portion of such securities, and as a result, we accrued $857,000 in potential liquidated damages as of December 31, 2013 and December 31, 2012. Potential liquidated damages were capped at 10% of each holder&#8217;s investment.&#160;The accrued liquidated damages of $857,000 were converted into common stock at December 24, 2014.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"><u>Preferred Stock Dividends &#8211; Series A</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">Unpaid preferred stock dividends and interest of $6,913,416 accrued at December 24, 2014 was converted into common stock at December 24, 2014.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;"><u>Preferred Stock Dividends &#8211; Series B</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 9pt;">Unpaid preferred stock dividends and interest of $3,046,553 accrued at December 31, 2014 was converted into common stock at December 24, 2014.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_PreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_PreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6753413232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">NOTE 9 &#8211; STOCKHOLDERS&#8217; EQUITY</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px; text-indent: 13.5pt;"><u>2015 Financing</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On July 31, 2015 we closed an upsized $15.5 million direct placement of registered common stock with institutional investors, including Soros Fund Management and Perceptive Life Science Fund, and two members of our Board of Directors. The financing was comprised of 2.83 million shares of our common stock at a price of $5.50 per share.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">During the second quarter we received additional financing of $4.6 million through Warrant exercises of our $5.00 warrants.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On May 11, 2015 we closed a $10 million private placement of common stock consisting of 1,250,000 shares of our common stock, at a price of $8.00 per share, and warrants to purchase 625,000 shares of our common stock with an exercise price of $10 per share.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.2pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.2pt;">Also in connection with the financing, the placement agent received warrants to purchase 50,000 shares of common stock at $11.00 per share and which are exercisable for five years from the closing date.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On April 23, 2015 we closed an upsized $7 million private placement of common stock consisting of 2,333,333 shares of our common stock, at a price of $3.00 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On December 24, 2014, we closed an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of $4.00 per share and $.01 per warrant.&#160;The warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance. The gross proceeds to the Company from this offering were $14,035,000, before deducting underwriting discounts and commissions and other estimated offering expenses.&#160;All of the shares and warrants in the offering were sold by the Company. In addition the underwriter received warrants to purchase 87,500 shares of common stock at $5.00 per share. The warrants are exercisable on December 18, 2015 and expire on December 18, 2019.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Just before the financing closed on December 24, 2014, the Series A and Series B preferred stock and unpaid dividends and interest and liquidated damages were converted into common stock.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Warrants</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">There were warrants to purchase a total of 3,799,024 shares of common stock outstanding at December 31, 2015. All warrants were exercisable at December 31, 2015. The warrants had various exercise prices and terms as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 90%;"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td colspan="2" style="padding-bottom: 1pt; text-align: center;">Warrants</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td colspan="2" style="padding-bottom: 1pt; text-align: center;">Exercise</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt; text-align: center;">Expiration</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom: black 1pt solid; text-align: center;">Summary of Warrants</td><td style="padding-bottom: 1pt;">&#160;</td><td colspan="2" style="border-bottom: black 1pt solid; text-align: center;">Outstanding</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td colspan="2" style="border-bottom: black 1pt solid; text-align: center;">Price</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;">Date</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 49%;">2015 Financing 7/31/15 (a)</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 14%;">20,000</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 14%;">6.05</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: center; width: 16%;">07/31/20</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>2015 Financing 5/11/15 (b)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">625,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">11/11/17</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left;">2015 Financing 5/11/15 agent warrants (b)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">50,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">11.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">5/11/20</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>2014 Financing 12/24/14 (c)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,572,881</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">12/24/19</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left;">2014 Financing 12/24/14 agent warrants (c)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">87,500</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">12/18/19</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">2012 Series B private placement (d)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">400,001</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">25.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">10/24/18</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td>2011 November private placement (e)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">42,898</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">100.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">11/10&amp;30/16</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; text-align: left;">2011 November placement agent warrants (e)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">744</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt; text-align: right;">83.50&amp;100.00</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt; text-align: center;">11/10&amp;30/16</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: center; text-decoration: none;">Total<font style="text-underline-style: double;"><u style="text-decoration: none;">&#160;</u></font></td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">3,799,024</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center;">&#160;</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 27pt;"></td><td style="font-weight: normal; width: 18pt;">a)</td><td style="font-weight: normal; text-align: justify;">In connection with the offering on July 31, 2015, the placement agent received warrants to purchase 20,000 share of common stock at $6.05 per share. The warrants are exercisable and expire on July 31. 2020.</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 27pt;"></td><td style="font-weight: normal; width: 18pt;">b)</td><td style="font-weight: normal; text-align: justify;">In connection with the offering on May 11, 2015, warrants to purchase 625,000 shares of common stock at $10.00 per share were issued. All of the warrants exercisable and expire November 11, 2017.</td></tr></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 0.5in;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">Also in connection with the offering on May 11, 2015, the placement agent received warrants to purchase 50,000 share of common stock at $11.00 per share. The warrants are exercisable and expire on May 11. 2020.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 27pt;"></td><td style="font-weight: normal; width: 18pt;">c)</td><td style="font-weight: normal; text-align: justify;">In connection with an offering on December 24, 2014, warrants to purchase 3,500,000 shares of common stock at $5.00 per share were purchased and issued for $0.01 per warrant. All of the warrants are exercisable immediately and expire on December 24, 2019. At December 31, 2015, 2,572,881 warrants are outstanding.</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">Also in connection with the offering on December 24, 2014, the underwriter received warrants to purchase 87,500 shares of common stock at $5.00 per share. The warrants were exercisable on December 18, 2015 and expire on December 18, 2019.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 27pt;"></td><td style="font-weight: normal; width: 18pt;">d)</td><td style="font-weight: normal; text-align: justify;">In connection with a private placement offering on October 25, 2012, warrants to purchase 400,001 shares of common stock at $25.00 per share were issued. All of the warrants are exercisable immediately and expire on October 24, 2018.</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 27pt;"></td><td style="font-weight: normal; width: 18pt;">e)</td><td style="font-weight: normal; text-align: justify;">In connection with a private placement offering on November 10 and 30, 2011, warrants to purchase 42,898 shares of common stock at $100.00 per share were issued. All of the warrants are exercisable immediately and 37,148 warrants expire November 10, 2016 and 5,750 warrants expire November 30, 2016.</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 372 shares of common stock at $83.50 per share were issued. Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 372 shares of common stock at $100.00 per share were issued. All the placement agent warrants are exercisable immediately and 372 warrants expire November 10, 2016 and 372 warrants expire November 30, 2016.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6766134672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK OPTION PLANS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTION PLANS</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">NOTE 10 - STOCK OPTION PLANS</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px; text-indent: 13.5pt;">Our stock-based employee compensation plans described below:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px; text-indent: 13.5pt;"><u>2015 Equity Incentive Plan</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">We have a stock awards plan, (the 2015 Equity Incentive Plan), under which 5,000,000 shares of our authorized but unissued common stock were reserved for issuance to employees, consultants, or to non-employee members of the Board or to any board of directors (or similar governing authority) of any affiliate of the Company. The 2015 Equity Incentive Plan, approved by our shareholders on May 7, 2015, replaced the previously approved stock option plan (the 2005 Equity Incentive Plan).</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">For the 2015 Equity Incentive Plan, the fair value of options was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in fiscal 2015: dividend yield of 0%; volatility of 102%; risk-free interest rate of 0.86%; and expected lives of 5.0 years. The weighted average fair value of options granted was $6.90 per share during 2015.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Summarized information for the 2015 Equity Incentive Plan is as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">Weighted-</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">average</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">exercise</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Options</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">price</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td>Outstanding options at January 1, 2015</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; width: 70%;">Granted, fair value of $5.18 per share</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 12%;">1,994,000</td><td style="padding-bottom: 1pt; text-align: left; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; text-align: left; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; text-align: right; width: 12%;">6.90</td><td style="padding-bottom: 1pt; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt;">Outstanding options at December 31, 2015</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">1,994,000</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">6.90</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: justify;">Exercisable at December 31, 2015</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">35,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">7.34</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">There was no intrinsic value related to the outstanding or exercisable options under this plan at December 31, 2015.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Further information regarding options outstanding under the 2015 Equity Incentive Plan at December 31, 2015 is summarized below:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 92%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;">Number of</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">Weighted average</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;">Number of</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">Weighted-average</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">options</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Remaining</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Exercise</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">options</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Remaining</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Exercise</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">Range of exercise prices</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">outstanding</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">life in years</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">price</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">exercisable</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">life in years</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">price</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; text-align: justify; width: 22%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: justify;">$4.38 - 7.34</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">1,994,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">9.0</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">$</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">6.90</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">35,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">9.0</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">$</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">7.34</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>2005 Equity Incentive Plan</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Under the 2005 Equity Incentive Plan, as amended, shares of our authorized but unissued common stock were reserved for issuance to employees, consultants, or to non-employee members of the Board or to any board of directors (or similar governing authority) of any affiliate of the Company. As of January 20, 2015 no additional shares were available for grant under the 2005 Equity Incentive Plan. A total of 330,084 options were outstanding and exercisable under this plan at December 31, 2015.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">For the 2005 Equity Incentive Plan, the fair value of options was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in fiscal 2015: dividend yield of 0%; volatility of 102%; risk-free interest rate of 1.41%; and expected lives of 4.6 years. The weighted average fair value of the options grants was $4.52 per share in 2015.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The assumptions for fiscal 2014 are: dividend yield of 0%; volatility of 102%; risk-free interest rate of 0.79%; and expected lives of 5.5 years. The weighted average fair value of the options granted was $14.50 per share in 2014.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Summarized information for the 2005 Equity Incentive Plan is as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 85%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;"></td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">Weighted-</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;"></td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">average</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;"></td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">exercise</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Options</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">price</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td nowrap="nowrap" style="text-align: left; width: 74%;">Outstanding options at January 1, 2014</td><td nowrap="nowrap" style="text-align: center; width: 1%;">&#160;</td><td nowrap="nowrap" style="text-align: center; width: 1%;">&#160;</td><td nowrap="nowrap" style="text-align: right; width: 10%;">28,784</td><td nowrap="nowrap" style="text-align: center; width: 1%;">&#160;</td><td nowrap="nowrap" style="text-align: center; width: 1%;">&#160;</td><td nowrap="nowrap" style="text-align: left; width: 1%;">$</td><td nowrap="nowrap" style="text-align: right; width: 10%;">59.00</td><td nowrap="nowrap" style="text-align: center; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Granted, fair value of $14.50 per share</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">212,500</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">18.50</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 1pt;">Expired/forfeited</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(31,200</td><td style="padding-bottom: 1pt; text-align: left;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">37.61</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Outstanding options at December 31, 2014</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">210,084</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">20.19</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt;">Granted, fair value of $4.52</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">120,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">3.25</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt;">Outstanding options at December 31, 2015</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">330,084</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">13.49</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">Exercisable at December 31, 2015</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">319,884</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">15.02</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The intrinsic value related to the outstanding or exercisable options under this plan at December 31, 2015 was $13,000 and $12,000, respectively. At December 31, 2014, the intrinsic value related to the outstanding or exercisable options was none.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Further information regarding options outstanding under the 2005 Equity Incentive Plan at December 31, 2015 is summarized below:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 92%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;">Number of</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">Weighted average</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;">Number of</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">Weighted-average</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">options</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Remaining</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Exercise</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">options</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Remaining</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Exercise</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">Range of exercise prices</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">outstanding</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">life in years</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">price</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">exercisable</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">life in years</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">price</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; width: 22%;">$3.25</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 10%;">120,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 10%;">4.0</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 10%;">3.25</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 10%;">110,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 10%;">4.0</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 10%;">3.25</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left;">$11.50 - 18.50</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">200,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">7.7</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">18.33</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">199,800</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">7.7</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">18.32</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">$30.50 - 42.50</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4.1</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">32.19</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4.1</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">32.19</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left;">$69.00</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,400</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4.0</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">69.00</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,400</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4.0</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">69.00</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">$113.50 &#8211; 157.50</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">4,684</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">5.0</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">119.99</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">4,684</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">5.0</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">$</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">119.99</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-decoration: none;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">330,084</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">319,884</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6766223648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ABEONA THERAPEUTICS LLC ACQUISITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>ABEONA THERAPEUTICS LLC ACQUISITION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ABEONA THERAPEUTICS LLC ACQUISITION</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-transform: uppercase; text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">Note 11 - Abeona Therapeutics LLC Acquisition</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On May 15, 2015, we agreed to issue an aggregate of 3,979,761 unregistered shares of our common stock to the members of Abeona Therapeutics LLC (Abeona Ohio). Abeona Ohio&#8217;s principal activities were focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Abeona Ohio's lead program is ABO-101 (AA NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively) in collaboration with patient advocate groups, researchers and clinicians, anticipated to commence clinical trials in 2016.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The initial consideration of $31,758,000 was calculated using the Company&#8217;s stock price on date of the closing, May 15, 2015 of $7.98 times the number of the Company shares (3,979,761) issued to Abeona Ohio members.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt; text-indent: -0.25in;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">There is a contingent valuation on three milestones. Per the merger agreement with Abeona Ohio each milestone would consist of either cash, our stock or a combination of both, at the Company&#8217;s election, equivalent to a stated dollar amount. The fair value of the probability of achieving all three milestones was estimated at $6,489,000.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt; text-indent: -0.25in;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The following purchase price allocation is as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt; text-indent: -0.25in;">&#160;</p><table align="center" border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 70%;"><tr style="height: 12px; vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 47%;">Total purchase price</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="height: 20px; vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;">Initial consideration</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 20%;">31,758,000</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;">Contingent consideration</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">6,489,000</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;">Total purchase price</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 20%;">38,247,000</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 47%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 47%;">Allocation of the purchase price</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 47%;">Cash</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 20%;">3,697,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; width: 47%;">Accounts receivable</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">1,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 47%;">Prepaid expenses</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">28,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; width: 47%;">Property and equipment</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">51,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 47%;">Other assets</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">1,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; width: 47%;">Accounts payable</td><td style="width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 20%;">(153,000</td><td style="text-align: left; width: 1%;">)</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 47%;">Total tangible assets</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">3,625,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 47%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 47%;">Licensing agreement</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">2,156,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; width: 47%;">Goodwill</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 20%;">32,466,000</td><td style="padding-bottom: 1pt; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 47%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: left; width: 47%;">Total net asset value</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 20%;">38,247,000</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">In connection with the acquisition $375,000 in merger costs were expensed.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px;">The first milestone of receiving IND allowance from the FDA to initiate a Phase 1 clinical study from MPS IIIA or MPSIIIB by November 15, 2015 was not met after the&#160;measurement period ended. The Company recognized $3,898,000 in Miscellaneous Income for change in fair value of our contingent consideration liability.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px;">Goodwill is not expected to be deductible for tax purposes.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1497-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1490-128463<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1486-128463<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1500-128463<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1524-128463<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7000-128479<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4922-128472<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4934-128472<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4926-128472<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1383-128463<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6996-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6748136016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">NOTE 12 - INCOME TAXES</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Income tax expense differs from the statutory amounts as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table align="center" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 80%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">2015</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">2014</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: center;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: center;">&#160;</td><td style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; width: 64%;">Income taxes at U.S. statutory rate</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">(4,939,000</td><td style="font-weight: normal; text-align: left; width: 1%;">)</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">(9,105,000</td><td style="font-weight: normal; text-align: left; width: 1%;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left;">Current year reserve</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">6,257,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,254,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">Other</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">(1,318,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">)</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">7,851,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in;">Total tax expense</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Deferred taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities. The temporary differences that give rise to deferred tax assets were as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table align="center" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 80%;"><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="6" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">December 31,</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">2015</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">2014</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">Deferred tax assets</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left; padding-left: 9pt; width: 64%;">Net operating loss carryforwards</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">68,636,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">68,263,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">General business credit carryforwards</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">2,497,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">2,486,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">State credits</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">2,055,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">2,061,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Property, equipment and goodwill</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">(25,000</td><td style="font-weight: normal; text-align: left;">)</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Stock options</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">3,678,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">542,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Derivatives</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">(92,000</td><td style="font-weight: normal; text-align: left;">)</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">(92,000</td><td style="font-weight: normal; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Deferred revenue</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,669,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">92,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Intangible assets</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">595,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">464,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Accrued interest</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">253,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">253,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left; padding-left: 9pt;">Other</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">231,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">231,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left;">Gross deferred tax assets</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">79,497,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">74,300,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">Valuation allowance</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">(79,497,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">)</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">(74,300,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 9pt;">Net deferred taxes</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">At December 31, 2015, we had approximately $209,666,000 of net operating loss carryforwards and approximately $2,497,000 of general business credit carryforwards. These carryforwards expire as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 2in; width: 60%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Net operating</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">General business</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-size: 10pt; border-bottom: black 1pt solid; font-weight: normal; text-align: center;">l<u style="text-decoration: none;">oss carryforwards</u></td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">credit carryforwards</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">2016</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left;">2017</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; width: 44%;">2018</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 25%;">3,324,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 25%;">112,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">Thereafter</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">206,342,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">2,385,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 2.5pt; font-style: normal; text-align: left; text-decoration: none;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">209,666,000</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">2,497,000</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">As a result of a merger on January 25, 1996, a change in control occurred for federal income tax purposes, which limits the utilization of pre-merger net operating loss carryforwards of approximately $3,100,000 to approximately $530,000 per year.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Additionally, we acquired MacroChem Corporation on February 25, 2009 and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both corporations were loss companies at the time of the acquisition. Therefore, the net operating losses related to those acquisitions may be subject to annual limitations as provided by IRC Sec. 382.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6826837968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NatureOfOperationsPolicyTextBlock', window );">Nature of Operations</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"><u>Nature of Operations</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">Abeona Therapeutics Inc. (together with our subsidiaries, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;Abeona&#8221; or the &#8220;Company&#8221;) is a Delaware corporation. We are focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA, respectively). We are also developing ABO-201 (AAV CLN3) gene therapy for Juvenile Neuronal Ceroid Lipofuscinoses (JNCL) also known as juvenile Batten disease; and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including PTB-101 SDF Alpha&#8482; (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF&#8482; (Salt Diafiltration) ethanol-free process.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Certain amounts have been reclassified to conform with current period classification.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Principles of Consolidation</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">The consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"><u>Use of Estimates</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Segments</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The Company operates in a single segment.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;"><u>Cash and Cash Equivalents</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.&#160;At December 31, 2015 and 2014, we had no such investments.&#160;We maintain deposits primarily in two financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (FDIC).&#160; We have not experienced any losses related to amounts in excess of FDIC limits.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Receivables</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Receivables are reported in the balance sheets at the outstanding amount net of an allowance for doubtful accounts.&#160;We continually evaluate the creditworthiness of our customers and their financial condition and generally do not require collateral.&#160;The allowance for doubtful accounts is based upon reviews of specific customer balances, historic losses, and general economic conditions.&#160;As of December 31, 2015 and 2014, no allowance was recorded as all accounts are considered collectible.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Property and Equipment</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from three to five years. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned and the related accumulated depreciation are eliminated from the accounts and any gains or losses are recognized in the accompanying consolidated statements of operations of the respective period.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_LicensedTechnologyPolicyTextBlock', window );">Licensed Technology</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><font style="font-weight: normal;"><u>Licensed Technology</u></font>&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">We maintain licensed technology on our consolidated balance sheet until either the licensed technology agreement underlying it is completed or the asset becomes impaired. When we determine that an asset has become impaired or we abandon a project, we write down the carrying value of the related intangible asset to its fair value and take an impairment charge in the period in which the impairment occurs.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">Generally licensed technology is amortized over the life of the patent or the agreement.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">We test our intangible assets for impairment on an annual basis, or more frequently if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate or new information regarding potential sales for the drug. In connection with each annual impairment assessment and any interim impairment assessment, we compare the fair value of the asset as of the date of the assessment with the carrying value of the asset on our consolidated balance sheet.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">In 2015, we did not impair any licensed technology.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Gene therapy license agreements</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On May 15, 2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children&#8217;s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. This portfolio comprises 1 patent family: &#8220;Products and methods for delivery of polynuleotides by adeno-associated virus for lysosomal storage disorders&#8221;. Additionally, Abeona has secured FDA Orphan drug designation for both Sanfilippo A and B, which will provide 7 years of post-launch market exclusivity for both ABX-A and ABX-B in the U.S. Abeona will be seeking Orphan Drug Status within the EMA, which will grant 10 years of post-market exclusivity in the European Union.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The license is amortized over the life of the license of 20 years.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Plasma-based therapeutics license agreements</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">On September 22, 2014, we entered into an exclusive, worldwide licensing agreement with Plasma Technologies LLC (&#8220;Licensor&#8221;) to obtain rights to utilize and to sub-license to other pharmaceuticals firms, its patented methods for the extraction of therapeutic biologics from human plasma. Under the terms of the licensing agreement, as amended on January 23, 2015, we paid a license fee of $1 million in cash, will pay $4,000,000 in cash or 1,096,151 shares of our common stock in 2017, a regulatory approval milestone payment of 513,375 shares of our common stock upon the first FDA regulatory approval of a drug derived from the Licensor&#8217;s proprietary SDF process, and a tiered royalty on annual net sales of plasma fractions produced with Licensor&#8217;s proprietary SDF process.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The license is amortized over the life of the patent of 11 years.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">License Revenues and Royalties</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>License Revenues and Royalties</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Our revenues are generated from licensing, research and development agreements, royalties and product sales. We recognize revenue in accordance with SEC Staff Accounting Bulletin No. 104 (SAB 104), <i>Revenue Recognition</i>. License revenue is recognized over the remaining life of the underlying patent. Research and development revenues are recognized as services are performed. Royalties and product sales are recognized in the period of sales.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Goodwill</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">As of December 31, 2015, goodwill of $32.5 million was recorded on the Company's consolidated balance sheet. The implied fair value of goodwill represented the excess of the Abeona Ohio&#8217;s value over and above the fair value of its tangible assets and identifiable intangible assets. In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) No. 350 &#8212; <i>Intangibles &#8212; Goodwill and Other, </i>goodwill is not amortized, but is rather tested annually for impairment and whenever changes in circumstances occur that would indicate impairment.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Research and Development Expenses</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Research and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel expense, lab supplies, preclinical, development cost, clinical trial expense, outside manufacturing and consulting. The cost of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses are capitalized when acquired.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and administrative expense</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>General and administrative expense</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">General and administrative expenses primarily consist of personnel, contract personnel, personnel expenses to support our administrative and operating activities, facility costs and professional expenses (i.e., legal expenses), and investor relations fees.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_OtherIncomePolicyTextBlock', window );">Other Income</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Other Income</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">In 2015 and 2014, we recognized miscellaneous income of $4,026,000 and $45,000, respectively, due to the termination of the milestone recorded on the contingent consideration liability in 2015 and sales of platinum and monomers in 2014 and write-offs and settlements of other accounts payable for both years.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">In some of our license agreements we are responsible as agent for arranging the manufacture of MuGard (mucoadhesive oral wound rinse) and have entered into supply agreements with our license partners. Terms vary with each agreement but generally we arrange for the manufacture of MuGard with a third-party and receive a fee to cover our administration, handling and overhead costs. The income is recorded in other income.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Income Taxes</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><font style="font-size: 10pt; font-weight: normal;">We account for uncertain income tax positions in accordance with FASB ASC 740, <i>Income Taxes</i>.</font><font style="font-size: 10pt; font-weight: normal;">Interest costs and penalties related to income taxes are classified as interest expense and general and administrative costs, respectively, in our consolidated financial statements. For the years ended December 31, 2015 and 2014, we did not recognize any uncertain tax positions or interest or penalty expense related to income taxes. It is determined not to be reasonably likely for the amounts of unrecognized tax benefits to significantly increase or decrease within the next 12 months. We are currently subject to a three year statute of limitations by major tax jurisdictions for the years ended 2012, 2013 and 2014. We and our subsidiaries file income tax returns in the U.S. federal jurisdiction.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Income (Loss) Per Share</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt;">We have presented basic income (loss) per share, computed on the basis of the weighted average number of common shares outstanding during the year, and diluted income (loss) per share, computed on the basis of the weighted average number of common shares and all dilutive potential common shares outstanding during the year. Potential common shares result from stock options, preferred stock and warrants. Common equivalent shares have not been included in the net loss per share calculations for years ended December 31, 2015 and 2014 because the effect of including them would have been anti-dilutive.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">Basic and diluted net loss per share were determined as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">(in thousands, except share and per share amounts)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">For the year ended December 31,</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: justify; width: 64%;">Net loss allocable to common stockholders</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;">(14,526</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">)</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;">(29,653</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: justify;">Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">27,597,434</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">1,942,905</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: justify;">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(0.53</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(15.26</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: justify;">Net loss allocable to common stockholders</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(14,526</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(29,653</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">We did not include the following securities in the table below in the computation of diluted net loss per common share because the securities were anti-dilutive during the periods presented:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">For the year ended December<br /> 31,</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify; width: 64%;">Warrants</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 15%;">3,799,024</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 15%;">4,164,756</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; text-align: justify;">Stock options</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">2,324,084</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">210,134</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: justify;">Total</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">6,123,108</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">4,374,890</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Stock-Based Compensation</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">We account for stock based compensation expense in accordance with FASB ASC 718, <i>Stock Based Compensation</i>. We have two stock-based compensation plans under which incentive and qualified stock options and restricted shares could be granted to employees, directors and consultants. Our 2015 Equity Incentive Plan was approved by shareholders in May 7, 2015. As of January 20, 2015, no further grants can be made under our old plan, the 2005 Equity Incentive Plan. We measure the cost of the employee/director/consultant services received in exchange for an award of equity instruments based on the grant date fair value for the employees and directors and vesting date fair value for consultants of the award. We use the Black-Scholes option pricing model to value our options.&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">The following table summarizes stock-based compensation for the years ended December 31, 2015 and 2014 which was allocated as follows (in thousands):</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 95%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt; text-align: left;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;">Year ended</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"><u style="text-decoration: none;">December 31, 2015</u></p></td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;">Year ended</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"><u style="text-decoration: none;">December 31, 2014</u></p></td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; width: 64%;">Research and development</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">773</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">104</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">General and administrative</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">3,595</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">1,201</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left; padding-left: 0.375in; text-indent: -17.1pt;">Stock-based compensation expense included in operating expense</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">4,368</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">1,305</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">Total stock-based compensation expense</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4,368</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,305</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">Tax benefit</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in;">Stock-based compensation expense, net of tax</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">4,368</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">1,305</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>Recent Accounting Pronouncements</u></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">In May 2014, as part of its ongoing efforts to assist in the convergence of U.S. GAAP and International Financial Reporting Standards (&#8220;IFRS&#8221;), the FASB issued ASU 2014-09 related to revenue recognition. The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. In August 2015, the FASB issued ASU 2015-14 which defers the effective date of ASU 2014-09 one year making it effective for annual reporting periods beginning on or after December 15, 2017 while also providing for early adoption as of the original effective date. We are currently continuing to evaluate the impact that this standard will have on our consolidated financial statements as well as the appropriate method of adoption.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_LicensedTechnologyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for licensed technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_LicensedTechnologyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for business description. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_OtherIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_OtherIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph k<br> -Article 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02, 03<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e4975-111524<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3-5<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6741623296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">Basic and diluted net loss per share were determined as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">(in thousands, except share and per share amounts)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">For the year ended December 31,</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: justify; width: 64%;">Net loss allocable to common stockholders</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;">(14,526</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">)</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;">(29,653</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: justify;">Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">27,597,434</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">1,942,905</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: justify;">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(0.53</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(15.26</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: justify;">Net loss allocable to common stockholders</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(14,526</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(29,653</td><td style="padding-bottom: 2.5pt; text-align: left;">)</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">We did not include the following securities in the table below in the computation of diluted net loss per common share because the securities were anti-dilutive during the periods presented:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 80%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">For the year ended December<br /> 31,</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: justify;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2" style="text-align: justify;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify; width: 64%;">Warrants</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 15%;">3,799,024</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 15%;">4,164,756</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; text-align: justify;">Stock options</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">2,324,084</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">210,134</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: justify;">Total</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">6,123,108</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">4,374,890</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based compensation allocation</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.7pt;">The following table summarizes stock-based compensation for the years ended December 31, 2015 and 2014 which was allocated as follows (in thousands):</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.7pt; width: 95%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt; text-align: left;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;">Year ended</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"><u style="text-decoration: none;">December 31, 2015</u></p></td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;">Year ended</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0px;"><u style="text-decoration: none;">December 31, 2014</u></p></td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; width: 64%;">Research and development</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">773</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">104</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">General and administrative</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">3,595</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">1,201</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left; padding-left: 0.375in; text-indent: -17.1pt;">Stock-based compensation expense included in operating expense</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">4,368</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">1,305</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">Total stock-based compensation expense</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4,368</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,305</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">Tax benefit</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in;">Stock-based compensation expense, net of tax</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">4,368</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">1,305</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6771255392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="padding-bottom: 1pt;">Property and equipment consists of the following:</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">December 31,</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 64%;">Equipment laboratory</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">139,000</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">-</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Furniture and office equipment</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">209,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">14,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 1pt; text-align: left;">Leasehold improvement</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">33,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">-</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">381,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">14,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; text-align: left;">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">31,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">10,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: left;">Property and equipment, net</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">350,000</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">4,000</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6764253520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSED TECHNOLOGY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>LICENSED TECHNOLOGY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of licensed technology</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Licensed technology consists of the following:</p><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">December 31,</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 64%;">Licensed technology</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">7,156,000</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">5,000,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; text-align: left;">Less accumulated amortization</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">547,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">9,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: left;">Licensed technology, net</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">6,609,000</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">4,991,000</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Amortization expense for intangible assets</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>The aggregate estimated amortization expense for intangible assets remaining as of December 31, 2015 is as follows:</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; width: 40%;"><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: right; width: 51%;">2016</td><td style="font-weight: normal; width: 7%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 40%;">582</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: right;">2017</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">582</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: right;">2018</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">582</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: right;">2019</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">582</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: right;">2020</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">582</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">Thereafter</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">3,699</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: right;">Total</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">6,609</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6757940320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum payments for operating leases</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">The five year lease payment schedule is (in thousands):</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.5pt;">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; width: 40%;"><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">2016</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">349</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr><tr style="height: 16px; vertical-align: bottom; background-color: white;"><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">2017</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">241</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">2018</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">246</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">2019</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">250</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 1pt; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">2020</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">836</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 25%;">Total</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; width: 4%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 9%;">1,922</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1%;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6766150752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial assets and liabilities measured at fair value on recurring basis</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 and December 31, 2014 are summarized below:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>(in thousands)</u></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 90%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: justify;">Description</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">As of <br />December 31,<br /> 2015</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 1</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 2</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 3</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Total Gains<br /> (Losses)</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify;">Liabilities:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-left: 0.25in; width: 35%; text-indent: -0.125in;">Contingent consideration</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">2,591</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">2,591</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">3,898</td><td style="text-align: left; width: 1%;">&#160;</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;"><u>(in thousands)</u></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 90%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: justify;">Description</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">As of <br />December 31, <br /> 2014</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 1</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 2</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Level 3</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Total Gains <br /> (Losses)</td><td nowrap="nowrap" style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify;">Liabilities:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0.25in; width: 35%; text-indent: -0.125in;">Derivative liability- preferred stock</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">-</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">(23,110</td><td style="text-align: left; width: 1%;">)</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6766185168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding at various exercise prices</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>The warrants had various exercise prices and terms as follows:</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 90%;"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td colspan="2" style="padding-bottom: 1pt; text-align: center;">Warrants</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td colspan="2" style="padding-bottom: 1pt; text-align: center;">Exercise</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt; text-align: center;">Expiration</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom: black 1pt solid; text-align: center;">Summary of Warrants</td><td style="padding-bottom: 1pt;">&#160;</td><td colspan="2" style="border-bottom: black 1pt solid; text-align: center;">Outstanding</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td colspan="2" style="border-bottom: black 1pt solid; text-align: center;">Price</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;">Date</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 49%;">2015 Financing 7/31/15 (a)</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 14%;">20,000</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 14%;">6.05</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: center; width: 16%;">07/31/20</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>2015 Financing 5/11/15 (b)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">625,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">11/11/17</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left;">2015 Financing 5/11/15 agent warrants (b)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">50,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">11.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">5/11/20</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>2014 Financing 12/24/14 (c)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,572,881</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">12/24/19</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left;">2014 Financing 12/24/14 agent warrants (c)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">87,500</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">12/18/19</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">2012 Series B private placement (d)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">400,001</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">25.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">10/24/18</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td>2011 November private placement (e)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">42,898</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">100.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">11/10&amp;30/16</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; text-align: left;">2011 November placement agent warrants (e)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">744</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt; text-align: right;">83.50&amp;100.00</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt; text-align: center;">11/10&amp;30/16</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: center; text-decoration: none;">Total<font style="text-underline-style: double;"><u style="text-decoration: none;">&#160;</u></font></td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">3,799,024</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center;">&#160;</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 27pt;"></td><td style="font-weight: normal; width: 18pt;">a)</td><td style="font-weight: normal; text-align: justify;">In connection with the offering on July 31, 2015, the placement agent received warrants to purchase 20,000 share of common stock at $6.05 per share. The warrants are exercisable and expire on July 31. 2020.</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 27pt;"></td><td style="font-weight: normal; width: 18pt;">b)</td><td style="font-weight: normal; text-align: justify;">In connection with the offering on May 11, 2015, warrants to purchase 625,000 shares of common stock at $10.00 per share were issued. All of the warrants exercisable and expire November 11, 2017.</td></tr></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 0.5in;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">Also in connection with the offering on May 11, 2015, the placement agent received warrants to purchase 50,000 share of common stock at $11.00 per share. The warrants are exercisable and expire on May 11. 2020.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 27pt;"></td><td style="font-weight: normal; width: 18pt;">c)</td><td style="font-weight: normal; text-align: justify;">In connection with an offering on December 24, 2014, warrants to purchase 3,500,000 shares of common stock at $5.00 per share were purchased and issued for $0.01 per warrant. All of the warrants are exercisable immediately and expire on December 24, 2019. At December 31, 2015, 2,572,881 warrants are outstanding.</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">Also in connection with the offering on December 24, 2014, the underwriter received warrants to purchase 87,500 shares of common stock at $5.00 per share. The warrants were exercisable on December 18, 2015 and expire on December 18, 2019.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 27pt;"></td><td style="font-weight: normal; width: 18pt;">d)</td><td style="font-weight: normal; text-align: justify;">In connection with a private placement offering on October 25, 2012, warrants to purchase 400,001 shares of common stock at $25.00 per share were issued. All of the warrants are exercisable immediately and expire on October 24, 2018.</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 45pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="margin-bottom: 0px; font: 10pt Times New Roman, Times, Serif; margin-top: 0px; width: 100%;"><tr style="vertical-align: top;"><td style="width: 27pt;"></td><td style="font-weight: normal; width: 18pt;">e)</td><td style="font-weight: normal; text-align: justify;">In connection with a private placement offering on November 10 and 30, 2011, warrants to purchase 42,898 shares of common stock at $100.00 per share were issued. All of the warrants are exercisable immediately and 37,148 warrants expire November 10, 2016 and 5,750 warrants expire November 30, 2016.</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6769241712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2015Member', window );">2015 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized information of stock options</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Summarized information for the 2015 Equity Incentive Plan is as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 90%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">Weighted-</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">average</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">exercise</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Options</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">price</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td>Outstanding options at January 1, 2015</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; width: 70%;">Granted, fair value of $5.18 per share</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 12%;">1,994,000</td><td style="padding-bottom: 1pt; text-align: left; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; text-align: left; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; text-align: right; width: 12%;">6.90</td><td style="padding-bottom: 1pt; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt;">Outstanding options at December 31, 2015</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">1,994,000</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">6.90</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: justify;">Exercisable at December 31, 2015</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">35,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">7.34</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Information regarding options outstanding by range of exercise prices</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Further information regarding options outstanding under the 2015 Equity Incentive Plan at December 31, 2015 is summarized below:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 92%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;">Number of</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">Weighted average</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;">Number of</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">Weighted-average</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">options</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Remaining</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Exercise</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">options</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Remaining</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Exercise</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">Range of exercise prices</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">outstanding</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">life in years</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">price</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">exercisable</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">life in years</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">price</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; text-align: justify; width: 22%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td><td style="font-weight: bold; text-align: right; width: 10%;">&#160;</td><td style="font-weight: bold; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: justify;">$4.38 - 7.34</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">1,994,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">9.0</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">$</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">6.90</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">35,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">9.0</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">$</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">7.34</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member', window );">2005 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized information of stock options</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Summarized information for the 2005 Equity Incentive Plan is as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; width: 85%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;"></td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">Weighted-</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;"></td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">average</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;"></td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="text-align: center;">exercise</td><td nowrap="nowrap" style="text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="text-align: center;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">Options</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center;">price</td><td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td nowrap="nowrap" style="text-align: left; width: 74%;">Outstanding options at January 1, 2014</td><td nowrap="nowrap" style="text-align: center; width: 1%;">&#160;</td><td nowrap="nowrap" style="text-align: center; width: 1%;">&#160;</td><td nowrap="nowrap" style="text-align: right; width: 10%;">28,784</td><td nowrap="nowrap" style="text-align: center; width: 1%;">&#160;</td><td nowrap="nowrap" style="text-align: center; width: 1%;">&#160;</td><td nowrap="nowrap" style="text-align: left; width: 1%;">$</td><td nowrap="nowrap" style="text-align: right; width: 10%;">59.00</td><td nowrap="nowrap" style="text-align: center; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Granted, fair value of $14.50 per share</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">212,500</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">18.50</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 1pt;">Expired/forfeited</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(31,200</td><td style="padding-bottom: 1pt; text-align: left;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">37.61</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Outstanding options at December 31, 2014</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">210,084</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">20.19</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt;">Granted, fair value of $4.52</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">120,000</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">3.25</td><td style="padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt;">Outstanding options at December 31, 2015</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">330,084</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">13.49</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">Exercisable at December 31, 2015</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">319,884</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">15.02</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Information regarding options outstanding by range of exercise prices</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Further information regarding options outstanding under the 2005 Equity Incentive Plan at December 31, 2015 is summarized below:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; width: 92%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;">Number of</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">Weighted average</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt; text-align: center;">Number of</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">Weighted-average</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">options</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Remaining</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Exercise</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">options</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Remaining</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Exercise</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">Range of exercise prices</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">outstanding</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">life in years</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">price</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">exercisable</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">life in years</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">price</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; width: 22%;">$3.25</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 10%;">120,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 10%;">4.0</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 10%;">3.25</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 10%;">110,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 10%;">4.0</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 10%;">3.25</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left;">$11.50 - 18.50</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">200,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">7.7</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">18.33</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">199,800</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">7.7</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">18.32</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">$30.50 - 42.50</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4.1</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">32.19</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4.1</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">32.19</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left;">$69.00</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,400</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4.0</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">69.00</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,400</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">4.0</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">69.00</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">$113.50 &#8211; 157.50</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">4,684</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">5.0</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">119.99</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">4,684</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">5.0</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">$</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: right;">119.99</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-decoration: none;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">330,084</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">319,884</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=accp_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6771280528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ABEONA THERAPEUTICS LLC ACQUISITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>ABEONA THERAPEUTICS LLC ACQUISITION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of purchase price allocation</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">The following purchase price allocation is as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt; text-indent: -0.25in;">&#160;</p><table align="center" border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 13.5pt; width: 70%;"><tr style="height: 12px; vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 47%;">Total purchase price</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="height: 20px; vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;">Initial consideration</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 20%;">31,758,000</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;">Contingent consideration</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">6,489,000</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.25in; width: 47%;">Total purchase price</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 20%;">38,247,000</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 47%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 47%;">Allocation of the purchase price</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 47%;">Cash</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 20%;">3,697,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; width: 47%;">Accounts receivable</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">1,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 47%;">Prepaid expenses</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">28,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; width: 47%;">Property and equipment</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">51,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 47%;">Other assets</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">1,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; width: 47%;">Accounts payable</td><td style="width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 20%;">(153,000</td><td style="text-align: left; width: 1%;">)</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 47%;">Total tangible assets</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">3,625,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 47%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: left; width: 47%;">Licensing agreement</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">2,156,000</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; width: 47%;">Goodwill</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 20%;">32,466,000</td><td style="padding-bottom: 1pt; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 47%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 20%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; text-align: left; width: 47%;">Total net asset value</td><td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 20%;">38,247,000</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6741017360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Income tax expense differs from statutory amounts</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Income tax expense differs from the statutory amounts as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table align="center" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 80%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">2015</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">2014</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: center;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td colspan="2" style="font-weight: bold; text-align: center;">&#160;</td><td style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; width: 64%;">Income taxes at U.S. statutory rate</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">(4,939,000</td><td style="font-weight: normal; text-align: left; width: 1%;">)</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">(9,105,000</td><td style="font-weight: normal; text-align: left; width: 1%;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left;">Current year reserve</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">6,257,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,254,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">Other</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">(1,318,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">)</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">7,851,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in;">Total tax expense</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Temporary differences that give rise to deferred tax assets</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">Deferred taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities. The temporary differences that give rise to deferred tax assets were as follows:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table align="center" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 80%;"><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="6" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">December 31,</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">2015</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">2014</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">Deferred tax assets</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td><td style="font-weight: bold; text-align: right;">&#160;</td><td style="font-weight: bold; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left; padding-left: 9pt; width: 64%;">Net operating loss carryforwards</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">68,636,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">$</td><td style="font-weight: normal; text-align: right; width: 15%;">68,263,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">General business credit carryforwards</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">2,497,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">2,486,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">State credits</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">2,055,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">2,061,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Property, equipment and goodwill</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">(25,000</td><td style="font-weight: normal; text-align: left;">)</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Stock options</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">3,678,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">542,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Derivatives</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">(92,000</td><td style="font-weight: normal; text-align: left;">)</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">(92,000</td><td style="font-weight: normal; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Deferred revenue</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">1,669,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">92,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Intangible assets</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">595,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">464,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left; padding-left: 9pt;">Accrued interest</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">253,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">253,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left; padding-left: 9pt;">Other</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">231,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">231,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left;">Gross deferred tax assets</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">79,497,000</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">74,300,000</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">Valuation allowance</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">(79,497,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">)</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">(74,300,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left; padding-left: 9pt;">Net deferred taxes</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock', window );">Net operating loss carryforwards and general business credits expiration dates</a></td>
<td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>These carryforwards expire as follows:</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0px 0px 0px 13.5pt;">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 2in; width: 60%;"><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">Net operating</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-weight: normal; text-align: center;">General business</td><td nowrap="nowrap" style="font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap" style="font-weight: bold; text-align: justify;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="font-size: 10pt; border-bottom: black 1pt solid; font-weight: normal; text-align: center;">l<u style="text-decoration: none;">oss carryforwards</u></td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: normal; text-align: center;">credit carryforwards</td><td nowrap="nowrap" style="font-weight: normal; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left;">2016</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">$</td><td style="font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; text-align: left;">2017</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal;">&#160;</td><td style="font-weight: normal; text-align: left;">&#160;</td><td style="font-weight: normal; text-align: right;">-</td><td style="font-weight: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; text-align: left; width: 44%;">2018</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 25%;">3,324,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td><td style="font-weight: normal; text-align: right; width: 25%;">112,000</td><td style="font-weight: normal; text-align: left; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">Thereafter</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">206,342,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; font-weight: normal; text-align: right;">2,385,000</td><td style="font-weight: normal; padding-bottom: 1pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="font-weight: normal; padding-bottom: 2.5pt; font-style: normal; text-align: left; text-decoration: none;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">209,666,000</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="font-weight: normal; padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; font-weight: normal; text-align: right;">2,497,000</td><td style="font-weight: normal; padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards and general business credit carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_SummaryOfOperatingLossCarryforwardsAndGeneralBusinessCreditCarryforwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6829215712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>Institution </div>
<div>License </div>
<div>Plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Highly liquid investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained', window );">Number of financial institutions deposits are primarily maintained | Institution</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">32,466,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">$ 4,026,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NumberOfYearsSubjectToStatuteOfLimitations', window );">Number of years subject to statute of limitations by major tax jurisdiction</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted net loss per share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss allocable to common stockholders</a></td>
<td class="num">$ (14,526,000)<span></span>
</td>
<td class="num">$ (29,653,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding (in shares) | shares</a></td>
<td class="nump">27,597,434<span></span>
</td>
<td class="nump">1,942,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (15.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss allocable to common stockholders</a></td>
<td class="num">$ (14,526,000)<span></span>
</td>
<td class="num">$ (29,653,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in computation of diluted net income (loss) per common share (in shares) | shares</a></td>
<td class="nump">6,123,108<span></span>
</td>
<td class="nump">4,374,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NumberOfStockBasedCompensationPlans', window );">Number of stock based compensation plans | Plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,368,000<span></span>
</td>
<td class="nump">$ 1,305,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Stock-based compensation expense, net of tax</a></td>
<td class="nump">$ 4,368,000<span></span>
</td>
<td class="nump">1,305,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Gene Therapy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Licensed Technology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NumberOfPatentFamily', window );">Number of patent family | License</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Period of amortization of license</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=accp_LicenseAgreementTerms1Member', window );">Plasma-based Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Licensed Technology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License fee</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology', window );">License fee payable</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock shares in lieu of cash (in shares) | shares</a></td>
<td class="nump">1,096,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Period of amortization of license</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_RegulatoryApprovalMilestonePayment', window );">Regulatory approval milestone payment (in shares) | shares</a></td>
<td class="nump">513,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 773,000<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,595,000<span></span>
</td>
<td class="nump">1,201,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,368,000<span></span>
</td>
<td class="nump">$ 1,305,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in computation of diluted net income (loss) per common share (in shares) | shares</a></td>
<td class="nump">3,799,024<span></span>
</td>
<td class="nump">4,164,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in computation of diluted net income (loss) per common share (in shares) | shares</a></td>
<td class="nump">2,324,084<span></span>
</td>
<td class="nump">210,134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of financial institutions where the deposits are primarily maintained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NumberOfFinancialInstitutionsDepositsArePrimarilyMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NumberOfPatentFamily">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of marketed products licensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NumberOfPatentFamily</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NumberOfStockBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to number of stock based compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NumberOfStockBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NumberOfYearsSubjectToStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of years subject to statute of limitations by major tax jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NumberOfYearsSubjectToStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_RegulatoryApprovalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory approval milestone payment in shares of our common stock upon the first FDA regulatory approval of a drug derived from the Licensor's proprietary SDF process, and a tiered royalty on annual net sales of plasma fractions produced with Licensor's proprietary SDF process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_RegulatoryApprovalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable For Future Issuance Of Shares For Licensed Technology outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_RemainingPayableForFutureIssuanceOfSharesForLicensedTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=accp_LicenseAgreementTerms1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=accp_LicenseAgreementTerms1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6768311392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - SCO Capital Partners LLC (SCO) [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 10, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 01, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=accp_ScoCapitalPartnersLlcMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Preferred stock dividends</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=accp_ScoCapitalPartnersLlcMember', window );">Unsecured Grid Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Unsecured grid note amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount', window );">Total amount drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_DebtInstrumentCovenantComplianceValue', window );">Total amount required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=accp_ScoCapitalPartnersLlcMember', window );">Second Unsecured Grid Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Unsecured grid note amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount', window );">Total amount drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_DebtInstrumentCovenantComplianceValue', window );">Total amount required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_DebtInstrumentCovenantComplianceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>States the value associated with the debt covenants throughout the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_DebtInstrumentCovenantComplianceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum month-end amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Industry Guide<br> -Number 3<br> -Section VII<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=accp_ScoCapitalPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=accp_ScoCapitalPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=accp_SecondUnsecuredGridNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=accp_SecondUnsecuredGridNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828932240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Components of property and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 381,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization on property and equipment</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment Laboratory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Components of property and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">139,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Components of property and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">209,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Components of property and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6830237040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSED TECHNOLOGY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Licensed Technology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Licensed technology</a></td>
<td class="nump">$ 7,156,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="nump">547,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Licensed technology, net</a></td>
<td class="nump">6,609,000<span></span>
</td>
<td class="nump">4,991,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization on licensed technology</a></td>
<td class="nump">538,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Amortization expense for intangible assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2016</a></td>
<td class="nump">582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2017</a></td>
<td class="nump">582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2018</a></td>
<td class="nump">582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2019</a></td>
<td class="nump">582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2020</a></td>
<td class="nump">582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,699,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Licensed technology, net</a></td>
<td class="nump">$ 6,609,000<span></span>
</td>
<td class="nump">$ 4,991,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6744679568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) PLAN (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>InvestmentOptions</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>401(k) PLAN [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Maximum annual contribution per employee under 401(k) plan</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NumberOfInvestmentOptions', window );">Number of investment options | InvestmentOptions</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company contributions under 401 (k) Plan</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NumberOfInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of investment options at the direction of each participant to invest in the assets of the 401(k) plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NumberOfInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the cost recognized during the period for defined contribution plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6769656864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Non-cancelable operating leases</a></td>
<td class="nump">$ 349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementLeaseRevenue', window );">Operating leases</a></td>
<td class="nump">$ 2,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_LeaseExtensionPeriod', window );">Lease extension period</a></td>
<td class="text">P5Y<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_TotalLeaseCostsAndUnamortizedTenantImprovements', window );">Total lease costs and unamortized tenant improvements</a></td>
<td class="nump">$ 1,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Lease Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2016</a></td>
<td class="nump">349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2017</a></td>
<td class="nump">241,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2018</a></td>
<td class="nump">246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2019</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2020</a></td>
<td class="nump">836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">1,922,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">219,000<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">New York Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Non-cancelable operating leases</a></td>
<td class="nump">171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Lease Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2016</a></td>
<td class="nump">171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=accp_Building2Member', window );">Dallas Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Non-cancelable operating leases</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Lease Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2016</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_LeaseExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents extend the lease for an additional five years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_LeaseExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_TotalLeaseCostsAndUnamortizedTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total lease costs and unamortized improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_TotalLeaseCostsAndUnamortizedTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementLeaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementLeaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=accp_Building2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=accp_Building2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6769159824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 24, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 2,591,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_DerivativeLiabilityPreferredStock', window );">Derivative liability - preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,300,000<span></span>
</td>
<td class="nump">$ 1,190,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Total gains (losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,110,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">2,591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Total gains (losses)</a></td>
<td class="nump">3,898,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 2,591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_DerivativeLiabilityPreferredStock', window );">Derivative liability - preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Total gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,110,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Preferred Stock [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_DerivativeLiabilityPreferredStock', window );">Derivative liability - preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Preferred Stock [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_DerivativeLiabilityPreferredStock', window );">Derivative liability - preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Preferred Stock [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_DerivativeLiabilityPreferredStock', window );">Derivative liability - preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_DerivativeLiabilityPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments related to preferred stock, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_DerivativeLiabilityPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828862160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREFERRED STOCK (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 04, 2014</div></th>
<th class="th"><div>Nov. 10, 2013</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 24, 2014</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted to acquire shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_DerivativeLiabilityPreferredStock', window );">Derivative liability - preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (23,110,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Gain on derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_AccruedPotentialLiquidatedDamages', window );">Accrued potential liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 857,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment', window );">Potential liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Cumulative Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_InitialConversionPriceOfPreferredStockIntoCommonStock', window );">Initial conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock', window );">Conversion of outstanding shares at dividends payable on preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,961,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Preferred stock dividends accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,913,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock', window );">Conversion of outstanding shares at dividends payable on preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Preferred stock dividends accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,046,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=accp_PreferredStockOffering2008Member', window );">Preferred Stock Offering 2008 [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightsWarrantsExpired', window );">Warrants expired (in shares)</a></td>
<td class="nump">9,992<span></span>
</td>
<td class="nump">72,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_AccruedPotentialLiquidatedDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued potential liquidated damages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_AccruedPotentialLiquidatedDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_ClassOfWarrantsOrRightsWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of warrants or rights expired during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_ClassOfWarrantsOrRightsWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of number of outstanding shares at dividends payable on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_ConversionOfOutstandingSharesAtDividendsPayableOnPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_DerivativeLiabilityPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments related to preferred stock, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_DerivativeLiabilityPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_InitialConversionPriceOfPreferredStockIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial conversion price of preferred stock into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_InitialConversionPriceOfPreferredStockIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential liquidated damages are capped at a certain percentage of each holder's investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_PotentialLiquidatedDamagesCappedAtPercentageOfEachHoldersInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph a<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=accp_PreferredStockOffering2008Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=accp_PreferredStockOffering2008Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6831578960">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($) </div>
<div>Director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May. 11, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 23, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 24, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceed from sale of stock from private placement | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NumberOfBoardOfDirectors', window );">Number of board of directors | Director</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock price per share (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Underwritten public offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_WarrantsIssuedPrice', window );">Warrants issued price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 18,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightsExercisablePeriod', window );">Exercisable period of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds from offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,799,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceed from sale of stock from private placement | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock price per share (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Underwritten public offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">2,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=accp_PlacementAgentMember', window );">Placement Agent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_TermOfWarrant', window );">Term of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_JulyFinancing2015Member', window );">2015 July Financing [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_MayFinancing2015Member', window );">2015 May Financing [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 11,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_MayFinancingAgentWarrants2015Member', window );">2015 May Financing Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 11,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PublicOfferingMember', window );">2014 December Financing [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,572,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 24,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PublicOfferingAgentWarrantsMember', window );">2014 December Financing Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 18,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_SeriesBPrivatePlacementMember', window );">2012 Series B Private Placement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 24,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PrivatePlacement1Member', window );">2011 November Private Placement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11/10 & 30/16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PrivatePlacement1Member', window );">2011 November Private Placement [Member] | Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 10,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PrivatePlacement1Member', window );">2011 November Private Placement [Member] | Warrant2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PlacementAgentWarrants1Member', window );">2011 November Placement Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11/10 & 30/16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PlacementAgentWarrants1Member', window );">2011 November Placement Agent Warrants [Member] | Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PlacementAgentWarrants1Member', window );">2011 November Placement Agent Warrants [Member] | Warrant2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In connection with the offering on July 31, 2015, the placement agent received warrants to purchase 20,000 share of common stock at $6.05 per share. The warrants are exercisable and expire on July 31. 2020.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">In connection with the offering on May 11, 2015, warrants to purchase 625,000 shares of common stock at $10.00 per share were issued. All of the warrants exercisable and expire November 11, 2017.

Also in connection with the offering on May 11, 2015, the placement agent received warrants to purchase 50,000 share of common stock at $11.00 per share. The warrants are exercisable and expire on May 11. 2020.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">In connection with an offering on December 24, 2014, warrants to purchase 3,500,000 shares of common stock at $5.00 per share were purchased and issued for $0.01 per warrant. All of the warrants are exercisable immediately and expire on December 24, 2019. At December 31, 2015, 2,572,881 warrants are outstanding.

Also in connection with the offering on December 24, 2014, the underwriter received warrants to purchase 87,500 shares of common stock at $5.00 per share. The warrants were exercisable on December 18, 2015 and expire on December 18, 2019.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">In connection with a private placement offering on October 25, 2012, warrants to purchase 400,001 shares of common stock at $25.00 per share were issued. All of the warrants are exercisable immediately and expire on October 24, 2018.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">In connection with a private placement offering on November 10 and 30, 2011, warrants to purchase 42,898 shares of common stock at $100.00 per share were issued. All of the warrants are exercisable immediately and 37,148 warrants expire November 10, 2016 and 5,750 warrants expire November 30, 2016.

Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 372 shares of common stock at $83.50 per share were issued. Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 372 shares of common stock at $100.00 per share were issued. All the placement agent warrants are exercisable immediately and 372 warrants expire November 10, 2016 and 372 warrants expire November 30, 2016.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_ClassOfWarrantsOrRightExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_ClassOfWarrantsOrRightExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_ClassOfWarrantsOrRightsExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercisable period of warrants and rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_ClassOfWarrantsOrRightsExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_ClassOfWarrantsOrRightsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_ClassOfWarrantsOrRightsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NumberOfBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to number of board of directors in a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NumberOfBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The warrants have an exercise price per share and are exercisable for this duration from the closing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_WarrantsIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single warrant issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_WarrantsIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=accp_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=accp_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=accp_JulyFinancing2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=accp_JulyFinancing2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=accp_MayFinancing2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=accp_MayFinancing2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=accp_MayFinancingAgentWarrants2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=accp_MayFinancingAgentWarrants2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=accp_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PublicOfferingAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=accp_PublicOfferingAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=accp_SeriesBPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=accp_SeriesBPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PrivatePlacement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=accp_PrivatePlacement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=accp_Warrant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=accp_Warrant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=accp_PlacementAgentWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=accp_PlacementAgentWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6831042880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2015Member', window );">2015 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized but unissued common stock (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 5.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding options, beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding options, ending balance (in shares)</a></td>
<td class="nump">1,994,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, ending balance (in shares)</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average exercise price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding options, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding options, ending balance (in dollars per share)</a></td>
<td class="nump">6.90<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, end on period (in dollars per share)</a></td>
<td class="nump">$ 7.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of options exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2015Member', window );">2015 Equity Incentive Plan [Member] | $4.38 - 7.34 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract', window );"><strong>Information regarding options outstanding by range of exercise prices [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit (in dollars per share)</a></td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 7.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">1,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average, Remaining life in years</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, Weighted average, Remaining life in years</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member', window );">2005 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.41%<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 4.52<span></span>
</td>
<td class="nump">$ 14.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding options, beginning balance (in shares)</a></td>
<td class="nump">210,084<span></span>
</td>
<td class="nump">28,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">212,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired/forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding options, ending balance (in shares)</a></td>
<td class="nump">330,084<span></span>
</td>
<td class="nump">210,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, ending balance (in shares)</a></td>
<td class="nump">319,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average exercise price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding options, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 20.19<span></span>
</td>
<td class="nump">$ 59.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.25<span></span>
</td>
<td class="nump">18.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired/forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding options, ending balance (in dollars per share)</a></td>
<td class="nump">13.49<span></span>
</td>
<td class="nump">$ 20.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, end on period (in dollars per share)</a></td>
<td class="nump">$ 15.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of options exercisable</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract', window );"><strong>Information regarding options outstanding by range of exercise prices [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">330,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">319,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member', window );">2005 Equity Incentive Plan [Member] | $3.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract', window );"><strong>Information regarding options outstanding by range of exercise prices [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average, Remaining life in years</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, Weighted average, Remaining life in years</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member', window );">2005 Equity Incentive Plan [Member] | $11.50 - 18.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract', window );"><strong>Information regarding options outstanding by range of exercise prices [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit (in dollars per share)</a></td>
<td class="nump">11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average, Remaining life in years</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">199,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, Weighted average, Remaining life in years</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member', window );">2005 Equity Incentive Plan [Member] | $30.50 - 42.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract', window );"><strong>Information regarding options outstanding by range of exercise prices [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit (in dollars per share)</a></td>
<td class="nump">30.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 42.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average, Remaining life in years</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 32.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, Weighted average, Remaining life in years</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 32.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member', window );">2005 Equity Incentive Plan [Member] | $69.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract', window );"><strong>Information regarding options outstanding by range of exercise prices [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 69.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average, Remaining life in years</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 69.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, Weighted average, Remaining life in years</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 69.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member', window );">2005 Equity Incentive Plan [Member] | $113.50 - 157.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract', window );"><strong>Information regarding options outstanding by range of exercise prices [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit (in dollars per share)</a></td>
<td class="nump">113.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 157.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">4,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average, Remaining life in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 119.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">4,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, Weighted average, Remaining life in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, Weighted average, Exercise price (in dollars per share)</a></td>
<td class="nump">$ 119.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=accp_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=accp_EquityIncentivePlan2005Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=accp_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6769559520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ABEONA THERAPEUTICS LLC ACQUISITION (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May. 15, 2015 </div>
<div>USD ($) </div>
<div>Milestone </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Total purchase price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Initial consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,758,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Allocation of the purchase price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,466,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,591,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=accp_BusinessAcquisitionsMember', window );">Abeona Therapeutics LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued in acquisition (in shares) | shares</a></td>
<td class="nump">3,979,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per shares) | $ / shares</a></td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued to company (in shares) | shares</a></td>
<td class="num">(3,979,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_NumberOfMilestones', window );">Number of milestones | Milestone</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Total purchase price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Initial consideration</a></td>
<td class="nump">$ 31,758,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent consideration</a></td>
<td class="nump">6,489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">38,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Allocation of the purchase price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">3,697,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(153,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Total tangible assets</a></td>
<td class="nump">3,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Licensing agreement</a></td>
<td class="nump">2,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">32,466,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total net asset value</a></td>
<td class="nump">38,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Acquisition transaction cost</a></td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,898,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_NumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to contingent valuation of number of milestones acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_NumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=accp_BusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=accp_BusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828963968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income tax expense differs from the statutory amounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income taxes at U.S. statutory rate</a></td>
<td class="num">$ (4,939,000)<span></span>
</td>
<td class="num">$ (9,105,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_accp_IncomeTaxReconciliationCurrentYearReserve', window );">Current year reserve</a></td>
<td class="nump">6,257,000<span></span>
</td>
<td class="nump">1,254,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="num">(1,318,000)<span></span>
</td>
<td class="nump">7,851,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">68,636,000<span></span>
</td>
<td class="nump">68,263,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">2,497,000<span></span>
</td>
<td class="nump">2,486,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">State credits</a></td>
<td class="nump">2,055,000<span></span>
</td>
<td class="nump">2,061,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, equipment and goodwill</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">3,678,000<span></span>
</td>
<td class="nump">542,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Derivatives</a></td>
<td class="num">(92,000)<span></span>
</td>
<td class="num">(92,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,669,000<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">595,000<span></span>
</td>
<td class="nump">464,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued interest</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">231,000<span></span>
</td>
<td class="nump">231,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">79,497,000<span></span>
</td>
<td class="nump">74,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(79,497,000)<span></span>
</td>
<td class="num">(74,300,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">209,666,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=accp_PreMergerMember', window );">Pre merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=accp_PostMergerMember', window );">Post merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=accp_TaxYear2016Member', window );">2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=accp_TaxYear2017Member', window );">2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">3,324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=accp_TaxYearThereafterMember', window );">Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">206,342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General business credit carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">2,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General business credit carryforward [Member] | 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General business credit carryforward [Member] | 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General business credit carryforward [Member] | 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General business credit carryforward [Member] | Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 2,385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_accp_IncomeTaxReconciliationCurrentYearReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to current year reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">accp_IncomeTaxReconciliationCurrentYearReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>accp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 2<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=accp_PreMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=accp_PreMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=accp_PostMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=accp_PostMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=accp_TaxYear2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=accp_TaxYear2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=accp_TaxYear2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=accp_TaxYear2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=accp_TaxYearThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=accp_TaxYearThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $^*?DB9D_GWS $  -,:   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,V9RT[#,!!%?Z7*%C6N[?(494/9 A+\@$FFC=4XMFRWE+_'3@%!51"O
M2G>31^]X[DW&.9N>WS\Y"H.U:;LP*9H8W1ECH6K(J%!:1UU29M8;%=.MGS.G
MJH6:$Q.CT1&K;!>IB\.8>Q07YS<K\E[7-+C<"+GWI%#.M;I24=N.K;IZJ^O0
MSF:ZHMI62Y.6E#%9TT'2B\&M\O%:F=2"K5O6"YLC+[/._L<P.$^J#@U1-&T9
MXE-+89?_1GEUGM),+=OX(^.7=U=Z:ON:T&CW8G6U3EU"^FU2)#5\RV%[X5?)
MM,E#<]W\PXI\_\MGV7J)*]-.O7K46P:KO8TIGTNC=+=K5(_6+QZL7?SG-J'\
M5#750^=3H8]ZQRY)Q;=)#2RU_I/WZTZIK*=O&>;"/7X4C?)4WT6?YKO[VWA?
ML+\<>:[]]6=#[\7 ^M,>(?&C' (DAP3),0;)<0B2XP@DQS%(CA.0'*<@.?@(
M)0@*43D*4CD*4SD*5#D*53D*5CD*5SD*6#D*604*604*604*604*604*604*
M604*604*604*604*624*624*624*624*624*624*624*624*624*624*6<<H
M9!VCD'7\1E;6_Y=U\0Q02P,$%     @ 3XI^2$AU!>[%    *P(   L   !?
M<F5L<R\N<F5L<ZV2RV["0 Q%?R6:?7%*)1818<6&'4+\@#OC/)3,>.0Q(OW[
MCMB PD.MQ-*O>X^NO ZIK XTHO8<4M?'5$Q^#*G*_=ITJK$"2+8CCVG!D4*>
M-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,41Y26M#;3"&>6X9MY6&3I
M//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO+0O]C^AY%.!)T:'B1?4C
M9@,2[2F]@OIZ (4QOCLEFI2"(S>C@KN_V/P"4$L#!!0    ( $^*?DAYY7JT
ML0$  !L:   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V<U.PD 4
MAN%;(;T I^>< 94 *S=LU1MH8* $^I/.&/7NK2P,_LP7%R3?IDT[R9EWT3QI
MVD4;R_EC.%7IT+6Q/O1Q\M:<VC@?[R^+.J5^[ES<U*&IXDW7AW9<W75#4Z7Q
M<MB[OMH<JWUP6I8S-US.*5:+G[,GZ^VR&-9;*2;/U; /:5F\=L,QUB&DZ,XG
MN1DW&)??^_"?[;O=[K )#]WFI0EM^J/"?6U0N'R0YH.4$F3Y(*,$^7R0IP1-
M\T%32M L'S2C!-WF@VXI07?YH#M*T'T^Z)X2)"60L>0D(:PY6@O@6CA>"P!;
M.&(+(%LX9@M 6SAJ"V!;.&X+@%LX<@N@6SAV"\!;.'HKT%LY>BO06TGOVNAE
MFZ.W KV5H[<"O96CMP*]E:.W KV5H[<"O96CMP*]E:.W KV5H[<!O8VCMP&]
MC:.W ;V-]*T$?2SAZ&U ;^/H;4!OX^AM0&_CZ&U ;^/H;4!OX^AM0&_CZ.V!
MWIZCMP=Z>X[>'NCM.7K["[UC70UA^Y2&0[N/UZ[Y-AP67> =T_LI7#_E/!4V
M7&B=QIV".Q^O_M2<IWZ&N%__@58?4$L#!!0    ( $^*?D@KP= 5Z0(  #T+
M   0    9&]C4')O<',O87!P+GAM;+U6P7+:,!#]%0V7DD-C0IA,RQ#/*$()
MGAK;M47:'!4C@B?&]E@*D_3KNY:!0B),X% NR*OW=K7OK34>9++3#\J\$*5*
MA$2OBS23?0A>M^9*%7W+DO%<++@\!T@&N[.\7' %C^63E<]F22R&>?RR$)FR
MNIW.E25>E<BF8OJUV"1MV8.J"BZ*-(FY2O+,'B=QF<M\IA!]C44ZL-X#- ,R
M1R)^*1/U9G=JS'9(8Z*8IX) +7O&4REJU+^@QI!\4?#LS:J?W"1[EI."Y4.N
MQ#9K=Z/./N>EF$+1G>R;H,:,WJ#/M.*2.<^>Q'0;^W%SK<6]*&75Z47WO ._
MC03K>)U;\&F2/04\*:4]6*K^4L0J+U<V+=6I+DWSN#)=WC,XGVRA1RY%M;QN
M+7F9\$RUD$S^P&.W59>MHWJ=%E*5]J^\?)9S(90<6)N@7FYCM]=)S^YU-0)6
MNTAKTYF]DFVG[RK"$I4*Z<\"7JK_)(7N:2U$;Z5$W>@Z!>+9%-%,P3@B)ZM+
M@7G;DFQ6Q/<BWW6&F-$ANL$N]@A%T8A2%AV+1^V '^9$#/[&U .\?XO\@(;'
M<B+FDQ,X5\=R"(Y&)W"^&3D>9I.0KEO&S($<"'O GXS'V*Q!2%U=(L A>T L
MQ%Z$B68:X4%8I09DE9;^G#A!=2PCU'4(]2)(S2@9>;[KWST8<;W.1?OY# 5@
M\QXEQF.'U=U754$9YGAWU",.-1_R%CLANL?NA*(QQ1%HHME[&J*W- RUR#[Y
M8<3HG9'O#FD8?=%=,W,K&@CB5_KIALPU\0WU/8S8"$P*Z(0Y)$*N2Q FD#IR
MC!S' QTH8OCWGJ8;S>]>G,#I'C$!J,WX(UQ39Y\=A69"H^>H?8SKZT*?=K;Y
M9!\M;L8W>MW]?M#KYNR-!EZ:3=__QJ/V4*BC3 <\3U*SMD;35P1S-ULWP0%D
MXWQ<FF_AO?-15_K,[7#@5.9I.DQY-TZ-A,9YZID=WYTG4_H/GR'O/CJLW8]E
M^R]02P,$%     @ 3XI^2&%$6+@^ 0  :0,  !$   !D;V-0<F]P<R]C;W)E
M+GAM;,V334_#, R&_PKJO4NS2AN*NAX <6(2$D,@;B'QMK#F0XFGKO^>+.M:
MOBZ[<:MKOX]?QTDE'!/6PZ.W#CPJ"%<'W9C A%MD6T3'" EB"YJ'2:PP,;FV
M7G.,H=\0Q\6.;X!,BV)&-""7'#DY G,W$+.ZDH()#QRM[_%2#'BW]TV"24&@
M 0T& Z$32K+ZV>R,;4U%1GU=1<<-#[BT4JT5R)MN+/N=BIT1O XG.<BA??K[
MIX>4(5E?>0AJJ&K;=M*6J2X.3,GK\N$IG4VN3$!N!$154 P[!XOLW/FEO+U;
MW6?UM*"SO"CSLEC1.:/7C,[?CI-]\S<:UOT0_];QV6#:+BILX,+=)HU,RTV?
M"20A"*\<*FLNPB7,%W&"A?W[!PB\'-0+TV7;0==:+T.=[M<8'5].7-G&^NZ4
M^A%]>U7U)U!+ P04    " !/BGY(F5R<(Q &  "<)P  $P   'AL+W1H96UE
M+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.'X41
M6(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DO
MV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O67.!;
M&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$35T$F
MN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'T=)(
M@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+<!P$
MX%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMWW=..
MB<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8<';6
MS-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\313%!\
MKT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_::L!
MI^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E)3+/
M[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@MNN01
M.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)
MVH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V</!T3
M$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S&L%&
MKQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV&G*U
M%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0$;\>
MACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'HYI9
M";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y?RY]
MSZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@YG\#L
M_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2GD(;
M;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*]+',
M<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*TU*0
M;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[
M7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B?$R,
M1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]
MM!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./FQW%.
M4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R
M_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2D 83
M <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7<N/O
M[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@2\-Z
M;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F$RQ#
MI'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?
MD@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_
MV]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    ( $^*
M?DB<3%A61P(  %P*   -    >&PO<W1Y;&5S+GAM;,U66VO;,!3^*T(9(X41
MVPEUZ6H;1B$PV,J@>>A;D6W9$>CBR7+F]-=/%]\2",VZ6_*BHT_G?.?3D9RC
MJ%9[BA^W&"O0,LKK&&Z5JCYZ7IUM,4/U0E28ZY5"2(:4GLK2JRN)45Z;($:]
MI>^''D.$PR3B#5LS58-,-%S%<#5 P,7?BQS'\'G^_GLCU-T[X,;9A]G,?[ZZ
M.\;G=N$* L?Q.8]A$%Y#[WS2A7^:5Z\=48<GJ'MW2S8?9T?A-R;<ZTJ01(7@
M8R66T %)5+^ ':+:/S#NF:!" J5+K?-8A".&G<<]HB25Q( %8H3N';PT@#V=
MSH\1+J3-[3(<YUGX8R99IC'TN]_YZ=*1W0YF>X32P^UI((DJI!26?*TGH+,W
M^TIOC@N.G4CK]XIW*=$^6%Y/ NR@\Z9"YE@.F0/80TE$<:%T@"3EUHQ*5$:Z
M4$HP;>0$E8(C:BC[B,[0M!FF]-%\"T_% 7=; .=CSMB'P*CH35V(SARO@2VJ
M-V5SW%/:M_&"MA@2Z&A4573_B9*2,^S$.F@MNMEK],$)^B1"/2O8"DE>M+^Y
M")D&L(1@AZ4BV13Y(5&UP:WJ;K#7%J<4OG7+?U/3GZ_:J$9?P7]=GO^:?'HV
M]C.$1WK..(J'AJ58KNW_[Z\+6]U<JC+3NBY66GBYTB[V0%>WOZG,ZQK#I/L<
M])X!!6E#J"*\EX#,:^'!R*8';6'L.YHS;\>68U<52O53[R"+)LMQ@1JJOI&=
M4'8QAJ/]Q<@/PL%K,U#$<+2_XIPT[-8J&-^3R4]02P,$%     @ 3XI^2$]K
MB9OD P  "PX   \   !X;"]W;W)K8F]O:RYX;6R5EU%SFS@0@/^*AI=S7\Y&
M8#?QU)TA6(F9P^ #G%X?%5NN-<'@07+3]M>?A.-V:39N_ 0"]+%:?0O2!S5^
MJIO'A[I^)-]V9:7&S<39:KT?]_MJM14[KOZN]Z(R]S9UL^/:-)LO_7JSD2LQ
MK5>'G:ATGPX&HWXC2JYE7:FMW"OGF:;>0E/[1O"UV@JA=^41MN.R<CY^4..-
M+,6]:)0!$[[?)WPG)LZWTB$E5YJMI1;KB>.;9OTD.A>:P_[F($O;& Z&3M_"
M3D-=-&15K\415FRE^O1\PR%KL>&'4A<FV--[)XY+?4I'1X9][%Z*)P6!]@+A
M*RV_BH(_3)R!0_A!U[>RU**9<BWNFOJPE]47PW+(1C9*YW:X[9,[6<F=_&'C
M-BVUK9]F=2-_U)7F9;YJZK)L>]D;;2?S!O7SBHE1RU7G0<T?,CL3$V<T,,"O
M4LD'64K]?>*TYZ6P(^G_-I0V_;_.2-4FYS3%A%=KPBIM*"2JCI-G4F-C, ]'
MZ_;%S5B:DR9:N\=405"8)GD:1].@8%-R$\1!$C*2SQ@K<@"A $(O@I#>@@.0
M!T#>'T!Y80YSEAA(>DO2!<L R <@_R)07J0A  T!:'@I: 1 (P :700*@WP&
M0.\!Z/VEH"L N@*@JY>@)"B6&3OE-B@B R9!8J#+^3R R;X&H.N7H(S%;3"+
M("L^DR(+DCP(6QST< !%'+RD+#(;A@'8$-B_RVAAQP4)'941E^,H9$EN BE8
M.$O2.+W[#+M#B5W$8G_@]A[?D871%W:#RKJHL_-Y5!SGP(9NYJ>(DCN6A!'K
M)  JZR+.W@911NZ#>,G(G 6YF9L6"A%05A>Q=9&Q6Y9EK1AI^ _L"O5T$3_;
M#K,TGK(L_ZO-?]')'K321;1L^QN3[+RW.>P$#E5T$1>#&Y8F 2EF1L0%6Q91
MF),X#DD0FD#R"**@C"YB8Y28&6&D"/[KI)]"_RCBW]ERH"Y$01$I(N)Y%(6H
MSI<5D1*O"M(S/YM2J'<0!46EB*A(>: <Z"E%OZUGA"<]B(*^4L375Y0_A051
MT%_Z1G_1X4&1Z9M$1C'0:'JIT?0:HJ#1] ]&8[%X4&WO4K4]J+8'U?80M5__
MUI/>5&B(@FI[%ZAM,%R6</*]SK+AK6H_<SJ9@FY[B-O@'X #H-$>NEXX4QP>
M7"]XT&@/,?K5XCC&!5'0:0]Q^K?_ CXT:+2'&(U7&$:"0GN(T%B)(1P?>NTC
M7I^M,1]Z[4.O?<3K;HUAP4"=??J\5/^U.C<;%%F)M=V[J)9N%O\KNZ$QA^/R
MPQ_:?Y=MS\TF9^+8G8C9=!S*,C37TBJN>;M>/Y)/6YB/_P-02P,$%     @
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M3%6;]_5!WY&L>Y0[8\V5_P=02P,$%     @ 3XI^2'MF]V&" P  NQ   !@
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M0:FW7;^;V/UF_+8>#SIS./]4</F]8OD'4$L#!!0    ( $^*?DAV.@![T $
M -0$   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC93;CILP$(9?!?$
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M6/3/G#YPU[E-/^@;Y>^YRCHW^K9*V2)YZ^<9)4^#A$TD]*I(W.37# S+\,1
M>)!@#16<X!DX6@/W\7Q: \?C!1HO?+R8QHN@!X-$>4DS2(C[%$A0"93)/)O*
M/M%(E$9"&AG0#))TDD;P#-) &6=JEB9%:5)(DP8T*4A#B2 0!^IR)F=Q%(JC
MX*-6>'R&QF>PG"PH)X/-553"<J".<SY;3H[BY! G#W!RV%W!&=)>*.2*LEF@
MWMPP/R  29'0$ A()26%1(B.TGF@&8.B$(B&0!0FRF66(DA0*8A,YZ%03WND
M#$(!VV0@U1W-I,"H$"FG_$:O<".D'&+Q$(LC'6 8%"*<_UPI;JT4>JL*O774
M?*H>XT%D,KOQ@N/V2J&_JM!?*71.0 ,E=XS[UWN.!S=8"AU6A0Y+H74*@GD
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MRTC1(<Z.C+M[23!R4B:4/\N#B%N]'A-46+W4KY["#P4NB R4;PAQ<^4"IM#
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M0T(2!Q])9]"U^FE$$D8D 42R=Q3$^:=,"B80((S8T9B0&A#2A834''RJ;0K
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M>96/"XPJH::IG#-SNYF%H-W]KA[_,/+_4$L#!!0    ( $^*?DB*JN;6GP$
M +$#   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL?5/;;MP@$/T5Q <$
M+[NY=.6UE$T5M0^5HCRTSZP]ME& <0&OT[\O8*_C)&Y?@!GFG#DS#/F ]L6U
M )Z\:F7<@;;>=WO&7-F"%NX*.S#AID:KA0^F;9CK+(@J@;1B/,MNF!;2T")/
MOB=;Y-A[)0T\6>)ZK87]<P2%PX%NZ,7Q+)O61P<K<C;C*JG!.(F&6*@/]'ZS
M/^YB1 KX*6%PBS.)VD^(+]'X7AUH%B6 @M)'!A&V,SR 4I$H)/X]<;ZEC,#E
M^<+^F*H-ZD_"P0.J7[+R;1";45)!+7KEGW'X!E,)UY&P1.722LK>>=07""5:
MO(Z[-&D?QIO;+Q-L'< G )\!=UD2/B9*,K\*+XK<XD#LV-I.Q!?<['EH1!F=
MJ>YT%X2ZX#T7F[LL9^=(-,4<QQB^C)DC6&"?4_"U%$?^"<[7X=M5A=L$W[Y3
M^(_\NU6"72+8_;?$M9B/*MFBIQILDT;'D1)[DP9UX9VG\YZG-WD++_).-/!#
MV$8:1T[HP\NF_M>('H*4[.J:DC;\G]E04/MXO UG.X[4:'CL+A]D_J7%7U!+
M P04    " !/BGY(B"@KA* !  "Q P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q]4\%NW" 0_17$!P2O[4U7*Z^E;*HH.52*<FC/K#VV48!Q :_3
MOR]@K^.V5B_ #//>O!F&8D3S;CL 1SZ4U/9$.^?Z(V.VZD!Q>X<]:'_3H%'<
M>=.TS/8&>!U!2K(T2>Z9XD+3LHB^5U,6.#@I-+P:8@>EN/EU!HGCB>[HS?$F
MVLX%!RL+MN!JH4!;@9H8:$[T87<\YR$B!GP7,-K5F03M%\3W8+S4)YH$"2"A
M<H&!^^T*CR!E(/*)?\Z<GRD#<'V^L3_%:KWZ"[?PB/*'J%WGQ2:4U-#P0;HW
M')]A+F$?""N4-JZD&JQ#=8-0HOC'M L=]W&ZR0XS;!N0SH!T 1R2*'Q*%&5^
MY8Z7A<&1F*FU/0\ON#NFOA%5<,:ZXYT7:KWW6NX.6<&N@6B..4\QZ3IFB6">
M?4F1;J4XI__ TVUXMJDPB_#L#X7Y-D&^29!'@OR_)6[%[/]*PE8]56#:.#J6
M5#CH.*@K[S*=#VE\D\_PLNAY"]^X:86VY(+.OVSL?X/HP$M)[O:4=/[_+(:$
MQH7C%W\VTTA-AL/^]D&67UK^!E!+ P04    " !/BGY(OE&^/* !  "Q P
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M^#F<[312D^&QOWV0Y9>6?P%02P,$%     @ 3XI^2.[5PF"? 0  L0,  !D
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MX653_UM$#T%*=G=/21_^SVHH:'T\O@]G.X_4;'@<;A]D_:75;U!+ P04
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MZG^-Z"%(R:ZN*6G#_YD-!;6/QV_A;,>1&@V/W?1!YE]:_ 502P,$%     @
M3XI^2.TQ<3.? 0  L0,  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M?5/!;MP@$/T5Q <$+[MIJI774C95E!XJ13FT9]8>VRC N(#7Z=\7L-?K)DXO
MP SSWKP9AGQ ^^I: $_>M#+N0%OONSUCKFQ!"W>#'9AP4Z/5P@?3-LQU%D25
M0%HQGF5?F!;2T")/OF=;Y-A[)0T\6^)ZK87]<P2%PX%NZ,7Q(IO61P<K<C;C
M*JG!.(F&6*@/]'ZS/^YB1 KX*6%PBS.)VD^(K]'X7AUH%B6 @M)'!A&V,SR
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M;9PT_*#ML#!C.70PPT2+\[TA&[O"ZC]02P,$%     @ 3XI^2.E15]>] 0
M>P0  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL=53=;J0@%'X5X@,4
MA]%I.W%,.MUL=B\V:7K17C-Z5%)^7,"Q??L".M9,Z8W X?LY!SD4H])OI@.P
MZ%UP:0Y)9VV_Q]A4'0AJ;E0/TNTT2@MJW5*WV/0::!U(@F.2ICLL*)-)6838
MDRX+-5C.)#QI9 8AJ/XX E?C(=DDE\ S:SOK [@L\,*KF0!IF))(0W-('C;[
MX\XC N"%P6A6<^1S/RGUYA=_ZT.2^A2 0V6] G7#&1Z!<R_DC/_/FE^6GKB>
M7]1_AVI=]B=JX%'Q5U;;SB6;)JB&A@[</JOQ#\PEY%ZP4MR$+ZH&8Y6X4!(D
MZ/LT,AG&<=JYO9]I<0*9"60AW*4A\<DHI/F+6EH66HU(3T?;4_\'-WOB#J+R
MP5!WV'.)&A<]ER2[+_#9"\V8XX0A*\QF06"GOEB0F,61?*.3.'T;S7 ;Z-NU
M^]T/_EE4( L"V=H_3Z]*C&%^,,FC)GE$@%R9Q##;N,DN:K*+"&17)C%,?F6"
M5[=#@&Y#$QA4J4&&EEM%ESY[(.%V?<'+HJ<M_*.Z9=*@D[+NCH:;U"AEP:62
MWKB"._<2+ L.C?736S?74W-,"ZOZ2ZLO[TWY"5!+ P04    " !/BGY(ZI4
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M_S,;$FH7CK?^;,:1&@V'W?6#S+^T^ 102P,$%     @ 3XI^2%+F30VB 0
ML0,  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL;5/;;N,@$/T5Q <4
MAZ2WR+'4=+7:?5BIZD/[3.RQC0J,%W#<_GT!QZZWZQ=@ACEGS@Q#/J!]<RV
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M_)_%4-#X>'P(9SN-U&1X[&\?9/FEY3]02P,$%     @ 3XI^2-K6N6WE 0
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MUYP7'"KCIHF=JZF/3 LC^VM;G'MS_A]02P,$%     @ 3XI^2.R4C_NC 0
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MUQ^TSR'2A#FKA/EU\K.0K+Z%N$Y-/KIGV9CGM7L3Q7T8'!#T <$0@#X/P'T
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M5\%RFS 0_16&>P-: 08/9B9VTFD/G<GDT)Z)+=M, +D@Q^G?5Q(8&[0X^&)
M?OOV[:(GI/C$J_=ZSYBP/HN\K!?V7HC#W''J]9X5:?W #ZR4_VQY5:1"/E8[
MISY4+-WHH")WP'4#ITBSTDYB/?92)3$_BCPKV4MEU<>B2*M_2Y;ST\(F]GG@
M-=OMA1IPDMCIXC99P<HZXZ55L>W"?B3S9PH*HA&_,W:JK^XM)?Z-\W?U\'.S
ML%VE@>5L+11%*B\?;,7R7#')S'];TDM.%7A]?V;_KLN5\M_2FJUX_B?;B+U4
MZ]K6AFW38RY>^>D':VOP%>&:Y[7^M=;'6O#B'&);1?K97+-27T_-/\$Y# ^
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M_AZN<W..'U>$L1A4RO ?+0%A9D#$'UO3EO=^-+HY $0#X0&EA&6P LF!-!#
MMV7P"2A7;X'4=Q 2EVL&!6 SH-)B 5R-IDHIQ#2<"R;C9):EH"AASXS8Z[8F
MH%: @R)T% )N!Q@=5W4IM''1^#G"4,4PSC=T+Q7>88H"K)CE&XJ>02-*!K-O
M8MS& DV3)&;#6UD#@%H@SSWPNO#TY3H5BP+Q(^":R$2 &V?\)' #I2;1AXFE
M)GT?:B,'!FYXC]'#(QPX^TQ$R>?9&%'@^$!T0,0A\"'/67(,.8KS&##R_ AH
MO-ZDLT=BU'#B]V%%/0,X."+9:(EH?"1>_ C7[@KNOPTP=FLA=,MA #SQMSG
M%W0@C%,!>*51_$(X^IQ81QFM )CYAL '(S]&,. R>"%DB)8 L_ SZLGZ6&<)
M"@EBY0#<(OW%5HB)!!#1S\,YQ2J=\2J -:C'QT:8@9OM[&+,MS,1^BK)"5>
M3<"C,"^<'QKN8"5IR)$4 #6UFFA%Z\L(W7 D#UD$PL$*JRU\QOM*XYU0K/ >
MC]((-!W8,3!"7V)0"%84Q_-,+^$]-4\V]_EB$RM>P>? %+<A)A%BN!(2%E%5
MBI?S,ZSA$90;7CSR2Q#G<A!F4DU546J=% S'ES']:OC//"&@"4>!QV($$_S6
M(B+8LE*4,UEJV*P3O "?HO"95H3"$UY?>EF:1_M "? 5,#4Y&M]>DH=&UV2)
M+ZH5(TK3F$U8#>ALUOH<9&2]31&K HJ;,DMF@9@)DWQF<8QR'IQORRN$-4]4
M6+/GCG86;%#3Y&0J:GF%V+DH,^C- @C=[7!%82S588SJZ1+D#) (D#0T<\*G
M0X0TBN*PF6#U@"\+&T/>D",= LJC#08@-+',DG16R^!'BBY9A<\@=M'*[\,<
MS5-LW\;+(/R<A\*!"],1B-C>B8&7CM%7:,R)F5F$*W;8K-!*"WIOR@,(SZ8#
M@(L/Q9]Y2P2(S+YMX(Z8(X\+[F$(2MTPUP+3;%"(DK5#$W$><Z\K+F\=]HJ9
MP ,LE!DI<P-U="!C_9LAY7J)J2B[F$A&==49;4%?1]K:<V>L/39_=5AH4!DC
M4K:G+O 7#V4)()*(E$:<V35,\  80BBZ60&6Q[0?8*)11G[W.,1Q17&D0P#4
MP$!&.*@E'B >U/=XV<!=,0\19R(2_5%^6,D;< ?)6_HE'!(E?3Y'CV3Z'P$J
M=.<\HR@.'.2903T+TI26I2,Q[0-'$ '&DQ."9@-LQZO(BMTD'$&!!U;$"Z -
MP]V8LO^#I&(6MN$OOIOP.^OA!/ *B>>]9H<N:*(NS>&OH5 IPWVAE[U&13?7
M$%70)SZ>DW-DDU;VQ(1DKV9%T%TATT>N&@%G1$).4%M'!@T/X26\@*'FJ#@D
M0FD42<_S<Y@K2Z)1"E2#EQ BS^;A 1="9VC-B9=U^#E"OC5Y,HR!92>6I$CN
ML6%,J\K3"$9,Z1>4Q*.E/2QN,,OX85L92/$N73/QFY"X&;!!M$MYQ%A6^D_
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MV+Q.\/(K"QL75^/K#Q/O;O3':A%#^[=M<>@=[&U1>,%TV-79=5Q[RXIW5 5
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MSNKZ+]I(CL%A>JU2MTK*B66J"Z>8']-"U4?<<<BFU&JY4]N<K_L"[O94G2^
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MZ9=P2-23^.0I7RA!LP@7O4)%!AC5<T/?#XTBY1YSY';*B_TQ$*M0BL-8.%H
MMQ5]#%)3Y$]4%?B+;T2*?S(/D]D-R.V]YKHN:*(E0O?C(;IFN"^, Y<['BJ(
M*NC3=9%3Q:.-JV\>J7C6:JC^E]B/J/BYSZTXT-:!]P!WM(FP-\0<U:XD5<X.
M$-9X?C8MLG@=I4!G>-<A\FP>'KBY5Y#;<U('N<\1<KK)DV$E,RD:219-KDMF
M7N)P9"F?22W!L";JTAX6-YAE_+"M$)&+<<WLPD0,:^\AL:*5_A-[)MCA9 #$
M>;K!HIJP?Y:>4RI-)J7 J-_]<AUBKPX@W>*SO@T;CG=0T[ ZSYY&RR@0.&;#
MLJ+N8#=3W"P+XM T]\0Q6B[O+<4GR&D[0:?9W18 /W,.5Z#J7KB[/4B!M;+B
M84UG.ID[:5,*$F_C4+17[7H R)$8PTMG*;!*8DR!VC*C6I%J0LK^OGN=4E<.
M/86NII5Y'37_(EB"5O 5VE!OE$F3VEU8G6;%*$I*S3J)7U:;.$SR"!M]@+A?
M8XK$%^.7+,F2):FC"<5/*DM<]M.?_U)V \AAX/6@FGECW,!UNL8>,411JM:U
MBG2FZL$6+'CWITJ-(?>@R%W>L41.TB8RD+F"S8I4'2I(K(X8=3<]\NCTCX<C
M.;0_'IYJ\P$J-[):U4<Q"\-/5*V-5WN&JT7[PB:SNVI,/HP*:^-P_TZ[M#3'
MFM0 &Q1!*>5$^2$T3FZ_;=236%E*)Y7=V&;MW*8$-S7]C/;)]=V3>1%&X$%C
M!\4E EZJSLIDW/]/T%W99 /I0J &^(6]VSE!!9=?SV)6%)44Z,-8A!(_KXN*
MX8U-H6B,[L#L]OHZ'U9^Q!NHX[>'1WYGT&D*&>7HP6.?W)(/*&M3G <E@**@
MK\-^5/\_3'7H]/S>\:!I6-(E<QT]A'3M&IY<H$+I*?<G4Z*\P0**1RU8L96!
M6@J*>L IR8>?O 1Q_L+B$=V6J*_S)8NDQCBW2)75DWTZX;S8T+MIPM<2H!+W
M%A@IS/17(_RK3K3,C6]I)U'5I-K\-*5NI_HGN.99)=<ZDL9)$WHJ;C CV!CJ
M]P6BJG:L^, 8HKH\,JE2VK!([;=0-68MGNZNR1A9XV*A0N60)DXWH+/#)^\J
M:0%#['O[T]$I?CCP=5/>6Q[=87UW9[7K@*L:6X-O8D@H(K9K5= LV!L$=\4*
M^;NL48BY8TV!'!1%B4K/EH8B>$NJM;%@D:Q0"KZ6]Y](9IYC?YDGE[Q&;OV2
MGD"U7ZBWV2*2)E6E1]A953HAZURF:/$BG_\XF9OV#LB71],QL60\L1[%\/]/
M*SHFH[_U$>!**.[%KX3JW]J8=V9AWD0,TJ]^P;NM0V9IE5IKEJA]41O'12GQ
M*5-3]7XCFR,9)GUDC&DB.P8M,D/A/5;O^]2T%ANTQ>3C1AN&:!-^9:%^*;;;
M#(*F2+Q/X=K9+(!]L<&>RP!2\B<5T[%M+*I]:5:R76'42#"K=!K3$C+Y.&M9
M@TD&8%--D$M)AYCZ:9,R)<V/-EG5H,36<#57A16J\!W"^CEVJN%"U$_Z]%[_
MAK?]$=M:;D5]Z[/T39,2Z[O*46<LBU K/H[Y*\Y&'CL=,V) Z:L#>?%,8U]@
MM8N0JCL&U@3[42ML^=*)5GU[H!J/2^%QKL9-F9"A(Y24@]$X5+/I-Z6<%;T0
MENUL68B;E1 D2JWSV]TCDW76'U2SSGR['ZK=A%A8HA$[RCQY>^"MR@REV>W+
M'VWQ2U9VT#Z-9G;)KN0ZF&AV.DP6"^E)2)U_C.F/ [_+L=Y:=1#A&H"6"1P0
M!1P2M80'(#1P_<R9I08-V1)29?0E0&B"IS$_;-YCLO;^<C-+@OEC2#IJ@NC]
MG&"A9DS7"SF*A.BR(*03%WHIK$4%XJAU8K_5%:=<D"C[A/*/98/00CPR0^.!
MH#VE%*JF9&GWPL5K1JU1#G&R%S$?4^DN^&7!%F[R.56("*,K0-F:QXKYX5./
M&%=#A*,R8-C2:%WGV*XAY^1#_*T:7<VOW&&,9--OI0#GM-Q,QV0LBAW%\N:^
MB+;1<H;B5OR^13.U JJP5GP1D9\,?>3/S^&^@"-1C8FW!RZ;POZ53L64MB@E
MB>N6I[U3EOW;Q#P7.1U%VK$-]G--L.>N(-'=(-FE$JX"CJ>'M]A-;(?8!X3M
MR&."SR(+,68P+%@#M^R]&+'G#L56XH,5O(^'PVY1"@>C)F'2<YIC 2C4;/NN
M2 &RVLWHG0C^&C]%<?5BKF8CK>K"2J(EPL3JC3RRTJ2,=\UV3['%I[I4X<[D
M*\KU<0<ZA)3ZO[(_D4/&F!:$$E1'6#LT-5&QD XE0??(.NZW?:]$=1)7;5V/
ML$W62RP7<52F3BM"B80^&49W(+)<E@[I@&8K7UN1PZCI"L(P12-VZV!?,($:
MK0JMH :612!2U)?JDY *2%[T[FH  U<4>7>LEETXI<+J &0:()87[I?U8IIX
M&^: R:@:,8GH 8:+B#'&BN2BV(-92M%JA&+RV3*/K0"Y,">%8R9TX*&$CV%_
M="M:5OR?E!K"225TL]CAL_<OXO[$9?T(0G(VCV:F*D3Y.+B6HNX=PG46O@]U
M;)4=3@6G;%@(D6D(O'BE?01D(U3QV/;4=;?-_B7PQ0/*4IRB'64G#;?F71U+
M8=1,] K-U'KW8WK>*OV/EN%-;L0J[J"K"B&6$^1-'J<R\HCEQXJ0L(*($,:^
MQ#O%&_;2_:KK(.H%%8P;LR$<M(MEYP7;C6**+XESBPPH=D$T5N<JA;]-\X<Q
M#V,E?,J(.NZ%0N[L_N<JN)PN35,L0V7K:E3>C:N@VS789&P]4!?3P@HVS3'P
MGO-=30B@U>/N"6Z04\(D^S0="Z28>HNGV#D:A4;&/AD_UKE5T-\J[\]<YJ#
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MI%#$:/J1%GC8'MJ"KG)"I,9QP$H9!F,\8+,-LMM+1 V9(O 7C*<[S/)P[1I
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M[=7UY?7['VI/:CI[#.>;6&SME8#LG8[LTI$K\?KS<HT"1*C+I>U9;4$JP"W
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M!U!+ 0(4 Q0    ( $^*?DB9D_GWS $  -,:   3              "  0
M  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L! A0#%     @ 3XI^2$AU!>[%
M*P(   L              ( !_0$  %]R96QS+RYR96QS4$L! A0#%     @
M3XI^2'GE>K2Q 0  &QH  !H              ( !ZP(  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 3XI^2"O!T!7I @  /0L  !
M             ( !U 0  &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !/
MBGY(8418N#X!  !I P  $0              @ 'K!P  9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " !/BGY(F5R<(Q &  "<)P  $P
M@ %8"0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $^*?DB<3%A6
M1P(  %P*   -              "  9D/  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ 3XI^2$]KB9OD P  "PX   \              ( !"Q(  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( $^*?D@X+"UVB (  '\)   8
M      "  1P6  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !/BGY(>V;W88(#  "[$   &               @ ':&   >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 3XI^2'8Z 'O0 0  U 0  !@
M             ( !DAP  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( $^*?D@O%MJ!/@,  *X-   8              "  9@>  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !/BGY(PP.%VO8'   4
M-@  &               @ $,(@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ 3XI^2'2?WCW] 0  .P8  !@              ( !."H
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $^*?DB44SD*
M] 0  *L:   8              "  6LL  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " !/BGY(M_3#9/L!   \!@  &
M@ &5,0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 3XI^
M2(JJYM:? 0  L0,  !@              ( !QC,  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( $^*?DB(*"N$H $  +$#   9
M      "  9LU  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ 3XI^2+Y1OCR@ 0  L0,  !D              ( !<C<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !/BGY(DQ-OQZ$!  "Q P
M&0              @ %).0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( $^*?DCNU<)@GP$  +$#   9              "  2$[  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 3XI^2$(P<<R@
M 0  L0,  !D              ( !]SP  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " !/BGY('?V7.*$!  "Q P  &0
M@ './@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $^*
M?DCM,7$SGP$  +$#   9              "  :9   !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ 3XI^2.AHS$2@ 0  L0,  !D
M         ( !?$(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " !/BGY(<+@OKZ !  "Q P  &0              @ %31   >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $^*?DB.=7)CGP$  +$#
M   9              "  2I&  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ 3XI^2(%NLVN@ 0  L0,  !D              ( ! $@
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !/BGY(],G'
MRX "   A"@  &0              @ '720  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( $^*?DCI45?7O0$  'L$   9
M  "  8Y,  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M3XI^2.J5 )>D 0  L0,  !D              ( !@DX  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " !/BGY(K[BL(J\!   6!   &0
M            @ %=4   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( $^*?DA=!DZ1HP$  +$#   9              "  4-2  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 3XI^2%+F30VB 0
ML0,  !D              ( !'50  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " !/BGY(*S)NQZ$!  "Q P  &0              @ 'V
M50  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $^*?DC:
MUKEMY0$  *<%   9              "  <Y7  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ 3XI^2.R4C_NC 0  L0,  !D
M     ( !ZED  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $^*?DBO5803A0(  $X)   9              "
M ==G  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 3XI^
M2#1B()[N 0  ,04  !D              ( !DVH  'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " !/BGY(W2!1PM("  #L"P  &0
M        @ &X;   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( $^*?DCQPU\,% ,  $P.   9              "  <%O  !X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 3XI^2 #\^7P0 P  + T
M !D              ( !#',  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " !/BGY(8&XMMFP&  "[*   &0              @ %3=@
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $^*?DABQP%!
M\08  &\L   9              "  ?9\  !X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ 3XI^2" [_/$P P  5PX  !D
M ( !'H0  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !/
MBGY(W8\97H8$  "K&   &0              @ &%AP  >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( $^*?DB?OL! ;E4  '=I 0 4
M          "  4*,  !X;"]S:&%R9613=')I;F=S+GAM;%!+!08     ,P S
+ -<-  #BX0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>157</ContextCount>
  <ElementCount>297</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>030100 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>040100 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060200 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060300 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060400 - Disclosure - LICENSED TECHNOLOGY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/LicensedTechnology</Role>
      <ShortName>LICENSED TECHNOLOGY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060500 - Disclosure - 401(k) PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/KPlan</Role>
      <ShortName>401(k) PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060600 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060700 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>060800 - Disclosure - PREFERRED STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/PreferredStock</Role>
      <ShortName>PREFERRED STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>060900 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061000 - Disclosure - STOCK OPTION PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/StockOptionPlans</Role>
      <ShortName>STOCK OPTION PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061100 - Disclosure - ABEONA THERAPEUTICS LLC ACQUISITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisition</Role>
      <ShortName>ABEONA THERAPEUTICS LLC ACQUISITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061200 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>070100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080300 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://accesspharma.com/role/PropertyAndEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080400 - Disclosure - LICENSED TECHNOLOGY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/LicensedTechnologyTables</Role>
      <ShortName>LICENSED TECHNOLOGY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://accesspharma.com/role/LicensedTechnology</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>080600 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://accesspharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>080700 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://accesspharma.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>080900 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://accesspharma.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>081000 - Disclosure - STOCK OPTION PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/StockOptionPlansTables</Role>
      <ShortName>STOCK OPTION PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://accesspharma.com/role/StockOptionPlans</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>081100 - Disclosure - ABEONA THERAPEUTICS LLC ACQUISITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionTables</Role>
      <ShortName>ABEONA THERAPEUTICS LLC ACQUISITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisition</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>081200 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://accesspharma.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>090100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090200 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090300 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090400 - Disclosure - LICENSED TECHNOLOGY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/LicensedTechnologyDetails</Role>
      <ShortName>LICENSED TECHNOLOGY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/LicensedTechnologyTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090500 - Disclosure - 401(k) PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/KPlanDetails</Role>
      <ShortName>401(k) PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/KPlan</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090600 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090700 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090800 - Disclosure - PREFERRED STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/PreferredStockDetails</Role>
      <ShortName>PREFERRED STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/PreferredStock</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090900 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>091000 - Disclosure - STOCK OPTION PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/StockOptionPlansDetails</Role>
      <ShortName>STOCK OPTION PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/StockOptionPlansTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>091100 - Disclosure - ABEONA THERAPEUTICS LLC ACQUISITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionDetails</Role>
      <ShortName>ABEONA THERAPEUTICS LLC ACQUISITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/AbeonaTherapeuticsLlcAcquisitionTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="accp-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>091200 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://accesspharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://accesspharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>accp-20151231.xml</File>
    <File>accp-20151231.xsd</File>
    <File>accp-20151231_cal.xml</File>
    <File>accp-20151231_def.xml</File>
    <File>accp-20151231_lab.xml</File>
    <File>accp-20151231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001144204-16-091600-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-16-091600-xbrl.zip
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MDTV&M< ]TSU!3<Y&8++3:@-F!(7X)(T__ G@U_DK*63#F$,%B0#\#1833@#
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M#S:F@<N^@OE &WM+D1L[H@J3\BD!YD4=PC["'$][B4(4&0-6,59U$WMP@H#
M5J*[E)0"JP=.P8W:?;/ <#'!*L%@/MT$1+H>R5D-SSH8R*U.*0";\,G?-<RY
M$='46'KAE7)JGG LV&K(N)G8UJL^%+^BC?/CY.&$7?(AM27Y*J  J\%__=R"
M/4[: A\OOUZ=?XHL@/V*RWSEP7YIZYB\@54K@!@6R"K>\1I^<H</EVX2I [E
M\."80+BQ[J[>1U-)YVJAIY#U<]6VIVC[47IH.CTP</VO%O3P2U,,5IEICY!J
MJATN*EUE62SINT>+:J6@5+-=S))D>TJPS+&M,F<?09'07Y]2[D;TO?^Y__%F
MU:":IUTE#5LFSUVB56<J"*8HC7XWIU5GY]I\97!F$6E9M%"PL_4@2@GVQ3NW
M-1U(?[<XLWN>IPS5<6Y'LB[]K7V/+BU_)!HH>.C(ITY"%>7Y]<RG9W=.8@RU
MSL09UYJYN6V.V C[U,I!:>9L/6IC.&R"6/:VCT-83Y,%S:#!"'M%A\_$4#6^
MM$E@GJA,'"O>U9G NO.A2H%,I@^!+X%"=05+66P=KY@_>BDL6% J9"7O%I4
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MX8RP7EOF<QTCZK.">&.9VOH8;9]V3Y>!&8Y>**1I&D TN]V,D";*&K;K 49
MGZ.PQ =^_[*58I?8Z2=3J?:D(;<*;K:"^$O!)<C"#!S+@2U M>WIR++?5'NX
M>N\(TJNNX=OSZ*=KR=MIMY7,("DFW,FBTBB\TV:WM?&BDFTK&]Y?;4+9A(+L
MY.CUV_W>"G,)QRX.R!3HQ0O'QL9 WKHOW%[-&/C66D92:X411R,7!V(:0S,'
M$/'O<[(Z68R+@0FX24V6_&9G*]<!?XB18@/)88*&<>NLLWVZ0L6DFKKDB$C#
MDRN%>P-$1%K2H6E,%3STU_DC>63.R">1#_(UZY/GV/824A GGR7X[+B.Y1%\
M$WQ2D':>GV@GB\EG/\RZ&/P[>" =1S7J<PM_B56BW^0,9&ZDXP?D>*T_4:.^
MV&OH?4JC3/S?Y&31,0;FT)^(ICG#6:(OX!SK<$&GO>*@G0-<!X_G-$%SW5[R
M27#7B+[G#K=?Y2W]0--L#T"NB;]XK#/L&JCU!P?H_:'EP-&.L^OLD)T5=ON:
ML!P(!M,86UO%8&S']IL;UQBU-Q87 T$_Z51[>/K6SVL?R=/,5K;%II*<%.;+
MZ@5_5]_UL3>&Y9C !P2(K3]YHEH%''/X>&)84\YEK91V0_GX^R>LD3L77080
M@+5*X=7^"#BMG&! XT<?8MO#"SFZN S;\!YK3B]O",Y^X"A;1\IX=;D<<70N
M@\6BR'%"A##$R%UZC. N&.F!OM&B5R\X/MN.UI2)V==>TU<^L6$@5;29AW\9
M/##-!J+.C7QV8YD3VQIZ6E(H:708W$8B7VXHQ;.[V<)Y=KFD3/PW:YAG6Q$M
M0XV\M0SN8/&YTJ33F?5;K9YQBVO)VI-W[:50%BE[5G70 A]%__&Y"/'08? -
MWD-G\ZT9_I9X-;*VW*^8J6"X,Z&]#F\HLUZ*C>"_QQ8)2TNG;TR*WRY5W::H
M^[/I=ZYBEAC:3I<V_\/CIB9"BX)W(F\X 7"KHX5:<*8\[<_:+ANA9F$(5A$X
MFXV9RPMG2^*RL@9DM3;D/WS.,!@Q>+H<;=%QYEO#!_A*T22^V9M55XOF"?5M
M6.>3\ALB?A49%D?^E1G_RYTHPN8LK0T:#DU1B<' <EP:-G1J^$/N18K)AL5"
ME0:KLX?'V_/_9K=WCU>W-^SN>G!S^(5!97*^#B8Q?1V! @LJ4ABIY+#@D*1%
M61(/20[P/(;3/L%;3]RPW@JO]_=>)D0%F4F41X\G='>*$4[P(NH/M.5WG2?N
MU_A496"P*F[JD7@U]A$3D1;#_JDF3TRB]5IG)C\8E10F)$72(N$,@TK1SS:-
M1'J_<=!JMO!>#:DP ;Y%=PU8<U1R&*P+$Y \P\6ZV35L\@9/L>9JP(-CVC-H
M<H3^S(+UR/<HXTG\>\2&.EB'K@5O?H2GC@ZJ2+79L_7*;1.W40FU._V$;^.G
MZFBD&SK&!LJQY2'R!).QEJ"IQM0)%16%]4\)(X2?%]!+!*C)L(![SZ]F:W-J
M4R0JK(()^ZI;GH,E4OU!!,)D058DE$^GQB(Z'6E%ADM9WF(9:2C5#FP6F2N*
M+#L1S@"L=L$!IC%MK+(4[5"2GQJ?,;S$?19LAM55Z@\:$!497]+&UJEN^]@:
M<B.L&CNR\'8+'[Q1E44<';A.?08I!)X?R_D]1PK"LR@2#X;*"'9IL EQ/3\'
M(?QLJG.#6+KQGU_8JP4;-KH(I_B+TFC";[;N_%X?V2 <03*&+=?1.#GMPAMX
M>,.B(!H"8]"U*SSLG#3\*K[(X7/0)N/-[PE'U4*Z)_U&F'3+AI[M%[(_4IY\
M\,;P"BE#W03JCL5F.5K)JE@[%S JF,<I?A_-A#U1-W=GQ7(;L6*Y_4S%<J-E
MJTSKS58G?_D@_OLA":E($FZO+@:5XU" 'L"B22U6RPEA.1;[J]1/]>( S%(H
MK6*L4@VUP6+E?E>Q5<56>2Z6R_;7Q\A7*TM=YHC_+.4]H]/>"H-V^VO:8YSA
MD2<]0^>SH@+K\PIO5]A#RS_CP&GP;ZKIJ?:4R2)G<VM.62UTK@+F^A66Z<L$
MXV?=F39:09;>"?D"OJUBML2L\LC1\X\<W\3AMS9S-OZI<Z*<AN?@A4M=-D=!
M!8U%V=6M%$WV)VF&)6/[U%$G&S[R@#XG1&\7OA0H17_+MJ#=05WT9O02(E$M
MSU6?3(V-YD(W1UY5G@L:.Z)$LTO4HD+,ZS)J-BQN!YI%V,HD+.N!EO=F5.26
MO;[14<24![.4+:A)NA]_DRV;3'0J&W%.]5W!].V%.'>2RS:3QDR:)BW25H*8
MB7@K1XM0M-59JA"+!ZS\*.J=M-J%@E5X#?ZR7_M@N4Y.5V*FA;=PMFXZNB8/
M"+8,WG$MT6HS:MG8C$?$U3=TQ+6[^Z*+F_I$,3[2"[9+SZ8D[NCMFLV?53MF
M*49Q["-SZ>U;$H;Q2LX)[_.V%."R7Q=SK=C-7#/GF[F8;L) KR7;WAH>MT35
MEW2*RL/EEGJRA1ZR&X_8TQKM8(';PV!W;:?ERITLZ3:19;W]V4><5ERY9UQ9
MWQ%7YGRCM /]79A0+"*9E?$::2V@RXR >SY6=8RI/%X47&2]ZCTX#%124$G!
M%J0@Y_UIX[T[](W<J^8SW07Z81\4'LPWDXC"S+Y<C9;(8?N@;< MH=/01QC)
M+4*S*X1NCM!L02L5(A<B,N*JK-!9"7KI$+H302\J'BGEV3EHF-U,'WV2,'3V
M$)85\*T;&;-BV)FXF$89X:UP6>&RC/!6N*QP649X*UR6+2YSO5NAF#O_I_9)
MZY356?;8D[5,S?P=.MN8+5-HYWI$V3RH:!-ZE GF19COGU0X3Y?:L3&JET;D
M[B.N]U??K!,V67)BE GF2MGL7-GD8WF4.12V'!&9.)>L@K6H0A$!ML,J6#\B
M(:"+8*QA^15US.'58>WH2EP-:#H_Z;79D!&P)DP),H%W^ZKA(X46JKZJ,!U&
MGP8UC&*1MHO0#%/!0K#T)<S7:C5JC=-V6),)1X[&[HK"16& =!48G:(:UF(.
M/_)J6,I)6UE8#:M]TLU0#8L"^:,5L00*X=3;:48*8L$RCI@E$8]1(B-]0ZJV
M&6 HMSIGO?Z2.F>=32CKUSI3@+:-.=JVCY2V*PN=+=)"5:&SM(7.3CM5H3,[
M7%=A<)5CB55YLXJ=<EQB5=2L8J;<EEB5,BMW6:ZJE-G1ES)+(PFQ>^9>6UJ7
MJ0J@)7A2TXM>EJOXG8VZX':_>5KKG1[^ZA-#$!*<\^LCLM,_2;IO*F#%113E
M653X;<8I,+>^E-<H>9>Y:2K-6F?)]=Z^E.M13@&]><VV@X)FP57:Q?M$M_GP
M\\BR1QSX:[AP445>1Q=V\[R ?!];2JVY<?T_&NK342"LU3OI*GF@:ZO*,66M
MOOE==&?:D:Z=]EX[-ALG2G\/M&,YL5?$E >SE&U6V?VPS,#""[6C4/U*LY%#
MK=RT0!X2YEHGS?1E8'>P9U:5<',:.TKSUO(MO*J#&]$LK9/V8C.A*H1;F0QE
M,!ER*80;@GEL57"5?NUTB3ZLRN""'NR<-!;;DE4=W)PBOK93_E;&9+6H(2W&
M??VD-*E!+8;@8@28_LH-#&Q-\$.(0,C-X13U?DU^I"%@FY7B71@?5I7B72]T
MK"K%F_;*N"IZF@Z#52G>BBO+A\&J%.^>Z._"A&(1R:HBI%41TJH4;R4%E114
MI7BK4KR'; -6%3KW$Z%5*=ZJ%&\9T5D)^B$(^KHF2;HC\OKW4C16)A*5 Z)J
M+=5:JK4<X5I*$\HQ5]W\IZ7!?HF#;E@'=B5L>0Z\('=J56SH=@$^ (2VLY;A
MVWMD9BRTEP*'V25Q[Y%8I(@KE8A7(G[$(KZ5/BK+'<<_*0IF\];9\K33_8Q^
M;#;R4#"''2':.^D=%GXV5@EB;SH]:;4."S%YAQ;W^[732K@JX5I/N+86E5Z"
MQ(R?6@VQR;:;A[?)KM'!H^Q<GC>&3A;7-]A+_.2C!5K-9:G\>XF82K0JT3H.
MT2K#T;6;7%YKKQE:J;4KD5\A\@>&GWQ$/KLPE!XQE6A5HG4<HE7:_I8Q1W$+
M#[%B#:=-1?G"E$XOZWGV2%O/M6O=K)4*#KP+6F%31+#>.;#.<SGR_V+-F&N'
M5Z5_TL]X$"DY#<H$<Z5MRH3U0],V&UL,Q:%Z5WIE6R4BHP7)AERS;*HT@FLQ
M>6KZ537PCKL&7FD W'.66U%FK%PXK%BN0E>%KOPJ>\9KVGT>ZJ_X]Y\_>T[]
M654G/W_5'<VP',_FMR/L+,Q-A_;J>U%9[=QR7.<!VV2<J0X?WJG3,3==YQ'@
M.3,L[?=?_O?_8NS/_U&OW]E\Q&V;XTJPL[+?(I3:PH;_F*A3A*<^"#L4WZGZ
ML XOG:L3'7L,__,[U1'[?_6Z&#R$5 X23/6 ,YVKS@NV9T84W?/17SYH6"ZN
MH304U\*_E&9+^>W!A<4@Y*)\&2X4+!%8R.!==WX+@4%8KDP)B8#C [:.%B/_
M:#24#PSL&1T,,@=K@_W2B&)R(7SK8@F+AG&'#5CX'8VY QP)4 ;Q<7>/H4>;
MJ\"\TYWAQ0>@)/C(;]W+5]$\[74:C6+7<L]=53?A[0N5FJ,[.R"O#X,/0AH*
M;P,W4C.<E48SG)5-,P"48\O<&5;$]"7!Q0:K[@2K[JS6"AE7$;P#-L#&&YX8
MX=R#CTQW8 YO+%,3_YBGI-)LMD/ZG1NJX]R.:*+-]KIN7VFUE6X2%A:#MQH=
MZTAY[NA80\!;C7:WTVJMB8Y Z]]QFY$)6F-WEJ%K4_9/^5\T0QG9H7.8\+^&
MC^E;\45@MZ[D\U_07 9)BKGD1NI8-Z8_LS_-5'G]4U#FU1%E7NEM1_\W%U5A
M0Y?9UBK>PEP>_G%E:M:8LX_7EN-\"E%)AP$O.!846)'7E?"Y"%_/A^]7SE[4
M5ZSRQ!TL03%D3RJ6==8EN :!&_3HJP&]QA,/WP.=CL6(\74'"T;A/X2K-*Q&
MRDR_JB9^A]L C1(O;#ST;/P/?H\E1&I4D7JH&S1+P7#@5*IAB.FPBO+$<K&>
M,AQ_4@-\ M*0_!'\SS-<-K*ML=P?9'VY&N([MG$@(&^JC8U\G!,F]TP.&]JK
M:J"ND",2K4S+94^<FX@<PQL2E@@:D[L,$17BB6FJH7F&*LI)CRQ;5&EA(/OP
MV7RI: 0#-1&,KZF>PVE8/AIQS47DB0GEXL?LS?*,H8")X '@];J/RNT6]NXM
M<#YL??XS$I\H"R=0Y8W#_S?D+K?'9%BK2!O#L-Z<X@MSEP--'XEE+<\!3,%7
M_%WC$\GEA+P05^K8\D H/BV LP <[+@:N423G_QYVLBY&GD295>ZQ3*T=EXY
M5@[5B*-KB)9.NK3L0"\G*+D"UU5@$_;=$BG_[N')+63R!'Y_$)&^._;62WJM
MPX)9D%G<-&6 8F=][UCBSBTWDZ[?N/[&-TK ^K4TVO!<*S!?T21]L0Q@ZH2"
M?LMGSUZP89W;VO3E&]:ZKPV&[\CQ/RKM6J?9W?BZ:!;N])V9#QN]S7ZMVUF<
M)I\7>HL*NRE"528,7<[>=0>TE'(I;>F@F7%ES#LD"KJC+V<43;-7Z_1[M79K
M7P)IRHE&I=9O-VO]1M;.M_L0Z)@D1BO<,E&_7=GX(.?-5VRXC9,<MMNU3)C]
MQ)?2.<G!_"O"*$FSZ53VR6$LI2S:M*C3XY[JAGS.AD>D37,Z[JU2I\?91_A7
M#C;.D&X)Y04AN<3%!1/>W3E<\VS=Q8@&>7$H;CRH,ZS_D[A?%8UIK=%JJREV
M8QB9@:ZZ8A>#T?M3&$6W,$#&OWZN&M-65T&%7P7AY$\V^XRO5==");H-J:Z%
M)"*J:Z'J6BC/P][<_<^O,M9HH0V6_:)AI3=^K9/4W%U!J];K]VN-YF+_7QZ
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M^H?<<RPRB.,^X$4'-9K[Z%<K;#:^7%W>/P3_5+Y\$EW(J"F+[CA8,'WP\(,
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M_#>47WM&MYDW+JATP5_%L75FLA6^P-$$VL+2NWNKS 8_14>)YP3S@F"C3+:
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M&J\C8+NN6&%8T7@97.3$UZAP@:AQ$-5CC55AQ4MIO!:EJ#O (<6ZSG1/@E\
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MAMQ9#+B^@KUH^H69-0TO%4M\C.06^'@6[)P20JB-G7_1'Q4UY.94AA7AK;!
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M<-\_!K<F*+?\.\*7^[K2'SC$-WW-SG\8[A]\">$*\#=\D$-_HE5F0_GWV7>
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M536HNYH@@18GP9=OGX%SYO-1#B)46DXK*+BOD&X#%-S:SD4JYQZ@H*9JXXZ
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MU9E;'U)ENG/K0&L%H^7L^'N_JE>W#HS6XM6M#X6UHJK-"Y<75:U/W-4453V
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M]F_OE&\D11X,$(\?[@QS"<97X"92I^]<Y>^VRXO?B C#.;>SN6^!'"[BO-O
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M=0KAN@ZZ4!K0)C<N&_M6S>%%PQNRQM#4^Z%UO1^VTWMFY$QF'V>R&LYL#,#
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MJF3" YMU\L=DW+O0/_\?4$L#!!0    ( $^*?D@#D.C"(!(  $40 0 5
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M05:8P9VYL)!]=+J(YUE;TL'#F[N4VEZ3ZG$V.V)371?$_H//R5PG2)DD>]9
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M9*VJY5\WT<&\W+7!-YLG?<+Z=4,CS+TZ2(4== TPN^^M0"_5Q+^9(XE%#S#
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MSM=X;-F9G9VI=5*MFZ-W94LER3O)IQ3%AB1FV40/R9;5^^M?@$UV\W( '!
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M?2%;H<T;'UM 1M-O;XQ1TN\;('6KR"GH$,IXD>N]T_,S<]@5S;+K9/=;]Q0
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MR[=.&.\PJ),=Q66"3A7E,U7'*?6:NR5.)NA_2)"R#W\">SKA]YTKVM_'Z^'
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MNJ%9+O.+X'/EF,YGKSTC-P;OF@Z?;LB(<B++W_G_/009^8__#U!+ P04
M" !/BGY(E9"FQ9ZS   =(PL %0   &%C8W M,C Q-3$R,S%?;&%B+GAM;.R]
M>W/C.)8G^O^-N-\!6SL14Q7AK"IG]3RJ=T8;2MM9[6BG[;&=W=N1<6."EB";
M6Q+I)BEGNC_]!4!2X@./ _* @)P9N]/E%,\#$GZ_<PX>!/[C?W_9K,DSS?(X
M3?[SN^,??_Z.T&21+N/DX3^_V^9OHGP1Q]_][]G_^__\Q_]X\^8WFM L*NB2
MW+^0L]/?YC>K>,U$<W)]<\7^I.0//_[,_Q\Y29]>LOCAL2#'O_[Z+^0->?OS
M\;^0V^UF$Q?D?9Q$R2*.UN0ZBY."&3@B%Q<G/Y+Y>DV$5DXRFM/LF2Y_?/.&
M.V=>?O\C_Y_[**>$-3K)__@EC__SN\>B>/KC3S]]_OSYQ\^__)AF#S^]_?GG
MXY_^SX>+V\4CW41OXB0OF#?Z'6'R?\S%AQ?I(BK$-VZH?[G/UK6!7W[:^5)*
M\'^]J<7>\(_>'+]]\\OQCU_RY7=5$_EC@)-:_$M/OOI.[$?\]2?Q="?*#,4:
MT[NOS7X]0LK?+TO7](:N"/_OQYMSI?:O/W&)GQ):7$3W=,U<"O7BY8G^YW=Y
MO'E:T_JSQXRNY';66;8SPW^=7_FO<_RO_-?YGWO+/XUIW@.'XEU:1&N<=@I[
M_;;VW(QO]"763ZMK\B7FK\Q"!)W@5VZX&=_H:YK%Z?(L6;IO>-<55N-OBRB;
M "I]9^._@/M62YJZYA]=L+]:?NF7@B9+NJP]<]N:V"E<BV K+.]LIXN6U37/
M(FDF_3K"8$X7/SZDSS\M:<P,'_^!__&&__'FY^,J4?Q/]M%_SS>L=>S_BO?K
MZ*$V)[[)?WXG?5;$!?\"G6<_M5O+]5OM92DUW68+VO'0:\%_K^_75K]4JZ/+
MIJF,;M;,+:\M:/+FX^UW)%ZJ9&>[CPC_[#]^VK>Y_SWG6;MKHFQ1-XC]:?@2
ME<1/BY3ERZ?B3>O[K+)TH^J%U/#C5;^%L/='TA(C14H4NC]- [J3;99QOW&^
MB-9_HU'&@M<I8U4''2:QZCNJQ4:@4F44"Z &^RJL:M5FU5-2/B;\.6$"A$OX
M!;&Q*U/XS]Z&MDJC1KG>XD2 /TT76\ZT7:J6H%TK4WUGA<P(G$LM8H%<9UR%
M<+7.K'Y$RF>!0%O?;RGP9VZ#6BI>(UIC:R(XG[&!<_'R5[I>_SE)/R>W-,K3
MA"[/\WQ+LP[(0++5MS?(CH"YUC(6W"%.5+ WZ\Y*$<)EWOS.A4@M14HQOSR
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M@" !@I'H\LZ"$'BO:29FUTM@A /'C7<O<@.RDT;<>\*I8O2>_!8VNK8%5.L
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M<<;L7UZ0&IMN/[C$O8-W2!&:@[1M7.5@QA2*.'G@6WX63=TPXL-(5 [;0F[
MQN ]Y1*[ W>9*UOHG4 ^7K'0-,4M>^Q?PSAJ;;JK;7WCFA)&X9(ML+5>5>NE
M*]EL*%$O90\O!Z"6[6L#L^7IXIRI+3ZK!F#;D((@R-OLMKM)[3%=,V,YW_DR
MOZ=I$I&KQS@5%V9&^P+[8$(@&/7#XJ$-W ;'1I.3@8$2UO:PJ.NC7H&V:T+>
MLDKF/&%$Y,?$'>0H( !:CJ]9//(RL&IF\$1I]W9)L>7A[C%*?DO3Y>=XO3;7
M.^Y].U@D O@.:,W(V-I0EY"@#9]J10G6GMF%N ^9'TT5/624;JCO R+]T,[1
M\I,5FMVM1AF;X6IQ"OC]O>>7YGQ^__8[@Y1F70KCUCF%7==K4+#;WG2:TO6F
M(*YI,W6H865)>SV:0L&TBN3_6C),W@N>7Z;)HKF[R&%]I?7GH*92^ NHCI*V
M<(H9*2<MGJIH4K=A)AX%<>KP=,1Q5!49L>FN$I*Z=E7]:+[G(42*( _ET+;6
M>YAP=_A&&7[V/BO-;Y'(,?9?>R@*;'9OO^>D-659?Z&7_5< K4Y:VM*N1X)M
M.5G& 'IW/#MFW1#[A0H;^\HM2F1=:P07( >@TK@P,0 <D)4(H%GSVH-5^WS3
MQZKL&;AF;]D<IRPZ/JR=?C[)8[6.YX,]KL[]MFC"6QOZ .Y91VF04P*]_9:'
M1L D5"J]#:LP5MVJ#!%5E[5X-R[KC#LN2FTN8C:JS^;OSJXNY^3N3V<W\^NS
MCW?G)[?DXN*$S$_^Z^/Y[?G=^=5E,-?Z@CI?SUK U<XZ+0/E]-<^>UWG$[L1
MK_G%#N;5OKZL>LVO*8N_\K>W[GC]K^?(<A6PH[^?%FOL[#PJCR8LK]<01Q4N
MT_4ZRG+R1+-@CRV4@$&_7BCO,^.JX5[-L';8M1\2RR[8!^<%W0"6U'NB:HXU
M1/$IMC/NF&%=/Y8$:ZLKUMJY$!%2@60J;7_K:23M%R.+=EH&$G6L>^<08/,F
MO"*$6K!_'\-E_6CRZ?/]BG$E)\BJ]!*JD$M/,,J&;;0>5*B:C W<-ZTM:R>"
MOH_W$[K^'>#>_LW);YRPGYQT38K EA5/XWRQ3O-M1N_HE^(=<_Z[.6MJE-2)
M4JJ$'R D;AS/LJ@]6@8!E2'(S$MP_-9A1$]I0P\:22S1-_!6Z3$DID)V.-2;
MQZ4['2YI 2^,77@;M]T4[LW/%C)H^T+9:FK97@<[R*Q:,)NO!=]XB9.N2/%(
M#V@ X(1-XW=^#8$LRK8OJ&.$35]VWS'\T.%[[ZEM6SW'C;'[3H]([>U(O065
M^?P6?:9!_6L./X$-#0=OJ;W.TB>:%2_7C/A%=0+GTP:T,]6=3P?O.FE\!O06
M@[*5H;XO;FKP5.\RZ-LQJQ^+M$#K9P<9_ <RRM&K!R# NGO[0.G>U1L(AN][
M:"G!E/&FF7N89LXAU &#]1P#7U#S,,?@;VZAN9"8L/)=O+Y*GJ/U]C O"@'S
MP7W=/OELP01E>LBS X<P*^!Q-F#*68!OH0,1RJ\I=O@<VE?W8/#_-.["N$[7
M\>)%M>AKI5-U%%!G9! %><$<VMHXU(4WN!UQMXV(,^*/AK3?^&('BG1$G[6I
M#U)O$MG"7V"LG!<G49:]Q,G#7W@IJEBO':2K9:E2UPE;%=[<LU;OV)Z].GMJ
M%@>S5C ,1T9B [H70G"%&3/1M?[#)OP0H@\A^#3$1M_J8.-U-)L[+%[P/VC8
MN5B%#%O*CJ2J-451AM=@3U:#Y2>:Q>GRMHBR @69IE&PA2$U-DE4D'OZ$"<)
M/[\V79$7&F6O';"*@:,[Q(X_4P#LRNKL@!*R9VPXB@%8TRD!%H;T@*7L\Z\$
MJHIW_-U!M?_.OC.H_C)I"5][1$'H+YJB_8A#M-8@?_&_4. >I;],C=)?@BO/
MKT4H/4\6&8UR>DK+_\(FR[2J^CDSA:J;J3.I,_05Q '.!\RFJ<W-^&1O7#UA
M?Y0IZ% *>P.8S'-MQDX&3;E)K0!FWC3>)\8TVD+9$,>8@#[6YJI2C]2*Y/M:
MU?.I$5.CVVI,@ ]OW\L^5A--5C-,CJ>6)IY3&CV99)I%^E/\\+A^(>N8R2U9
M]GFF>;$)(]G8%X]#YXW@U>($,T6(4T2F-#%^0@@V$Q3Z: 4;:9K@C@4UKP%\
M'>7YU>JOK$U14EQE-RR&%&=?:+:(\_)4H]W#O'J:'W?C^A@;=;@?9F,L1X=X
MQ4\.(UJA)?5@N[/Z8T(K<=TI8;[+O5'P2Q'1T D10\RU(L?P]OCB!5Y*&],"
M)Z1@"; 6(]??R&"&0"AL\)@FL$]C'M40)ZQXVV!%F2+2%?E<9X]O#-&B(A2&
M^#QLN6KT;9$N?K]0'%>IE6D7D%T9'.:WK:)N(=,X !!6HC<3CS@-Q<. 3J'4
M=V.?6>I?74J<MKB$&#)[OG'?)NMINHGB!#*\:DOJ!E&UI(L<6-IVP >-&^LT
MUM#><Z,2(6E&A!#Y5(J%01%M7YM24+]3 'FF5#)FDZ;MH*B3%Z=10=^S'_&O
MC_'BL9OFJBS(WZL L,O>F(: -L8<<!3N?I)Y#>OFV-+=TD%OID.\F;5D)L(+
M! -@:8@5P\!A#B=PNZ:(8]M"[PQR.@-BWQ2W]#G69-0CPBT1#F?RF=LB.ZK5
M(CEIV/O&-R64PB5<<$L7S8OD=?5SZ\)Y3?5<RKFHG;OWV#NIG!M.K.OFG:ZN
M:N9"(=;,K?XU5<S=K@#4RUS%6"WO[89%DLOMYIYF;$!,%]M,O$A\$JW7=/GN
MI4MW")7LK>D(9V/-!2WA_IV3U[HIUA2W]+ OEA_X?^B2,R JWU"O+@SB46*1
M;C9I0G(Q_<2G@(.X2P@+NZ9@,@Q @) #-VP,3+9M]$\TW&MAD1KDF&_'.\*1
M.,^WC&[?R 0#2<AL"JYD-JRZ&(1UN1Q]'49AWGDF'K RHS.@*ZA#6ZTQ=;^)
MP?#U&X6>D7Z!K>B(52;=0HY$0+*&B;MLTS#I:O72=I&FJ]1;MPQI04;69XH%
M2^#R2T-6M509[&)+<;4M\B)*EG'R $D:$G%=VFB)NT@<#0?.4T??EW7RZ)K8
M#\,:3P*O#640,*4.13<!DD?S=S&ECYZ7L*AV!URS; OJZ'7G;*VQ-.V<4G<C
ME@<;RKHJ3$B%D7ITO6QB4*\_ -RY@ZP2-"W[XTNZV<3E&T[\?;DT*1B':;)@
M [ N8<R2-6-TDF,IH[9MRQG(7E&C-RUW#-JSAD#Y@G-3Q#-Q +V=6G=+ASIJ
MI19W3+;=0@IO,=KL9P2:COMP.GFM<%+-4:'@R>O<DKIIYOL_ARF;8[:+^T#M
MW$T;V8==$SK X.SDZL.'\[L/9Y=WMV1^>4I.KB[OSB]_.[L\.3^[#9:PP M#
MAW<QF-6&"T2'M&!R7$^17C2N<2%M2D)DK\?&!TR3"%7?@P0/6+=/8>A@#S[1
MJ0Y5'J)KD^;P#E6V\88ZY!_@>'0DZ!RJK,MMX1RL/ A+MLP''*QL8\::]J$<
MK"SVM(AI>>G1-HK'#>JV'R.PLVD0FX 2VR:.]51F)\U]0&_(/_WX\S%YBK+R
M J3_1:)M\9AFXEH4UK"CG\O_J^:P_U>]Y>&7MT?_]H=?CGX^_H6?-G)*%Y0O
MMI-?CH\([ZJ=W/&O1[_^Z\]'_\Y\2.3^X)^J4GBDL"[M$ZXIV>54WTH(M+D5
M_7HN>DO-'IE4GT1M*3PN->TZHI3$!9!9/<T6P8[J#7C!;14R=*Z< JJ>4#*A
MJ: @1-]F.+R8[X*AB1M]214_FI+8'-G;=LJ3GALKKG2TY7QII*%P.2/I=!UO
MY+UCX,Y>2<N?KNT0.'0=95?9;1$5="FRWC7-1&/57#)I]#FEUL#CELJ'(XX9
MW &YIK72X=RN_ OS:! +?,CI!^E )0U5R@HZZGV%0,L/H@97D[#]O$^Y^CD>
MP4J+CNC4,@XD3T.GIDJU_:U\$L <@[RSY/CO_[Y*M)>B"FPW[?A$\A--<G%'
MXSQ9WM BSBB?KH!,\]EJ[M$/UQS/"Z@O9,98NC5PR<K:[ \_'W__^P_D^F)^
M&=)4GC5>TM$=V:,FU$B'M':^O=(Y3?ALX]7JE*YHEM'E7?1E7MZSJB8R6*=!
M88 . GF-7O"/]+#P:F(MS,YL+\JWZA64_2N+LA>RC%=,CS).Y:1XC KR$#]3
MDL7E8>K+RB@IHB_EO>L!W8AH!:IT1)_W&6Y4[W(;Z&\J-&,N.<,]HD#YN(OE
M6IHP\?HR\*\'H^I59$<@];MFG.3I.EZ*-&FX%1L@NLLT.M'1E%0;QRT'C7[T
M]#.HSZZS.%G$3^ORY?26O&^. 7HZM>^1+J'46FT>F:S[9,\SJTQ8NZHWH]Z]
M?$SBOV_I*<T76?PD:D_)P2^6:GM6 =7&,PSD")EM-CX-S(.;FI6S&GL=TI *
MXQ@96[2DXWJRQU*0A0YC+;R&P]X+U0OG1D$50R_P7C17FG;*PJX7*]Y==%XN
MWW,LQ$. S9VL(Y:T.PQ4NI"^2FZP' Y=YIMTFQ3EQP5=]FY?@<JKR-.7Q^90
MUX-3*BF<63%*:H,5DO6 K=S2M(R?XR5-EM[?3X$"0$<L71\9^-55U=),[F<*
MQ"$?(01U.1IXQ]*0?D1*6;(3?JTH5$X48,/0\P1!NX'2][ZU0JKXCO2^M]2L
MTT@.?L];K2@OAH)XNUO?ESJ2F-[JELIKV1#&V]R=1EU&&RH_1\<LJ>)"4Q*;
M$'O;3EG1<V-%C8ZV/+-PH5#.WP'TM8XK\DXQ$&:OI&5-U[9'ZN3B%8JS+WPI
MEJH7,_5B.]*HQ$8S1FX8ERY:'WJN:%1G]:>^Z6#HPM3NY^X20:[19H'.:C 4
M,$#? 'ETJ%LOQ*=%M-8//Z0.;/!=XOJ.>R(T2'1#4 U'LP[%2*/0OE'$]6JY
M<=L>%Z/)O'K!.<R@!NUVY<#0KM]]#OMZ"]:_I>GR<[Q>LS:>)P7KV)A5YN6C
M#NJ&J%8_E)WJ2%;8.$/?KS3 N8Y0UN9F^T^K74A^J38(-.GXSFPSU,9*D[WV
MWB?&+EJT'^(8$[@L2TAV)QV16DUDCP:VYU\AMA7I9RIP!Y6VQ&LH[%^]PAL@
MJ4I*34EL'N]M8PX^S6ZL.-K1GHE_DP43B8/CFJ1;==22__X&(NV5M+SIV@Z'
M)?4'Y\DBW72Q"I16L:4KC<V8MGWWA9K4GQ5])!;V22VCSS39>KYT#MKE.B:I
M^\7 IK:BEE$R'^[QY:Z8DOL:"2Y5R;3[L!1]C8B#5D*C(!="O7-31HV3+?M'
MTIU>UPMUXG97"(E.;;,N:ANI!PAU)(JSZA_D*<V*:@EJ&62$5O2IA";J'I"3
MHRTOXX3,8BA,N&0_'80,?3DY'YIRN)386W;(BIX3"V)T=&<7:?+PAM5-F[ I
M(>E9-2ODG: EQEY%PXVN7>_TV _BLS17K<?"A)5SMFUA])FNIGFG@V29)[NY
MK)Z!?246X.N?P&[7SDRI.L<T%=74TT\^]3V$0ZI+:J120T1%("&"31MF%'VM
M5^/$BB>UVHS]T7I!VO<"H+;W=#SH_-H&]/.OK</\SIHC4+@;T#8<#$&$:NC*
M?S!6DO/3A<1;@62^7J>?(]:/AXT7Z'@5")@01J:[-ET]T2SB!^E>L !^$F79
MRRK-/D?9TC@S;]9415*=)C:7U+Z<%BE&MU:\,U@3 3JM9<B:"9%%4RHP^@&0
MHV,EK$L-7%4;T5+8Y#L<8HN*##2" (T<'(T8W!<_33?VPX227^)/V1DQ@1&K
MW9W&$8'M2, \ G"TBZ(V[7"_1-/%,)@H]T!P@<,'"GC[ API815"Q6/O[$F]
MD+*\*870*QENUOU":M.-79&R4YR)/P.#?+OKM/5%]X<VE1)<7E\U["TZ0X6[
MV-AR,0P2JMCX2H "C8T62 DJ-K(_3C*^C:A5\?Y&$U8,K]]M\SBAYEK3RH@J
MM@*-8+,,Y-9];+9IAA51X89GU8?DOOJTVF 6](#3#GHZREL#P1 10/:T$<.B
M1=Y8X2XW637!#254N8W_75H@+1-L1%!1J+;RC2W0!#HA70))P!=Q=!^OXX)?
M<D:S^#DJXF?=KFF]?#^MJN3Q8H7< SA9_EI&A80^\)L+@.E2ZQ,8!C0V9HT/
M@B&OH>?E/#5WCI*1<E4%^71^IH":BPRD]S8:9=V\TI#DNT1?/0#-.0$)@8%$
M^C(_[19/=VNGIG&56D,UB))I8->&?1]N([[!JU7II[ RVR]L1X$N;&NPH*O3
M])UEJ,GZRMH"3.5K&@"Z&XFH_2%@3S7&"'^K!2HBH<,$%$@&E1;8'_5GU5D$
MG8M4WK$1S"HN<G&EU[LHI\NF #_' # _A^5",WLWWH6#68RQC9IDY@^ID;:3
M("ANJ^.\4W'&=#@5*S[P#;,AF$ S3Y6,]6::2,'Y-H'RV>F<)58#?9!9-]^Y
M>U Y.&I=$R9.@:B='!'AYLT]]],6XYZ^Q0@4\+Z.(!%X*79#<YH]4WY0U'RQ
MR+;1.A?_98/7_:2#??EE919><@'-N@_+H(;X**UL&C8R L-=S:K/29RP[T@/
M($+:X=<N*EICQSH0@CQ8!C^+5@=$ORDK(:M&3<4]NXJG-BNJG=KP$:GIV[#]
MC<%6\#LL"@=2LS1:=9WQ=T2*EVM&FH(?:OGW;?RT4;^+;ZFM75O6:#M9_E/Z
MFVS=V=0"^_5!O<59_?B(T/J!"$$/U;EPP40;*U 95PU!/0U90E0:,B\H&MHP
M/<(=+W<;?2.#6[L4OL>]T"T/*JZUOT;06RV<NT*]Y_07)WPF(2FR^'XK+BAE
M;?P0?8DWV\T\25C6;C[,KVEVMGE:IR^4EA?]]#,BDL%]DAQM<'Q4&=D$Y!=H
M<5ICB#P83F:5 HLT7(,L&BJ$,8+02H=LDR7[YQ]^/O[^]Q_($W/E/1QAP3AU
M!:1>S!IINQ/&4%H:6F#CTZ0W=)$^)/$_Z!(6N^0Z^O#4U7$3@=I>)@@R4H<#
MXHC$SHS/9D?)2RM&Y/NX0'A@N XU,"@P8N:^N@M!]&ZK Q@L\^>1I$\97<3U
M"@<+'%D1_T/\LT=-H^2.D!K)T314VG8P^6[RI>>=7GO6%!#C@*@A0GAVKDI6
M\9"&,D@PHR"U[JXNT91*;7H9;+N%&N*HU>AG!,Z.VT#CF[&?UG2'N:;X$;E,
M$P:ZY7;!__F:@*8<96(@S>_H<=^T7<_" [E)11+1U2J(?%,YP2VPP/Z@_-.:
MT0?\<-AFQ(2"=I ^4]-/I:WBH=Z;1S[6;VO\%L4)/W?I*ME_)CO;$2B_8Z)1
M?C0-#1X<U%DPCWH60FS,^$/R/3]S[ =>82UW$K[I!T5!.K"CNL0SJ+99!_(S
M!>RL:JYGFMVG",@S%V @(S/^A(-N\<@L4<* N(KBC#Q'ZRTM#X>O==ZP,%<M
M(.1\*_)K!:>R*L-&9[]"<P+/M^AKM4"GH^'Y]AL\-=WI&IYOIX'G+WB5,]#;
M:%S^4M_A^\!D\C)ST_R'UXJX7Z9"W"_!E,C-QFEK8YF@M"AN"Z(2JVD:=RAJ
M\ (G4D^YK'F#+7:EW:KDC:H#='QIZJB)TK?LCR!QOF"!;IO1JU7S!8,;NN85
M@[CF>?\*PG7TPJ>%\SOZI7C'6O5[ET4XUFJJC;4VEH_C_-N2%C*&0&F1EN (
M'F:W=U<G?R97UW?G5Y?D^F)^>>LY"B#!,G6"C4X\&6>X%70PVNB?0WB+'SAM
M<4P?OHBRL\('0ZTW "M#XDW SIN"M37RB=LCPJ#O&WJ"))YJ*B HYGE=Z($V
M_[[9?-7E7"C&;$L"A;&IHIG4/6H5C]$2E$BF=B"I \*Y.PP'E4,"DQ$; \.2
MU.Z@J*1IH<>8]!PO:;+,K^L)07%RQDF4/_8"CE%R%TTTDJ-#A=(V;APPN=&3
M7*\]NV[/OI)EK<#G;/?_>(I>HONU[[$^H-]3ZP[JDE&IU&::P;9;<,$J9HNU
M ;.[$2@[;L)LAZG7A"5EP8D!)K^%8MVT,@!45RO/DZ7Z/F,+E5Z8UJF@44KM
M!'\W MPIC& &,YIX'I7OZH9".P XI/R#=9Z*AVIM.2%-WB;").(,"=PA!B#%
M7$>-P.NPB@@W"#2F EP(^DP.9U&6Q,D#?U=(C"JNTW6\>%$M'0"EJY_-*#V2
M>0;[#J;V81YUI(-8F)TGBW1#R?<78EL:$RVG$/V2#MKWZ: .:C/-H-@D&<B'
M>Z"A17>@KY$88S&]EMKCZXB4DN13]=]@IJC=8$\1YG'!%U)P?Q?E\8*EG]-X
MO66C2<5<L*66(M@KM9"YJ/ S0?#7>[8AJ,[23#P4;P<LR\<DH45Y2S)_6SOG
M!H*9L;7%CH:P@([5\U9A0,=?K<_I@.LLF1A\(F%6D5SV0*YTOC+4 M,-+FP#
M3C]V:<<NW;AF*^;J ,S5"&ZJ\L@NA[#1QB9-JE3R/5\T2-?K*&LD&,\;;*'8
M@!-S<!JQX.$4:</%2S! ER,1>6PL;;Y26 [+$Y:X#"DO ,<AP(&'LY'&T*&%
M<8'!X,B&9^VA@V(>*=BZRZ;0LA\/0"HIIQ7_)"7^F)K>6,2_.N0 8ZTM=+Q&
MU^K(KUN:/<<+*K^:@%\5M1!_7:WV1P^QKQ*GY1:CBSBAYP7== _^=V2]CN78
MUL<R&+<]J*,&)TW31@L''F>U45)955ZK<D3VIOF&Z\8)6Z7U<K<U^<0=$.'!
M=XQR1)5T$GQV B*NHU8<=?$=_$=?OG/C2EP8]H%N[FFFBJ,JN6Y$[,MAQ;:N
M92=12N$$%&^DNM6=;.7GC/;EHU HK^Q5&7EU':"@85=%2BBY79>PL:IJS>,B
MDZO!Z#E^[?!1U;6C\1-\97L7?:ENY7K/?M/FD^H*C"$%+=BH31T+,#I%^6IL
MQN15*[1%HXM5F*,9/[/_OI0+)#[@8-6VD+1"RH#ZT6C?NFP$MMA?1*O/<)77
MB/*G=8SI/AT;+-KV4%DO-:VEKT1CMK_<@54-:<8[Y264S*WHJA3T^W:XTA9L
M@5YFPRMZBQ?.JC1A;3I--U'</5M4*]- LD0& <\]J]BH5CDP85NN-RL?D=TS
M\JE\&@"ZU9V86OSF?:3WQ+MX5]CSAOKW49S]A9^!5MZQ-D^:5Z=]H!%_=7-Y
ME=Q0OL,[3A[*[=Y9_4^^%I??\>W@'=RBVZU^:T2[(QF)UA),%F,W2L=\7%\S
M;HX(>Z12%N\"\SL<*PVQMMXT03X)?<_Q!!_JJ6.4M>,6FHMFK$-N]T''1]7J
MDQ/;B'$2;^4)M36AQ4N;52=\?XVX>51=ABOB9/-6U=HP$:?Y**.IL![0DI,;
M?B '5\!R$ZH;[" ;RE+3[KLTD_^NY=(9!1N5;EC4JF!%.XT3)T',[ \4FTQF
M9OL8$L9\A1409/P'=I2"UAIM*5N-WOR3<']NC^J,+8AHEW1242RR28P[(9G:
M#XA<*O79^_GY#?G+_.+C&?EP-K_]>'/VX>SR+ISCJT =+B.7H6,4I))H2<FD
MM.Z?1.]>&DQ_G]&_;VFR>)E_B94# ;-&EU(Z#2QFJ7TX(9C1'8AG!BNSQE.R
M>\S(Q@1"(1H #3*^P;I+03NULI1])E\AD'#WYY]BFK'?__'E@CZS;M3R$*#4
MIZ)6"8^-&C>."&GV".2DR5!K-+N3"8V6$'#(F0GL.B4Y-?H*?AH]^J=H(X6K
MCFH!R6K*3;QC6K36';RG#_%G6WAV#FA15)Z!T$W;XX9Z$W XBU;-5''B'LQB
M](#VF@W(TRA4';<6=!I2 1T5C@\QQ49%/(SYW+ HG;_HIQ?IQHE!NKHY.[6N
MB\D[E3?GLW@&Q];3>5I[3<8V:J\@-FT, Y!IK@_2KX!)/Y49X^R?WG]03-\-
M[L#\5FAH6-W3<,#EC@_7#):[L^6MS$IKJ*28S0B6NBIL& BKZ3PS33O*)G)*
M??FG)'"I3ZSMF:;NQ]@:N,^@8VOB?04M[^@G'V"T!G/S0-_^K+DK(+B%A5%P
M'+&LKT3%N&7\EMDQR_:2]OGF#?Y(=$Q+G)+F6+;%YJBUOX;OI!'OESVFZR6+
M$O]<[056;+RI]ME\HY\)7*'R+XA1^'GRM"UR,9G[BWY[C%JRF\1EDEBAIF_;
M2>VM= ,*$@KMF?B$_!+:?A=-S\H(J>\"!=OZ2E(NJ6P'191C,%&.P40Y=DB4
MXVF(<CR**,=]HAP'3)1NSQJ((ND",U&.840Y#I8H;\%$>0LFREN'1'D[#5'>
MCB+*VSY1W@9,E&[/&H@BZ0(S4=["B/(V#*+$290LXFA]GK!:<,LGB62;2/12
M-4%44F/)(;>+2@RM"RTI-)JSW4.R?QK&Q@]#AZ96OWZ'$W*%%A]T-GUR(2[H
M1?Q,E^=)P3H\OE_7XZG%8KO9BOL]YYLT*^)_B#,*^C09:&#/(&L#X\EEZ1)_
MCG%H$PR\'&*4Y;!<W.)62Y"H(>*=M$/AE6)U>(_JEK8Z46!02[P@'F]V<+![
M?+@?BQ3%%-\(3;)7W<T)-K3)_!L5-%-Y'KC@==).W>+WVV*;T69CJ\-\5(MW
M"*;,&11@REUD,3IWL<UR?',&AAR8^5F+#+0Z06J59B3>QZ&H?/TWF)4%#*C"
M0I 59,"QR&@5&)6 K?/,J"FR-K@A+LD$R.27M#AJI7!2V3EB>,D7;)#Z-QIE
MY$/$W/&%OF^4,V J3,X%6A,P],&S?D/8G->%L+LXP\Q;CWC3(EH/S,Q[=P/#
M16U@=A$O.#:6I*"+QR1=IP\O1_SZGF#9W.QU&%\[?0,F)-,#4F[GP3G <$]F
MAOD;!['CKPEC]E'?&F3]R(V/LK<3%$0-5^, ]A94U+P^K+UUC[6W858)DMJ&
M%Z5WS'WO-,9Q5@ S[EHK#B<A-7ZGG24 M&3HG*3)\HQAY]^#938(8,")1F!O
MPR<;-0:A,X[&-OE#_R3S\( V. (^9$9>.H078W=AYAMK!LW1NZ=-H"/SW[(T
MEVSX (F;LV@E[BY@" =3KDDW'0Z, GL3LA%4L 1N=SV,J;WN 3-2: *IU_ R
M =*FR$$M9V-A!L@J0O9U(L\^&0R"7J#AG0WX[)==)4J@B=@IEE(;;J8,^WVW
MPR<WNB\P5BG@;I<"#F'Q1881\#3'J#7,ACY\UF.J=<F.JRERA<0E#C9AJXI?
M%5@'S0./0VN8B>5C3E?;]46\@D_,]56,2:6IXHRS>R?(>\JA_H:QM6-F5MVR
MG*Y:>U;YO]=EA@F5G1)<@+@I[S<H,??:,%IVO07(2=44Q'O&B]'3YTTC@V?/
M2R.33Q]RMT',G3<:@CN#N#/,9\Y_#97I(&R-F@+L]O38"4!N;]S\W[Y%WF#O
M<=*\V00WB!\W9<ZM?&,+VGPY'EW"K'J5K6:RXS-LP\CP#"N,3!]JF&P8&7;?
M$.1X4QMF&?;MSP<7,YK8&A<S.CT].F0PV9$A8]<B;[#WF6$;37"#^)$9ENE\
M8PM>AD6CRV%EV+O/Z?@=8'L;P_=_<1O3[W_YG :17??M0-X 4]GEH]=_.[1H
MT835N/TK[5X>O7GE<SIRZTK='E]X][G;:]\")U ?N=/K<_JULP1OCQ<230XG
MG\Y7!<U0AJU22X-R:\?2I!&GY=M[GI6U!B\$]:W/[AYI1B/^^2'%%#GT!D<6
M)0;&A)>6T>%!1M(VO_SPE)>E[7!(C<$Y6I#I,(>_KFF%DK9=\>IP4OA=Q)XJ
MKY9#,#4HB7=-31JEVLZ]IW%I<_""E<2\Q8$JAQ21%/@<')+4.!D3DMI6A\<D
M6>L\T\A3MI<WQ"6#]OE^+<_WTG1//@E+))Q+  .C%TK*=\>OPTGZEZS9=Y_I
M^IE^2)/BT>*M+0MC@Q)_W]BD,:OKWGOR5S0(+WA)'?#9\W\]I-BCQ.#@Z*-#
MPICPT[4[/ #)6^B=+IZ2O*HI;IDR>&#/C9'2&BG-?:.;$DGA\LUKRM]FK/G\
M(+=D^3[^PO_*Y5=3& 7K5*T1'!M7E*917Y4P>=%& [WR;/=<W&EVM5K%"RHN
M,WLJC^,/X[(*<U^GMKW2H9]2IT4M@V5OK/F-)C2+UN^V>9S07$X8K4SU:RAD
M1M)$:A63(3H'.G*H]6;5(W)?/2.+C"[C@BRB+'M9I=GG*%L&P@Y]QZ86_=#F
MA%2\20>-/=],8 2=+S<L$_(7!0N6"ZMT)^>$2;K-#K4T#D]4]M'?YX;Y Q!(
M:V%')9Y@HI98$+PQ=GZ?09 >DG))I2AAE=Z'>Z2AC7B OD;"[+B-L[9</4)Y
MC7A3C"=P >=S1&!HGJ[6@>G HCMN+:3WXJ V CD<P4%9[20A8E 5$Q ><#X"
M*RJ]N@4UPZBXTG3Y.5ZONQ3L?%RS;/?Q6")5AE"YTK:II4-3=%;_RS.LNS]Y
MJO^Y.N"L)%KX:VEYAQCC07=*ZSI=QXL7U58/>\4.3"&*2$ VN\(? -BZAC "
M:"PPSE@@1,(JN[Z3\\YL0\9,J.=)08HW=K!VBX?0XSU$124C604IM<BGZK_!
M;'&8$M2J\<<$J/8Z*E&W]#3.%^LTY]/$\J,%!^F:$Y-,UQWM^]Y<5&(VC@=2
M7V%O=G%^<G9Y>W9*[LY._G1Y=7'UV]^".<MM&()@'-=W+)CE?3- HJO\>Z/Z
M>;)(-_2VB K*U\0NN*<X320W@0,DJ]]/*SF2M!K;F!0UN]$1TJ0]*P7(3H+4
M(D%<$0[IZ=2Z2]KDTB@UJ62T'0IQ%-G0("4G#%J&4]AU2!2+K*73G)U<7=Y>
M79R?SN]8CKJ]8__Y<'9Y=TNNWI.KZ[.;^=TY$P@F8YEZ64T6<Q92*&A($E1F
MN8N^&$M&@&2+* I)%+)(;>,31N?&3!JU]NS\\N3JPQFYF_^?L]#XH>_@'D>,
M/2'CB52ISQ6-[5 22IWJ3M--%"?ZM"*7U5=CM:R;>JRT/D%%UG(TH"9KZ.NJ
MLE(L"!J9>MU<F?4[!U2;E6J ZJQIWW_ZJ9:3WM&$KN+B)$V*.-G&R</5$\U$
M<_.=Z WEOWZ\CLLBTY"MT QWDQN"8:Q<.+HI3E(G5JM F1;'61U<BNC+[O7,
M9;Q:T2PGG-VD>*0D9TS:,CZ\\&.\MTF1AY?!\4 O2_BH<%/4!Z-]2,L)I):'
M%BYAL0\6R%Q%)>N50],=W7H_ X)&==8*]]L, $%2VH*?UF0#, =E04]C&VWU
MSN!C($J.=XF"/=Z]9?Q])?'#:T",8DUM'&1\KI9)AI2J+1L04?54!]ZV#)UQ
M!R_0 MQ93GITMELT9ST"X8BNA_5S'8!M%3HMPVP'[M8)DP/\<*MQ- 9#[<"[
M%R*?@MGX@ TM4R >B:T@0K)^!YU)K!N*L7?'J0P[&33;;WK3JC;H0CV_"6WL
M1ADIP%O85!I2+D"VIWF@07O(J:BCYL5[NN0[LF_K:8B]?E1T,>S$=I=P.+:Q
M6(K1&B?41FP8*!Z@^6O,BM&<1 7Y^./MCXUIL(P)!A);4&$N"TC8Z%)$,0PW
MTM"'U_[0XN55\4BSW4?)PWE!-_+=47:J^FBG4'43S*3.)HA5.K\#0I':W$P\
M"C*6Z#%B#A7&O@-% JD5 -$UWGWR.*-13D]I^=_S9+Y8B 65Z^B%'P+'WSE;
M++(M75[$T3UK=Q%3":-'&-ES>Y"1\2P?X!:9[\-;8&#^4,.S6I(\E:+E6_NE
M<#TI[W\L,P9U*28&>G%C@+U.!!G<HH!BB8AXEZP+MUG&M]N)C=W&X*'54D8+
MA19Z>)#Z <>#7\MXD- '5L,M#3/!%I[MXH#:4IG\@SC_V!886D(;>\W$8*D!
M/64U/J=#)>:TLHU/)$"6D\U"BGQ?R_] XH240-WK5&_C?0V854]'.P2MYTGJ
M3C-/Z8JR!BYOZ#--MI(9-YB\,IOTY-$9V_'@MJ*4.[/CJ,S&K/Z09.6GH=%/
MU>]:XFFZQL2XCJJ>:U(_ 9&LVI&5/)Q$3W$1K=7;/"T5U46<4A$_8RI<N26B
MP:MEUM09FYT\,DN4I\JTEJOJ.C&86^_'#7\,C;5&_.CS)J!GC9E38<.0/+6>
M V+V#5W0^)D/),W#,8FLDK\M673*-JQ/,N#J^[/C9U=_UO@@-,K)>EG+,D5G
MF(C54--SJ6??-9P<CI0DGD8A23TJ>L4( X]ZAD(LK!'.=4:?HGA9UXCU96S)
M4HS0@%-I-D:401UF!)V>$+>3I &+AMBQ&FQX5DGN9MY%!9>*&9!Z^B/,*3LK
M &JC@2T<3%$"8D\?/N M\L8-ASG-I@EN:*'.@C5=ZK<"Q)T&@BUA3A).SQ)P
M,IV.)G[3K^KP(?6&6+#&+K$"-$9'"J,/)R\M0+WJ P',BNQ$+M^$AF,A'=Q9
M7:8:E=NT!/J:!H"(>0GL#P%[(N-T;[L,] T(EY!49@\7F/2<%RA#?,&RU2F]
M+^2WA^B%]M%?*C2>;Q*S3H9%&D<&:JD49_6SQG FD!=^M3V:VOS^/8I(Y#NL
M4%IT!A;,>*QQ,0PGQQV@\,=A7.6!@1-U+!T,E! BYC4K^15QLOFH$QW+1T@P
MY\;<5+M=\Q!<[\1G)U'^2,3XM+IU7CP/ \FMOI'@M_N;RD'+I610W6LC=S%Z
M_&H:MNG=9JSBGQU6KQIBD:E;_<:=9]82?K96N?O^,DUVR]Z].&06W<4EG>AH
M$*N-.XE;1G=ZI!O4VTEZPXIYNF;6:+K-69#C*K[) .CVU+Y[NEQ1:[6Y8[+N
M&%V((=/L: RP1$BM1:IW<HY(4^IUX4H9A'& Y35(Y_DV8C_DU>JV8*-[5KG^
M-<JR*"GR]VEV2[/G>$'SJ^QD'<7]UP:'Z-9AW$YW+/-LO%D?R66ZS&>(=RT]
MK>W-A"")F2(M:]R\$O-,U$$(2A$ZML-D&S,M:MO[GQK*>%EEB&=4'/.\4^F0
M=$5*4//2IM83T*XU"?N[U/W:0*[*5Y.AW&=&NX@*EFWOHB]_HU$FO8-4(U']
M8%*)D<25V'0PI%![T3%1I35CO_&_!W(UJ*[74O#/W&:$1+B)>Z4M-U! B]0:
M^P-0P*)N^42<+L:?O0I$*(+D,$AX#7AI\L!JT V?<KYCSB37'^E$ZI G%1D+
M=(E1S+<Y-/:U0%>IS?B3-_R16-(X(OQI$-<::7LPA?_B';!+I%MH5UH+!NW2
M*R;T0@K$(UTJ(3?K$O7@:R0TB@KD!W%UA*$W->@W718AE]<Q((CK(2[X-K['
M=+T\WSQEZ;.XOR*7E[IFR9H-.LFQE%#;1N6%T8V6' ;MV4Z -"1"*84 _9Q:
M=TB'+&JE%F-,MOW2)M^]$:AX=]8@U:2+3 J#*GV[Z#11NC!21*$YVWU< B6<
MZS],'=KEA?[7EW"BK]#C@\JF/R[LWS4^*5]7Z=) *5 S0"(P%OP]D]9S\:;K
M,90NM+B7*U678M2O^S1>W_8,>'77I= ?NP/SGFP+X0I+3M" -TFB-&\/!3Y%
MLG]P1*I'APL#U>3( !QXG1KIM4B5](V"RJB'E_J5IE&SO\F+'?H[!UR$'PJU
MZ1_4 R9*2(L @^40&**FA)H#F*!WF>OML-W,[B%"V8!=$%@5Z,3.W*Y2MF6N
M[B?I0^I,<S;6]&8@^7>>+,7B,9\9H%E^]O=M7+R8LS%(K1^7#&IX^-8Z<I2W
M(3Z!O#";FEV<S]^=7YS?G9_=DODEO]#^ZN3/?[JZ.#V[N?UG<GKV_OSD_"X8
M-L'P(J<:N"^5--1:4' 4X#58_EKRUI*OSGGJLN+0.1Q#3D5M(K9!Y0WI?R94
MR(?-S"&,',Y$&P9B%T)*)RZJ(ZVSL>AKUU$">&>O&&KFX@L%:W[+M(4X .0A
MHV*YYHYF&\5ZHEER%]PUDJ-II;2-6W*9W.BII->>_4832NX>:18]O82RC CH
MWM2Z'[K$42JU.6.P[9LM)VG>.^Y-]JC-A^H1#@&$,0>(;]H%0'PO/JL^(2OJ
M^=4R:4_TH=O[!:58%5(2<#:T?:,QEQ^[KGC:QF2.=:1ZQYX#9.;PX])E&CM\
M5F>C>Y\%DO=.'Z>RGU0*U5QRS+G4AD? )O1J=9+195R\C_B]6\7+V9>G.!,W
M<IU&!3WN@1BLL0,V0&,TV(T^< D =:<G!<S*[$-4;#->QBZ]WV)IT_WIX/[I
MLLFHW&88T%=0K/L0?8DWV\V[-,O2S^41Z>R)9%;'7E7#0[6J T*JG+EFIL&O
M+46UYF8?67!?;/F5'P]9O"1)6E 2;?C=9.$1UP@< X,A'6JFLLJ*B=-Z[T&1
MNS[Z@=],.R^N:1:GR[.D>P#0 $T-M96:#IBM\.6:V'JWMKS66=L?WN'_(NDA
M,#$0&=!_9AXKC)AHK/4=%(NK@/,A38I'FBROMD5>1,F2[R,5 1Z>JHTFS"E;
M8\)=ZE8ZG2B%F_P/3.5ZL]7Z3IG$R3*+/B?A!0 PL& I'=31X-2NM 9,\8;6
M> L2=?-DD_/29]4OUGDVDJ\M:YA$E!G6,:PO/ZL^"F1&7=XG*>"G;$.])=;$
ML$3?'SCC1 U.V;,:G.UG8\'9M(8*3HEA+3A[\K/JHU# *>V3%/!3=L#9%&N!
MLZ_O#9R7M.#'?%YGZ7.\I,MW+Q]SNCQ/WL=)E"QX>%\4\7.Y0Y?%_CC9LL^J
MMW;2)%?L5,,U6OVJ6$9'\@BG&9@$1&V1CKF(CLJS95?K]'-...O(JC9"HIT5
MS]<](J,X=8FA=N3!L=\,69@M#BW6[5]"1(QU XWJ8YVU43>QSK(9$\2Z82T:
M$.N&..K%NL8UMX''NJ$H-L>Z$1@"Q3I+^X!8-ZC%/F-=>:SJ19KG\^<H7O/K
M(^_2DW2S29/F9KMW41XO^D%MB/8^>MEICP]3-O[0]S</\V^(/M869TR)K)D\
MB=8<6/SF'X;JA5!I;8+V'FH&82M%Z?!>\+ QU(D2]FV8'NA6^Z@!)RD.; (R
MV(^_H1W6ZS[A/GXST0"G;Q$KS2&^D8'^M@1ZJ4:^YXH_D)TJ[Z!2F32UCXC0
M_QJ!_S8$X+\]B+KO-%YO"]K=^C!8W[KVV^E/%B0JC];UG^DD^Z$MP(D539NO
M+RMV438H/$@Z?FA\J$P-BQ"M=OB /=I;=8.]HV/^>%B&K"Q\K30872!B\<#G
M"WZ*B9[R8AKC1 ]L'MC2F'[^%VS,S;POT+V+^97QS1DPV6OC0 2AA;@PL;)"
M[E](7%MHS/1Z#SD8,#5/\ X "VAB%V@7,*%KU4+OC,),W0A-<4NG*JF+A9/K
M!I^^YY88JWX@.V-D;^V([.V1O<%OA%-B*5S&!5@7 !> 4->'4=>%/:\'3U47
MV#7'W2)PIR[8EJ%+NOH;9(BRA2C:HJ^KQ5Z\15Z7-8%%$US7!)9-<4LE<TVP
M/VO],&L"KX2SJPF\,,YS3;"?W-#-F>OFPW$G_=SN8["=HV[//WOGEZ1#5'-F
MP&EAY507_G2NNZE:ZVG8SFK[H?4K9)Y3V[$!CD. HRB[_:H#C:+,5[K>KVK9
MC GVJPYKD;LY%_U^5=DL9IC[58>B&&UV9?!^54O[>),MX>Q7'?&" 2S&61I#
M>>_(\_M&4\VYV#7'W4M&FK48V1M&008Q6YBBO5CDZH4BO!>)7,Z[6#3!];R+
M95/<TLD\[[(S=J#S+EX)9S?OXH5Q?L= G^>+!3]B@C6+?8>$_;DH;\^\3M?Q
MXJ7\WSOZI7C'FO%[KQ(8IK[+_;;JHV.3G4/<L<H@W_KH,\#D[(8N^'59>TW2
M5O4=1 9"*L7IYFZ<L+/4C@Q#6N$O%+ ^88%L/ZY)EKL@=E[0C7+&PU:O)C]<
M;RSKH9Y0Z6[I5,MS*UNSV^W3TUH +5J399POUFF^S2A)5R0I+1$FG>2\4/=?
M-%C#)QW9LQV&0TVTJ&WGUR>G=^OAY<3KV9<G?BQSG\-ZN3UG57+C.2JWC#_$
M-G@R$%&C6QV@QCC6V(405SNG:2GX@W>V&3HZM>R3'IOD*AWVZ.RZ1!+>T-+D
M93",^("P\7RW]?[LE0%(-3(;C2"?XZG=<GMY ?O[;<$2;W4@U77T(HJ_TRV5
MWWX^3+GZ^6R51[+,SAUF837(LXZ- PQRAKY9L'Q/R]=@]FQ="QM^.3H01RE&
M[[;);&>GR? A+9@<TE;9Q/B>XS#_N,AFR8=%MG_]^O"KR$93 O@ \I9B"F"@
MMEWF0IL.L/3G(7=93 T,L3C;[^0LM8[*_Y)*@7RJQ3T?%3H45_:1P#Q/8&EH
M0"@(9,Z@T]JRO+XMHD+,*(D/Y==^V2O* X!6$9?[&E?HQQA8N[:@O<E8@_$!
M%J@0I*@I#>Q#+9LU-C1$-GJ>%*QH4QOV;O&0>BQ+3M4,R$ZI3E>5WM>#95B1
MZ@3, 16G-ZQYU73/)364HG)9>=[IRN*RMVW=85$I=63!4(G^C']&JAGLH.BF
MZ%\UP]3=H.546TU#(YG]4(BC*CS/D[O/Z=]HE'4W>@[6MQO9-?6G&=OM/7H8
MW?6<(XSO.C;Y),Z_!454"^S8C][DW3EH_+8W-6 $UVV'?^(K7ZK32'3)B_B"
MG<0F^OJNV@>(9]U7[L0K3,USQ;WOF-!UG8P[D%?Q),)2_"._EJ>PBS^4L7M%
M3ZG6&)RT3D0[9$"8!A56B ABF%#57](;H?1"W=#7$<)">\NLDPI$Y@&$^+YB
M _/U2GP8%TD9NE*&?.4/K\!^2UX*?XE%_P3@;#R)LNQEE6:?HVR9W_%5:F5Q
MKY7NE?(*:;3"76K?39FN<P4KRM46FO-8/':VQ,@G(1@*@0P(D!;DQFY2E=]2
M17FQK?$1(,DNXH2*S9]@HO4TC&1K:#@CW,['-*3KNAM&O+85 _FX,!'2P3*P
M#PT0"Z5]!V7B3AG&QHZO !BI'9P/F]L:-J,UU3R6N\$SR"_"Q%5CXW0H5(3A
MP7Z6:O3<U( 9J2DWQKE<A#3Y1$*B=/FQ5*COFZTWR>3D-+"E1T>0';<S;B!F
M@YA',$WVOF>D&;5LTC-@NV[2,##5PLG.I9>5DZYWE*63ME&^=O+K01!;!J A
MBR?2+AVX>K*S-6CYI-.20$+ <I[GM ",[W3"4FKWA5%IW#7OCK(*3W!Z2@UT
MD_&2E%)!CN"TG:^DI:Z+=!3LZJGI)O<0"+5TL2!^IN.R:]> =7;=&Y@LN]8N
M_637CG><[-HRRK+KVY]#HJP5@ 9E5UF7#LVNM:UAV;7=D@!"0'=*"3QS"IXP
M=3A/ZG"'N,+5L*G1_:%MZ2Z=BDOL%DVI4#BI[&G0_.>0:4_8;"?R3(K,O(/)
M$Y6;X4@ZUD^NOQX8&><]AN/H(&8W[IC7<058WX+UOM"&A<EVANY\^MD;VG6/
MLSNT;97/<?Q[*%2U1]&@':+2;AVZ1W1G;-@NT4Y;_ 6#["%*XG^(78TG:9*G
MZW@I_C%/EM>,4*S%XI]7J^IXHVB]>T,D/]V=+,6D;^.')%[%BR@I&H>>\0/.
M8IJKC@_TY;X.0Y.['QO#)FZP;0!\IME]:JAQ_7P%;1#UT:39Y?SNX\T9N7I/
MKJ[/;N9WYU>7MV1^>4IN/W[X,+_Y&W]R>_[;Y?G[\Y/YY1V9GYQ<?;R\.[_\
MC5Q?79R?G)_=>@[@OLB;>D>3+'5,W))6WO'R*QQ@+,,;8'EJ?&AAC \&&V[%
MJ=1[QR1*EJ3IFI] N7.^?Y\W)WOW0J?1@-8QM543R"?>""):X7OZ_RL-@JK!
M\5<6!;T.Y,=\7]5!/I@V,:ILO$-_,%J!.B& V"!G::%];!!"R1K.T4*H2,>*
MQH!CB##,HX7-4(XL*AYI5KZ(I@IL:HDZ3,DDQ@:=ODW4$*(TKPT("JV9>%"_
MUQ@,3S4=EX)_Z0Z'^L(M1JAL^<5WN8U#ANOVDR:>ZR<8."YMN9@2ZEDWPK<A
M7<$V$I\$@-5.9W0QVO\5)=BL=CEU,=G4Q>U1O(%QWZY%9Q[7O3D_N-Y4#8A
MW>EU&,&;TC]/6Q9GU%+-F".3PD!KWRYZ+E6Z,&)8H3G[P,:5=,UT:;K-J[L
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MTDB'@1I5=!MJ6Q[1QK4T@"CV/D[B@EZP@+P\3PJ&[I@ULYRUA"Z-V%KH+X#
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MA491=5_+7^75=8KR'=VNDN+E6[GM$*@C'R#L;S+.JZN,WW6O,C80#<<N\*0
M"[N.#PP MV3*<P-L&S7F^  [7^UPHIAG)DV;/-PT!2N[1!@.+@0AL<#B[(%!
M +0[@@#LPN8D LMVAQ Z>5!_3-=+FN5\U%6\7*8%_6O$OTB17V4W_")!P-3P
M0#ORBL7&#FX] _?LL-JQ;H1%+61INQ7:/E>BS7NS^2'*S_RZART_Y[-Y7W8P
M[P ,A::ZP!J&$FWY!3>I*<YLVQ5"_)&?Z *Y"/7=2_\JU,''/J$YA!X+A>#0
M];%1HYLXZ;%26*T==>P43B-FYXVSJ#+ZP*H&'FJKPZA:X9<5DJ+D$$<I!QI_
M73/.YE K5$Q;'GHUVK?5H5A(WS2 ''%#<\H0]\CWPM-GND[%TD"CUCY)$W%+
MY%UZ33/.'/Y*6_'(4J%I+A['L&2"?JQAQ%G[<4UQ-96/TBKH_#Z"L\ZD?VFQ
M?'-F;[,YR#\BM5E.V\JP>%FV-!W:,!^-#(H5 CP8JI<-QOE0K25@M-Q?&*4/
MO)$W]"G-^#;DZW0=+U[*_U56RS8Z=?"#Z8R-:Q OJ"'+PJ$V&H'MS"I1W_6;
M%0;2$5W4H3-$O<54N#^/)%PSFP^_T81FT9I%DOF2'Z/ [[;F9QV=E0=2Y296
MCC&RH^DP(Z-Y.\0M_OOK8YJAI_=@P[-*2=0244NM/JG,=R08A;L4$P7=6#'$
M7CMX#&^1-TK@O;8^J@EN^,!?6B^5CTB3&6T#I+9P1$H;Y%/UWW!>7 ^ -JK7
MUCWRQNM+ZS3CUZI>9]697V(ZY /=W-.LEVN-DKN$JI$<'2*4MAVD1I,O/=_U
MVK-2@,S)R7:S79<<9@.G9\IJ-C[TVFE6^W$^E<K>.6R&06K=7UTR*I7:C#/8
M=HLUJYP#.93=[&X$WH[YCNTVH-XP[+U&4"E#/ :J^L$:&59O\4H9HY\1>'K;
M"&!?0Z1ZZQ)4;[U7 ._ %8!6LE4!*"11Z".U[>*F#*,W,X?4VC6%WAU,XM?W
M?H].QFZ2L4FJU&>3QK9;B%DE?F"5J74V F+2M/_N54)*F_;'8@HK[2L=(*=]
MK9\1>'K;B%E?0YS2IOVQH/*:]N6[=>]SL7#7S?P@X3KY&X3'\DAK'G\2 .).
M2RBS@>IM_G?]'?*?:CG?I((!(!W231UF:?5:Y )X<(XUO(EGD*MQ0.,3R:IW
M,5XSTE25 2+4O,[A2EL'"N&@T.V(1JA[$G0>[$G3B,K5%M/V(2MA+$+J>]3(
M$-L8;":$[RT%IA>05.\?51>E7NTW$?^5\I<#Z'+.!N71 VUO"4W7ZU6:<458
MF31! _2EE],&N$FQ#IOL/NY,T/H!A8#K1LUJX3<D*L4[V^_))ZY"WI<Z8=89
M4W#57+M,A'Y0.>2P+8 2R_DO<;#9ZC?Q&MMY4A[O]5N6YCER.M)X0,HW4@^>
M$XJD35--*B"TT65>4'F=B0=L0/E]G)0WR^0_''9PUR$?,7H;H(8;GB7.,..O
M\KN$26?7\S88[?/ 9=T,4<.X]K".(U+Y."*E%\+"0NF'?\(\?0L.",!]#=$A
MO%DSP%>ZB!-Z7M -6KG5,SBVNFH8]!5]=TT(8K3=;8V3R-IV,CZ.DD_<(A$F
M#W6PW(<V1H24@@LI'NYLHX2_3DO]!CLQ )8%K=:#9O"I'F $$6'*Q0:MKG$C
MM_?",]:;&\;(7$STQWF^I:Q$X1=EIBNR$'=<\"'-,EVOHZQQ<68(HYMVGW59
MU?NU)>P0,CV4-S11NQVWX&Z9A??X<:?+RVG)7;\>?&_KBD-#=P==BBE/CI.6
ME[KY/]N:#=\SM+C#].RZ"L1KZ_13;>AM'U5<(K>F-3479&2;F'PVY:<;5%O6
MJ7B-L"IHL;_[846@Z68'\=L=4/@!SB;JS_[53B?6+2!5$TC=!B(:\2V^>>#,
MUQC@@JZ>#=^T^C+\8";,RAG7*]*",]BKYU4K8#N#F%P=U&27:ULV+9DUA(\(
M39:$Y::G\I;3@ZR9D6F'N* U -.X:US !F"N>UE]Y\/+(.^C./M+M-[2>9YO
M-_57?J(+]CU/X^=XR0AU$Q5HN</6W]BL ??G*U] 6^AJYGV"-CM)%59MF-6?
MD)>8KI<'F@&LR8,1^X?@$RGJ0UVCQ'N[[WD(T<+_#BG;UGH/%#B[I[A'(ER2
MAL\C4GLENVC$_7X+1H[A_]JCT6%/73S%F=#9S=2@3U,H/:!-24@\>)]^Z+4)
M7$#^6F:$A#[P6T5=[H)7M]+M[(+<ZTP\H,N?5FFVHO&KV@^O8P'J#($6=MBS
M 3UGN"-_Q7<)D]K^JSUS^SRP&GD_?,/+?A7K6VA @.UKB V'78GM)CHOM[*S
M UW9QU\8JNU[#]2=%@6ZV--JW$3+.@V?O04<<05<Q%JQH*^I %/!W\T"31]Q
MSI9B2E>.%EV:W^-@8^O[<D"QY9?7)4M)\IAPV1ZE+4@Q>V1;/,?W4:T/*1=@
M?!&7>6-\^Q1#^]>V-P"'VX@)"8TBN,EK5+,P$QW"[W-X25$WM_V7E-^CL8Z+
MEZEV'<@]NMQWT/48XEIBNXWA')]BW>;)EQ0EK9CM/SO0_#* 0*Z7^]0(G6"]
MK^W<^8J?[+L>1M3P/RMMW]X 0L9$^Q#VCE_K3H1@@M.4NQ&\1Z>#G <O9YJN
M5N)I/M\6CVD6_X.B[4<PV1];<JKM^TH5JA:%4TX:6N@D$VA]EF$_)]'N8W*_
M+<@V*<^VX(=8[P\_./S)<2,G, (U!(9(45GE"B4&Z[]'B"3W7_V96C<YPW$J
MNVK))5V1*E[LG7R+!".Q>NBAX""++UE]>1/GO[_/*#U/6 % \\+UC*#.GXOY
M0+F_D,;ULA:&_AZ2ILV3#>R5;9CQ)V]6[!&)JV<D>UTC;RV+7(V[34!U..B6
MN78VY%9_ST,(&_[+0=O6>H\8;B<"N5?"W9+:[VN;!PPJ&DTQ!QA$. JO!"W7
MV^?)\ISA+BGB9WK-B)U?I^MX\0(J*D$6M&6BP8*3"*[UZ7X/$L2]?8PU6U7>
MQQEB:(,ARQBLP%T-B3Y:8^9X FA+8 &B.Y+^F"QI)E!4?A?1_G<O[:N(>,R<
M?XEAY\BC>- &F)$>G 2@46UR'Z PFF<?P,9[K3?-5\?D$?&4?.+/@SQI'@?\
MQAB(AC9(C!SES!Q#$;Y+8#$6OB^R<1<<JRVS.,GCA2@^D3?#&_W@7\O9]1/.
M[9OMEH6S2 MLZ407:DI\SW:?D6<QR$Y7U:7#.4GWFB'&94RJN+D54XU*9Y=?
MMETZNN-2]KU"C@7^)^^@K?06")#?-6_X.B+[$"/<?8LER*A^;<$DO"FXQA=3
M'MTL_N>.M6^>+'E]>QEMZ&FZB>+$MO ;X6+T_1XZ%]Z.T5<W:M)7$8>WS\VQ
M^ :WL[._;_GV:"%&/I5/@AQA(V$?Y?AY&-:PCIE7>\,Y3][T;<*-L_ $XN3(
M#Z5]_%%U($=^]%ID&UO+@\MOBR@K)AI+3W;ZA]SGK/%Q/6@^(O?T(4Z25WD0
MB)H4;FI>UP>!]%PY*G$U!X$$P7*K\7%)\[/$Z>F*RF9.SO)C!<U?ZV$__CCN
M?CP[$<G[X]<@6/XVP%FP=NLF)_=;A[->I9=OP6 D6 \]&+Q]'8.L"4_YLO2*
M/R +^N0N8#N'#=ZFJ^H\'\METQ)P_??:CN2R):*;G.#GF"U@ QRE#_]7VN*U
M=<#@<LHY).>WVF(VQ33CE*Y>\_6!AQ&/W ]C PQ(00UY38T-<2 ,:7,@8<CE
MH/FPK]1^%?'+_<@[P/@5WBA=?&K:0MW?0&VQXP3%P_B7.M0>_+W4H6I3("]U
M&)KGZ*4.K5=E2CCJ'_-"MMP\$?:K/$"$AZ-.N*]?#0EXZPH.B7!>#H&@%NWE
M$)4SI)=#]-\EL%@]*"7=L-'9^S3C#]U-H$J<X,^7MIR$,PQH-"ND&PNT+9RH
MQ.\ZGE4BY!-_0JI'009<-!JXJ:X5H'-62S?\.2J=>]_H8(/O;TRP4%U/(!Z>
M1@7='1:!')4'>D<*U];>/<=QR_8&]\;?L/:[#/]#6C3;S<=$U7S,BA_'TWM3
M\(&KO]*+:8;R%C&_C" #;N*Q; AF1AKT&QQ>$ OF5<6!;0\L@B&_UEBV8'][
MKF3"6H@0WI#&T67?(J!')GW-(3"\5RD'SOZ<)<NK5?G%Y_=YD46+PN4DM\:=
MBQEOJ;N0IK\E#0QV+ES=ULDFQE5-F)TGJS3;E/DGHP^,VXV=',T#-WA&$G&!
ME]FTGA5_XAYR\JDV&N0,C0/*N9H?-\#:X62YQ+.SF7/EMWP=J:$^4+XQ9U4E
M3)<9PNS51:+0>0TI7ZC;&6S:,#9YLNQA:,EL?X.&+'$$_B::.[JY2A(P+#O,
M%>H&.$L9IN_\NC)']22Z7],),X?:J\O,(?,:8N;HMS/XS*%L\N290]$22>:@
M>\E7GCDT='.=.?18GB!S]!O@/'.HOO/KR!P?GYYH)OZZB#>QTZDHA2L7.:+G
M*J3$T&E<L-E WL[)4H#,_>Q&,9-T1(1X-=.TY@H'M(:+3"A764 #7(>AO^/5
M6;R7?KO7$>0OTL]3!7F%*Q=!ON<JI"#?:5RP05[>SLF"O,R])L@+\:\KR*L(
MY2K(:X#K,,AWO#H+\M)OYS?(-[>HRB*S['DSG+:?8\3 ID5WQV](O!C#3D]G
M]B[(8\ND?=9EK.IGEM"L*=KC1M^."Q X._U YL@:",>O"@FZ'3]64$!ZF[UK
M%O>]<YEU:P#4[W*WW\,^5 #H7EVV H#?UX'3K+BCV>9=FF7I9]:B_FJ$4F*7
MX202HR'=L^E@U[W*AQ[9<JV9>/"&>=WD)$D+5A!'+WQ"TC>^U=V7@G_O+L1[
MPFV0*VRYP03B)F:E_0& .&XB@IS2^^*0@:#,=D.0X'6?:!$58OOK19S0<_9G
M+]XI!>IP)Q$8B^R>2=2Y")5U+:KE2K/=Y^03?T+$(]\[ ]5=ED)_Y ZN>[(M
M6"LL^0?UU4H,KQ_3-1MIY^65'*H=S#8Z7>CK=;#8H//BA"  AR#.&.W,3JXN
M;Z\NSD_G=V>GY/:._>?#V>7=+;EZS_YU=?+G/UU=G)[=W/XS.?NOC^=W?PMG
M$ZX5:F3L@W:J@I Z=2E'S?Y"H.U)E#^^7Z>?<S-;E:)]DDI$\;C9,^Z(DBH_
M0";*U74$/)G?_HF\O[CZZVV(M%-WOYQMVFY2DJRGI>"6PKI_2I5$Y[/1:<+^
MF<MN'X?(=DDEE\5BE<RZ+:V>:7:?&D:^ '\@>BGUZ^O ]H_"N',;U.4R(IEZ
M1L$DF9J42FK[KK&%-WZ&>!H%J^.O!U>J 3<:L((8A-_Q"3)56&X][,;AZB$6
M.80Y)P5,TS((_'N%YF!;?!H*RML](X-U[_=4P%C(27';L. ?I[<+FD19G.JJ
M")E,%[5M&2SP-JTZP;#$ 0C*/;U9_4E845O:=3)8JWYI!;J;XE*0]^WYQ_K5
MZGV<1,DBCM;7:1Z+4P.,@U*C2G]PJE'!&Z0JG3@:K)K\ 0>M>C/MP>N[^<7\
M\N2,W/[I[.PNR"&K&1SRH2NH\Y1#6*6V8BAK\.:?F"?K*,^KZ2Q=(E+)=2G8
ME\/B7=>R$[(IG( 8)M6=B4_YGL;RL."@4I2R4V74T?W^"KYT5:0DD=OUR S6
MCO,\W]+EZ3:+DX?RV %Q'LU\P<8])8_[1+%3V_$&JC::1C!'N*RR\JDGF86I
M&1N8;M*$Y()QL=#BT)O?TS2)R-4C*Q6KJ7O?1+0$33JN0[LTA5EHL];&:Y D
MEF\KMJ"SW@" V"H##BDN=XF_^VEH$X9R7V-4%07HYFF=OE :,/<-" -& 7.?
MP^.!W!8T,NA:X@7TB-/30]WC(YYO#A-8+S5)J;H[YU%H'[4.B6S?<G%)"UZG
MOD^S%8V+;?8U,T0Y4SX]1?S.J:M;7'[,T')+LV?^EI9%"E7J K*G1-=A#.EY
M<[)R:N]_:/B0VY/FRE6:D;R2"C<2J*$$# +:'H;3OV<&RGR%_ZDQ/4E*5'I&
MA3,L$9[O47[[E:)\0);#A7F N:U\F^:&/O.QCI"Y?5K'!3"[F;3U^4VM[28:
MJ/Q-E^,,+1@0%K069_/E4DQ01&L2+?_O-B\V8KL'#P)9J5+EP)PK!?1*X4"X
MF:,#! .@\* R! @0^C9,CWW7N=#D&QGVAGQ8OSY9*5<+%:7ZUXAZNZSH"/8!
M9\:\R.)%09?EB@T_W?^W+,TM$Z3!""Q/*HVX#1D*MQ,LG<!:,")\Z S/]H_)
MPC"W>C"9TX1#>"@!H,(JH"CL6<05;8M"BRYBD'!)/XLG-G-)/1W '%)#Q^$X
M>^=EXCFCKM^A@^NV'=D<T1%)RDGC19H'6BPH, (<-DN[$#Y:WJE#1\D=?U.!
M<Y+)GYY'%%S")GN82BGPZD$Z8$YG'$H#K%1%(T_2A!?6;+!_M2K_+N+[-;VE
M"R99Q%8Y!FP+D'L MAS2WNA]J@U T(8,#1(P^[-KAD::92QPE'EM48JR?\<)
M8T.SS@TW<L#A"8PH5BB!!QJC66@  K8OM+A4%N:61:Y""3)"=E[F=MQ,-@)&
MJ'!EAF;B,,G/#$(%3<C3]GX=+UAURP)$'-2U-'9 @0YAA]>Z'7WP$'62:E?B
MRJK<';NX@5'V2BV9!V1?%V2'S-N.Q&R M6_92J3BU](8)"=Y*W^![J?:$VO7
MG,$Q [\,/I"@@ED3#X".10S"J(JM6NB=7].LKX*;XI9<P-77O2V>OAO6R-[<
M-[HID10NWP*L$<08>N1"+LP&8#YL\F5<O=>IYK\<+.("[-JLX089;8"P \YS
MX:W:ZLU!Y[4.;,VVNHO#^JU8M1YD!#'%>[%]3Y/-;>&\&:NP9?%J[('4^0/?
MD]5WL$4U8?FFK,KOE#">=/I+YAP-S[O:ND(R0VRT%_D:$3RD($:!<(!E;MG0
M,>][0RQ 4M:T;WSK?$X[O87]SK?1JO&E[P.)":/?;X5BP"),#'[!U=P6/SR8
M9AH*_35PLUG0A-/!OP@^$5.&9%1G5 DVRY:?6[\-;E"&Y%:)LLMPTG,W;495
MN1\<1^0&C2^$'T@>52,+&ABT_6T1$GIVP-% T8+)03[IL%'9 ER@=W=1E(CF
MX\AU3+=B(T64/W[=8!^2 )'1CG"=I;5/O+LN![G&Q?E;6$UXO@_T09^)X!3O
MJCLX)\2[U]L[>6M;-QM=I@4]C?/%.LW98.".?BG>,?^_RRH\&[UF<0?3PX@!
M$$^NWM>R\&VD/]C63';W5P"LMH)*E]"VO2BA,L1$C\5POU-B%7<BP\8K&DSK
M28M*GN&TO).%JY"]#OG$M8A0\WZ*\E0@UA5@3E'L?;8!=N>D25"9:! O!U"9
M1E\V'GZ/I%:YPSXJ)$(CF/Z(?T@7F!@D/\Y?;SD@BG N@VDB$];69 [ITC3O
MEC(23_9)K$.=L"]7!?6[,3<-85-3SYR$@F65D4E&]CA@C/6T<UI$:[L1RB!Z
ME)2XX][*.;7 <PJ, 3:HUR/=T>C >ACP5,Y!%%%6V*/"OO2O:OQW$=-9T,,%
M ;@6-Z, :5*S9]=JXK*$P5FRM <!:)92HG7X(-#-$%J"H#_3AP."7]Q54+5Y
M^[[_13'(GQ=%%M]OB_K>QNLHHTEQN/CX!0\?O_BLA+;W>;R,HRRF^0>ZN:=9
M!X)J@;H2D@B,A7O/).IX065="W:YTNSVY(J<1$\Q+X48I(N$[ZJ^N#@A4;(D
M\]4J7L=107/RJ53R/5!0=V8*_?D[>._)MO"NL.0?[B^WT9IJ[L0SR77!WY?#
MXD#7LA,J*)R &"'5G?$/ [L2S]BG,@[H?GX%%;HJ4D;([7HDQM/36MS5%ZU/
MHOSQ_3K]?)ZLTFP3Z2YRM=/:D0:H-9I"(#^XA+)QJ:<7W-*L*5SN9EDQ<1+O
MY?_HFWMV0$E']6*7ER #;99:^/3&V;OHRTE&EW%Q$F79"VL=?Y50DLR,<M7O
MI9$;R42E94SNF9SHV*;7G;''I'Q.F@)!I#5S[Z:6'=&FCU*E21B#W; H<L?'
MH!".M 1U)*D$7;!$F'9.DZ87:Y[LE=5$$3(A,J7=QR:J]'H#P)6[>LH#:MDG
M6\IM:_(DTG^VYT3SV7@:[*TA([]GV #VCKS =_E9*+%?TBDIX+?LX78OUH%J
M5]\_.D_3311WW^Y4/.TBM'Z*A='2GA.4MDR#<-K0:"&U_#P4K'8Z2(;6_J^J
MP&LI*$5LTT98]<=\DVZ3[E :(*DMTRM))X6ZL.V^5&^ZL2_6]]JJ*N2(E$+>
M>6#L:&/%WNL12,TNE,Q5>\-V6+RYC#94%?LATCK^-*5=<&AOWSF/>JZLN=2Q
MH.83%PPGO8 P8**6O*, ]-HK&BG6]1$6S2[BA)X7= .:1NH)ZTC6$';!L9UY
MYQ3K>K)F6-N >MC,Y8@0#)%>_<XWL4O:10!R[?2,W.IX\$>M+$KR%<WR>;(L
M7_N*DX>KU?LXB9)%'*W/D[S(MN)JTCO6EES^2)[N')BN:8MJ>BS)$1N#&A+P
MVZ4-(-CN9KOGI"$02AYW >[4/:@Z00S12RODH;?>8X"D4;[-7L0*>'V=81&S
M@-X+=R;!7?!2"XX.12K3X,#R_[?WK;^1X\:^_PJQ")!=P%FL[=TSR9<&//9,
MCN^=71LSDP0'P<6!W&*WE:C%CJ2VQ_O77S[T%BGQ4934;7_(9MPBJRCQ5P\6
MB\6_",62X&V0X\%4S%%FP]IBL//JFJ5EQB@OFBVMWKO&9!/3:>F*IJI/6]"&
M*7O%$]A9SW$V]E ZIVYK"2+>HGG+-&]U.DA29(1#0&G.\Y>MD4FS/P=:R)0N
M4/ZGA"9X!28U#VV1:.:!?FWKTV6D>P[-G@K[8PF?DL9*L ^D? )!PH^F;-.W
MP$-/-YX$('2TH#8BYM1[?TLR=GT##F_P0R[5>P,MBI>7MG $N80FN-Y3\QC"
MN:K7JGJ _II&H2CEL RL#TTAT?[F;:A+&C>AKJ3E!Q=@RF^ O@4HSINH8(].
M A *Y6>'B%F57X;O-A^R/-JQ@RE=O2=]6*J\SD-75+?(00;HI)0'D=SOL**_
ML?,+U:\S@U<^,43G<W80VVK7 JN$PFPP_4>0ID$BM\[29\5;=IXY8K1%#1*B
M,L)#".VW7Q4_+>5LF7Q2B,:W;..SU:P)3TG_^=")H^UCCL.K)YP&6_S;@8WI
M;B-6]W>'/,N#)(R2[?L@B]9=]-KT+=%MUM<5_2;<0*7#@O&@]!C36Y5=4"#Z
ME&5C2=UZ.5%3.T@1@)GNR*X)F99LF_-?I.QWAWJ5A#=1?,A[FQIN1#2TP1 1
MCVI!S78J_3 Z EM%,4*XKS$2WEO<U"WJ3Q^I"M$ I*8NT8.'OE)1T]/5+F,C
MLE SP7HME,?Y1:$ZV"__*PH^W-(92/+H"=]3$-+)^47JX6JU+3[32%M+81\?
MLJE AV3-MY]E-RMI<Y,)KV;G55&/HVJ#6"-TM4TQ/^J)OO^N^O=W/Z H0P&*
M\9:=J"6)."+Z@/-GC!/ZX)JD>Y***S]8J8>(^N'U!404>_N4/$4A1ODCKAZ@
MYRA_I,W9A=N8?O><%:%G#1K4?D1?Z0_[ _U!+$!I<_G Q4F-+$]QLJ5$!*5-
MN=V?L;X=VNCAI1@74SU114[L69!]=3M8ZVW$B#A+=C,$?;V ?9H=#D3C(.<?
MYPRE. ^BY(Q_CQVAE.DRDGX[P9Z^$TXSDB0X_A']%2=4$N/XY8P/L7R=(-Q%
M292Q;Q.RL0:M2VO8'[LHSS$CNF.?)V3ON.,SG-&QQ9C?>?KP(H; K[&@[QGD
MG,D^YG%H]DT%U_>$I=A1"C=12GN2-/MQ7A6L)_3$5#;;VG2P&Y].3>)>]8IS
M:%.?C;U&.5>I%-9L(:MR8$PIHJ! H+*OEJ9'WZAJFG(G19^7/;0NOEMQ$,GQ
M=9+04A1< X*6W6T+)I[<N8$GUVT[Y,F=^_/DSB?UY,Y=/+GS-T_NS9,[;D^N
M)_2#JE$FFQJ:\5Q+,Y[[]>3.I_'DNFSL-<J )W>^:$_.'E,FGIPYJ'QX<N<3
M>G)=7O;0XI[<^1%Z<O;0,O'DS*$%ZLE]II.*OSX3J>LF?UB\5/>A"]S;M,"]
M,2EY):(EK5?\-Y0_$V9DA7=!W0]^!QKU!9BOP,PSG<+2\]BRG5H<SFR&%1-(
M1C][&[CM=A529=UA40!C.^5T#>;_O 0 _74A&LMX9A7F3GMJ'0U:GR"@!9,3
M-YA@:J/^<'[^XR\_H3^A\S^S_S_26598'NU9AK<M7Z)O:MO2>]BT+8V'SLBK
M:/FQ+5WRP]!KMRY42Q9].T+;TI] ,OK9)="LVK6AV>D.BP) V]*C:S#_E6VA
MORY)ZYC,[)!MT9E:"-O2(@AM6WK$#2:8V9:??[S\,S4M[WZ\_/E8YWC(LNC,
ML8=5"VV"!]8M_<>ME4OSL;MG4U/SM'KI,1AQ;SKMRQ4,^_D([8QL,HG&!,C<
MH+IEQQ'JDH!&!>1JID_9" _UBH8#8D$ZR72F!]<UFE,-LK9IDP1?W?3)&TTX
MLT*7/XD5SL\72UOA&,[YX"I'<\[A[=''Z&G '/6?-JU1\ZDS%&MB?FQ1C_XP
M$CO-"\6S82'@XS-$DFDDX]]>@M.Z81NF70+ : "T07W")CBH+!#[>4G*R&R&
MA\R/WA1#&)\V16C;TZ=N,M$BMG99!-=^>;<PVV,VW4.61V^Z/=@=BHT!N]-[
MVK([C:?N**R(>;([7?HC,&PW+^T._?48[4Y_&LGXMY>AM&K806F' # :(.U.
MC[ )#FJ[PX"P)$5D-,.#=D=KBD'L3HLBN-WI43>9:&9W_NLO/_ZT+&MC-,F#
MUD9KDN&MS5TRL,CI/6S:FL9#9^!5M/Q8FB[Y8=RU6Q?JA23'N+SI3R 9_>P2
M<%;MVMCL=(=% :"%Z=$UF/_*OM!?EZ1Y3&9VR+CH3"V$:6D1A+8L/>(&$\PC
M:3]>+"4KTGARAXR*SN2"FI3[X(5=^W5SP)^H@DPRTC4KZ@;%\&4-7,#7IP=N
M8I0LE"A4]%@5-YKLQ6,4'C"*BP8S6Y.!>2-:7[J-SG[;"J$J,O @@+$P:MJ&
MTT\MS7UCXLM'1SKO"IMC//%VE<44ZND3#C+\X5M.J5-9%M=J=? RU*1X%7D3
M%WS**(*KJ0$F2J0J^ZP^XSU](UYG'[/G(3^XP@ZRL)A,RLX&!6$8L<$$L=@=
M>,'![ =9!J>7:$Y'&]*RUA6HU:1\X 5&HPU1-T8*U6K\D4!)QA=/_.$1XT"A
MVZR  *K?OI(\B#FG:Y+EV542_BT)=B3-H]]Q^!4G=%UZNV/'[/A)PMY]2':]
MR[K9IKU=!,"0&;@NM>.O%!X;<DT-G+/^A?)=,PK\E.&AIH&B1G?T&(C3A]2Y
MW%"=3>B2@)KA1ZJR692#J6GV5XZ><8K1+@B%1F?Z_0$G>!/E/!+" B(IHAPP
MROD0Y];MMO@E[J#J%) V(U3I"*L!3"Q&,";&DC&D +&2YJ-B(X#=DIY7AW%5
ME?3I0 YJ(]\?HI@=,K^0AKT53XM7[SUU$;X.,7 ;):>O%"%9\]7'8!W%[)CG
M(XY#;@7HS(2'-3_P>:!B$R7K^,"ZG:&'0XX2DE.CLHM$O;(S:B<V="TG#KV'
M49:G$6W%?,"-(!SAN8V&:L+)^"RUY:'3L,*[E  P;F"4LH*P"6*H4JU^74A
MU6*"%1K/8(8=(^82BH A<P5UDWF^^&YU$\1QD*$[+N''.]>*\+G!7(,&T$OZ
MEX/6Z7+0.EU"6J=+S];ITLPZ7;Y.Z]2=\"Z@);,DQ_.E L^7T-;ITI=UNC2T
M3I=2ZW2Y,(UE,,$CUDECAH&LTZ57ZW1I:)U:[5?7,7[",1/L11HH@^D>,5 :
MTPV[PTL?XC3%(;_^ZNHAXQ6VNKN\@XW*G5Y%(Z>-/BE-P,V^0?KJ#;^!;JO[
MSQ\^?OC\^<,-^O+U[OK_HG^6SV?&ZL@D$OU/WMD"E':HMP&'Z,'AF-U?5-\@
M?$V>>.2!%76+(W:C[-^#^-"%F%&?XJ4U^[B 7HL%N -GPE4I&/I$5E]R<;W/
M(T9/[%<49!E91^SN85&\D#T)V>U<ZX(,:YR2P_:1'$2=O13O69PIV19;4#,[
M=V9P(K:SW98^K>Z5,!HPFP3!,%K<B)T[=JF.Y[?&U8W/4-D<U>W/$.]QTIA4
MF 1/H'3T<[7Y 'J_1CS=H7E1;H($(O,LQ?\YS'_3M6<0*CQJ3R $];Z_8/K9
MPNH21G9%*;NA5!HLTFI;?(*1MBY2-$@:W"O1X:84F_'.JSOJ1Z3"S2 /<;05
MY7]98&E-XI@Z(VD0\YU#5L\XQN%6%/5E^UO;8"N.$*2(<"IQA-F.NZC#G-"W
M>/DC*V"<X=EWTO6@0TQGN"UO@]TJ.=,@[A6=,!Z'%AM[7%(/0[1!R[V^&!A3
M"D\""%2@2\TO:W(=["-J9N^#-$^H_?\4K^4J>[QEJ;"'6CH)A)HPO+(>Y:46
MB9&NJ[OG!!=I3+Q&/HDSM O^15*V7U#4GW\BN:@VWRYY+W3QW"I8 PK$;,XZ
MDJ+N5,O)&&&/2 -2O.-,;#'&E.[U'2J:H+(-^O3I>BDJ%PY#*G7K#B+'1=H(
M=<"EF08G6RA=#$#I>_KDA],#E&(1!@ HT 77-;_HDH>B;[/L@,.OY$-Y^TAU
M.<=5$EZ3)#O$>=#/JG:@4'P:*PHN,F7!$-PWL!^#4@AM2997:42[/=NH:%Q_
MRB^GB3@MAL[J7IHS%);T>'+!NJ;(+X])"A\#A8>4'QY_Q,L(2;N E<"@IZT/
M+(A5>L)Z(#/(#HRWX\ <6FJH=W1M+R6O5@H4?M8,8N#HEUERU?/7_B+D(,%;
MMOVG]-@<Q@ M#LS#Z\A!!?ZSQO5L;W+0P<'L<@"</4/6&(?91_I]V2#83L'=
MIC&RWW#._LYZ;J1%SRK/QJ"G6_*--B/X&@S&O >2=<Q(K=@=A.L@>T11LHG)
M,V+"PUVZQ@'H=;&TX[&H,LV4(G,Q\28;?!&WB>^F!6D3:>0*&3*>$-Y0"6?&
M3*& S5+3BAZ(=4%E'W2W*10Q$C:-]F.K(M[SU:!8F=WF'<:.GIDA-Z,(VA-.
M'\A #,V"-Q2<+QIPYAKZ#W]FQ01[2WE&)D,)+A;ZKPG2"J=K DA/ZV3=)=C>
MSY)VUG6U.IV]BG&+U_0.EXR]O2SWJ;T2MTL.-VT!5X+ 4,1;=/2E7,)^6LQ/
MY(5)^0*B7=\78V4JC\@?@X:WK5<&A6_?OEF/(> &IQUS0)3W7;1?V.T"Q^^B
M0:/<UE&#0CGPD><L2G"6488/4<(=CFMJKJ-DRQ-KDRP*<=KR0PJ),>]8'936
M[^AV4%*7CX?CU8:L!\Y7&E$J:YA2R8R2=<IKZWP?8O&O'\H4*W&"ATMO28J'
MO2M:K&& $BISS,/[GAWM#E).M?CM!XK=_QRBC'MZ/Z+?BI91AD*\H0,.49 Q
MSY"D.T$P>&#'@((XIK\^X8QG?K%H.VU, <__8@?'EW'JVQC8Q ERW:.ENC0:
MIT[-V$XG55"'STUY LD3/[(N.J!&#U1W0:T^KP2XRC/PGI'K?'+>A!GHH7I3
MQD#X94?Q:ZCNHIAJ7I)@[GQ</6"Z2$=WCQ%!.YZ^-;,?-QE\E6?Z/<,7U&\K
M3.Y=RK+PBC^N:ILLBCBSDF[KA,1D^](1"-ONQ2<S[^XBN*;<P/TYRP$HI=B*
M'@^Y!0W_+J>THX>8'\L.<I;7]D'DM7'?C'Y0A1OW"GPX:W@3 ,BUU8HII4JY
MV UA:CF#\?!L.8-*&/7V2B&X2WD:>"44C:ZH[(MHYT?1^Q6"7>$#3HIV1W_0
MAB6@5VC+'A3SU$.L\)Q7>!;QOX:'^ H!KO 2)P4XJ,=X6P2$;HIPT*W*5_VU
M7"=TA,:>0/$);0BX"+@Y/W#/T7H(2BFWI#@2&:0_QU'P( HZIGA-M@D_2!^D
M%)_4L^,*01DN7-I!"@>D$A#LM'6&.:U*:]@.8WJQ@7$$[7D#"PQU!F\K.;FI
MY.16'?Q#5?]7"GZ%2S@Y^AW=0CNF@(ZA_0" 9: =/FRK_-TK![O"/9P<[-/F
M[GU])O:Y>]+.NKE[G<Y>TSQ:O*;/W9.QM\_SZ%-[);E[<KAIIWTH06"8]=&B
MHY_U(6$_+>8GRMV3\@5$NW[N'NW*<_?NCB-W#QK>MKE[4/CVG;O78SAE[IZ4
M.2#*^[E[/_>.5QQ1QAXTMFTS]J"P#>JD?67>X2%]X:RN&?.X(Q #+<KK(F4M
MG.ZRZQ,$=YS4/-0WTRFZK*H4..;/"/E8\\=C>Z9Y&B09V^=4[YDVFF1E:"PH
M F-BJS8DO&@E_:"'F!<^XU12O,;1G@*-,N4_[(,7<7M;D;=7Q-;0=_>-(7V'
M>,GV3#AGE#BOLDVEOGBYQF@:3$7E-3.^,]^]-P!JHH?"SA5Z_<;U-7DJ0AYD
M!.A.1S5Q4^E@=S,63X1K=(;$PZ,%@.H217,$.'HI"JJ@ISP'>)@B@06 BL]2
M H+KRJ,%@L(1L ""YZVYVZ(JYGWP$CS$^"ZYB9ZB$"=A-^IBTU6Y'3?4%3:D
MJN8TP1;<*'.#..H(+1YKD6VX-;;,NA=C,+-;547="[JL4G584J;.QCH.6)EA
M=J_:(=D'4<@:8%$IC=?5Y5E89;V;AY=&W(;G;)%#GN7T'Y3KXO;J- "LCMWJ
M 6LL:*NF,A"N'6,]I03YVHT;YPHF.\T=N+(/$XVR%[JO1:/J^(JPK+W=Y@',
MX%MLP^Q _2,;YF"@OF"@+O#;4NF%GG]%^-7>0?. 7]A=,\'B(TD_'O)#BNN8
MT)=':J4S^J"1W?4HS<=WHE'NH=G1<(JZVK"$WU%S&(4Z"&M-M)%J57IO[';<
M#2=3':%FCS-.B3^-)5F80<8:/00Q;Y\]8IRC,,CQW#MO3E@E4-#IQ')MR-4A
M7?O!S"(^0)MS+NSA!8=MU;G(RZN6"M7VW3QBX;J99\L7MER:RRC@Q>.B%H\R
M<B^7DG+7[TU81F&R"&$!OC(AH;C.J*=$^>(TPMG[]IV^?^/AHLH;ODK"TE6F
M__P4_><0A=S1N@EVP19G]"$1XV]M<4HO4)J%=W5-PZ2\W8IS3SA4<&=[CM$/
MU .?>C"KFB73M8(I>E_?JUWL)A=1V7J!SZ*N5527_1'7W*E7S]FS!J14W)V;
M+N8N1CZ':).Y):9;_WS"830JIT_^\D>EW: N[YAAV,O1:^?S*;:%W*[URC2<
M\JJ35Z'BG*]7F7B\@+FJLXQ].8KN0D/1B7QPP;G>6N2Z[;:IZ!KLT4U3T7VI
M%%TKP_Q-T<TI.J]2T7F.+5S-&%N8@+<RMN"5-ZQE\CC4"6(+_D=O8)I\#Z9I
MF>XJRW0U;IFNFI;I2F&9;AN6J7/V:6D&:0K15ANDB21FS!YY',: /?+^\D>E
MW7S%%B88]G+TVOE\BFVQ+O=):SCMV,))JCCPV(+G\7J-+4PP]N4H.E5L04/1
MG6QLX:05G79LX205'? 1J"B/@KA^B?LT8KD3[5=@8VJ,I7<6RH%&=2C*BH9;
M-KP%2P_'I.Q',9 >;TMT571E!6A*C;IGG7E:;6=/BBO&YI[2[&>:7(!(H'#1
M3:RW(-?(L+<>S"RR 74 RH$]O%2<UV+1<#3N2['H>AE<+)83YYE9*I3GI681
M"^<35)9\0>L4.HP!7C@N!FS&]U&"0A+'09JQ0[8B$^&'5RT.RN-7LX@#[#Y5
M'&34:?U'D*9!DF=WZ>=H^YAGY=\?ONTC.I3N!I-1IW)G2+.34T! BP?\7HP)
M6_4:7)_*ZFJ[3?$VR#%*#GQE0TW:<]&0I;JGO"O"HD]Y@GX1Q6D,P4.LI[:S
MT-3J7Z\0#=A-@UB@^+H1/P"LLH@V:\P0^H\&0D6'L_JWHL^)@U,5[_6%3M<(
MJS8CR-"H$5, C%)WJ()AJ3*9&R22,&?V?;Q#4A69\P5)4/_EAIJT)VJ8G_"G
M\DZ&M@/50;5V^^)C:+1WD:]1\N"^BBY'I5CI$5A]#*)4W)Z;%8>S65F=_@'M
MYG4:; ,@K6KN5?=HI,$Z+RYNV[%NC- ZC:@2B0)^ZAN+"]76["@YA20[QA>P
MRC_E0.GJ/LO3@RC4E^(XR 5P.[&Q,[Z;\/P8K1\1%7RF"O"Z:/K _F3#.D1T
M["&S8(2.(WV.,HS"*-L3=F:0#B;8Y,P=2S!ZP4'*VCW@%Y*$?-0)NR N1F3/
MRY/30:]?UC$^0Q']!B39XO2L+#W*:Q!M-IB].?US%V2,+'THKI)C0K7%_(5F
M=N?T!8K88+ZMDT:[5NI(DXEWV87QVK19N4DM]=7J=HU+;CIR<I* 4SAFP(AS
M=,>T> !Z8MK\W'!WH<#=GUX%\A3^%S#R0+VNJ_4Z/>#PGN2L3EX0ESNB."PV
M1#O@U6Y?? *-]BYB-$H>W.O2Y:B4(ST"JZ(9VI?MJA-F+ HD6L[L,.AC@=A,
M5UN(1KM60J3)Q#OL8!P&;59N@#NO$5<U1'7+,AOG) &G<!B $>?H,&CQ '08
MM/FYX>Y"3].=).X4[@(P[F"K_BE970?[/0ZO\GM, 4SMYQ;?;3X$Z\?_)C%=
MOF>W_/)T9ED[X :D6%8$A*#H5,C)?0#PU0+!QJ2N\03$8G4_H AX.&?-Z:$@
M1P%:XS0/HH3MB!6T690%4^KHD9/_(TLA+1G,7400$.S$#]HZQ:'<B=>EHJ &
MN@#9!"I%"#<8WU)YWA3+OE^(KALB>=\21482%3113?1-$,>@M7A)=*UW"#,*
MV.J'<&/R+9$7PX;R3;[&\+)X^?)6QN"NO@=#G'6XRJL#$E7I\,'-5R!JDE(#
M5M2@CIY9,/=:#L!^/%KGPVS)=PY\U8EKC0M6RKI7[.*W;KU_Q%-46_L!<Z>R
M >%9=BC+$53J4U86A*7GIJP'.+/8P9]3=QB(3X'KU:FSE[,W,=/;+5Z0G $>
MK;8<@:?#T@ZC\2EMO0/-]M*VH-S#Y4F>QCGBF24/-G3>(G^WH7_0X=#Y^[.T
M])=N\S+H/=K<[9[Q8>KPX6H]A@.7B6OTKU.%BQL#V0T#)$FPN#?X.<H?>P)-
M"E)S!Y)UT4$L9K![7_APS\8-X3HL?,,0*#*KR<D)@"RFVCF\6C9$K.5"REMX
MP9HJR@D)MK[CY*"^Q1D^KB=N^!FL>WX$Z^\L+_HW_,R?=#!KTJ7X#'I=7&1(
MAP.X.C=@JI0H;1JK#^)&V&BW#]95"C9/8.?1"OQ<%E 06K]Q*6UYU_QMLHX/
M(?7S"G>OM@\!NZ56G+?='Q[B:%U9!)8@'K!K:$D2!NE+]_',!L,(B\02*VU9
MUNE=R;,^JRG #V-$3+@YPYX:$V%"1%LD&B/1&O'FB+87CT\8BPK#X@6,CBMS
M73: RV\3ELZ0Y OIQI4'A19EAWK^\.<??_I):-?RG,R:9/G,NU9>@:E8[GH!
M)NC"5<%4+*0_8[;(QKS-EWT<Y=E=HND':1 8]HH&"7@0S %^4WE,XT,PE=HQ
MBJO/.#R(!3%U?_C1MVJ[I_".>@X4.[,7%.?_^$DZ^F].OU $&>.P3(=(!Y0C
MDJ\)$RTU,$!K3"F,#F-Z"?'J5FGP!I:-89>K*%E9]"[6]Z(_H@1>*?K-W#-_
M\/?CNHTPU7/D_B+PG_"J,*&I*Z<Q!& QH&[>US1(,KK.1<&6Y<&L29H6053J
M3OPLT_[+V1F9313,'$)_HC"=LV@6)Y/WT7$)O4;*VBRF=?P<8V42(JO?*F].
M(S"V8$DU79^II]% ''47:#)FDT!S H_+-9(EHZ+A5RT[E@6%21MWR1Z4/IVB
M:0-:<I[NT+0(:1V)I^..51M_QAZK4W@MK;B:=EQ+U<M@B\]7!*O+9):-/OM8
ME93,VW:?923;8"4SA!OS<+;&DD7.<"*)F&[WSR$V):=CL >XV" 4)$@==@,M
M43K!GJ!1- EL6] A@"2GH_:D?OGQE^/<''1$J\,6H25:IX_]&&X/&OM1DF[>
MUS23;P"ZNU)R.B<7#3*.UKHX.3T*9JL:_QMS4_HY2HX@2#4+$2W6U8$%JTNP
MR!:M4X2,)O-WE&Q!,&OA\1Q9[,@5P"X1)%L 3Q9'JNNGXW0=9;VK6*SZ:L24
M)'U]+5!ZK":-+ZFX6ZU6Y,16?R_#2BT1[J0[\8K?1;_F=2[+=)A& *:SC!F<
M=_VU3(^,UHI&P7Q2C/N/&"G9PJ%[T*<Z$^&CUBTO1=]7A6J+@!(@K#T&EZ3\
M)@HQ*7G#@9LZ7Q\:*IDZ7#_]5"GF5X5@BR 3((*G"SA9^ELCG76"3]-X7 I>
MTP:BH'RN(6J-H%1U,=[WI+C.$AV2*,]^J/RM5IQJ?4A3EH^X_'B5M9QKH,!@
M,64LZ(/LIP7]!-$L,"=LD)Q&9.M(G#!_V+8)=4&"VV?8:R9/;(0Y(,0'?;$C
M"7GY +5-^ L2U).%PAP.#8[WUPB)37=D4,UNTM 8Y('!$8)UB&RM"'8?S5E
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MZ2A9ISC(,/H^Q.)?/W"!J_,4N?:CFFXMV*'OK^YOKW\H+JMF/CK306C]2%^
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M*)2UEZF<8).S.7M<BN)1S1K1^-(=7'9:UL"4DH">?B#MHZ!L-/%,_]"?%Z:
M;&9:I8),IAI4"=TF:[+#U+/ZC-F[1G'$1?CZD*94G)F[]1EG.'WJPL:X7_'"
M!OU< *W-!ES1F7)6"H(9(9Y9O"=IF3,LDH@W&TP;K_$9>L#Y,\8)!1:["S;B
MM'FH '_;XR3#[$#: T[P)LI9$"'%C!:NSJ>)P: O]+TQSW)AI]SJ G%\'XO]
MR:BM1;\A#O39_I"+TW3!?A^_E/7F0MHIRZ,UVN"0;XIEE..!@OFE23%ENV%,
M1JB_R?XN'HE[L$E"+<2!$2QVWDB2G5'B04Y-!@KR/(T>#CG?<*<4UN)SBHA)
M*C[HS";$7+2("^K;FDB;1*6B#)E.)M4P]LN8)8P\4XM7B!R+\;1[H**+"/T4
MG5X%9!76TS-F'8-*1KP \RF,^<(@EYTFE.C45X%/143+,SY];,)0;R+%?&DU
MM!6C:M7>D.FW HC1=HGZVIQ1\!D+UTJ[J39JZL8+2AM0SBW1GPAI8+?;H1O>
ME1/T!!G0'1T5 QNP-'=W&OA8QM(7 "+#^STV&('9^Y%1]K$#I.)C@Y4+OOH[
M.8@,[P_90 2VQ&1QY(LQR[X<'OY%%[Y?R1>^7L5WFT_1+A+6176(6K]CYU2U
M3D>(@XKC?+R=N]9F/7J649-2XVPCL\D9*_+#NC!8B1@$/Y 4U]U8[&(7_(O%
M0:BB_M<AC;(P6D3M'G-\=0]'FLV\_+#D.(W>Z4E=MM.!&_8DMSY/(%BWSGKS
M+NA+C>LO-:X;_5X)>$>.B'M#+] A<CUF'DZ5ZS,&PO %J&Y^)>@>.<CN#=V@
M'M9GO#W$K/7+U7Z?DJ<@_C6*<9:3!-\'+\R/Z$B(?H?BL^AT<)'6<?K@'I0V
M2Z5X:E)8U>W8'@YOB'9E2[0735%UTQH34?JAVM40#WLB-I@V49KEZ./-%4HE
M9&G7 (7I88M"G/(RC'ROAW7\%*UQDI'TCRS[B.S3".?L<.:7FX_L[S7.BO/@
M <HCS&XL2,E+$.<OB#(.DN1 J;-3X5D0BR'NXR#;!92^J,/(J8:'->WX'.6/
M&NQF]OX,9(!8H;2M4<;[5II$EXU_@8/QZO1Y.8K:N::LG2CP%)X:./(</3,]
M)H >F3Y#1_Q=Z.KZQ5RKZ0V+"K\*'(N@?I2P6?AJFV*>O/$5I[OL7+JQH].T
M>/7AIBZ2-$09W%_28*84G]&^*_Y+71*&-T=!V3Y#AX0Z-'R/E*+ZD3LJ(7["
M,=EST 1I2AD7;2E+5M^FN(LIH#_P9!?FJ/!<&)RR$CEJ8JP7H>-(YW91M$!&
M#,'0%LBA7I4HCI/VB6(8)T2'BS5^J>-1-$%5&R0@?;Z0?090+"D\#1 P.7H7
M8^0!_0H=5M:0HK[$/5]A_>DAR*@J8]LTP1X?\FB=G2*D% X#"*2 @RV[($K8
MM=W!"TN._$C2CX?\D&)6A#B@'^MNPVL/9_1!,;#P*UX_)B0FVY=>( :"6!6D
M<2/FYM2[\/80W $8SL!JP)GZJNC*+YD5G5'9FQ7,$OWYTY("JDD@<LBSG/HM
M= QS+R!  $S 8=1==[C0;:Q)W(<WKY1!170@QN%1OG@DJ"""G$3M3;SD^%FH
M?#G'IEP' !JW@AB,1RF[J)<]&\RC6XS.F\3( ;%0B?&2Z\7O-W[/%B[79,=.
M-7%/C2YHE$E>&CTZV5V#/2!2!P88>,OG&N<YFBTP1H):Q@W5.PQ"]0T;8I=1
M+#77C6[\<HRYXV F&.FF 6A.HGS[?Z!S;]]_E-$$D(3-PM)@Y@K&5MX5;XMX
M8]1LC7CSDX7@2((5( :!4JI&N'C(I=+@Z(K$5O;4L#8\622.)$,!(M&+T_$Q
M2JC'$P7Q;9+1-SCPM)0;O"=9E&=7_&JP79!&\<NOU&7*Z?]PJ'!&'"AUG!0K
M2A!":L'8FU-C/Y91J;8EW1#V34D"10T:Z)F=BQ!G[0MRJ+@Z5!!$NXKB0MPC
M%]1V-84C?.0*Q()H3[%8#VQ&H8)URQP&X4N<6FY<10,UB:";IA15=%!-Z$V(
MNG!9G!0!.9"6W#TXE@XC\25+%QJV:=0BO<E2%S.+DR50%_BOA(3/41Q?/60\
MSZDC?:K'Q4?I/W:1\BXU. NHHJP417F'5?DS^F?Y8.9,"N7\$)UOVH9VMVF%
M5P4-Z*D&U-(J\D;S?7$J\ZU094;S[67=?1_D=!7X,=A1':=84,N:=%;*[280
M;D:3HK>UK83)J&?0Z],(R>>MBZ^IX?@W9IFLXG -M?A%;NQ2UIS2B>W:;M5$
MR&URLW7/V/9)^4 *[()-1MT8(ZTEUIX_1!O^](B!,++2,4(":+7/FT+\KY+P
M0T(']W);7ZNJ\+%,NA2OJ]?%!> Z'.  ;\)-*0#Z1%9E4Y[!+QJC1NO%F'LC
M:!#;J6O+D$[W2J8,>,')V!T[8B$*N-T3:M9>5)=LCS<L7GVHH8L4J>F"NQ6C
MK)1R,])S==.Z,+HX(\/2X_:\=7WJI:@2.[.#H3'IQ&AZVN*A[E,)Q1A9?XB"
MT<;C/"RQ1#4O;U 6._ZG:+.<:WG!L*/0K<[@<5QV#Q,'7("/,[*$T$4;0B<"
M%\4*W1DNL*OV@*4'5M>LDB0;MK[:[<OU_'A[IR7;&'GXE;XF1_623HN EH&N
MKCX.<;9.HSVOHE9?FM[XM?CW ZO_SD(*? RB_#S]QKS&2+H-DNAWX2I3FQ\?
MV'$2RB)'"<E%E2 1[FZVY*7FT\-:D,O0+GA!#Y@7IX_69;'X1Q)S6BQWAO;$
MV1E=LJ:EIYX='K(HC%@YD)3?4T*_R&.TIXWJUXN>HBSB!>FKWPY)E#?_SO"6
MG_<]0\%FPRO_8G%/=-18 @0/A+Y/%FV3:$/'1T= GA.J\RB_\K2Q*.'/AHNY
M[SMW9$5;WHB-2'16VF-=ZV6W'A/OH@T4FM%EY2;4+&@C!(]BK6ZY/(_)$^A4
M\1U8U+GN2NOP@-Q[UN7GAKT+.?9.$F>J75Y8G/FH-=(XC#'LAFFW;U<=&6H/
M<,Q>3=Y7_9%1CF,G[D<(:+EAY28,RBM:RR@5H@$/8C.#TD/YZJ[=D_EC3+PC
M$;2&R#@K-PS6U42: %N>T^ )<\/%1:! !U-F9)@'?*V1<7YNT+MH0&\I9Z ]
MP6RXX @4S$!]ANLXR+*[S3]XM:L\NTL_1]O'_,.W?22<EANZ!.Z U:1+\2'T
MNK@(CPX'</_!@*E2AK1IK.K?4!B(LLLX6#^B-:/ _GHN:+#;_E)&)6L6]9C9
MFS!"#;&<U;;<Z?2N1$^?U10PA7$N3+@Y Y2Z&-<E$LO&Z"Y%O#EJ@)=U.&$L
M*GP-+V!T]#ATV8!>PF/"U!F4%RVU>>+(4[@?7I 'ZH24W%B!"1S>IU$/K@,M
MBI>5MG 1#@E!< ="S4.)?%67%?^GJ-:>47,?X](?$+>USYW=.32#1.^3MV$M
M:5RA6$G( R!@3/4 <5,H4$-<V5\Q]>P\SWIFS><P_PJ+:@$ 1WNIH JX)A_@
M8 J#"P4,>*7PD,0QN\UECU-1-7SFHN$.Z%!8/0MTP%[FBM-=94<[8)(^*X;?
M>>9TK6*3%+CMDE%7WZ#8:\RN3:Q7K(_!$\LD0/@;3M=1A@NH5O 4UXBDN&S
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M[AT,\U&*QU"WHTQ?'9MJHC\O;2E0=*BP/TC0$X)@[/L( QOL4%O.GBXSC14
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MK;ZR-^_Z%F]R#PO!$Y/[*B35Q,DG^B_Z8_D3_<]#D.'5_P=02P,$%     @
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M"G #Z?KE]>68)S'*"CH,Q\\93O%3"^GS*(T_Z4@FXSB!K%;%-.O+>(WR<DL
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M@.AHYA(&G%N$F&ZN_O7#R+1S\L.$A^_\V 0SR#Y&Q4.EZ:9X_Q1%:XK;/WY
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MX_M4\1R[?#M[,6]17OUCM-J54N[6O@+*<(  5U@3&<(*]%^MF^;$I2_L(E/
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M;ZO7*89QK0,?IU.TS<6B5-1[)!M80@VO:A7IKW+X?L0Y-&>DQ^;YEG1$UO.
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M7HCTZ4W"-_ >XQX!_)< A5%-L&*CF"59,7>'%Q3PK*BBX>_M+''_NUN9F0$
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M&"K.MGN:)E?<C#[++#YGM,1W=,1HS-?=5+H2@OT\%O-;.[7M?_.MFP LO]>
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MC8JBN2/%F(Y(Z5IWQZ=SIF-7%.:DA$_0:,4B.&5WG=PO"-K%()_KF"LT@VO
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M @EQ>#!44M\0?K*Z],<<40(//T:=JTT5I-6Q0/,L@?JR!LQ*/F(!6/EH3(;
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M"3>D9!?,>)Y&1;%X_%KB^#?&6"VE:R^J\NF<Z=@5A3D,\PG:R\@, H=731N
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M(H 6EFNFVLY,CLZ" :<;P(KR@BP.Z8KQU^<D?AZZK2;-+?"2I3HSP?"EPBP
MB%JUEXW!2Z5RW_((<=)D=62N9Y]"S,J+B5.6,8H%AT.P#<P0)ZK&84J?"3=$
M\WJ3N[Y #]D,9180;80."@0 /66]K6R #BH(/ 4/TPB=7$2052:#7+2,[)$'
M #-%G:TL!'OL#1+P>+G'<7JO8FITVGBX0A6RX!<L/AXTKDQUQK=.\LH.=#(+
MG>ZQRLCF>OTRP0$-IKVU65Z_CA9(WES%9\NM 28-+!T-E Z )!Z0-$X/1(L%
MUT:'71 ;-XVE6V(=QN$FNP/F..,95Y[S3EP!U[A'D?INL:;L;M,H*UPGOKM(
MBCC%Q28G<Y9SO%JCK*AT;=ZO/<=%652'C@]109^SW5:7#CB)\>PPV^4M-6/F
M[E!]G[.1BG=&Q>LJ,*-X?JJ"AXJS[9ZF46'V+<J7K#Q\UOFV1_/V^+K;-")]
MB8:7,NXZL#[M Z [GYP+S[R]P/XX4,!^7K[:)5]G-(-X\D+#W3)N4BX0;2.Q
MA-9=<E>VF;&:=H.TKCV>=$B3\/(MDI I[@\*(!C2BD#P0W @X&BG!8(?)DW2
MY\"&PSL&0C_&-EE[A6!8--SK O:'<"P<X+@)N\UJ[S9*Z#DQV*9HWB#8E,\X
M3_Z-EK^0:7X^G+N?;7N;?G?4>*S+EM/5T W"M5U#B"TRUH5](W2Z&LQ;A%^#
MO8&]8OLU>66.Y.R/C6+#C^Y<Z81MB"5&&+A5^Y)0!SN4P+?)827?(D-\#(T^
M=C'4^7C4&.(9X7 8ZDC@6P+H2K[[;YB/H=''+H8Z'X\:0SPC' Y#'0E\RP-=
MRT=(!)Z(\;F'H^[GXT82UQ 'Q%)7!M]R3%<27N%-S@?3^&L72]VO1PTEKAD.
MAZ2N"+[=!ZD%3%X$7FG\M0>DSM?C!A+/# <$4D>$*7)4A]%BTMT&?(BEL[56
MYZFSN[YK6XW3OB2R!!7@OM>$VYN3"!]P8CF917D&G7.2M]AC*-QQ4V,8GGEW
M-V8'P+1E;1E_4^/S^7LV@&HAD^L$[5D>,EJJR,[W?48R.]N\=-P_KZ(D_T>4
M;M"L*#:K:HR@X;PHIL^U-\\/WXVC8P]6GVG_A=?WUONS9LMXU;_A.NC/=#RY
MA3B)C?Z!4\(F3<KMH?H\N\8I>_VPQE._UVR=8'K^4 MG!P0>]OR[I/CM*D?H
M.B.ZH:*<NM^+ZINBU[/K._5YK9;QOL>S== _PO%IK'^0V^A!Q2O2S$;#J[S3
M5]3MXQ-5=$R=^Q!M,5FOGDAX9P=ICH?O>@>W^%Q=F+S.ZGPJOR)ZZ0PM9\15
M14^H^ECE^6GM:&LP-ZO==&C7K?V8?(&S5O-JV-?5R-G+OGYXC4["DCN<IE<X
MIQ\M.P=Q)99\ *^28VB:>G]ZNE;I\[??("W_\-PN#,$67+&L-2PY6Z$^-APP
M0P_],Y1UG3NZC/(R=$?;'Y@^Y[BP=K(LKV&2:593PZE/&[1(*+V:J<DQO!EA
M8)-]4IJ=82SW:$$-EGHTLX93CS9HD5!Z-%,3C1.0G^L>G:$GFMPD]#Y]\#GW
MOSZ=9MT^S;I'[1%*?^;/NS7.-^IY]V46?'_NY)F>I#]S^5L;GT?\3[U9NS5"
MZ<L,/?0/-YR'Z'NUXPW:BO1Q8YLGN/Y;),&&YH\M,MCG[U]C(-9ZG'I;6U$
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MWV,(.GHN7$U6RX=]!VS^BZ2(4UQL<F+,KOYW**79;,]Q419[1]RH7S#'*NM
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M,#$U,3(S,2YX<V102P$"% ,4    " !/BGY( Y#HPB 2  !%$ $ %0
M        @ &!]@  86-C<"TR,#$U,3(S,5]C86PN>&UL4$L! A0#%     @
M3XI^2!'\*8EX,@  U6D# !4              ( !U @! &%C8W M,C Q-3$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( $^*?DB5D*;%GK,  !TC"P 5
M      "  7\[ 0!A8V-P+3(P,34Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !/
MBGY("S"])J54  #JZP4 %0              @ %0[P$ 86-C<"TR,#$U,3(S
?,5]P<F4N>&UL4$L%!@     &  8 B@$  "A$ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
